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ABSTRACT OF THE DISSERTATION 
APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE 
SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES 
by 
Joshua Zolton Seither 
Florida International University, 2018 
Miami, Florida 
Professor Anthony DeCaprio, Major Professor 
There has been an emergence of novel psychoactive substances (NPS) in forensic 
casework globally. Although the reported prevalence of these compounds has been 
relatively low in comparison to traditional drugs of abuse, published case studies suggest 
that some NPS have significant pharmacological effects that may cause severe 
impairment and/or death. Because of these effects, it is important that toxicology 
laboratories have the capability of identifying these compounds to complete a 
comprehensive toxicological analysis for human performance and post-mortem 
investigations.  
 Recently, mass spectrometry has gained favor over traditional screening assays 
such as immunoassays for the identification of NPS in biological specimens. This trend is 
mainly a result of the fact that mass spectrometry provides the required sensitivity and 
selectivity for a broader range of analytes. High resolution tandem mass spectrometry has 
been suggested for analysis of NPS, as this technique further increases selectivity by 
increasing mass accuracy and providing MS/MS spectral data. The main goal of the 
present study was to investigate the applicability of using high resolution mass 
vi 
 
spectrometry to screen for and confirm a large number of novel psychoactive substances. 
The present study consisted of three main tasks, which included 1) the creation of a large 
high resolution MS/MS spectral library and database, 2) the development of a solid phase 
extraction (SPE) method and acquisition methods, and 3) a collision induced dissociation 
(CID) study of regioisomeric NPS compounds.   
The MS/MS spectral library created contains spectral data for 252 NPS. In 
addition, 875 NPS entities were included in the compound database. The library and 
database can be used by toxicology laboratories to aid in the identification of NPS in 
casework using MS/MS spectral data and full scan MS data, respectively. The analytical 
method developed used SPE and high resolution mass spectrometry (HRMS). The HRMS 
method demonstrated limits of detection ranging from 0.5- 5 ng/mL for NPS from 
various structural drug classes. The CID experiments demonstrated that relative ion 
abundance alone could be used to differentiate some sets of regioisomers. The present 
work can aid toxicology laboratories in the identification of NPS and demonstrates the 
applicability of HRMS for their screening and confirmation. 
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1. INTRODUCTION 
The identification of psychoactive substances is necessary in forensic toxicological 
investigations, as questions of impairment or cause of death typically arise. Currently, 
forensic toxicology laboratories employ methodologies that can readily detect the 
presence of traditional drugs of abuse in different human matrices. However, over the 
past decade there has been an emergence, in some cases a reemergence, of compounds 
known as novel psychoactive substances (NPS). These substances are manufactured 
and/or used to evade current laws but are intended to provide comparable 
pharmacological effects as more common illicit drugs of abuse. NPS are diverse and are 
classified by chemical structure and/or pharmacological effects. Identification of these 
substances is challenging to forensic toxicology laboratories, as routine screening 
techniques, such as immunoassays, cannot detect the presence of many of these 
substances, as traditional immunoassay panels often have low cross reactivity with these 
compounds. Additional challenges include identifying structurally related substances, 
including isobars and isomers, varying legality and pharmacological effects, and rapidly 
changing popularity and use of these substances. In order to identify NPS in routine 
casework, many forensic toxicology laboratories have turned to mass spectrometry in an 
attempt to detect and confirm these substances.  
The present research was designed to help forensic toxicology laboratories identify 
NPS by exploring the usefulness of high resolution mass spectrometry (HRMS) in 
identifying these compounds. In order to accomplish this task, a high resolution MS/MS 
spectral library was created using NPS standards. A database containing structural and 
molecular information was created to supplement the spectral library. A sensitive 
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analytical method was developed that is able to identify NPS from various drug classes in 
human blood specimens. Also, an investigation into the reproducibility of MS/MS 
spectral data generated by collision induced dissociation (CID) was performed, to 
determine if select regioisomeric NPS could be distinguished from each other using CID 
MS/MS spectral data alone. The work will aid forensic toxicology laboratories in the 
identification of NPS in routine case work. 
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2. LITERATURE REVIEW 
2.1 Novel Psychoactive Substances Background 
Novel psychoactive substances (NPS) are psychotropic compounds that have been 
manufactured and/or used to evade current drug laws [1]. They are intended to produce 
pharmacological effects comparable to those of common illicit drugs and are often 
structurally related to illicit or restricted compounds [2].  NPS are also commonly known 
as “designer drugs,” “research chemicals,” or “legal highs” [3-4].  NPS have recently 
experienced an increase in the popularity among drug users [5]. Perceived benefits of 
NPS use include evading current drug laws or punishments associated with illicit drug 
use and a belief that these substances are safer than traditional drugs of abuse.  In some 
cases, NPS are easier and less expensive to obtain when compared to traditional drugs of 
abuse [6-7].  Typically, these substances are produced in China and South East Asia, sold 
on the internet under various names such as “research chemicals,” “legal highs,” “bath 
salts,” “plant food,” and generally are labelled “not for human consumption” [8-10].  
Many of the NPS have been “rediscovered” from previous scientific research. A 
prime example of this phenomenon is the synthetic cannabinoid drug class. Many of the 
synthetic cannabinoids were originally investigated by pharmaceutical companies or 
research groups in an attempt to learn more about the cannabinoid activity of these 
compounds, with the hope of identifying drugs for legitimate medicinal use [11]. During 
these investigations, hundreds of compounds with slight structural modifications were 
created and documented in the scientific literature [12]. Ultimately, these compounds 
were determined not to be suitable for human use and further studies were not performed. 
Around 2006, some of these compounds started to appear in seized drug materials and 
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later were observed in forensic toxicological investigations [11]. Since then multiple 
synthetic cannabinoids and/or metabolites have been detected in drug seizure cases and in 
forensic toxicological case reports [13-16]. Many of these compounds, specifically the 
JWH series of synthetic cannabinoids, were documented in previous scientific work [12, 
17],although there have also been emerging NPS compounds that are novel derivatives 
previously not reported in literature.     
Because the vast majority of NPS have not been evaluated in animal or human 
pharmacological studies, available health data are limited for most of these compounds 
[18]. Consequently, there is a risk of unintended pharmacological effects, including 
severe impairment, toxicity and even death when using these substances [19].  The 
potential dangers of NPS have been documented by poison control call reports, reported 
emergency room visits, and forensic toxicology reports involving both antemortem and 
postmortem cases [20-27].  
In response to the proliferation of NPS, many governments and organizations 
have created programs in an attempt to address this issue. Early drug detection programs, 
such as Sweden’s STRIDA project, the European Union’s European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) Early Warning System, the United Nations 
Office on Drugs and Crime (UNODC) Early Warning Advisory on NPS, and the United 
States National Institute on Drug Abuse’s National Drug Early Warning System 
(NDEWS) have been created to identify and report on new NPS that have been observed 
in literature, poison control reports, hospital and forensic cases [7, 28].  
In addition, governing bodies have enacted legislation in an attempt to combat the 
use of these compounds. The United States Drug Enforcement Administration (DEA) has 
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federally controlled many NPS from various structural and pharmacological classes, 
including cathinones, phenethylamines, piperazines, synthetic cannabinoids, synthetic 
opioids, and tryptamines, using either analogue-based or emergency scheduling 
procedures. Similar efforts have been observed in many other countries [29-30]. As a 
consequence of this legislation and the reported effects of these substances, a need has 
been created for forensic and clinical toxicology laboratories to be able to reliably detect 
these compounds in human specimens.   
2.2 Novel Psychoactive Substance Classes  
Novel psychoactive substances encompass a large, structurally diverse group of 
compounds. Typically, these substances are classified on the basis of their chemical 
structure and/or purported pharmacological effects. The NPS classes that have been 
identified in previous literature include but are not limited to arylcyclohexylamines, 
benzodiazepines, cathinones, phenethylamines, piperazines, synthetic cannabinoids, 
synthetic opioids, and tryptamines.  
While there has been progress in determining the mechanism of action for NPS 
substances by assessing receptor binding affinities with in silico and in vitro models, the 
mechanism of action is not known for every NPS. In some classes, such as the 
cathinones, structurally related analogues have varying pharmacological effects. In 
addition, various analogues in the synthetic cannabinoid class have been reported to have 
significantly different cannabinoid CB1 and CB2 receptor binding affinities, which also 
results in varying pharmacological effects [31-32]. The elucidation of the mechanism of 
action is further complicated by the fact that controlled human studies have not been 
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conducted for these compounds and the fact that psychoactive metabolites may be formed 
which can prolong or create pharmacological effects.     
2.2.1 Arylcyclohexylamines 
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Figure 1. Selected novel psychoactive substances that are in the arylcyclohexylamines class.  
 
Arylcyclohexylamines are compounds that consist of an aromatic ring, a 
cyclohexane ring and an amine moiety.  They are commonly believed to have 
phencyclidine (PCP)- or ketamine-like pharmacological activity [33]. 
Arylcyclohexylamines have been reported to have high affinity for the N-methyl-D-
aspartate (NMDA) receptors, where they act as antagonists [33]. Some derivatives were 
also reported to have noticeable affinities for the serotonin transporter and/or for the 
sigma receptors [34]. In addition, some derivatives are also thought to act as dopamine 
reuptake inhibitors [35].  
Arylcyclohexylamines are classified as dissociative anesthetics [36]. They are 
reported to produce anesthesia, agitation, euphoria, insomnia, tachycardia, ataxia and 
hallucinogenic effects [37]. Acute toxicity of methoxetamine has been documented in 
three hospital cases, where each patient was described to be in a “dissociative/catatonic” 
state with acute sympathomimetic toxicity symptoms present. These symptoms included 
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tachycardia and hypertension [38]. Fatal intoxications have also been reported involving 
structural analogs of PCP [39].  
The first arylcyclohexylamine to be reported in literature was 1-(1-
phenycyclohexyl)-amine (PCA) in 1907 [40]. The most well know arylcyclohexylamine, 
1-(1-phenylcyclohexyl) piperidine (PCP), was first synthesized in 1956 and human trials 
for PCP began in 1957 [40]. Phencyclidine, also known as PCP, was used for nearly a 
decade as an anesthetic before being withdrawn from the market in favor of another 
arylcyclohexylamine, ketamine, which had fewer documented side effects compared to 
PCP [40]. Phencyclidine is controlled as a Schedule II drug by the United States DEA 
[39]. Ketamine is still used today in the medical and veterinary fields. In addition to 
legitimate medicinal use, illicit ketamine use has been documented, which led this 
compound to be controlled.  It is currently listed as a Schedule III controlled substance by 
the United States DEA.   
Many arylcylcohexylamine substances were synthesized and explored by 
pharmaceutical companies and research groups for medicinal use. Like other NPS drug 
classes, some of these derivatives have appeared in the illicit drug market. Examples 
include N-ethyl-1-1phenylcyclohexylamine (PCE), N-Propyl-1-phenylcyclohexylamine 
(PCPr), and 1-Phenyl-N-(propan-2-yl)cyclohexan-1-amine (PCiP). They were reported in 
the illicit drug market beginning in the1960s to the 1990s [33].  
More recently, over 25 additional arylcyclohexylamines were identified in the 
illicit drug market by drug seizures and toxicological investigations. At least a dozen of 
these compounds were first observed after 2005, suggesting that there is still interest in 
this drug class among illicit drug manufacturers and users [40].  For example, Backberg 
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reported that 3-methoxy-phenylcyclidine (3-MeO-PCP) and/or 4-methoxy-
phenylcyclidine (4-MeO-PCP) were detected in over 80 patients between July 2013 and 
March 2015 from emergency rooms and intensive care units in Sweden [41]. In 2016, 
Fassette and Martinez reported that methoxetamine was identified and confirmed in an 
impaired driver [42]. In 2017, two fatal polydrug intoxications involving 3-MeO-PCP 
were reported by Mitchell-Mata, et al. [39].   
2.2.2 Benzodiazepines 
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Figure 2. Selected novel psychoactive substances from the benzodiazepine class.  
 
Consistent with benzodiazepines that have medicinal use, designer 
benzodiazepines have a core structure that consists of a benzene ring fused to a diazepine 
ring. Typically, this core structure has a second benzyl ring attached to it. Most 
benzodiazepines bind to γ-aminobutyric acid (GABA) receptors in the human body, 
where they act as allosteric modulators. The binding of benzodiazepines to the GABA 
receptor increases the affinity of GABA to the receptor and enhances the effect of the 
GABA neurotransmitter [43]. It also has been documented that some benzodiazepines, 
such as 4-chlorodiazepam and diazepam, also bind to the translocator protein (TSPO) 
[44].  
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Benzodiazepines are classified as central nervous system depressants. Amnesic, 
anxiolytic, and sedative effects have been well documented with benzodiazepine use 
[45]. However, benzodiazepines such as 4-chlorodiazepam that only bind to the TSPO 
have been shown to create anxiolytic effects without the sedative effect [44]. Duration of 
action can vary greatly among benzodiazepines. In addition, some benzodiazepines are 
metabolized into psychoactive metabolites which can further extend the duration of 
action of the initial benzodiazepine ingestion. Acute intoxications resulting in 
hospitalization and death have been documented with nonmedical use of 
benzodiazepines, including designer benzodiazepines [46-47]. Benzodiazepines have also 
been confirmed in impaired driving cases, as well as in drug-facilitated crime cases [48-
50].   
The first designer benzodiazepines, phenazepam and nimetazepam, were  
identified in Europe in 2007 [44]. Since then, many benzodiazepine related compounds 
have been seen in the illicit drug market. The majority of these compounds are failed 
pharmaceutical candidates diverted to illicit use, with their synthesis and relative potency 
well detailed in literature.  In contrast, some compounds, such as flubromazolam, appear 
to be novel and as such have not been described in literature [51-53].  
Recently, there has been an increase in the number of different designer 
benzodiazepines confirmed in forensic toxicological investigations. Hoiseth, et al. 
reported that clonazolam, diclazepam, flubromazepam, flubromazolam and/or pyrazolam 
was detected in 77 criminal cases in Norway from July 2013 to May 2016 [54]. In 
Sweden, between February 2014 and November 2015 there were 191 clinical samples 
that tested positive with immunoassay screening by CEDIA, but were negative using a 
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traditional benzodiazepine confirmation assay that included at least one designer 
benzodiazepine. In the Swedish study, 11 different designer benzodiazepines were 
reported, with flubromazolam and meclonazepam being the most frequently observed 
[55].     
2.2.3 Cathinones 
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Figure 3 Selected novel psychoactive substances from the cathinone class. 
 
Cathinones are β-keto substituted phenethylamines. They act as modulators of the 
plasma membrane monoamine transporters, which include the dopamine transporters 
(DAT), norepinephrine transporters (NET) and the serotonin transporters (SERT) [56-
57]. The function of these transporters is to regulate the concentration of the monoamine 
neurotransmitters by removing them from the synaptic cleft.   There is variability among 
the different cathinone derivatives in terms of their interactions with the different 
monoamine transporters, which may explain the differences observed in their 
pharmacological effects [58].   
Synthetic cathinones are classified as central nervous system stimulants and have 
pharmacological effects generally comparable to amphetamine, cocaine, 
methamphetamine and/or 3,4-methylenedioxymethamphetamine (MDMA) [20, 59-60]. 
Pharmacological effects that have been documented with synthetic cathinone use include 
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agitation, blurred vision, dehydration, dysphoria, increased blood pressure, increased 
body temperature, insomnia, nausea, paranoia, psychosis, sympathomimetic effects, and 
tachycardia [20, 61-62]. Hospitalization and/or death has also been attributed to the illicit 
use of cathinones [63-66].  
  Cathinone is the main psychoactive compound that is found in the fresh leaf of 
the Catha edulis plant, which have been used since the eleventh century for its 
psychoactive effects [67-68]. In 2010, the first cases of synthetic cathinone use were 
reported to United States poison control centers. Within the first eight months there were 
over 1400 cases reported to the poison control center [69]. In 2011, the DEA added the 
first synthetic cathinones methylone, MDPV, and mephedrone to the Schedule 1 
controlled list [70]. Since then, newer synthetic cathinone derivatives, such as ethylone, 
pentedrone, alpha-pyrrolidinopentiophenone (α-PVP), and N-ethylpentylone, have 
appeared in the illicit drug market [25, 71-72].  
In Italy between 2013 and 2015, the most frequently observed synthetic 
cathinones in seized drug material were 3-methylmethcathinone (3-MMC) with 35 cases, 
4-methylethcathinone (4-MEC) with 33 cases, and MDPV with 16 cases [2]. Adamowicz 
reported that α-PVP was found in 66 cases from Poland between early 2014 and mid-
2015 [73].    
2.2.4 Phenethylamines 
Phenethylamines are compounds that contain a phenyl ring and an amino group 
that are bonded together by an ethyl alkyl chain. The structural drug class includes both 
amphetamine and methamphetamine along with many other derivatives. Phenethylamines 
inhibit the dopamine, the serotonin and/or the norepinephrine transporters, thereby 
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increasing levels of the corresponding neurotransmitters in the synaptic cleft [8].  
Alternatively, a few can act as agonists of the receptors themselves. 
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Figure 4. Selected novel psychoactive substances from the phenethylamine class. 
 
Phenethylamines are in general considered to have CNS stimulant properties [6]. 
In addition, some substituted phenethylamines, such as compounds from the 2C-X 
subclasses, have also been reported to induce hallucinogenic effects, as most of these 
compounds have affinity for the serotonin receptors [74]. Agitation, convulsions, 
dissociation, euphoria, hallucinations, hyperthermia, kidney failure, liver failure, 
psychosis and respiratory deficits have been observed with phenethylamine use [74-75]. 
Hospitalization and death have also been reported with phenethylamine intoxications [24, 
76-78].   
One of the most well-known phenethylamines is 3,4- 
methylenedioxymethamphetamine (MDMA). MDMA was first synthesized by a 
pharmaceutical company in 1912 and began to be seen in the illicit drug market in the 
1960s [79].  In the 1970s and 1980s its popularity increased as a recreational drug, 
prompting eventual control by the United States DEA [80]. In 1991, Dr. Alexander 
Shulgin, a medicinal chemist who had formerly worked for BioRad Laboratories and 
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Dow Chemical Co. before becoming an independent consultant, published a book entitled 
PIKHAL (Phenethylamines I Have Known and Loved) which described the detailed 
chemical synthesis and human pharmacological effects of 179 phenethylamines [81].  
Some of the compounds detailed Shulgin’s book have been subsequently identified in 
forensic toxicological investigations. 
Recently, the most commonly identified phenethylamines in forensic casework 
have been the N-benzyl substituted phenethylamines, which are known as “NBOMe” 
derivatives. They are considered highly potent hallucinogens due to their increased 
affinity for the 5-HT2A serotonin receptor and have been sold as alternatives to LSD [77]. 
The N-benzyl substituted phenethylamines that have been confirmed in biological 
specimens are 25B-NBOMe and 25I-NBOMe [76, 82]. In addition to toxicological 
investigations, Kaizaki-Mitsumoto reported that six new phenethylamine compounds, 
including three NBOMe derivatives, were identified in drug material obtained in Japan in 
2015 [83].      
2.2.5 Piperazines 
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Figure 5. Selected novel psychoactive substances from the piperazine class. 
  
There are two main piperazine structural groups that have been observed in illicit 
materials, benzylpiperazines and phenylpiperazines [84].  Piperazine derivatives typically 
contain a substitution on the benzyl ring or the phenyl ring. Pharmacological activity 
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varies depending on the substitution of the piperazine structure and whether the 
compound is a benzylpiperazine or a phenylpiperazine. Benzylpiperazines have been 
found to stimulate dopamine, serotonin, and norepinephrine release and also inhibit the 
reuptake of these neurotransmitters [85]. While phenylpiperazines act directly on the 
serotonin transporters, they exhibit little effect on the dopamine and norepinephrine 
transporters [6].  
Piperazines have been generally recognized as CNS stimulants with some 
compounds having hallucinogenic effects [86]. Reported pharmacological effects of 
piperazine use include agitation, anxiety, hallucinations, hyperthermia, seizures, and 
tachycardia [85-87]. Piperazines are thought to be less potent then amphetamine, 
however, intoxications requiring hospitalization or resulting in death have been 
documented in previous literature [18, 86, 88]. 
Piperazine was originally synthesized as an anthelminthic in the 1940s, however it 
was observed to have effects similar to amphetamine. During the 1960s and 1970s, 
benzylpiperazine derivatives were explored as antidepressants [89]. Piperazine 
derivatives became popular party drugs in the 1990s [18, 90]. In 2010, Dickson reported 
the confirmation of the most popular piperazines; 1-benzylpiperazine (BZP), 1-(3-
trifluoromethylphenyl)-piperazine (TFMPP), and 1-(3-chlorophenyl)-piperazine (mCPP) 
in urine specimens [91].  The popularity of piperazines decreased substantially when the 
cathinone class appeared on the market and gained favor among drug users [19].    
2.2.6 Synthetic Cannabinoids 
Synthetic cannabinoids are compounds that act on the cannabinoid receptors CB1 
and CB2 [8]. The synthetic cannabinoids class is a very structurally diverse class with 
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most of the compounds not structurally related to delta-9-tetrahydrocannabinol (∆9-THC), 
the main psychoactive compound in marijuana [92]. Many classes of synthetic 
cannabinoids incorporate various chemical skeletons such as indole, indazole, naphthyl, 
or pyrroles moieties.  
N
O
JWH-018
N
N
NH
O
H2N
O
AB-CHMINACA
N
O
F
XLR-11  
Figure 6. Selected novel psychoactive substances from the synthetic cannabinoid class. 
Synthetic cannabinoids were originally thought to act like traditional 
cannabinoids such as ∆9-THC. However, while this is true for some synthetic 
cannabinoids, atypical cannabinoid pharmacological effects have been reported with their 
use [93]. The affinity and agonist activity for the CB1 and/or CB2 receptors vary among 
the different synthetic cannabinoids, which may cause the different observed 
pharmacological effects [32, 94].  Reported effects include agitation, anxiety, 
hallucinations, hyperthermia, paranoia, psychosis, renal failure, seizures, tachycardia, and 
vomiting [95-96]. Hospitalization and death have also been reported with synthetic 
cannabinoid use [97-99].        
In attempt to find compounds that could create the analgesic and anti-
inflammatory effects of ∆9-THC without the psychoactive side effects, various research 
groups and pharmaceutical companies created and published synthesis details for 
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hundreds of CB1 and CB2 agonists [12, 18]. Some of these synthetic cannabinoid 
compounds have been confirmed in herbal products that were sold over the internet and 
in forensic toxicological specimens [11, 100].  
Synthetic cannabinoids were first confirmed in Europe in the mid-2000s and were 
identified in the United States shortly thereafter [101]. The synthetic cannabinoids JWH-
018, JWH-073, CP 47,497 and HU-210 were the first derivatives identified in herbal 
material [11]. Since then, many more compounds have been seen. Synthetic cannabinoids 
are considered to have multiple synthetic generations, as newer derivatives rapidly appear 
on the market after governments ban existing compounds or the popularity of particular 
synthetic cannabinoids declines [96].  Tynon reported that between March 2015 and 
December 2015, 537 blood samples contained at least one synthetic cannabinoid. The 
most commonly identified synthetic cannabinoids in the Tynon report were AB-
CHMINACA and ADB-CHMINACA [102]. Previously unreported synthetic 
cannabinoids continue to be identified in seized drug material to the present [103-104].  
2.2.7 Synthetic Opioids 
Synthetic opioids are compounds that are agonists or antagonists of the δ, κ, and µ 
opioid receptors [105]. Synthetic opioids are made with chemical precursors that are 
readily available and cheaper than the opium extracted from poppy plants, which is 
needed to produce traditional opiates [106].  There is some structural diversity in this 
class of NPS, which can be generally classified as fentanyl analogs and non-fentanyl like 
synthetic opioids. Synthetic opioids have a wide range of potency according to preclinical 
data [105].  
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Figure 7. Selected novel psychoactive substances from the synthetic opioid class. 
 Synthetic opioids, like traditional opioids, act as opioid analgesics. Opioids block 
the transmission of painful stimuli and in some instances produce euphoria [107]. 
Opioids are typically used therapeutically to manage pain from surgical procedures or 
from chronic pain. They have also been used as antitussives and for their antidiarrheal 
properties [107]. In addition, there are opioid antagonists that are used to treat opioid 
intoxications and withdrawal symptoms. Potency of the different synthetic opioids and 
their affinity for the different opioid receptors have been cited as the main differences in 
pharmacological effects [108].  Many synthetic opioid intoxications have resulted in 
hospitalization and/or death [109-112].     
 Between 2002 and 2011 it was estimated that 25 million people used prescription 
opioids for nonmedical use [113]. In 2010 there were 16,751 opioid related deaths in the 
United States, which prompted local, state and federal governments to create programs to 
improve opioid prescribing practices and to penalized doctors and clinics for writing 
unnecessary prescriptions [113]. As prescription opioids became less available, it appears 
that many users turned to illicit opioids, as evident by the increased use of heroin and 
other synthetic opioids [114]. Over time, illicit laboratories began to synthesize fentanyl 
and other synthetic opioids as cheaper alternatives to heroin or other controlled opioids.  
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Recently, fentanyl and other synthetic opioids have appeared in heroin, drug 
material sold as heroin, and in counterfeit benzodiazepine or opioid pharmaceuticals 
[106, 115]. In addition, there are drug users who intentionally seek out new synthetic 
opioid analogs, behavior which has also been observed with other NPS classes [106].  
Acetyl fentanyl may have been the first synthetic opioid that was used as a novel 
psychoactive substance. Since then, many fentanyl derivatives and other synthetic opioids 
have appeared in the illicit drug market [105].  Recent literature has reported the 
confirmation of carfentanil, furanyl fentanyl, and 4-fluoroisobutyryl fentanyl in forensic 
toxicological investigations [116-118].  Other synthetic opioids that are not structurally 
related to fentanyl have also been reported.  The most common of these non-fentanyl 
derivatives reported in literature include AH-7921, U-47700 and MT-45 [109, 119].       
2.2.8 Tryptamines 
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Figure 8. Selected novel psychoactive substances from the tryptamine class. 
 
Tryptamines are compounds that contain an indole moiety with an ethylamine 
side chain and are structurally related to the neurotransmitter serotonin. Tryptamine 
modifications include substitutions on the indole ring, alkyl chain, and/or the amino 
group [120]. Tryptamines primarily act as agonists on the 5-HT2A receptor of the 
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serotonin receptor family. Sigma-1 receptor activity has also been documented with 
tryptamine use [121]. 
In general, tryptamines are considered hallucinogens, with some derivatives 
having stimulant like activity [120]. They have a relatively short duration of action, 
however some tryptamines have been reported to have a relatively quick onset of action 
[122]. Clinical effects observed with tryptamine use include anxiety, diaphoresis, 
diarrhea, drowsiness, dysphoria, euphoria, hallucination,  hypertension, nausea, 
rhabdomyolysis, tachycardia, and tachypnea [123]. Hospitalization and/or death has been 
reported with tryptamine intoxications [120, 124]. 
The compound N,N-dimethyltryptamine (DMT) is found in hundreds of plants 
around the world and endogenously at low concentrations in humans. The tryptamine 
DMT has been used for many centuries for religious and spiritual purposes [121]. Other 
natural tryptamines have been identified in mushrooms (4-phosphoryloxy-N,N-
dimethyltryptamine; psilocybin and 4-hydroxy-N,N-dimethyltryptamine; psilocin) and 
secretions of the desert toad Bufo alvarius (5-hydroxy-N,N-dimethyltryptamine; 
bufotenine) [123]. 
Arguably the best known tryptamine analog, lysergic acid diethylamide (LSD), 
was synthesized in 1938 and was eventually banned in 1966 [123]. In 1997, Dr. 
Alexander Shulgin published a sequel to PIHKAL, entitled “TIHKAL: the continuation”, 
which detailed the synthesis and provided user information for 55 tryptamine derivatives 
[125]. Some of the compounds described were subsequently identified in forensic 
toxicological investigations [124]. However, as evident from recent poison control center 
reports, self-reported drug use, and prevalence studies, it appears that tryptamines are not 
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as prevalent as they once were, with only a few cases of tryptamine use recently reported 
[19-21, 126].   
2.3 Identification of Drugs of Abuse and Novel Psychoactive Substances 
2.3.1 Routine Forensic Toxicological Analysis  
Forensic and clinical toxicology laboratories routinely employ screening and 
confirmation techniques for detection of drugs in human specimens. Screening 
techniques in a forensic laboratory typically include targeted immunoassays coupled with 
an untargeted mass spectrometric analysis. Screening techniques are typically less time 
consuming and more cost effective than confirmation techniques. Using the results of the 
screening assays, specimens are typically further analyzed by a more selective 
confirmation assay utilizing mass spectrometry. A qualitative or quantitative result is 
generated using the confirmation method.      
2.3.2 Immunoassays 
Immunoassays have been employed in forensic laboratories as a screening method 
because minimal sample preparation is needed, lower cost, the time of analysis is 
typically shorter than those of confirmation methods. Immunoassays are also readily 
available commercially. Various immunoassay techniques, which include but are not 
limited to Enzyme Linked Immunosorbent Assay (ELISA), Enzyme Multiplied 
Immunoassay Technique (EMIT), Kinetic Interaction of Microparticles in Solution 
(KIMS), Cloned Enzyme Donor Immunoassay (CEDIA) and Homogeneous Enzyme 
Immunoassay (HEIA), have been used in forensic toxicology laboratories. Immunoassays 
typically utilize competitive binding of the free target analyte and a modified target 
analyte in order to detect drugs of abuse in case specimens. The modifications of the 
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targeted analyte are different among the techniques used but can include labelled target 
analytes that can be conjugated with enzymes or microparticles. Absorbance at various 
wavelengths is typically measured to determine if a drug is present in a sample [127].     
Immunoassays use antibodies that are targeted for a certain drug or drug class. 
The specificity varies among antibodies used and the purpose of the assay. Some 
immunoassay panels are created to target for one specific analyte, while other panels are 
created to be cross reactive with as many compounds from a drug class as possible. In 
both types of panels, both endogenous or exogenous compounds may be present that can 
create false positive or negative results [128]. While immunoassays can be very sensitive, 
they are not selective enough to confirm the presence of a drug of abuse or NPS in 
forensic toxicological investigations [129]. A positive result from an immunoassay needs 
to be confirmed by a more selective methodology. Typically, mass spectrometry is used 
to confirm drugs of abuse.        
Successful identification of NPS using immunoassays varies among individual 
compounds, the immunoassay technique, and the reagents used [130-133]. For example, 
the designer benzodiazepine drug class has exhibited the most compounds with 
significant cross reactivity across multiple immunoassay techniques [43]. However, the 
majority of NPS have low or no cross reactivity with commonly used immunoassay drug 
panels [134]. For this reason, many forensic toxicology laboratories are moving towards 
screening assays that utilize mass spectrometry in an attempt to reliably identify NPS in 
routine case work.   
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2.3.3 Sample Preparation  
Sample preparation is generally needed before a specimen can be analyzed by a 
confirmatory assay that utilizes a mass spectrometer. The most common sample 
preparation techniques utilized in forensic toxicology laboratories are liquid/liquid 
extraction (LLE) and solid phase extraction (SPE) methodologies. However, “dilute and 
shoot” and “crash and shoot” sample preparation methods are also gaining favor among 
laboratories that utilize liquid chromatography mass spectrometers.  
LLE methodology isolates the analyte of interest by using two liquids that are 
immiscible with each other. Typically, these methods consist of an organic solvent and an 
aqueous solvent. The target analyte will favor one of the solvents because of its relative 
solubility in each solvent. As most drugs of abuse and NPS are considered weak acids or 
weak bases, manipulation of the pH can be used to favor one solvent over the other in 
terms of solubility. The LLE approach also helps remove compounds from the specimen 
that do not have similar chemical properties of the analytes of interest. The technique 
enables the use of wash steps, also known as “back extraction,” as solvents that do not 
contain the target analyte can be discarded and replaced with another solvent to help 
further remove unwanted compounds. Typically, the organic solvent is the final solvent 
that contains the target analyte(s). The organic solvent is then dried down under nitrogen 
before being reconstituted with an appropriate solvent prior to mass spectral analysis 
[135].           
SPE methodology utilizes a cartridge with a sorbent bed mass consisting of silica 
or a polymeric resin containing certain chemical functional groups. The typical 
methodology implements a column condition step which is used to prime the extraction 
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cartridge to ensure that the functional groups of the bed are active. Then the buffered 
sample is added to the extraction cartridge. Wash solvents are added to the extraction 
cartridge to remove unnecessary compounds found endogenously or exogenously in the 
sample such as carbohydrates, lipids, and proteins. The analyte of interest is retained on 
the extraction cartridge bed mass during the loading and wash steps. The analyte is 
finally eluted when the proper elution solvent is added to the extraction cartridge. The 
eluent is then dried down under nitrogen gas before being reconstituted with the 
appropriate solution before mass spectral analysis [135].   
In SPE, analytes are retained on the basis of the chemical properties of the sorbent 
bed mass and the analyte itself. Typically, ionic bonding and hydrophobic interactions are 
used to facilitate the retention of the analyte. As in LLE, the pH of the solvents and 
solubility of the analyte in the various solvents can greatly affect whether or not an 
analyte or other compounds are retained on the sorbent bed mass [135].  
Dilute and shoot methods typically incorporate a hydrolysis step for urine samples 
before being diluted with a buffer or mobile phase. Crash and shoot methods typically 
employ an acetonitrile protein precipitation (crash) step for blood samples before being 
diluted with buffer or mobile phase.  With both techniques, the diluted samples are then 
injected onto the liquid chromatography mass spectrometer (LC-MS) which, unlike the 
gas chromatography mass spectrometer (GC-MS), is compatible with aqueous samples. 
While sample preparation is considerably quicker than LLE and SPE methods, “dilute 
and shoot” and “crash and shoot” methods do not remove as many endogenous and/or 
exogenous compounds.  Not removing these compounds could be a concern during the 
analysis, as matrix effects are observed more frequently using LC-MS methodology. In 
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addition, more maintenance may be needed in order to maintain the performance of the 
LC-MS instrumentation.   
All of the extraction techniques mentioned have been described in the literature as 
methods that can identify NPS in human specimens. Tynon et al. and Knittel et al. both 
utilized LLE methodologies to identify synthetic cannabinoids in human specimens [102, 
136]. Concheiro et al. utilized a SPE method to identify 40 NPS, mainly from the 
synthetic cathinone and piperazine drug classes [137]. Bell et al. described a “dilute and 
shoot” method that could detect eight compounds from the synthetic cathinone and 
piperazine drug classes in urine specimens [138]. Adamowicz et al. described a method 
that utilized a protein crash before analyzing blood specimens that could detect 143 NPS 
from the various designer drug classes [9].  Many more analytical methods for the 
detection of NPS in human specimens have been reported and reviewed in recent 
literature [139-141].              
2.3.4 Instrumental Analysis 
2.3.4.1 Gas Chromatography Mass Spectrometry 
Gas chromatography mass spectrometry (GC-MS) is a powerful analytical 
technique for the identification of compounds in forensic toxicology specimens. Gas 
chromatography mass spectrometry, known as the “gold standard” in forensic toxicology, 
couples two analytical methodologies which enables it to have high resolving power and 
high selectivity. The first analytical methodology employed with GC-MS is gas 
chromatography. Gas chromatography is a technique that is used to separate analytes of 
interest from other endogenous or exogenous compounds that are present in an extracted 
forensic toxicology specimen. The separation is accomplished by first injecting a small 
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amount of an extracted sample into an injection port. The injection port is kept at a high 
temperature and the liquid sample is then vaporized into gas. The vaporized sample is 
then carried through an analytical column by a carrier gas typically consisting of helium. 
The sample then interacts with the analytical column and compounds are retained on the 
column for different amounts of time due to the affinity of compound with the analytical 
column itself. Retention times are established for each analyte of interest and are used to 
aid in the confirmation of a target analyte.  
The second analytical technique is mass spectrometry. After compounds and 
analytes of interest are eluted from the GC analytical column they are introduced to an 
ionization chamber of the mass spectrometry. Typically, electron ionization (EI) or 
chemical ionization (CI) are the ionization sources utilized in GC-MS, with the EI 
method being the most commonly used.  In electron ionization, compounds and analytes 
are bombarded by electrons which create a positively charged molecular ion by removing 
one of the electrons in the molecule. Most of the time this molecular ion is unstable, 
which induces fragmentation or rearrangement to form more stable fragment ions. These 
ions then enter a mass analyzer. Typically, the ionization source is set to 70 eV to ensure 
reproducibility across different laboratories and manufacturers. 
 The quadrupole is the most commonly used mass analyzer for GC-MS analyses 
in forensic toxicology laboratories. A quadrupole consists of four rods that uses the 
combination of both radio frequency and direct current voltages to filter ions with a 
certain mass per unit charge (m/z) value. Full scan MS and selected ion monitoring (SIM) 
are the acquisition modes that can be used to acquire MS data using a single quadrupole 
[142]. In the full scan MS acquisition mode, the instrument quickly cycles through a 
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defined range of masses at a defined step size in an attempt to collect as much spectral 
data from a larger range of masses. This acquisition mode is used for screening.  The SIM 
acquisition mode only obtains spectral data on select ions that are predetermined. The 
instrument spends more cycle time filtering these ions, thus the sensitivity of the GC-MS 
is increased when utilizing the SIM acquisition mode. The SIM acquisition mode is used 
for targeted confirmation assays where the targeted analytes are already known.     
2.3.4.2 Liquid Chromatography Mass Spectrometry 
Liquid chromatography mass spectrometry (LC-MS) is gaining popularity in 
forensic toxicology laboratories because of the increased selectivity, specificity, and 
sensitivity [143]. Similar to the GC-MS, two analytical techniques are couple together in 
LC-MS methodology; a separation technique and an identification technique. However, 
unlike GC-MS, the sample and mobile phase remain in the liquid phase until they reach 
the ionization chamber of the mass spectrometer. The sample is injected into the mobile 
phase and then carried to the analytical column. Separation of analytes of interest and 
other compounds occurs in the analytical column and the duration of retention depends 
on the affinity between the stationary phase and the analyte itself. After compounds are 
eluted from the analytical column, they are then carried to the ionization chamber of the 
instrument.  
The most commonly used ionization source in LC-MS methodology is 
electrospray ionization (ESI). Electrospray ionization is considered a softer ionization 
technique which allows the formation and detection of the molecular ion to occur more 
frequently than harder ionization techniques such as EI. Gas phase ions are created in the 
electrospray chamber by first nebulizing the liquid stream coming from the LC system. 
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The liquid mobile phase creates what is called a Taylor cone at the end of the nebulizer. 
A fine mist of droplets is emitted from the Taylor cone which is then subjected to heated 
gas which helps rapidly evaporate the solvent [144]. The droplets continue to shrink until 
they reach the Rayleigh limit, where the surface tension of the droplet can no longer 
sustain the Coulombic force of repulsion between the ions. At this point a Coulombic 
explosion occurs and many smaller droplets are created from the larger droplets. This 
process repeats itself many times until the gas phase ionized analytes are formed [145]. 
Ions then enter an ion capillary and then analyzed/filtered out by the mass spectrometer.  
One major concern with electrospray ionization is that it is susceptible to matrix 
effects [146]. Matrix effects are defined as differences in analyte response associated 
with the presence of co-eluting compounds from a sample matrix. An increased analyte 
response is considered ion enhancement and a decreased analyte response is considered 
ion suppression [147].  
Many types of mass spectrometers have been coupled with liquid 
chromatography. They include quadrupole, ion trap, and time of flight mass analyzers. 
Tandem mass spectrometry is frequently used with LC-MS, which increases its 
sensitivity and selectivity. Many forensic toxicology laboratories currently utilize LC-MS 
instrumentation.    
2.3.4.3 High Resolution Mass Spectrometry  
High resolution mass spectrometry (HRMS) is a term given to mass analyzers that 
can achieve a resolution of 20,000 (full width half maximum) or mass accuracy below 5 
ppm [148]. These include time of flight (TOF), ion trap, and ion cyclotron (ICR) mass 
analyzers. The primary advantage of HRMS when compared to lower resolution mass 
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spectrometry is that this technique has higher resolving power, which results in increased 
mass accuracy. As a result of this high resolving power, some compounds that are 
considered isobaric on low resolution instrumentation can be identified solely on the 
basis of the accurate mass determined for the molecular ion.  
The TOF mass analyzer is able to achieve high resolution by measuring the flight 
time of an ion through a flight tube and then assigning a mass to charge ratio, m/z, using 
the time of flight. The flight time is directly proportional to the root of the mass to charge 
ratio of the ion and this calculation is shown below.      
𝑡𝑡𝐹𝐹 = 𝐿𝐿𝑣𝑣   (Equation 1) 
𝐾𝐾𝐾𝐾 = 𝑧𝑧𝑧𝑧𝑧𝑧 = 1
2
𝑚𝑚𝑣𝑣2 (Equation 2) 
𝑡𝑡𝐹𝐹 = 𝐿𝐿� 𝑚𝑚2𝑧𝑧𝑧𝑧𝑧𝑧     (Equation 3) 
Equation 1 displays the time of flight, tF, calculation, where the length of the 
flight tube is represented by L and the velocity is represented by v. The kinetic energy, 
KE, equation is shown in equation 2 where the charge, z, the electronic charge, e, and the 
voltage difference, V, are used. Kinetic energy can also be determined with mass, m, and 
velocity, v, which is also shown in equation 2.  Equation 3 is created after substituting the 
velocity in equation 1 with equation 2. When determining mass in the time of flight mass 
analyzer, the flight tube length is fixed and the kinetic energy is assumed to be equal for 
all ions entering the flight tube. Therefore, equation 3 shows that the time of flight is 
directly proportional to the root of the mass to charge ratio of the ion [149].  Reference 
masses are constantly present during the full scan acquisition and are used to make in-
29 
 
time x-axis corrections to ensure high mass accuracy. Measurements with mass errors 
less than 5 ppm are typically observed using the time of flight instrument. 
HRMS is gaining popularity in the clinical and forensic toxicology fields, as 
evident by the increasing number of application papers published [150]. Typically, these 
applications utilize a full scan acquisition method in a systematic toxicological analysis. 
There are targeted acquisition methods published as well. The benefits of HRMS for the 
identification of NPS include the acquisition of full scan data even in targeted acquisition 
modes. The full scan data collection allows for spectral data to be collected from 
unknown or untargeted compounds. In addition, the spectral data can be retrospectively 
analyzed without processing a second aliquot of the sample, which can be useful when a 
new NPS is identified.  
HRMS was shown to perform better as a screening technique for the identification 
of synthetic cannabinoid substances than immunoassays specifically created for these 
compounds [151]. The flexibility of HRMS is also an advantage over traditional 
immunoassays. HRMS allows laboratories to create analytical methods that can detect 
newer NPS quicker than the time it takes to develop an immunoassay for the same 
compounds. It is expected that more laboratories will turn to HRMS as the cost of the 
instrumentation decreases.              
2.3.4.4 Collision Induced Dissociation 
Collision induced dissociation (CID) is a common dissociation (fragmentation) 
technique in tandem mass spectrometry. It is used to created product ions that can be used 
to help identify a compound in a specimen. Collision induced dissociation can occur in 
space or in time, depending on the mass analyzer used. For CID experiments in space, the 
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dissociation occurs in a collision cell which is positioned in between two mass analyzers, 
such as in a triple quadrupole or quadrupole-time of flight instrument. For CID in time, 
an ion trap is used to isolate a precursor ion before collision energy is applied.    
In both techniques, an inert gas such as nitrogen is present in the collision cell and a 
single or very few collisions occur between the precursor ion and the gas molecules in 
low energy experiments [152]. CID is typically described in two steps; the activation step 
which is created from the kinetic energy transfer of the collision and the dissociation step 
which occurs shortly after [153]. Products ions are formed after the dissociation step.   
The product ions formed by the dissociation step are used in various ways depending 
on the acquisition method of the mass spectrometer. If a targeted acquisition method is 
employed in the second mass analyzer only specific predetermined product ions are 
analyzed. This technique is commonly used in tandem mass spectrometers to measure 
known transitions. This allows for a more sensitive and specific method of identification 
of known compounds in forensic specimens. If a scan acquisition method is employed 
after the dissociation, then all product ions generated from the precursor ion can be 
observed and used for identification. This technique is used to generate MS/MS spectral 
data. 
2.3.4.5 Mass Spectral Libraries 
Mass spectral libraries aid in the identification of compounds in forensic toxicological 
Specimens, as they provide a spectral reference for known standards. Some extensive 
libraries that contain thousands of compounds have been created using both GC-MS and 
LC-MS instrumentation [154-155]. Many are commercially available, including a library 
produced at the National Institute of Standards and Technology (NIST).    
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In an attempt to ensure reproducible spectra across different instruments and 
manufacturers, standardized MS conditions have been employed. For example, spectral 
libraries generated by electron ionization utilize conditions that are standardized at 70 eV. 
Differences in LC-MS instrumentation has initially limited the generation of universal 
libraries. In-source fragmentation can vary greatly among different LC-MS 
manufacturers and techniques. However, it has been observed that when CID is 
employed, the spectral data are more reproducible than in-source fragmentation across 
manufacturers [156-157]. The reproducibility of MS/MS spectral data is credited to fewer 
experimental factors at play compared to in-source fragmentation techniques. The two 
factors that do need to be standardized in CID are the collision energy and the collision 
gas pressure [158]. 
While there have been extensive GC-MS and LC-MS libraries created and used, 
many do not contain a large representation of NPS. Consequently, there is a need to 
update or create new libraries to ensure that NPS spectral data are present. In addition, 
these libraries need to be able to be modified quickly and easily, as new NPS appear on 
the illicit drug market frequently.          
2.4 Regioisomers  
Among the various NPS classes, there are many compounds that are structurally 
related to each other and which include many isomeric compounds. Isomers are 
compounds that have the same molecular formula. Isomers are divided into two major 
groups that include constitutional isomers and stereoisomers. Stereoisomers differ in 
spatial orientation of their atoms, while constitutional isomers, also known as structural 
isomers, differ in the attachment of the various atoms that compose the molecule. 
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Regioisomers are a type of constitutional isomers in which a certain atom or substituent 
varies in the location of the molecule. Typically, these substitutions are observed around 
an aromatic ring or on an alkyl chain.    
Identification of regioisomeric compounds can be challenging for forensic toxicology 
laboratories, as such labs are often restricted in their choice of analytical methods because 
of the requirements of the various analytical techniques. For example, the sample purity 
and the sensitivity needed for an identification of a compound using NMR is not 
compatible with toxicological samples as these samples are complex with endogenous 
and exogenous compounds and typically have trace amounts of drugs present. Most 
toxicology laboratories use mass spectrometry as the analytical technique of choice as 
this provides the necessary sensitivity and selectivity needed for the proper identification 
of compounds. Unfortunately, regioisomeric compounds commonly produce very similar 
if not identical mass spectral data, which can complicate the identification of a specific 
compound. In order to unequivocally identify a specific regioisomer using mass 
spectrometry a separation technique, such as gas chromatography or liquid 
chromatography, is typically employed, where retention times are utilized as an 
additional parameter in specific compound identification. 
Previous work from Kusano et al. described the successfully differentiation of two 
sets of regioisomeric synthetic cannabinoids, JWH-122 and JWH-201. In this work, many 
of the regioisomers could be resolved using gas chromatography, with a few co-eluting 
regioisomers. In order to successfully distinguish the regioisomers from each other, 
MS/MS data along with the retention time were used [159]. Takeda et al. described the 
successful separation of regioisomeric synthetic cathinones using a naphthyethyl 
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analytical column in an LC-MS/MS application where spectral data were identical for all 
three regioisomers [160]. Differentiation of regioisomeric phenethylamines and synthetic 
cannabinoids by GC-MS/MS or LC-MS/MS has also been reported [161-164].     
2.5 Challenges in Identifying Novel Psychoactive Substances  
The identification of NPS in human matrices poses one of the biggest challenges 
facing forensic toxicology laboratories today. Identification of these compounds is 
complicated because of to the sheer number of different derivatives, many of which are 
structurally related. There are hundreds of NPS that have been observed and reported in 
literature, from drug seizures and toxicological cases, and on drug user forums. In 
addition, with the observed NPS structural skeletons, there remains the possibility of 
hundreds of additional derivatives as different substitutions on the skeletons can be made. 
Also, the possibility of novel or unique skeletons exist, as has been observed in the 
evolution of new synthetic cannabinoid and synthetic opioid NPS. For example, 
compounds with skeletons not previously observed were first detected in drugs such as 
MT-45 and AB-CHMINACA. 
Another major challenge is that NPS fall in and out of favor very quickly as a 
consequence of user reports, legality and availability. Multiple structural generations 
have been seen in the different NPS classes, specifically in the synthetic cannabinoid 
class [96]. As new NPS compounds enter the market, a need for new updated methods to 
ensure detection of these compounds in case samples is created.  
In attempting to keep up with the constantly changing drug targets, obtaining drug 
standards and validating new methods can be very time consuming and can deplete the 
resources of the forensic laboratory quickly. In addition, identification is sometimes 
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better with newer instrumentation such as LC-MS/MS, LC-TOF, or LC-ion traps because 
of the sensitivity and the spectral data collected by these instruments. Many of these 
compounds are structurally alike and spectral data may look nearly identical when 
analyzed by GC-MS, which is commonly used in forensic toxicology laboratories. 
Typically, LC-MS instrumentation is more expensive than GC-MS instrumentation, so 
cost may create another issue for forensic toxicology laboratories in their detection of 
NPS.   
While there has been an effort to profile the metabolism of some novel psychoactive 
substances with in vitro metabolism studies, there are many NPS with unknown 
metabolic pathways or major metabolites. The unknown metabolites may be a challenge 
for some forensic laboratories where only urine specimens are submitted for 
investigations, particularly for synthetic cannabinoids. Parent compounds from some 
NPS classes may not be detected in urine and thus the use of a compound may be missed. 
While parent compounds from other classes, such as synthetic opioids and synthetic 
cathinones, have been identified in urine specimens, synthetic cannabinoids are typically 
metabolized into multiple products before being excreted in the urine. In fact, some of the 
synthetic cannabinoids share common metabolites with other structurally related 
synthetic cannabinoids. The shared metabolites can prevent the unequivocal 
determination of the parent NPS used.  The lack of available metabolite standards from 
commercial sources may also hinder the confirmation of NPS use in toxicological case 
samples, as these standards are needed before identification can be reported in case 
samples.   
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 To further complicate identification of NPS in toxicological cases, use of such 
derivatives tends to be somewhat regionalized. Compounds that are found in seized 
material in Europe and Japan may not be found or not found as quickly in material that 
was seized in the United States. In addition, many of these compounds are brought into 
the United States via online purchases from China.  Determining which NPS to target in 
analytical methods can be difficult. Forensic toxicology laboratories should consult with 
local forensic laboratories who identify compounds in seized drug material. However, 
ideally an analytical method that is sensitive and non-targeted should be employed for the 
identification of these compounds for forensic toxicological analyses.  
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3. DEVELOPMENT OF A COMPOUND DATABASE AND HRMS SPECTRAL 
LIBRARY  
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3.1 Abstract 
 With the recent rise in popularity and use of novel psychoactive substances 
(NPS), there is a need within the forensic science community to be able to 
comprehensively screen for the many possible drugs in this class.  Traditional drug 
screening methods, such as immunoassays, are currently unable to detect many of the 
newer NPS.  To detect NPS for screening purposes, liquid chromatography (LC) coupled 
to high resolution mass spectrometry (HRMS) instrumentation has been suggested.  In 
the present project designed to explore the screening potential of HRMS for these drugs, 
an LC-QTOF-MS based high resolution MS/MS designer drug spectral library was 
created with the instrument operated in positive electrospray ionization mode.  The 
library contains data for 252 NPS from different classes including cathinones, 
piperazines, phenethylamines, tryptamines and synthetic cannabinoids.  High resolution 
MS/MS spectra were collected by flow injection analysis under standardized conditions 
at three different collision energies (10, 20, and 40 eV) for each compound.  In addition 
to the spectral library, a compound database was created to further enhance the screening 
potential of the LC-QTOF-MS.  This database contains chemical and structural 
information for 875 potential designer drug compounds and metabolites that can be used 
to help aid in the identification of unknowns in a full mass scan.  To demonstrate the 
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applicability of the HRMS library, 13 blind spiked serum samples and four authentic drug 
seizure case samples were analyzed by LC-QTOF-MS.  The HRMS library search 
successfully identified all compounds present in the blind samples except for three 
synthetic cannabinoid compounds.  In addition, results of the QTOF-based seized drug 
analyses were consistent with the official forensic laboratory results.  The combination of 
a high resolution MS/MS library, compound database, and accurate mass LC-QTOF-MS 
based analysis represents a useful tool for the identification of NPS in forensic screening 
applications.  
3.2 Introduction 
 Although the concept of emerging drugs of abuse (“designer drugs” or novel 
psychoactive substances; NPS) is not new, such compounds have experienced a 
resurgence in many parts of the world, as evidenced by the emergency scheduling of NPS 
by the United States Drug Enforcement Administration (DEA), European Union and 
other countries [1-3]. There have been different motivations for the creation of these 
designer drug entities.  Some were developed by the pharmaceutical industry in drug 
discovery programs but then diverted to illicit use, while others have been created for the 
sole purpose of recreational use.  Perceived advantages of using NPS include avoiding 
legal liability, an assumption that they are safe, and a relatively low cost compared to 
other abused street drugs [4-5].  In addition, NPS have been relatively easy to obtain; a 
simple online search will lead to multiple websites where designer drugs are for sale [6]. 
Many such drugs have chemical structural features in common with a scheduled drug of 
abuse, often representing just a slight modification of the original structure.  In any case, 
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these modified structures are expected (or assumed) to produce pharmacological effects 
by acting on the same receptors as with typical drugs of abuse.   
 Information on the pharmacological and toxicological effects of NPS are, for the 
most part, limited, with most data available from case reports where the actual drug used 
may not be confirmed and where polydrug use is often the norm [7-8]. The vast majority 
of these drugs are not tested extensively before being sold and used [9].  Recently, there 
have been efforts to assess NPS pharmacology with in silico and in vitro models [10-12]. 
However, due to the fact that there are new NPS compounds being introduced on a 
regular basis, it is difficult to keep up with the generation of relevant data.  The 
indiscriminate use of such untested compounds, some of which may have high potency, 
has led to reported cases of emergency hospitalization and/or death [8, 13-16].  
 Due to the increase in use and new federal and state legislation banning some 
NPS, it is important to be able to comprehensively screen for such compounds in clinical 
and forensic laboratories.  While the need to be able to screen for NPS is undisputed, 
there are limitations that must be overcome in order to develop successful screening 
approaches.  First, most labs do not have methods in place to detect more than a few NPS 
entities.  Traditional drug screening methods such as immunoassays do not detect the 
majority of NPS, and most compounds do not cross-react with the commercially 
available immunoassays that screen for traditional drugs of abuse [17-18].  While there 
are ongoing efforts to create immunoassays for the larger universe of NPS, this process is 
time consuming and very costly [19-20].  Another major issue is the constantly evolving 
chemical identities of these compounds due to the rapid replacement of emergency 
scheduled drugs with new entities designed to avoid legal implications of continued use 
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of those that are banned.  This trend makes it extremely difficult for forensic laboratories 
to keep up with screening and identification.   
 In order to overcome these issues, many labs have turned to mass spectrometric 
screening approaches for NPS.  The majority of such methods employ GC-MS or LC-
QqQ-MS instrumentation [21-23]. Recently, high resolution mass spectrometry (HRMS) 
has begun to gain popularity for the comprehensive screening of drugs, including drugs 
of abuse [24-26]. The HRMS screening approach offers a number of advantages, 
including high resolution and high mass accuracy, both of which increase the confidence 
of compound identification and selectivity of the method.  A molecular formula can be 
generated based on the accurate ion mass and isotopic peak pattern [27-28]. In particular, 
this approach would be expected to be effective in identifying the minor mass differences 
that are often present in NPS. 
 Standardized spectral libraries are critical to screening and identification of 
known and unknown compounds present in a sample [29]. While there are extensive 
libraries available for GC-MS spectral data, LC-MS and LC-MS/MS spectral data 
libraries are more limited [30-31]. In addition, these libraries typically have limited novel 
psychoactive substances. The present study reports the development of a comprehensive 
compound database for 875 unique chemical entities considered as possible designer 
drugs, in addition to a full HRMS spectral library for 252 of these compounds.  In order 
to test the preliminary applicability of these tools for unknown drug identification, 13 
blind spiked serum samples and four authentic seized drug samples were analyzed. 
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3.3 Materials and Methods: 
3.3.1 Chemicals and materials: 
 Drug standards were obtained from Cayman Chemical Co. (Ann Arbor, MI) and 
Cerilliant Corp. (Round Rock, TX) and were provided as neat weighed solids or as 
standards in solution.  Optima grade methanol (ThermoFisher Scientific, Waltham, MA) 
was used to prepare 1 mg/mL stock solutions from the neat standards.  For some 
compounds, dimethyl sulfoxide (ThermoFisher Scientific) was used due to solubility 
issues encountered with the use of methanol.  Standards provided in solution were used 
as received.  All standards were then diluted to a concentration of 10 μg/mL using 
methanol.  Finally, working solutions were created by diluting the 10 μg/mL standards to 
a concentration of 1 μg/mL with methanol.  Each standard was given an in-house 
identification number (i.e., FIU-nnnn) which aided in the traceability of the compounds 
throughout sample preparation and analysis.  Solvents used for liquid chromatography 
included acetonitrile (Optima LC/MS grade) and water (Optima LC/MS grade) from 
ThermoFisher Scientific.  Liquid chromatography additives used included formic acid 
(Optima LC/MS) and ammonium formate (99%) from ThermoFisher Scientific. Pooled 
human serum was purchased from BioreclamationIVT (Westbury, NY). Solid phase 
extraction cartridges (Bond Elut Plexa PCX 30 mg, 3 mL) were purchased from Agilent 
Technologies (Santa Clara, CA). 
3.3.2 Instrumentation and Software: 
 Analytical instrumentation included an Agilent 1290 Infinity UHPLC system 
coupled to an Agilent 6530 Accurate-Mass QTOF MS (Agilent Technologies, Santa 
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Clara, USA).  The QTOF-MS was operated in positive-ion electrospray mode with Jet 
Stream ESI Technology.  
 Agilent MassHunter LC/MS Acquisition software for the 6200 series TOF/6500 
series QTOF (Version B.05.00) and MassHunter Qualitative Analysis software (Version 
B.05.00) were used to acquire and process the data.  MassHunter Personal Computer 
Database Library (PCDL) Manager software (Version B.04.00, Build 92.0) was used to 
create the high resolution MS/MS spectral library and the compound database.  
ChemDraw Pro (Version 12.0.2.1076) was used to create and import the chemical 
structure of each NPS into the PCDL.  
3.3.3 Creation of the comprehensive compound database:  
 Chemical compounds to be included as potential NPS entities were identified 
from multiple publicly available sources, including peer reviewed literature research 
articles and reviews, government publications, commercial standard supplier 
documentation, and websites including online drug forums.  Once a potential NPS was 
identified, chemical and structural information were verified by attempting to find 
multiple corroborating sources for each drug.  After verification, the structure of each 
drug was recorded using the ChemDraw software.  The chemical structure was then 
imported into the database as a .mol file using the MassHunter PCDL Manager software.  
Using the chemical structure, a search was performed using SciFinder to identify 
chemical information such as CAS Registry Number and IUPAC name.  A similar search 
was done on ChemSpider to obtain a ChemSpider number.  For each NPS in the 
database, information such as compound name, chemical formula, monoisotopic mass, 
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chemical structure, and IUPAC name were added to the database, in addition to CAS 
registry number and ChemSpider number if available.               
3.3.4 Creation of the HRMS spectral library: 
 Flow injection analysis (FIA) was employed for acquisition of MS/MS data for all 
NPS standards.  The FIA method employed an injection volume of 1 μL with direct 
injection from the autosampler into the ion source.  The mobile phases consisted of 5 mM 
ammonium formate and 0.1% formic acid in water (A) and acetonitrile/water (90/10 v/v) 
with 1.0% formic acid (B), pumped at 0.4 mL/min of 50% B.  A positive mode 
electrospray ionization (ESI) targeted MS/MS method was used to collect the data.  The 
source parameters were: drying gas temperature 325 o C; drying gas flow 5 L/min; 
nebulizer 30 psi; sheath gas temperature 375o C; sheath gas flow 12 L/min.  Scan source 
parameters used included: VCap voltage 4000 V; nozzle voltage 0 V; fragmentor 140 V.  
The quadrupole used a narrow isolation mass window of 1.3 amu.    
 Three discrete collision cell energy levels were used in the CID; 10, 20, and 40 
eV.  The MS range was 50-1700 m/z.  The MS acquisition rate was 10 spectra/s while the 
MS/MS acquisition rate was 3 spectra/s.  In order for the spectral data to be added to the 
MS/MS spectral library, a compound had to produce a base peak of at least 1000 counts.  
If the NPS standard achieved this requirement, then the compound information and 
fragment ion spectrum from each collision energy was exported to a compound exchange 
format (.CEF) file and then imported into the PCDL using PCDL Manager software.  An 
arginine standard was run with each batch of standards as a QC check to make sure the 
instrument was properly tuned and calibrated.   
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3.3.5 Analysis of blind samples: 
 Thirteen blind samples were created by spiking up to five different NPS standards 
per sample into pooled blank human serum.  The final concentration of each drug was 
approximately 1 μg/mL. The spiked serum samples were subjected to solid phase 
extraction (SPE) utilizing a positive pressure manifold and polymeric mix mode 
extraction cartridges prior to instrumental analysis.  The SPE sample pretreatment 
consisted of adding 1 mL of a 2% aqueous formic acid solution to 0.5 mL of sample.  
One mL of methanol was added as a conditioning step prior to adding the pretreated 
sample to the extraction cartridges.  The wash step consisted of adding 1 mL of 2% 
aqueous formic acid followed by 1 mL of a 50:50 methanol: water solution.  The SPE 
cartridges were then dried down for 5-10 minutes with N2 at maximum pressure.  The 
elution step consisted of adding 1 mL of a 50:50:2 ethyl acetate:methanol:ammonium 
hydroxide solution.  The samples were acidified with 100 µL of 25 mM HCl.  The eluent 
was dried down under N2 at room temperature.  The samples were reconstituted with 100 
µL of HPLC grade water.  
 The reconstituted samples were then analyzed by LC-QTOF-MS under two 
different acquisition methods; a full scan MS method and an Auto MS/MS method.  Full 
scan MS method was more sensitive and generated better chromatographic peak shape 
when compared to Auto MS/MS due to the fact that, in full scan, the quadrupole did not 
isolate specific ions and therefore the duty cycle was faster.  While the Auto MS/MS 
method was less sensitive, it was needed to provide MS/MS data for compounds with 
abundances greater than the set acquisition threshold. These MS/MS data were used for 
subsequent library searches.  
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 The LC gradient used for both acquisition methods employed a flow rate of 0.4 
mL/min using an aqueous mobile phase (A) consisting of 5 mM ammonium formate plus 
0.1% formic acid in water and an organic mobile phase (B) consisting of 
acetonitrile/1.0% formic acid in water (90/10 v/v).  The gradient was as follows: a hold of 
20% B to 1 min, an increase to 70% B at 5 min, an increase to 100% B at 8.75 min, and a 
hold of 100% B until 13 min.  An additional post-run time of 3 min was used to allow for 
re-equilibration at 20% B.  The column used was an Agilent Zorbax Eclipse Plus C18 
Rapid Resolution HD (3.0 x 100 mm, 1.8 micron).  The column was maintained at a 
temperature of 40oC.  The injection volume was set to 20 μL.  
 Source parameters for the full scan method were: drying gas temperature 325 oC; 
drying gas flow 8 L/min; nebulizer 35 psi; sheath gas temperature 400 oC; sheath gas 
flow 12 L/min.  Scan source parameters used were: VCap voltage 3500 V; nozzle voltage 
0 V; fragmentor 125 V.  MS range was 100-1000 m/z and the acquisition rate was 1.5 
spectra/s.  The Auto MS/MS method used the same source and scan parameters.  In 
addition, the MS mass range was 100-1000 m/z with an MS acquisition rate of 3 
spectra/s, while the MS/MS mass range was 50-1000 m/z with an acquisition rate of 3 
spectra/s.  MS/MS fragmentation was performed at three collision cell energies of 10, 20, 
and 40 eV.  The quadrupole used a narrow isolation width of 1.3 amu.  Reference mass 
correction was enabled, using masses 121.0509 m/z and 922.0098 m/z. 
 Agilent MassHunter Qualitative software was used to perform library and 
database searches.  This process entailed using the “Find Compounds by Auto MS/MS”, 
the “Search Accurate Mass Library”, and the “Search Database” commands.  The “Find 
Compounds by Auto MS/MS” command created a list of potential compounds that met 
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the MS/MS acquisition threshold and MS/MS spectral data was collected.  The potential 
compound list was typically greater than 500 compounds per sample.  This compound list 
was then subjected to an accurate mass library search.  Both a forward search (matching 
peaks in the sample against the library) and reverse search (matching peaks in the library 
against the sample) were employed.  The parameters of this search included precursor ion 
expansion of ±10 ppm + 2 mDa and product ion expansion of ±20 ppm + 2 mDa.  The 
acceptable mass error window for the product ion is larger than expected when using 
HRMS.  However, this was used to account for the fact that the MS/MS library was not 
curated, therefore there may have been mass errors in the product ions at the time of 
spectral collection.  The library search parameters used set the minimum forward and 
reverse score to 70.   
 Compounds that were identified by the library search were then selected for a 
database search which compared the mass of a compound in the sample to the molecular 
formula in the database.  The mass tolerance was set to 10 ppm for the database search.  
Criteria for a positive identification were a “database” score of >70 and a library score of 
>80.  In addition, the mass error had to be <10 ppm and the extracted ion chromatogram 
was visual inspected to ensure the signal was not due to noise.   
3.3.6 Analysis of authentic seized drug case samples:  
 Methanol extracts of four different seized drug samples were obtained from the 
Miami-Dade Police Department Forensic Laboratory.  Two 10× dilutions of the methanol 
extract were made with water and were analyzed by LC-QTOF-MS by both MS full scan 
and Auto MS/MS acquisition methods.  The method parameters and data analysis 
procedures were the same as those previously described for the blind serum samples. 
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3.4 Results and Discussion:  
 There are numerous advantages in using high resolution, high mass accuracy MS 
for screening of clinical and forensic related samples, many of which have been discussed 
in the literature [27, 32-33].  Arguably, the biggest advantage of using high resolution 
LC-QTOF-MS instrumentation is that an analyst may potentially identify a compound in 
a sample based on the accurate mass and isotopic distribution with high confidence.  
Another major advantage is the extended dynamic range available in newer instruments, 
which allows for high mass accuracy at both low and high analyte concentrations and 
which facilitates screening of cases where the concentration of an analyte is unknown.  
Furthermore, the MS/MS capabilities of the QTOF allow for identification of a 
compound based on fragmentation patterns, which can be useful to distinguish among 
structural isomers, i.e., compounds have the same chemical formula and thus the same 
molecular ion.  
 Another advantage of using HRMS instrumentation such as LC-QTOF-MS in 
clinical and forensic laboratories is that the instrument acquires both high resolution full 
scan MS and MS/MS fragmentation data when a MS/MS acquisition method is selected.  
This approach allows the investigator to obtain more information about potential 
unknown compounds that were not subjected to MS/MS, either because they were not 
specifically targeted (i.e., when using a targeted MS/MS method) or when the abundance 
of the precursor ion did not meet the threshold required to trigger MS/MS (i.e., in auto 
MS/MS methods).  The supplemental full scan MS data are very beneficial for the 
analyst, as they allow a retrospective analysis of a sample to be done by simply 
reprocessing the data file with an alternate compound database.  This is a valuable tool in 
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the case of screening for NPS because as new drugs are created they can be identified in 
cases that were previously analyzed with an older database without the need of re-
extracting the sample. 
  To further realize the full potential of the LC-QTOF-MS as a screening tool, 
comprehensive high resolution MS/MS spectral libraries and compound databases are 
needed.  There has been considerable work by various groups directed towards the 
creation of HRMS libraries containing up to several thousand drugs and toxic compounds 
[30, 34].  Several recent published reports have used high resolution MS instrumentation 
for comprehensive screening of licit and illicit drugs [35-38].  For example, using QTOF-
MS and both negative and positive ESI, Broecker et al. generated an HRMS library for 
more than 2,500 drugs and other toxicologically relevant xenobiotics [30].  
Fragmentation profiles for each compound determined at three different CID energies 
were included.  The applicability of the method for screening purposes was evaluated 
with both spiked blood and urine and a set of authentic postmortem specimens.  Rosano 
et al. reported a validated comprehensive screening method for almost 1,000 drugs using 
UPLC coupled to QTOF-MS based on “MSE-TOF” analysis [35].  In this approach, CID 
energies were ramped from 10 to 40 eV to generate qualifier fragment ions specific to 
each drug entity.  The method was further validated by assessment of 300 postmortem 
specimens and comparison of results to those obtained by single- and triple-quadrupole 
LC-MS instrumentation.   
 The results of both of these reports confirm the value of HRMS as a screening 
tool in forensic toxicology.  However, previous work has primarily focused on typical 
drugs that are seen more routinely in clinical toxicology rather than on NPS.  A few 
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reports on the application of HRMS specifically for NPS analysis are available, primarily 
using LC-TOF-MS based methods which have only targeted a small number of drugs, 
typically from a single class of compounds [39-41]. In contrast, comprehensive HRMS 
based screening and confirmatory methods for NPS are not currently available.  
 The major goal of the present project was to create a HRMS spectral library for as 
many NPS standards from the synthetic stimulant, hallucinogen, and cannabinoid classes 
as were currently available (260 at the time of the study), using an LC-QTOF-MS based 
approach similar to that reported previously [30].  In addition to the spectral library, a 
linked “compound database” was created that contains relevant information for 875 
current and/or potential NPS entities.  For the purposes of the project, the compound 
database was constructed as a repository containing names, chemical formulae, 
structures, and neutral masses as minimal information for each drug entry.  Such a 
database was anticipated to be a useful stand-alone tool for identifying NPS in authentic 
samples following HRMS analysis, based on comparison of the high resolution spectrum 
of precursor ions with the accurate mass and isotopic ratio patterns of compounds in the 
database.  However, once MS/MS product ion spectra are added to the database, it is 
more accurately referred to as a “mass spectral library”.    
3.4.1 Compound database: 
 In order to include as many NPS as possible in the full compound database, 
extensive literature and on-line searches were performed.  Initially, government reports 
were reviewed to identify compounds of potential interest.  Literature reviews also 
produced relevant information and additional reports described the presence of designer 
drugs in authentic cases.  Product lists from commercial sources were also of value.  
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Online websites, such as those based on the books written by Dr. Alexander and Ann 
Shulgin (“PiHKAL” and “TiHKAL”) [42-43] were very useful for selecting compounds 
for inclusion in the database.  Online forums were also important for identifying new 
NPS entities being discussed by drug users, as were websites of companies selling 
“research chemicals”.  Although such sources are not peer reviewed and their reliability 
may be in question, it was important to include any compounds that may be emerging on 
the street market. 
 A total of 875 unique structural entities considered to be potential NPS 
compounds were identified and added to the compound database (see Appendix 1 for a 
complete listing).  Most of these compounds belong to the cannabinoid, cathinone, 
tryptamine, piperazine, and phenethylamine structural classes, although compounds from 
other classes were also represented.  Within the cannabinoid class, numerous structural 
subcategories were also identified.  For each drug entity, information such as street or 
common name, chemical formula, monoisotopic mass, chemical structure, and IUPAC 
name was added to the database.  Additional information, such as CAS registry numbers 
and ChemSpider numbers, was also added if available.  Figure 9 displays a representative 
screen shot of the compound database generated by the software (i.e., MassHunter PCDL 
Manager) with details for the compound 4-fluoroisocathinone shown.  As can be seen, in 
addition to the information described above, the entry for each compound also indicates 
whether HRMS spectral data were successfully acquired (i.e., “Num Spectra” column).  
The development of the compound database is an ongoing and dynamic process; as new 
drugs are created and reported for the purpose of circumventing existing legislation, they 
are added to the resource.        
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Figure 9. An image of the PCDL software that was utilized to generate the database and the MS/MS 
spectral library.  
3.4.2 Development of the high resolution MS/MS spectral library: 
 A total of 260 designer drug standards (selected from the 875 entities in the 
compound database) were commercially available for the creation of a high resolution 
MS/MS spectral library.  For this purpose, each standard was initially analyzed via flow 
injection by QTOF-MS.  A targeted method for each standard was created.  Source and 
acquisition parameters were chosen in order to be comparable to previously created 
libraries using similar instrumentation. Three predetermined collision cell energies (10, 
20, and 40 eV) were used to promote fragmentation of the target ions.  In order to qualify 
for inclusion in the MS/MS library, each designer drug standard had to produce a base 
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peak of at least 1000 counts, a requirement which ensured that background noise was 
minimized in the MS/MS spectral data.   
Structural details of all standards included in the database are shown in Appendix 
2, Appendix 3, and Appendix 4.  In addition, complete information on relative ion 
abundances of each ion at each of the three collision energies for all standards are shown 
A 
B 
C 
Figure 10. Images of the PDCL software showing the MS/MS spectral data of 4-
Fluoroisocathinone.   MS/MS spectral data is shown at various collision energy levels: A) 
10eV, B) 20 eV, and C) 40 eV.  
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in Appendix 5.  Based on the requirement for a 1000-count MS threshold, spectral data 
for 252 of the 260 available standards were added to the final library (Table 1).  All of the 
compounds that failed to produce the required base peak intensity were synthetic 
cannabinoids.  These included CP-47497, CP-47497 epimer, CP-47497 para-quinone 
analog, CP-47497 C8-homolog, CP-47497 C8-homolog 3-epimer, CP-55940, CP-55940 
5-epimer, and JZL-184.  Difficulties with directly analyzing cannabinoids from the CP 
class using positive ESI have been previously reported in the literature [44].  In an 
attempt to overcome this limitation, these analytes were analyzed by negative mode ESI.  
Five out of the eight compounds successfully met the 1000 count base peak requirement.  
The three compounds that did not meet this requirement in negative ESI-mode were CP-
47,497 para-quinone analog, (±) 3-epi-CP-47,497-C8-homolog, and JZL-184. 
Electrospray ionization may not be suitable and alternative ionization sources may be 
needed for analysis of these compounds.   
 
Table 1. The amount of NPS by structural class included in the Compound Database and MS/MS Spectral 
Library 
 Structural Class 
Number in 
Compound Database 
Number in 
Spectral Library 
Stimulants/Hallucinogens  
Arylcyclohexylamine 14 1 
Cathinone 131 56 
Indane 6 3 
Phenethylamine 274 25 
Piperazine 25 7 
Pyrrolidine 2 2 
Tryptamine 75 7 
Other 10 3 
Cannabinoids  
2-Naphthoylindole 14 14 
Adamantoylindole 4 2 
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Adamantylindazolecarboxamide 3 1 
Adamantylindolecarboxamide 2 2 
Benzimidazole 4 0 
Benzoylindole 18 12 
Cyclohexylphenol 11 0a 
Cyclopropanoylindazole 1 0 
Cyclopropanoylindole 18 2 
Indazole 33 0 
Indole 35 4 
Naphthoylindazole 2 0 
Naphthoylindole 122 69 
Naphthoylpyrrole 9 9 
Naphthylmethylindole 1 1 
Phenylacetylindole 18 13 
Pyrazole 1 0 
Other 42 19b 
 
Total 875 252 
 
aSeven cyclohexylphenol cannabinoid standards were analyzed (see text) but none reached the 1000-count 
threshold required for inclusion. 
bOne “other cannabinoid” standard in this group (JZL-184) did not reach the 1000-count threshold required 
for inclusion. 
 
3.4.3 Analysis of blind samples: 
 To test the applicability of the high resolution MS/MS spectral library for 
screening and identification, 13 blind human spiked serum samples were prepared and 
analyzed by the LC-QTOF-MS.  A gradient method using a C18 column was developed 
to provide separation of the various NPS.  Two acquisition methods were used; a full 
scan MS method and an Auto MS/MS method. The full scan method offers higher 
sensitivity and better TIC peak shape, since it does not collect MS/MS data.  In contrast, 
the Auto MS/MS method offers higher selectivity based on the MS/MS spectral library 
search of the product ions.  Potential compounds of interest were identified using the 
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Qualitative Analysis Software “Find Compounds by Auto MS/MS”, “Search Library”, 
and “Search Database” functions.  Initially, the Find Compounds by Auto MS/MS 
function identified over 500 compounds per sample.  This list of compounds was then 
subjected to a library search in which one to seven potential compounds were identified 
per sample.  The library search utilizes MS/MS spectral data to generate a match score.   
Forward and reverse library scores are provided based on how well the sample spectra 
matches the library spectra and vice versa.  The Search Database command was then used 
on the compounds identified by the library search.  Finally, a database score was 
generated based on how well the mass matches the formula in the database.   
 The library and database searches both successfully detected 32 compounds 
present in the blind spiked samples, with the library match score ranging from 80.43 to 
100 and the database match score ranging from 51.17 to 99.65 (Table 2).  Based on this 
identification technique, which used the “Find by Auto MS/MS” results, library scores, 
and the database score, there were a total of three false negative results, thus 
demonstrating a true positive rate of 91.4%.  The three false negatives came from the 
synthetic cannabinoid class of NPS, including CB-13, JWH-250, and AM 2233.  In 
addition, there were four false positives using this technique, including ethyl 
amphetamine in one sample and N,N-dimethylcathinone in three samples.  While further 
investigation is needed, these false positives may have been due to impurities in or 
degradation of the standard. 
 LC retention times, which can be added to the database and which are sometimes 
needed as an additional identification tool, were not utilized here, in order to demonstrate 
the practicality of this database/library for laboratories that do not have access to 
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standards for every compound of interest.  The combination of database and library 
match scores generated a very high true positive rate, which suggests that this technique 
could be useful in presumptively identifying a compound without a drug standard.  In 
contrast, the “Find by Formula” score, which is a popular identification technique using 
this software, when used alone generated a low true positive rate, suggesting that while it 
can be useful in preliminary screening for compounds, there should be more caution with 
presumptively identifying a compound by this approach.      
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Table 2.  Compounds identified in the blind spiked serum samples. Library and database scores are shown as a percentage. Detection of compounds 
utilizing a 1,000 and a 10,000 peak area filter are designated “+” for positively identifying the compound and “-” for not identifying a compound.    
          
Drug(s) Library Score 
Database 
Score 
Detected 
at 1000 
TIC 
Detected 
at 10000 
TIC 
 Drug(s) Library Score 
Database 
Score 
Detected 
at 1000 
TIC 
Detected 
at 10000 
TIC 
Sample 1 AM-1220 99.96 88.82 + + 
Sample 8 
3,4-Dimethylmethcathinone 99.81 99.31 + + 
AKB48 96.20 94.45 + - 
Sample 2 
methylone 98.23 90.37 + + AM2233 - - - - 
2C-D 98.75 90.21 + + JWH 200 98.82 85.63 + + 
CB-13 - - - - RCS-4 99.67 96.29 + + 
Sample 3 
MDPV 95.38 90.88 + + 
Sample 9 
AM694 99.77 98.22 + + 
AM2201 100 95.11 + + JWH 203 99.18 88.57 + + 
JWH 081 99.12 88.03 + + JWH 398 100 95.11 + - 
RCS-8 99.35 74.94 + + Cannabipiperidiethanone 99.49 97.98 + + 
Sample 4 None - - - - Pentylone 96.40 81.39 + + 
Sample 5 
2C-I 97.18 77.69 + + Sample 10 4-MMC 99.50 93.16 + + 
2C-T-2 98.73 94.31 + + 
Sample 11 
JWH 018 100 78.17 + + 
2C-H 98.13 80.84 + + Methoxetamine 94.23 86.39 + + 
JWH 250 - - - - 
Sample 12 
2C-E 98.53 82.38 + + 
Sample 6 
2C-T-4 96.41 96.32 + + 2C-N 81.29 79.65 + + 
2C-C 99.43 94.9 + + 2C-P 96.64 79.77 + + 
Sample 7 
JWH 018 
adamantyl 
carboxamide 
99.78 99.19 + + JWH 073 99.34 51.17 + - 
JWH 019 98.92 98.99 + + JWH 122 99.55 60.04 + + 
JWH 022 97.45 99.65 + + Sample 13 None - - - - 
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3.4.4 Analysis of case samples: 
 To demonstrate the applicability of the high resolution MS/MS spectral library 
and compound database to identification of authentic case materials, four seized drug 
samples were obtained from the Miami-Dade Police Department.  The samples were 
provided as methanol extracts, with no information regarding the identity or 
concentration of the drugs present.  Similar to the blind serum samples described above, 
the case samples were analyzed by LC-QTOF-MS using two methods; a full scan MS 
method and an Auto MS/MS method.  For these samples, the full scan MS method was 
used to determine the retention time of candidate unknown compounds in the methanol 
extract, while the Auto MS/MS method was used to identify such compounds based on a 
spectral library search.  For the latter, analysis was done with the Qualitative Analysis 
Software using the “Find Compounds by Formula” and “Search by Accurate Mass” 
algorithms. 
 Similar to the serum sample study, this process generated multiple hits for 
potential compounds in the sample based on molecular formulas provided in the 
database.  A library search was then performed on the identified compounds, a process 
which generated two high quality matches based on accurate mass data, isotopic 
distribution, and MS/MS fragmentation patterns (Figure 11).  The matches for all four 
samples included methylone and 2,3-methylenedioxymethcathinone (2,3-MDMC), which 
are structural isomers with the molecular formula C11H13NO3.  The correct identity was 
ultimately made by including LC retention time in the analysis, as shown by the TIC data 
of standards and case samples (Figure 12).  The high MS spectral matches for both 
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A B C 
Figure 11.  MS/MS spectral data of the case sample (column A), the methylone standard (column B), and the 2,3-MDMC standard (column C) at 
various collision energies (10, 20, and 40 eV).  
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compounds in this case sample illustrate the importance of LC separation for the 
identification of isomeric designer drugs when using LC-QTOF-MS as a screening 
method.  Without separation, methylone and 2,3-MDMC would have been difficult to 
differentiate based on MS/MS spectral data alone.  As a result of these analyses, it was 
confirmed that all four case samples contained methylone, a finding that was consistent 
with the official laboratory findings. 
 
Figure 12. Overlaid extracted ion chromatograms of the 208.0968 m/z ion for Cases A- D, the 
methylone standard, and the 2,3-MDMC standard. 
3.5 Conclusions: 
A compound database containing information for 875 NPS was created in order to help 
confirm the presence of such drugs in forensic related samples.  This database includes 
information such as chemical formula, chemical structure, IUPAC name, 
CAS/Chemspider numbers, and monoisotopic mass for each compound.  A high 
resolution MS/MS library was also created that contains spectra for 252 compounds from 
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multiple NPS classes, with the greatest number coming from the synthetic cannabinoid 
and cathinone classes.  Three collision energies (10, 20, and 40 eV) were used for each 
designer drug standard in order to obtain more information about fragmentation patterns 
and also to aid in differentiating structurally similar designer drug compounds.  
Standardized LC retention time data were also added to the library to further facilitate 
compound identification. 
Blind spiked serum specimens, each containing between zero and five NPS, were 
analyzed by the LC-QTOF-MS method, with successful identification of 32 out of 35 
spiked compounds with very high true positive and true negative rates. In addition to the 
spiked specimens, four drug seizure case samples were analyzed to demonstrate the 
practical application of the high resolution MS/MS spectral library.  Analysis of these 
samples and comparison to the library produced high match scores for the structural 
isomers methylone and 2,3-MDMC.  By using a gradient LC separation prior to MS 
analysis, the true match (i.e., methylone) was confirmed. Proving that this library and 
database can be used to help aid in the identification of novel psychoactive substances in 
forensic specimens.  
There are many potential advantages of using the high mass accuracy and 
resolution of LC-QTOF-MS for screening of NPS entities, including identification of 
compounds with high confidence.  MS/MS capabilities provide additional confidence 
when identifying compounds in a forensic sample.  Further work is underway to 
determine the limit of detection, matrix effects, and other formal validation parameters in 
order to evaluate this technique for practical routine forensic toxicological screening of 
NPS. 
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4. COLLISION INDUCED DISSOCIATION STUDIES  
4.1 Abstract: 
 Identification of novel psychoactive substances (NPS) is complicated by the fact that 
many such compounds are closely related structurally. There are many structural isomers 
and regioisomers among the various NPS classes that make it challenging to confirm 
their presence in seized materials or toxicological specimens. Previous literature has 
suggested that utilizing mass spectrometric methods that employ soft ionization followed 
by ion dissociation to produce characteristic fragments may be a useful approach to 
differentiate such regioisomers. Earlier work in this laboratory to develop a high 
resolution MS/MS spectral library for hundreds of NPS entities indicated that some sets 
of regioisomers had identical product ions but with different relative abundances.  The 
objective of the present study was to evaluate the relative ion abundances of 15 sets of 
regioisomers from several NPS classes, with the goal of determining if relative 
abundance trends of MS/MS spectral data could reliably differentiate such regioisomers.  
Parameters examined included reproducibility, the effects of relative concentration, and 
the use of different mobile phases for all 15 sets of regioisomers.  Results demonstrated 
that every set of regioisomers examined had at least one unique or semi-unique ion that 
could be used to aid in differentiating one or more regioisomers from the other members 
of the group.  In addition, the applicability of the approach to improve NPS regioisomer 
differentiation was further tested by spiking several sets of compounds into blank human 
serum, followed by solid phase extraction and LC-MS/MS analysis.   These findings 
indicate that MS/MS data alone can be used to distinguish some sets of NPS 
regioisomers, without the need for complex separation or analysis approaches.  
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4.2 Introduction: 
 Recently there has been an increase in the popularity and use of novel psychoactive 
substances (NPS) among drug users [2, 5].  Typically, these substances are available 
online as “research chemicals” or as “legal highs” [4].  They are generally classified by 
their chemical structure and/or their pharmacodynamic effect [165].  Some of the NPS 
classes include, but are not limited to, cathinones, phenethylamines, synthetic 
cannabinoids and tryptamines [2]. As these compounds are psychoactive, there is a need 
for forensic scientists to be able to identify and confirm these substances in routine 
casework, as questions of impairment or cause of death often surround these cases. 
 Identifying and confirming NPS in human matrices has proven to be challenging for a 
number of reasons.  One problem is that NPS often have low cross reactivity in 
traditional screening assays such as the immunoassay panels that are routinely used in 
forensic toxicology laboratories [131].  Another challenge is the ever-changing structural 
nature of such compounds, which necessitates that analytical methodology be routinely 
expanded or updated to include these new compounds.  As governments learn of a new 
NPS and enact legislation making the possession or distribution of such compounds 
illegal, new replacement substances rapidly appear.  For example, the cathinone 
methylone was very popular in the United States until it was scheduled by the U.S Drug 
Enforcement Administration (DEA) and the Chinese government enacted legislation 
which helped deter production of methylone. After these governmental actions, ethylone 
started to appear in forensic cases, later followed by the emergence of α-PVP and other 
derivatives as replacements.  As an example of this phenomenon, the number of α-PVP 
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positive cases in Miami, FL has dropped over the past two years, only to be replaced by 
N-ethyl pentylone in human performance cases.     
   Unequivocal identification of NPS in casework is further complicated by the fact 
that, among the various NPS classes, there are many substances that are structurally 
related, including isobars, structural isomers, and regioisomers [166-167]. Previous 
literature has reported the use of a variety of analytical techniques in attempts to 
distinguish regioisomers in both forensic drug chemistry and toxicology applications.  
Instrumentation and techniques utilized to identify isomeric NPS include gas 
chromatography-infrared detection (GC-IRD), gas chromatography mass spectrometry 
(GC-MS), gas chromatography tandem mass spectrometry (GC-MS/MS), liquid 
chromatography mass spectrometry (LC-MS), liquid chromatography photodiode array 
(LC-PDA), liquid chromatography tandem mass spectrometry (LC-MS/MS), and Raman 
spectroscopy [122, 163, 168-171].  
 Previous work in this laboratory on the development of a comprehensive, high 
resolution MS/MS spectral library for NPS that included many regioisomers revealed that 
that some regioisomers produced identical product ions but with different relative 
abundances.  The present study evaluates the usability of such relative abundance trends 
for distinguishing regioisomers of NPS.  It was hypothesized that if such relative 
abundance trends are reproducible, MS/MS spectral data of NPS regioisomers alone may 
be sufficient to distinguish them from each other.  This could be useful in cases where 
NPS regioisomers cannot be fully resolved using chromatographic techniques or in 
applications where a separation step is not employed, such as in DART or DESI-MS 
approaches.   
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4.3 Materials and Methods: 
4.3.1 Chemicals and reagents: 
 Drugs standards were obtained from Cayman Chemical Company (Ann Arbor, MI, 
USA).  Acetonitrile, ammonium formate, formic acid, methanol, and water were obtained 
from Thermo Fisher Scientific (Waltham, MA, USA).  Liquid chromatography solvents 
and additives were purchased at the HPLC grade or higher. Negative whole blood was 
collected from a willing volunteer and contained sodium fluoride and potassium oxalate 
as a preservative.    
4.3.2 Instrumentation and Software: 
 Analytical instrumentation included an Agilent 1290 Infinity UHPLC system coupled 
to an Agilent 6530 Accurate-Mass QTOF MS (Agilent Technologies, Santa Clara, USA).  
The QTOF-MS was operated in positive-ion electrospray mode with Jet Stream ESI 
Technology.    
 Agilent MassHunter LC/MS Acquisition software for the 6200 series TOF/6500 
series QTOF (Version B.05.00) and MassHunter Qualitative Analysis software (Version 
B.05.00) were used to acquire and process the data.  MassHunter Personal Computer 
Database Library (PCDL) Manager software (Version B.04.00, Build 92.0) was used to 
create the high resolution MS/MS spectral library and the compound database.  
4.3.3 Selection of NPS Isomers:  
 The approach for the selection of compounds for this study initially involved 
identifying regioisomeric NPS among the several hundred standards available in the 
laboratory.  These were then grouped based on the shared chemical structure skeleton, 
and the sets then named based on the compound name without inclusion of the positional 
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substitution (e.g., JWH 203; fluoroamphetamine).  The substitution patterns of the NPS 
compounds from the cathinone, phenethylamine, and synthetic cannabinoid classes 
consisted of modifications on the benzoyl or benzyl moieties, while substitution of the 
tryptamine class consisted of modifications on the indole moiety.  Of the 15 selected 
regioisomers sets, 11 included three regioisomeric compounds in each set, while four had 
two regioisomeric compounds in the set. The chemical structures of the regioisomers 
selected for this study are displayed in Figure 13.   
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Fluoromethcathinone Regioisomers 
F
O H
N
O H
N
O H
NF
F
2-FMC 3-FMC 4-FMC  
RCS-4 Regioisomers 
N
O
N
O
N O
O
O
O
RCS-4 RCS-4 2-Methoxy RCS-4 3-Methoxy  
JWH 203 Regioisomers 
N
O
Cl
N
O
N
O
Cl Cl
JWH 203 JWH 203 3-Chlorophenyl JWH 203 4-Chlorophenyl  
RCS-8 Regioisomers 
N
O
N
O
N
O O
O
O
RCS-8 4-MethoxyRCS-8 3-MethoxyRCS-8  
JWH 251 Regioisomers 
O
N
O
N
O
N
JWH 251 JWH 251 3-Methylphenyl JWH 251 4-Methylphenyl  
 
Figure 13. The chemical structures of each of the NPS selected for this study. Regioisomers were 
grouped and evaluated to determine if MS/MS data alone could be used to distinguish these 
compounds from each other.    
 
4.3.4 Collision Induced Dissociation Studies: 
Commercially available drug standards were each diluted to a concentration of 1,000 
ng/mL in HPLC grade methanol.  Each diluted standard was injected five times per day 
on three different days.  The method employed an isocratic flow injection analysis (FIA) 
that used the targeted MS/MS acquisition mode.  Mobile phase A consisted of 5 mM 
ammonium formate with 0.1% formic acid in HPLC grade water.  Mobile phase B 
consisted of 90:10 acetonitrile: water with 0.1% formic acid.  The percentage of mobile 
phase B used in the method was 50%. Injection volume was set to 1 µL.  The source 
parameters were: Gas Temp: 325°C, Gas Flow 5 L/min, Nebulizer 30 psig, Sheath Gas 
Temp 375°C, Sheath Gas Flow 12 L/min, VCap 4000 V, Nozzle Voltage 0 V, 
Fragmentor 140 V, Skimmer 65 V.  MS/MS Range was 50 - 1700 m/z. The MS scan rate 
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was 10 spectra/s and the MS/MS scan rate was 3 spectra/s.  MS/MS was performed at 
three different collision energies; 10, 20 and 40 eV.  The isolation width was set at 
narrow (1.3 amu).  Each analyte had its own method which varied only by the mass that 
was being targeted.  
  The “Find Compounds by Targeted MS/MS” algorithm was used to extract the 
MS/MS data.  Any product ion that produced a relative abundance greater than 15% for 
any set of regioisomers was noted and evaluated to determine the reproducibility of that 
product ion’s relative abundance. 
 The purpose of this experiment was to identify product ions that had relative 
abundances that were able to distinguish at least one regioisomers from another and to 
determine the reproducibility of the relative abundance of these product ions over the 
course of multiple injections over multiple days. It is important to establish that the 
relative abundances of the product ions are reproducible before evaluating additional 
variables such as concentration, mobile phase composition and solid phase. The product 
ions that were determined to be significantly different and did not have overlapping 
relative abundance ranges were selected and evaluated in further experiments described 
below.         
4.3.5 CID Concentration Dependence: 
 Drug standards were diluted to final concentrations of 100 ng/mL and 4,000 ng/mL in 
methanol.  Both concentration levels of each drug standard were injected five times on 
three different days.  The same targeted acquisition, data analysis and statistical analysis 
methods that were used in the first experiment were used in this experiment as well.  The 
68 
 
only difference was that product ions that were identified as significantly different 
between regioisomers in first experiment were analyzed in this follow up experiment.  
 The purpose of this experiment was to ensure that varying concentrations would not 
affect the relative abundance of the selected product ions. Concentrations selected for this 
experiment represented the concentration in the LC vial of an extracted sample with a 
low blood concentration and a high blood concentration after a solid phase extraction 
method. In routine casework, drug concentrations vary among samples so it is necessary 
to ensure that relative abundance remains consistent with different concentrations of a 
targeted regioisomer.    
4.3.6 CID Mobile Phase Dependence: 
 Drug standards were diluted to a final concentration of 1,000 ng/mL and injected 
under four different mobile phase compositions which included: 1) 5 mM ammonium 
formate in HPLC grade water with 0.1% formic acid, 2) HPLC grade water with 0.1% 
formic acid, 3) acetonitrile with 0.1% formic acid, and 4) methanol with 0.1% formic 
acid.  Product ions identified in the first experiment as ions of interest were analyzed and 
compared to determine if the mobile phase affected the relative abundance results of the 
individual regioisomers.  
 It has been documented that relative abundances of product ions may vary when 
analyzed in different mobile phase compositions. In order to determine if there were any 
differences in the relative abundances, four different mobile phase compositions were 
selected. Two aqueous and two organic mobile phase compositions. This experiment 
utilized 100% organic or aqueous compositions to replicate the extremes of a LC gradient 
where in some methods the mobile phase composition is either 100 % aqueous or 100% 
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organic. The initial reproducibility experiment was performed with a 50:50 aqueous: 
organic mobile phase.  If relative abundance differences were observed when compared 
to the original reproducibility experiment they were noted.  
4.3.7 Solid Phase Extraction Study: 
 Four sets of regioisomers were selected and split among three drug mixes. Each drug 
mix contained only one regioisomer from each set of regioisomers. These drug mixes 
were used to spike negative whole blood specimens to a final concentration of 100 ng/mL 
for each regioisomer. 
 The spiked blood samples were then treated with 1 mL of cold acetonitrile before 
being centrifuged at 3500 rpm at -10ºC for 10 min.  The supernatant was transferred to a 
test tube and 2 mL of 0.1 M ammonium acetate buffer (pH 4.8) was added and the 
sample was vortexed.  Solid phase extraction (SPE) cartridges (Agilent Bond Elut Plexa) 
were conditioned by adding 1 mL of methanol followed by addition of 1 mL of 
ammonium acetate buffer.  The samples were then added to the conditioned SPE 
cartridges.  Then, 3 mL of the ammonium acetate buffer was used for the first wash step.  
The second wash step employed (50:50) deionized water: methanol.  Maximum pressure 
(25 psi) was applied to the SPE cartridges for five min.  Two 1 mL aliquots of elution 
solvent, consisting of acetonitrile with 2% ammonium hydroxide, were added.  The 
eluents were collected in the same tube and dried under N2 at 35ºC.  The sample was 
reconstituted with 100 µL of mobile phase.  Ions of interest, determined from the 
previous experiments, were analyzed to determine if there was an effect on the relative 
abundances due to the solid phase extraction method. 
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 The purpose of this experiment was to determine if the relative abundance averages 
and patterns of product ions of regioisomers were consistent after processing a sample 
using a solid phase extraction method. This experiment simulated a commonly used 
extraction technique for blood specimens in forensic toxicology laboratories. This 
experiment tests the applicability of using the relative abundance to differentiate 
regioisomers in blood specimens.    
4.3.8 Data Analyses:   
 Initially, MS/MS spectral data was evaluated for every regioisomeric NPS that was 
selected for this study.  The purpose of this evaluation was to identify product ions that 
had a relative abundance greater than 15% for at least one compound in the set of 
regioisomers.  The mean, range, and standard deviation of the relative abundance were 
determined for each product ion of interest.  In addition, statistical analyses were 
performed utilizing ANOVA and t-tests to determine if there were significant differences 
between the average relative abundances of the product ions among the different 
regioisomers in the specific set.  
 In regioisomeric sets that contained three compounds, an ANOVA analysis was first 
performed.  If the result of this analysis suggested that there was a significant difference 
between the average of the relative abundances, then three separate t-tests were 
performed to determine where the significant difference was in the set of regioisomers.  
The Bonferroni correction was used in order to reduce the likelihood of generating a type 
I error when performing multiple t-tests.  In addition to establishing whether the averages 
of the relative abundances were significantly different, the ranges of the relative 
abundance were also evaluated to see if there was any overlap among regioisomeric 
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compounds.  If such overlap was present among a set of regioisomers, it would make it 
difficult to distinguish the regioisomers from each other based on relative abundance 
alone.  
 For regioisomeric sets that only contained two compounds, the t-test was performed 
to determine if the average of the relative abundance was significantly different when 
compared to the other regioisomer in that set.  In addition, the ranges of the relative 
abundance were evaluated to determine if there was any overlap between the two 
regioisomers.             
 In order to determine whether or not the relative abundance could be used to 
differentiate regioisomers form each other, the designations “unique ion” and “semi-
unique ion” were used in this study.  The “unique ion” designation referred to a product 
ion that could be used to differentiate all of the regioisomeric compounds from each other 
in a certain set of regioisomers, based on the relative abundance of that ion.  This meant 
that the average of the relative abundance of the product ion was significantly different 
and the range of the relative abundance did not overlap with any of the other 
regioisomeric compounds in that set.  The designation “semi-unique” referred to a 
product ion that could be used to distinguish one regioisomer from another regioisomer 
but not to distinguish all of the regioisomers from each other.  The same criteria as for the 
“unique ion” designation, which included the average of the relative abundance being 
significantly different and the range of the relative abundance not overlapping when 
comparing another regioisomer in the set, were employed for “semi-unique” ions.  
However, the semi-unique ion designation did not satisfy the criteria for every 
72 
 
regioisomer in the set, and thus could only be used to distinguish one regioisomer from 
another.      
4.4 Results: 
4.4.1 Differentiation of Regioisomers:  
 There was at least one unique or semi-unique ion that could be used to help 
distinguish a specific regioisomer from another based on the relative abundance alone in 
every set of regioisomers evaluated.  The number of both unique ions and semi-unique 
ions identified per set of regioisomers ranged from 0 to 7.  Figure 14 provides an example 
of the JWH 203 set of regioisomers. Unique and semi-unique ions are designated on the 
MS/MS spectra. The sets of regioisomers and the number of unique and semi-unique ions 
for each regioisomer set are listed in Table 3.  Specific data for each regioisomer set are 
described below. 
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Figure 14. The MS/MS of the JWH 203 regioisomers at various collision energies. Unique ions are designated with a “U” and semi-unique 
ions are designated with a “S”. 
74 
 
Table 3.  Ions Present in MS/MS spectral data with a relative abundance greater than 15% for at least one regioisomer. The ions that are bolded 
and underlined represent unique ions which can be used to distinguish all of theother regioisomers from each other in the set. The ions that are 
bolded and have an asterisk represent semi-unique ions which can be used to distinguish one regioisomer from another regioisomer but cannot be 
used to differentiate all of the regioisomers in the set.      
Group Compounds CE Ions 
AM 694  
AM694                                                      
AM694 -3 iodo isomer                                                 
AM 694 4-iodo isomer  
10 436.0568 
20  230.9301, 309.1523, 436.0568 
40  202.9352*, 230.9301  
Ethylethcathinone   
2-Ethylethcathinone                                         
3-Ethylethcathinone                                     
4-Ethylethcathinone  
10 159.1043, 160.1121, 188.1434, 206.1539*  
20 132.0808, 144.0808, 159.1043, 160.1121, 188.1434*   
40 105.0699, 130.0651, 144.0808 
Fluoroamphetamine  
2-Fluoroamphetamine                              
3-Fluoroamphetamine                               
4-Fluoroamphetamine 
10 109.0448, 137.0761* 
20 109.0448 
40 83.0292, 109.0448  
Fluoroethcathinone  
2-Fluoroethcathinone                             
3-Fluoroethcathinone                                 
4-Fluoroethcathinone  
10  150.0714*, 178.1027, 196.1132* 
20 103.0554, 123.0605*, 135.0479, 148.0557, 149.0635*, 150.0714, 163.0792*, 178.1027* 
40 77.0386*, 95.0292, 103.0554, 108.0370, 109.0448, 115.0554*, 135.0479*, 148.057  
Fluoromethamphetamine  
2-Fluoromethamphetamine                  
3-Fluoromethamphetamine                      
4-Fluoromethamphetamine 
10 109.0448, 137.0761*, 168.1183* 
20 109.0448 
40 83.0292, 109.0448 
Fluoromethcathinone  
 2-Fluoromethcathinone                          
3-Fluoromethcathinone                              
4-Fluoromethcathinone 
10 149.0635, 164.0870, 182.0976* 
20 123.0605, 148.0557,149.0635, 164.0870 
40  77.0386, 103.0542, 148.0557, 149.0635 
JWH 203  
JWH 203                                                    
JWH 203 3-chlorophenyl  
JWH 203 4-chlorophenyl  
10 340.1463 
20  125.0153, 188.1434*, 214.1226, 340.1463 
40 125.0153, 144.0444, 214.1226 
JWH 251  
JWH 251                                                    
JWH-251 3-methylphenyl                 
JWH-251 4-methylphenyl  
10 320.2009 
20  105.0699, 188.1434*, 214.1226*, 320.2009* 
40 43.0542, 105.0699, 144.0444*, 214.1226* 
Methoxymethcathinone  
2- methoxymethcathinone                   
3-methoxymethcathinone 
Methedrone  
10 161.0835*, 176.1070, 194.1176* 
20 135.0804, 145.0886, 146.0600, 161.0835, 176.1070 
40 58.0651, 77.0386, 79.0542, 91.0542, 103.0542, 105.0699, 117.0573, 118.0651, 132.0808, 
144.0808, 146.0600*, 160.0757* 
Methoxy-N,N-dimethyltryptamine  4-methoxy DMT                                          5-methoxy-DMT  
10 58.0651,174.0913, 219.1492 
20 58.0651, 159.0679, 174.0913 
40 58.0651, 130.0651, 131.0730, 143.0730, 159.0679 
Methylenedioxymethcathinone   2,3-MDMC                                          Methylone 
10 58.0651, 160.0757, 190.0863, 208.0968 
20 132.0808, 160.0747  
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40 58.0651, 65.0386, 91.0542, 117.0573, 131.0730, 132.0808    
Methylenedioxy Pyrovalerone    2,3-MDPV                                                     MDPV 
10 276.1594 
20 126.1277, 135.0441, 147.0804, 149.0233, 175.0754, 205.0858, 276.1594 
40 65.0386, 84.0808, 121.0284, 126.1277, 135.0441, 149.0233, 175.0754 
Methylethcathinone  3-Methylethcathinone                            4-Methylethcathinone 
10  145.0886, 146.0964,174.1277, 192.1383  
20 119.0855, 131.0730, 144.0808, 145.0886, 146.0964, 159.1043, 174.1277 
40  77.0386, 91.0542, 115.0542, 130.0651, 131.0730,144.0808 
RCS-4  
RCS 4                                                                    
RCS-4 2-methoxy isomer                   
RCS-4 3-methoxy isomer  
10 135.0441, 322.1802 
20 135.0441, 322.1802 
40  77.0386*, 92.0257, 107.0491,135.0441*, 144.0444 
RCS-8  
RCS-8                                                             
RCS-8 3-methoxy isomer                   
RCS-8 4-methoxy isomer  
10 376.2271 
20 121.0648, 228.1747, 254.1539, 376.2271 
40 69.0699, 91.0542, 93.0699, 121.0648, 135.0441, 144.0808*, 254.1539 
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4.4.1.1 AM694 regioisomer set:  
AM694 ((1-(5-fluoropentyl)-1H-indol-3-yl)(2-iodophenyl)methanone), AM694 3-
iodo isomer ((1-(5-fluoropentyl)-1H-indol-3-yl)(3-iodophenyl)methanone) and AM 694 
4-iodo isomer ((1-(5-fluoropentyl)-1H-indol-3-yl)(3-iodophenyl)methanone) differ based 
only on the substitution of an iodine atom on the benzoyl group.  Three ions of interest 
were identified in this set of regioisomers; 202.9352 m/z (C6H4I+) at 40 eV, 230.9301 m/z 
(C7H4IO+) at 20 eV, and 436.0568 m/z (C20H20FINO+) at 20 eV. 
 
Figure 15. The relative abundance of the ions of interest for the AM 694 set of regioisomers. Error 
bars represent standard error (SE). 
Reproducibility experiments demonstrated that the 202.9352 m/z at 40 eV ion 
could be used to distinguish the 3-iodo isomer from both AM 694 (i.e., the 2-iodo isomer) 
and the 4-iodo isomers but not AM 694 and the 4-iodo isomer from each other.  The m/z 
436.0568 at 20 eV ion could distinguish AM 694 from both the 3- and 4-iodo isomers. 
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The m/z 436.0568 at 20 eV ion was not reliable as a distinguishing ion in the 
concentration experiment, as the relative abundance ranges overlapped between the 
regioisomers in both high and low concentrations.  For this set of regioisomers, it was 
determined that there was one semi-unique ion that could be used to distinguish one 
regioisomer from the other.  
4.4.1.2 Ethylethcathinone regioisomer set:  
Three regioisomers, 2-ethylethcathinone (2-EEC; 2-(ethylamino)-1-(2-
ethylphenyl)propan-1-one), 3-ethylethcathinone (3-EEC; 2-(ethylamino)-1-(3-
ethylphenyl)propan-1-one) and 4-ethylethcathinone (4-EEC; 2-(ethylamino)-1-(4-
ethylphenyl)propan-1-one), differ from each other based on the substitution of an ethyl 
group on the benzoyl group.  Two ions of interest were identified; 188.1434 m/z 
(C13H18N+) at 20 eV, and 206.1539 m/z (C13H20NO+) at 10 eV.  
 
Figure 16. The relative abundance of the ions of interest for the ethylethcathinone set of 
regioisomers. Error bars represent SE. 
The reproducibility experiment demonstrated that the 206.1539 m/z at 10 eV ion 
could differentiate 3-EEC from 4-EEC.  The 188.1434 m/z at 20 eV ion could distinguish 
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2-EEC from 4-EEC.  The relative abundance trends in the concentration. For this set of 
regioisomers, it was determined that there were two semi-unique ions that can be used to 
distinguish one regioisomer from the other two.  
4.4.1.3 Fluoroamphetamine regioisomer set: 
Three regioisomers, 2-fluoroamphetamine (2-FA; 1-(2-fluorophenyl)propan-2-
amine), 3-fluoroamphetamine (3-FA; 1-(3-fluorophenyl)propan-2-amine) and 4-
fluoroamphetamine (4-FA; 1-(4-fluorophenyl)propan-2-amine), differ from each other 
based on the substitution of a fluorine atom on the benzyl group.  Three ions of interest 
were identified in this set of regioisomers; 83.0292 m/z (C5H4F+) at 40 eV, 109.0448 m/z 
(C7H6F+) at 40 eV, and 137.0761 m/z (C9H10F+) at 10 eV. 
 
Figure 17. The relative abundance of the ions of interest for the fluoroamphetamine set of 
regioisomers. Error bars represent SE. 
In the reproducibility experiment, it was determined that one ion of interest, 
137.0761 m/z at 10 eV, could distinguish 4-FA from the 3-FA isomer.  However, this ion 
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could not differentiate the 2-FA and the 3-FA isomers.  This trend was also consistent in 
the concentration experiment.  The other ions of interest had overlapping relative 
abundance ranges, which made them unsuitable for differentiating the regioisomers in 
this set.   
4.4.1.4 Fluoroethcathinone regioisomer set: 
 Three regioisomers, 2-fluoroethcathinone (2-FEC; 2-(ethylamino)-1-(2-
fluorophenyl)propan-1-one), 3-fluoroethcathinone (3-FEC; 2-(ethylamino)-1-(3-
fluorophenyl)propan-1-one), and 4-fluoroethcathinone (4-FEC; 2-(ethylamino)-1-(4-
fluorophenyl)propan-1-one), differ from each other based on the substitution of a fluorine 
atom on the benzoyl group.  Nine ions of interest were identified; 77.0386 m/z (C6H5+) at 
40 eV, 115.0554 m/z (C6H8FO+) at 40 eV, 123.0605 m/z (C8H8F+) at 20 eV, 135.0479 m/z 
(C8H6FN+) at 40 eV, 149.0635 m/z (C9H8FN+) at 20 eV, 150.0714 m/z (C9H9FN+) at 
10eV, 163.0792 m/z (C10H10FN+) at 20 eV, 178.1027 m/z (C11H13FN+) at 20 eV, and 
196.1132 m/z (C11H15FNO+) at 10 eV. 
 
Figure 18. The relative abundance of the ions of interest for the fluoroethcathinone set of 
regioisomers. Error bars represent SE. 
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 Two ions of interest had relative abundance averages that were significantly different 
and did not have overlapping ranges for all three regioisomers in the reproducibility 
experiment. These ions were 178.1027 m/z at 20 eV and 135.0479 m/z at 40 eV.  The 
150.0714 m/z at 10eV, 149.0635 m/z at 20 eV, and 163.0792 m/z at 20 eV ions could only 
distinguish 3-FEC from both 2-FEC and 4-FEC.  The 196.1132 m/z at 10 eV ion could 
only distinguish 4-FEC from both 2-FEC and 3-FEC.  The 123.0605 m/z at 20 eV ion 
could only distinguish 2-FEC from 3-FEC.  The 77.0386 m/z at 40 eV ion could only 
distinguish 2-FEC from 4-FEC.  The 115.0554 m/z at 40 eV and 150.0714 m/z at 10 eV 
ions could not be used to distinguish any regioisomers from each other, as each had 
overlapping relative abundance ranges.   
 In the concentration experiment, the relative abundances were the same for all of the 
ions except for the 178.1027 m/z at 20 eV and 77.0386 m/z at 40 eV ions.  The relative 
abundance range of the 178.1027 m/z at 20 eV ion overlapped between the 2-FEC and 4-
FEC regioisomers in the low concentration experiment, thus rendering this ion only 
useful for distinguishing 3-FEC from either 2- or 4-EC.  The 77.0386 m/z at 40 eV ion 
had overlapping relative abundance ranges for all three regioisomers in the low 
concentration experiment, making this ion unusable when attempting to resolve 
regioisomers based off of relative abundance. It was determined that for this set of 
regioisomers there were no unique ions but there were seven semi-unique ions that could 
be used to distinguish one regioisomer from the other two regioisomers. 
4.4.1.5 Fluoromethamphetamine regioisomer set: 
Three regioisomers, 2-fluoromethamphetamine (2-FMA; 1-(2-fluorophenyl)-N-
methylpropan-2-amine), 3-fluoromethamphetamine (3-FMA; 1-(3-fluorophenyl)-N-
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methylpropan-2-amine) and 4-fluoromethamphetamine (4-FMA; 1-(4-fluorophenyl)-N-
methylpropan-2-amine), differ from each other based on the substitution of a fluorine 
atom on the benzyl group.  Three ions of interest were identified; 83.0292 m/z (C5H4F+) 
at 40 eV, 137.0761 m/z (C9H10F+) at 10 eV, and 168.1183 m/z (C10H15FN+) at 10 eV. 
 
Figure 19. The relative abundance of the ions of interest for the fluoromethamphetamine set of 
regioisomers. Error bars represent SE. 
The reproducibility experiment demonstrated that both the 137.0761 m/z at 10 eV 
and the 168.1183 m/z at 10 eV ions could differentiate 4-FMA from both the 2-FMA and 
3-FMA isomers. However, these ions were unable to differentiate the 2-FMA and 3-FMA 
isomers. The 83.0292 m/z at 40 eV ion could distinguish 3-FMA from the 4-FMA isomer.  
 The relative abundance averages in the concentration were higher for the 
137.0761 m/z at 10 eV and 168.1183 m/z at 10 eV ions and were lower for the 83.0292 
m/z at 40 eV ion when compared to the reproducibility experiment.  Besides the overall 
difference in the relative abundance, the trends remained consistent, with one exception.  
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The relative abundance range difference for the 83.0292 m/z at 40 eV ion in the 
concentration experiment was 1% between the 3-FMA and 4-FMA isomers; therefore, it 
may not be a reliable ion to use. There were two ions of interest that were semi-unique 
and could be used to differentiate one regioisomer from the other two in this set. 
4.4.1.6 Fluoromethcathinone regioisomer set: 
Three regioisomers, 2-fluoromethcathinone (2-FMC; 1-(2-fluorophenyl)-2-
(methylamino)propan-1-one), 3-fluoromethcathinone (3-FMC; 1-(3-fluorophenyl)-2-
(methylamino)propan-1-one), and 4-fluoromethcathinone (4-FMC; 1-(4-fluorophenyl)-2-
(methylamino)propan-1-one), differ from each other based on the substitution of a 
fluorine atom on the benzoyl group.  Three ions of interest were identified; 103.0542 m/z 
(C8H7+) at 40 eV, 123.0605 m/z (C8H8F+) at 20 eV, and 182.0976 m/z (C10H13FNO+) at 10 
eV. 
 
Figure 20. The relative abundance of the ions of interest for the fluoromethcathinone set of 
regioisomers. Error bars represent SE. 
The reproducibility experiment demonstrated that the 182.0976 m/z at 10 eV ion 
could distinguish 4-FMC from 2-FMC and 3-FMC.  However, this ion could not 
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distinguish 2-FMC from 3-FMC.  The 103.0542 m/z at 40 eV ion could distinguish 3-
FMC from both 2-FMC and 4-FMC.  However, since the minimum and maximum 
relative abundances were less than 1% for 2-FMC and 3-FMC, this ion cannot be used to 
differentiate between these two isomers.  
Trends observed in the concentration were consistent with what was observed in 
the reproducibility experiment. It was determined that one semi-unique ion could be used 
to differentiate one FMC regioisomer from the other two in the set. 
4.4.1.7 JWH 203 regioisomer set: 
 Three regioisomers, JWH 203 (2-(2-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethan-
1-one), JWH 203 3-chlorophenyl isomer (2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-
yl)ethan-1-one), and JWH 203 4-chlorophenyl isomer (2-(4-chlorophenyl)-1-(1-pentyl-
1H-indol-3-yl)ethan-1-one), differ from each other based on the substitution of a chlorine 
atom on the benzyl group.  Four ions of interest were identified; 144.0444 m/z 
(C9H6NO+) at 40 eV, 188.1434 m/z (C13H18N+) at 20 eV, 214.1226 m/z (C14H16NO+) at 
both 20 eV and 40 eV.  
 The relative abundance of all four ions of interest were significantly different and did 
not have overlapping ranges in the reproducibility experiment.  While the relative 
abundance trends in the concentration experiment followed those seen in the 
reproducibility experiment, the difference in the relative abundance ranges between JWH 
203 and the JWH 203 4-chlorophenyl isomer was less than 1% for the 188.1434 m/z at 20 
eV ion.  Due to the difference in ranges being so small, this ion could not distinguish 
JWH 203 and the JWH 203 4-chlorophenyl isomer.  However, the 188.1434 m/z at 20 eV 
ion could distinguish JWH 203 3-chlorophenyl isomer from both JWH 203 and JWH 203 
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4-chlorophenyl isomer. 
 
 
Figure 21. The relative abundance of the ions of interest for the JWH 203 set of regioisomers. Error 
bars represent SE. 
  It was determined that three unique ions of interest could be used to distinguish 
the three JWH 203 regioisomers from each other and one semi-unique ion could be used 
to distinguish one isomer from the other two regioisomers in this set.                  
4.4.1.8 JWH 251 regioisomer set:  
 Three regioisomers, JWH 251 (2-(2-methylphenyl)-1-(1-pentylindol-3-yl)ethenone), 
JWH-251 3-methylphenyl isomer (2-(3-methylphenyl)-1-(1-pentylindol-3-yl)ethenone), 
and JWH-251 4-methylphenyl isomer (2-(4-methylphenyl)-1-(1-pentylindol-3-
yl)ethenone), differ from each other based on the substitution of a methyl group on the 
benzyl group.  Five ions of interest were identified; 144.0444 m/z (C9H6NO+) at 40 eV, 
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188.1434 m/z (C13H18N+) at 20 eV, 214.1226 m/z (C14H16NO+) at both 20 eV and 40 eV, 
and 320.2009 m/z (C22H26NO+) at 20 eV. 
 The reproducibility experiment demonstrated that the 214.1226 m/z at 40 eV ion 
could distinguish all three regioisomers from each other.  The 188.1434 m/z at 20 eV and 
the 320.2009 m/z at 20 eV ions could distinguish JWH 251 3-methylphenyl isomer from 
both JWH 251 and JWH 251 4-methylphenyl isomer, but could not distinguish JWH 251 
and JWH 251 4-methylphenyl isomer from each other.  The 214.1226 m/z at 20 eV and 
the 144.0444 m/z at 40 eV ions could distinguish JWH 251 4-methylphenyl isomer from 
JWH 251 and the JWH 251 3-methylphenyl isomer, but could not differentiate JWH 251 
and JWH 251 3-methylphenyl isomer from each other. 
 
Figure 22. The relative abundance of the ions of interest for the JWH 251 set of regioisomers. Error 
bars represent SE. 
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 The relative abundance ranges for 214.1226 m/z at 40 eV ion overlapped between the 
JWH 251 and JWH 251 3-methylphenyl isomers in the concentration experiment thus 
making this ion unreliable for distinguishing these isomers.  However, the unique 
214.1226 m/z at 40 eV ion could be used to distinguish JWH 251 4-methylphenyl isomer 
from both JWH-251 and JWH 251 3-Methylphenyl isomer. 
4.4.1.9 Methoxymethcathinone regioisomer set:  
 Three regioisomers, 2- methoxymethcathinone (2-MeOMC; 1-(2-methoxyphenyl)-2-
(methylamino)propan-1-one), 3-methoxymethcathinone (3-MeOMC; 1-(3-
methoxyphenyl)-2-(methylamino)propan-1-one), and 4-methoxymethcathinone 
(Methedrone; 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one), differ from each 
other based on the substitution of a methoxy group on the benzoyl group.  Five ions of 
interest were identified; 58.0651 m/z (C3H8N+) at 40 eV, 146.0600 m/z (C9H8NO+) at 40 
eV, 160.0757 m/z (C10H10NO+) at 40 eV, 161.0835 m/z (C10H11NO+) at 10 eV, and 
194.1176 m/z (C11H16NO2+) at 10 eV. 
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Figure 23. The relative abundance of the ions of interest for the methoxymethcathinone set of 
regioisomers. Error bars represent SE. 
 The results of the reproducibility experiment demonstrated that two of the five ions of 
interest, 58.0651 m/z at 40 eV and 146.0600 m/z at 40 eV, could distinguish the three 
regioisomers from each other.  The other ions of interest could distinguish one 
regioisomer from the other two in the set.  The 161.0835 m/z at 10 eV ion could 
distinguish Methedrone from both 2-MeOMC and 3-MeOMC.  The 194.1176 m/z at 10 
eV ion was able to distinguish 3-MeOMC from both Methedrone and 2-MeOMC.  The 
160.0757 m/z at 40 eV ion was able to distinguish 2-MeOMC from both Methedrone and 
3-MeOMC.  
 The concentration experiment yielded similar results to the reproducibility study with 
the exception of the 146.0600 m/z at 40 eV ion.  The average relative abundance of this 
ion overlapped between 2-MeOMC and 3-MeOMC thus making it an unreliable ion to 
differentiate these two regioisomers. 
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 Only one unique ion of interest was able to distinguish all three regioisomers from 
each other.  The other four semi-unique ions of interest were able to distinguish one 
regioisomer from the other two regioisomers of interest.    
4.4.1.10 Methoxy-N,N-dimethyltryptamine regioisomer set: 
 The two regioisomers, 4-methoxy-N,N-dimethyltryptamine (4-MeO-DMT; 2-(4-
methoxy-1H-indol-3-yl)-N,N-dimethylethan-1-amine) and 5-methoxy-N,N-
dimethyltryptamine (5-MeO-DMT; 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethan-1-
amine), differ from each other based on the substitution of a methoxy group on the indole 
ring.  Six ions of interest were identified for these regioisomers; 130.0651 m/z (C9H8N+) 
at 40 eV, 159.0679 m/z (C10H9NO+) at both 20 eV and 40 eV, 174.0913 m/z (C11H12NO+) 
at both 10 eV and 20 eV, and 219.1492 m/z (C13H19N2O+) at 10 eV. 
 
Figure 24. The relative abundance of the ions of interest for the MeO-DMT set of regioisomers. 
Error bars represent SE. 
 The relative abundance mean of the ions of interest were all significantly different 
from each other and there were no overlapping ranges between them.  The concentration 
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experiment experiment generated similar trends between the two regioisomers’ ions of 
interest.  The 159.0679 m/z at 40 eV ion had ranges that were very close to each other for 
the two regioisomers.  For example, in the reproducibility study, 4-MeO-DMT had a 
maximum relative abundance of 17.54% and 5-MeO-DMT had a minimum relative of 
abundance of 17.93%.  In an abundance of caution, this product ion was excluded due to 
these close ranges.  After the exclusion of the 159.0679 m/z at 40 eV ion, there were five 
unique ions of interest that could be used to distinguish the two regioisomers from each 
other. 
4.4.1.11 Methylenedioxymethcathinone regioisomer set:  
 Two regioisomers, 2,3-methylenedioxymethcathinone (2,3-MDMC; 1-(1,3-
benzodioxol-4-yl)-2-(methylamino)-1-propanone) and 3,4-methylenedioxymethcathinone 
(Methylone; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one), differ from each 
other based on the substitution of a methylenedioxy group on the benzoyl group.  Six ions 
of interest were identified; 58.0651 m/z (C3H8N+) at 10 eV, 91.0542 m/z (C7H7+) at 40 
eV, 117.0573 m/z (C8H7N+) at 40 eV, 132.0808 m/z (C9H10N+) at both 20 eV and 40 eV, 
and 190.0863 m/z (C11H12NO2+) at 10 eV. 
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Figure 25. The relative abundance of the ions of interest for the methylenedioxymethcathinone set of 
regioisomers. Error bars represent SE. 
 All six ions of interest had relative abundances that were significantly different from 
each other and did not overlap between the two regioisomers in the reproducibility 
experiment.  In the concentration experiment, the 91.0542 m/z at 40 eV ion and the 
132.0808 m/z at 40 eV ion both had overlapping relative abundance ranges, which 
eliminated them from being reliable ions to distinguish the two regioisomers from each 
other.  It was determined that four of the six ions of interest were unique ions and could 
be used to distinguish the two regioisomers from each other. 
4.4.1.12 Methylenedioxy Pyrovalerone regioisomer set:   
 The two regioisomers, 2,3-methylenedioxypyrovalerone (2,3-MDPV; 1-(1,3-
benzodioxol-4-yl)-2-pyrrolidin-1-ylpentan-1-one) and methylenedioxypyrovalerone 
(MDPV; 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one), differ from each 
other based on the position of substitution of the methylenedioxy group on the benzoyl 
group.  The ions identified to be of interest were 126.1277 m/z (C8H16N+) at both 20 eV 
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and 40 eV, 135.0441 m/z (C8H7O2+) at both 20 eV and 40 eV, 149.0233 m/z (C8H5O3+) at 
both 20 eV and 40 eV, 205.0858 m/z (C8H5O3+) at 20 eV, and 276.1594 m/z 
(C16H22NO3+) at 20 eV.  
 
Figure 26. The relative abundance of the ions of interest for the MDPV set of regioisomers. Error 
bars represent SE. 
 Reproducibility studies demonstrated that the relative abundances of the seven of the 
eight ions of interest were significantly different and their ranges did not overlap between 
the two regioisomers.  The only ion that did not satisfy this requirement was the 276.1594 
m/z ion at 20 eV.  For this ion the mean was significantly different but the range 
overlapped.  This ion was therefore not included in the concentration and mobile phase 
experiments.  
 For the remaining seven ions of interest, the average relative abundance varied 
slightly between the high and low concentrations of the same regioisomer.  However, the 
trends between the two regioisomers remained and the two regioisomers could be 
differentiated based on the relative abundance for each of the seven product ions.  This 
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data suggests that seven unique ions could be used to differentiate these two regioisomers 
from each other. 
4.4.1.13 Methylethcathinone regioisomers set: 
Two regioisomers, 3-methylethcathinone (3-MEC; 2-(ethylamino)-1-(3-
methylphenyl)propan-1-one) and 4-methylethcathinone (4-MEC; 2-(ethylamino)-1-(4-
methylphenyl)propan-1-one), differ from each other based on the substitution of a methyl 
group on the benzoyl group.  Four ions of interest were identified; 91.0542 m/z (C7H7+) at 
40 eV, 119.0855 m/z (C9H11+) at 20 eV, 174.1277 m/z (C12H16N+) at 20 eV, 192.1383 m/z 
(C12H18NO+) at 10 eV. 
 
Figure 27. The relative abundance of the ions of interest for the fluoroethcathinone set of 
regioisomers. Error bars represent SE. 
In the reproducibility experiment, only one ion of interest, 192.1383 m/z at 10 eV, 
could distinguish the regioisomers.  The other three ions of interest had significant 
differences between the average relative abundance.  However, the range of the relative 
abundance overlapped between the two regioisomers, rendering these ions not reliable to 
differentiate the two regioisomers based on relative abundance.  
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The concentration experiment exhibited similar trends, with the only difference 
being the higher relative abundance averages for ions 192.1383 m/z at 10 eV and 
174.1277 m/z at 20 eV.  The 192.1383 m/z at 10 eV ion could still differentiate between 
the regioisomers. It was determined that one unique ion of interest could be used to 
differentiate the two regioisomers in this set.  
4.4.1.14 RCS 4 regioisomer set: 
 Three regioisomers, RCS-4 (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone , 
RCS-4 2-methoxy isomer (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and 
RCS-4 3-methoxy isomer (3-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, differ 
from each other based on the substitution of a methoxy group on the benzoyl group.  Four 
ions of interest were identified; 77.0386 m/z (C6H5+) at 40 eV, 107.0491 m/z (C7H7O+) at 
40 eV, 135.0441 m/z (C8H7O2+) at 40 eV, and 322.1802 m/z (C21H24NO2+) at 20 eV.  
 The reproducibility experiment demonstrated that both the 322.1802 m/z at 20 eV and 
the 107.0491 m/z at 40 eV ions could distinguish all three regioisomers.  The 77.0386 m/z 
at 40 eV and 107.0491 m/z at 40 eV ions could differentiate the RCS-4 3-methoxy isomer 
from both RCS-4 and the RCS-4 2-methoxy isomer.  However, these two ions could not 
distinguish RCS-4 and the RCS-4 2-methoxy isomers from each other. 
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Figure 28. The relative abundance of the ions of interest for the RCS-8 set of regioisomers. Error 
bars represent SE. 
 The trends observed in the reproducibility experiment were similar to those observed 
in the concentration experiment.  The only exception was for the 77.0386 m/z at 40 eV 
ion, for which the overlap between RCS-4 and the RCS-4 2-methoxy isomer observed in 
the reproducibility experiment was not present in the concentration experiment. It was 
determined that two ions can be used to distinguish all three regioisomers from each other 
and two ions can be used to distinguish one regioisomer from the other two regioisomers.       
4.4.1.15 RCS-8 regioisomer experiment: 
 Three regioisomers, RCS-8 (1-(1-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-
methoxyphenyl)ethan-1-one), RCS-8 3-methoxy isomer (1-(1-(2-cyclohexylethyl)-1H-
indol-3-yl)-2-(3-methoxyphenyl)ethan-1-one), and RCS-8 4-methoxy isomer (1-(1-(2-
cyclohexylethyl)-1H-indol-3-yl)-2-(4-methoxyphenyl)ethan-1-one), differ from each 
other based on the substitution of a methoxy group on the benzyl group.  Six ions of 
interest were identified; 91.0542 m/z (C7H7+) at 40 eV, 121.0648 m/z (C8H9O+) at 20 eV, 
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144.0444 m/z (C9H6NO+) at 40 eV, 228.1747 m/z (C16H22N+) at 20 eV, and 254.1539 m/z 
(C17H20NO+) at 20 eV and 40 eV.    
 
Figure 29. The relative abundance of the ions of interest for the RCS-8 set of regioisomers. Error 
bars represent SE. 
 The reproducibility study demonstrated that the relative abundance of all six ions of 
interest were significantly different from each other and did not have overlapping ranges.  
In the concentration study, the average relative abundance followed trends observed in 
the reproducibility study.  However, for the 144.0444 m/z at 40 eV ion, the range 
overlapped between RCS-8 and the RCS-8 3-methoxy regioisomer in the low 
concentration replicates. Due to this overlap, the 144.0444 m/z at 40 eV ion could not 
differentiate RCS-8 from the RCS-8 3-methoxy isomer.  However, this semi-unique ion 
could differentiate the RCS-8 4-methoxy isomer from both RCS-8 and the RCS-8 3-
methoxy isomer.  The remaining five unique ions of interest could distinguish all three 
regioisomers from each other. 
 Four of the ions of interest had relative abundance averages that were consistent with 
the averages obtained in the reproducibility experiment.  The 121.0648 m/z at 20 eV ion 
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had elevated relative abundance averages greater than 5% for both the RCS-8 3-methoxy 
isomer and the RCS-8 4-methoxy isomer when compared to the reproducibility 
experiment. The relative abundance average for RCS-8 121.0648 m/z at 20 eV ion 
remained at 100% in every experiment. The 254.1539 m/z at 40 eV ion had a slightly 
different relative abundance average for the RCS-8 3-methoxy isomer. The relative 
abundance average difference was less than 3% for the other two regioisomers when 
compared to the reproducibility study.    
4.4.2 Mobile Phase Experiment 
 All of the sets of regioisomers were evaluated under different mobile phase 
conditions to evaluate how reproducible the relative abundances were using different 
mobile phase compositions. For this study two aqueous (5 mM AF in HPLC Water with 
0.1% FA and HPLC with 0.1% FA) and two organic (Acetonitrile with 0.1% formic acid 
and methanol with 0.1% formic acid) mobile phase compositions were used. Ten of the 
fifteen sets of regioisomers had ions with consistent relative abundances among all four 
mobile phase compositions. The five sets of regioisomers that were not consistent were 
all from the synthetic cannabinoid NPS class. The number of ions affected by the mobile 
phase composition varied for each set of regioisomers.  
 In the AM-694 set of regioisomers, three ions of interest had average relative 
abundance differences greater than 5%. These differences were observed in the 230.9301 
m/z at 20 eV ion for the AM-694 3-iodo isomer. The 436.0568 m/z at 20 eV ion and the 
202.9352 m/z at 40 eV ion both had variation in both the AM-694 3-iodo isomer and the 
AM-694 4-iodo isomer. These differences were observed when comparing the aqueous 
and the organic mobile phase compositions.  
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 Significant differences were observed in the mobile phase experiment for JWH 203 3-
chlorophenyl isomer’s relative abundance mean of the four ions of interest when 
comparing the aqueous and organic mobile phases to each other.  Interestingly, this 
phenomenon was not observed in JWH-203 and the JWH-203 4-chlorophenyl isomer. 
The organic mobile phase compositions produced similar results to the reproducibility 
experiment.   
 In the JWH-251 set of regioisomers four of the five ions of interest had at least one 
regioisomer with a difference in the average relative abundance greater than 5% 
observed. The 214.1226 m/z at 20 eV ion and the 144.044 m/z at 20 eV ion had 
differences in both the JWH-251 3-methylphenyl isomer and JWH-251 4-methylphenyl 
isomer. The 320.2009 m/z at 20 eV ion had differences observed in the relative 
abundance of the JWH-251 3-methylphenyl isomer. The 214.1226 m/z at 40 eV ion had 
difference observed in the relative abundance of the JWH-251 4-methylphenyl isomer. 
 In the RCS-4 set of regioisomers there were four ions of interests that had average 
relative significant differences among the various mobile phase compositions. Like the 
JWH 203 set of regioisomers, the RCS-4 3-methoxy isomer was the only isomer to have 
significant differences among the mobile phase compositions. These differences were not 
observed in RCS-4 and the RCS-4 methoxy isomer.  
 In the RCS-8 set of regioisomers, six ions of interest had relative abundance 
differences greater than 5% when analyzed utilizing the various mobile phase 
compositions. The 121.0648 m/z at 20 eV, 228.1747 m/z at 20 eV, and 254.1539 m/z at 20 
eV ions had differences in the relative abundance of both the RCS-8 3-methoxy isomer 
and the RCS-8 4-methoxy isomer. All of the RCS-8 regioisomers had different relative 
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abundances for the 91.0542 m/z at 40 eV, 144.0444 m/z at 40 eV, and 254.1539 m/z at 40 
eV ions when comparing the abundances obtained utilizing the various mobile phase 
compositions.  
4.4.3 Solid Phase Extraction Experiment 
 Four sets of regioisomers were selected for further evaluation. These sets included 
two cathinone sets (fluoroethcathinone and methoxymethcathinone) and two synthetic 
cannabinoid sets (JWH-203 and RCS-8). These sets were selected to represent various 
NPS classes and due to the fact that these sets had many unique and semi-unique ions 
identified in previous experiments. This experiment was performed to determine if the 
trends observed in previous experiments are consistent after a solid phase extraction from 
human blood.  
 Unless noted in Table 4, all of the ions of interest had relative abundances within 5% 
of the average relative abundance determined in the reproducibility study. Three sets of 
regioisomers, fluoroethcathinone, methoxymethcathinone and RCS-8, had at least two 
ions of interest that had a relative abundance greater than 5%. The difference in relative 
abundances were not seen in ions from the JWH-203 regioisomer set. 
 In the fluoroethcathinone regioisomer set, three ions had elevated relative abundances 
when compared to the previous experiments. However, the trends noted for these three 
ions remained the same in terms of differentiating regioisomers. The 150.0714 m/z at 
10eV and 178.1027 m/z at 20 eV ions can be used to distinguish 3-FEC from both 2-FEC 
and 4-FEC. While the 196.1132 m/z at 10 eV ion can be used to distinguish 4-FEC from 
both 2-FEC and 3-FEC.   
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 The methoxymethcathinone regioisomer set had two ions of interested with elevated 
relative abundances. Similar to the fluoroethcathinone regioisomer set, although the 
relative abundance was elevated the trends observed in previous experiments were 
consistent. The 161.0835 m/z at 10 eV ion can be used to distinguish methedrone from 
both 2-MeOMEC and 3-MeOMEC. The 194.1176 m/z at 10 eV ion ca be used to 
distinguish 3-MeOMEC from both 2-MeOMEC and methedrone.  
   
Table 4. All of the ions of interest in the four sets of regioisomers where relative abundances were 
inconsistent (>5% difference) between the reproducibility experiment and the solid phase extraction 
experiment for at least one regioisomer in the set. The JWH 203 set of regioisomers was also 
evaluated during the solid phase extraction experiment. However, there were no inconsistent ions 
observed with this set of regioisomers. 
           Reproducibility SPE  
Regioisomer Set Compound Product Ion CE 
Average 
(%) RSD 
Average 
(%) RSD  
Fluoroethcathinone  
2-Fluoroethcathinone  
150.07179 10 eV 
26.3 6.1% 35.7 0.1%  
3-Fluoroethcathinone  43.1 6.7% 52.5 1.7%  
4-Fluoroethcathinone  31.1 6.8% 40.9 2.3%  
2-Fluoroethcathinone  
196.11391 10 eV 
84.0 4.0% 98.7 2.2%  
3-Fluoroethcathinone  78.9 4.1% 100.0 0.0%  
4-Fluoroethcathinone  50.0 6.0% 72.8 0.8%  
2-Fluoroethcathinone  
178.1031 20 eV 
52.7 3.1% 61.7 6.8%  
3-Fluoroethcathinone  30.1 7.4% 38.8 1.2%  
4-Fluoroethcathinone  41.3 7.0% 53.2 2.2%  
Methoxymethcathinone  
Methedrone 
161.0836 10 eV 
17.3 6.3% 24.5 3.5%  
2-Methoxymethcathinone 24.6 5.8% 32.8 2.2%  
3-Methoxymethcathinone 27.8 6.6% 39.2 0.8%  
Methedrone 
194.1178 10 eV 
17.3 6.6% 26.8 0.9%  
2-Methoxymethcathinone 14.7 7.9% 24.5 2.1%  
3-Methoxymethcathinone 28.3 6.0% 41.9 1.8%  
RCS-8  
RCS-8 3-methoxy isomer 
121.0637 20 eV 
75.8 2.5% 95.3 1.1%  
RCS-8 4-methoxy isomer 33.9 3.1% 43.6 2.6%  
RCS-8 100.0 0.0% 100.0 0.0%  
RCS-8 3-methoxy isomer 254.1532 40 eV 64.9 2.7% 57.0 2.4%  
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RCS-8 4-methoxy isomer 10.8 3.4% 8.7 3.6%  
RCS-8 5.4 5.5% 4.3 5.4%  
 
The RCS-8 regioisomer set had one ion of interest that had elevated relative 
abundances and one ion of interest that had lower relative abundances when compared to 
the reproducibility experiment. The observed trends in differentiating the regioisomers 
also were consistent with this group. The 121.0637 m/z at 20 eV and the 254.1532 m/z at 
40 eV were both able to successfully differentiate all three regioisomers from each other. 
4.5 Discussion: 
 Mass spectrometry is the preferred way to confirm the presence of these compounds 
in forensic toxicology specimens as this methodology provides the sensitivity and 
selectivity needed to detect the presence of small concentrations of drugs in human 
matrices. Both gas chromatography mass spectrometry (GC-MS) and liquid 
chromatography mass spectrometry (LC-MS) methodologies have been employed to 
confirm the presence of novel psychoactive compounds in previous literature. The 
identification of compounds using these methodologies rely on retention time and 
fragmentation patterns. It may be difficult to distinguish structurally similar compounds 
from each other as they may have similar retention times and/or fragment/product ions 
using these techniques [172]. The compounds that pose the greatest concern are isobars 
and isomers as they have the same molecular ion or are undistinguishable thus needing 
retention time and/or fragmentation patterns to resolve these compounds. 
 This challenge can be observed in both GC-MS and LC-MS methodology. The use of 
electron ionization in GC-MS can make the identification of novel psychoactive 
substances more complicated as typically the molecular ion is not present therefore 
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structurally similar non-isomeric compounds can produce indistinguishable spectral data. 
The use of “soft” ionization such as CI, ESI, or APCI can help alleviate this issue as a 
molecular ion is typically generated using these ionizations techniques. The use of “soft” 
ionization techniques with spectrometers is the preferred way to confirm the presence of 
these compounds as molecular ion and product ions may be used to distinguish novel 
psychoactive compounds from each other.      
   Examples of this include Inoue et al. evaluating both electron ionization and 
chemical ionization with tandem mass spectrometry in order to differentiate bromo-
amphetamine and bromo-methamphetime regioisomers [161]. They concluded that CI-
MS/MS provide positional information that can be used to differentiate the various 
isomers. Similar results were reported by Westphal et al. in their study with 
fluoroamphetamine regioisomers and Negishi et al with their study of 
chloroamphetamine regioisomers [162, 173]. 
  In attempt to explore the usability of relative abundance of the ions of interest in 
differentiating regioisomers from mass spectral data alone, three experiments were 
performed on all fifteen sets of regioisomers available in the laboratory. These 
experiments included reproducibility, concentration, and mobile phase experiments. Four 
out of the fifteen sets of regioisomers were then subjected to a solid phase extraction 
experiment as well.  
 These experiments were designed to simulate common situations encountered during 
a routine forensic toxicological confirmation analysis utilizing mass spectrometry. First it 
is imperative that the relative abundance of the ions of interest were reproducible while 
injecting the same concentration multiple times per day over the course of multiple days. 
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The concentration experiment was performed to ensure that the relative abundances 
deemed reproducible from the first experiment are consistent over a broad range of 
concentrations as drug concentrations in authentic forensic specimens are unknown at the 
time of screening. The mobile phase experiment was used to evaluate if there was any 
difference in the relative abundance of the ions of interest in the different mobile phase 
extremes, 100% aqueous and 100% organic. Lastly, the solid phase extraction experiment 
was to simulate an actual case work up and used to determine if the same trends from the 
neat injections applied to the extracted samples. The extract was separated by a LC 
gradient before being analyzed by the LC-QTOF-MS.     
 In assessing the different product ions of interest, they were sorted in two categories 
if the ion could be useful in differentiating a regioisomer. The two categories were unique 
ions and semi-unique ions. Unique ions are able to be used to differentiate all of the 
regioisomers in the set based off of the relative abundance. Semi-unique ions are able to 
differentiate one regioisomer from the remaining regioisomers in the set, however the 
semi-unique ion cannot differentiate all of the regioisomers in the set from each other. 
The criteria used to establish unique and semi-unique ions was that the relative 
abundance average of the ion of interest had to be significantly different between 
regioisomers in the reproducibility experiment and the relative abundance range of the 
ion of interest could not overlap between the regioisomers.  
 All fifteen sets of regioisomers had at least one unique or semi-unique ion of interest 
that could be used to aid in differentiating regioisomers from each other. The sets of 
regioisomers that had the largest amount of unique ions were the methylenedioxy 
pyrovalerone group which had seven unique ions, the methoxy-N,-N-dimethyltryptamine 
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group which had five unique ions and the RCS-8 group which had five unique ions and 
one semi-unique ion. The substitution of these regioisomers consisted of a methoxy 
group (RCS-8) or methylenedioxy group on various positions of an aromatic ring.  
  The sets of regioisomers that yielded the lowest number of useful ions were the AM 
694, fluoroamphetamine, and fluoromethcathinone groups. Each set had just one semi-
unique ion that could be used to differentiate one regioisomer from the other compounds 
in the group. These compounds had an iodine atom (AM-694) or a fluorine atom 
substituted on various positions of an aromatic ring.  
  In this experiment the groups of regioisomers that generated those most ions of 
interest were regioisomers that had an electron donating group substituted around the 
aromatic ring (methoxy or methylenedioxy). While the groups of regioisomers that 
generated the least amount of useful ions had an electron withdrawing group substituted 
around an aromatic ring (halogen). While these trends were consistent with the groups 
with the most and least amount of useful ions, there were exceptions. For example the 
JWH 203 set of regioisomers, which has a halogen (Chlorine atom) substituted around an 
aromatic ring, had three unique ions that could distinguish all three regioisomers from 
each other and had one semi-unique compound. The semi-unique ion could differentiate 
the JWH 203 3-chlorophenyl isomer (meta-substitution) from both JWH 203 (ortho-
substitution) and the JWH 203 4-chlorophenyl isomers (para-substitution). However, it 
could not be used to distinguish the JWH 203 from the JWH 203 4-chlorophenyl isomer.  
 The differences in the relative abundance between regioisomers can be attributed to 
the differences in structures. While collision induced dissociation fragmentation 
pathways are not completely known. There have been conclusions deduced based on 
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physical chemistry computational experiments and observations from experiments 
utilizing the mass spectrometer. These conclusions include that some ions are favored 
more than others and more likely to be seen in MS/MS spectra based on the differences in 
protonation site, bond strength, ion formation, ion stability, steric and kinetic factors 
[174].  In addition protonation site is also important as this will affect the fragmentation 
patterns observed. It was reported by Wang et. al that various mobile phase compositions 
affected the relative abundance observed in various small molecules [175]. They 
proposed that the reason for this was the change of the ratio of the isomeric cations that 
were formed in the ESI process. The favored protonation site was different depending on 
the mobile phase composition.     
 Also of note was the differences observed in the relative abundance of some ions of 
interest following the SPE extraction method. These differences in relative abundances 
could be possibly explained by the different mobile phase composition at the time these 
compounds came off the analytical compound in comparison to the mobile phase 
composition of the previous experiments. Such that one protonation site if favored more 
than the other in the different compositions as suggested by a previous study. Another 
explanation could suggest that matrix effects may affect protonation. Future studies will 
be needed to evaluate this. 
4.6 Conclusions: 
The reproducibility of the relative abundance was evaluated by both inter and 
intraday experiments, a concentration experiment, and a mobile phase experiment for 
every set of regioisomers. A solid phase experiment was performed on four of the fifteen 
groups of regioisomers. It was determined that every set of regioisomers in this study had 
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at least one unique or semi-unique ion that could be used to help aid in differentiating one 
regioisomer from the other regioisomers in the group.  A few groups of regioisomers had 
different relative abundance patterns when subjected to different mobile phases, which 
has been observed previously in experiments analyzing different analytes. In addition, the 
solid phase extraction experiment generated different relative abundance averages for 
some ions when compared to the previous experiments.   
While MS/MS spectral alone may not be able to be used to distinguish every 
regioisomer from each other, this study demonstrates that evaluating the regioisomers 
relative abundance from collision induced dissociation spectral data may be a useful tool 
when differentiating regioisomers for some groups of regioisomers. This potentially 
could be used when separation techniques are not employed or when regioisomers are not 
resolved by a separation technique. Exact analytical conditions need to be known and 
used before employing this strategy as differences may affect the protonation site 
favorability of the compound and thus generate differences in the relative abundance of 
the ions of interest.         
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5. SOLID PHASE EXTRACTION AND LC-QTOF-MS ACQUISITION METHOD 
5.1 Abstract 
 NPS have been detected and reported in many ante-mortem and post-mortem 
toxicological investigations. Many of the methods used to identify these substances 
utilize targeted acquisition methods for a specific NPS drug class. The popularity and use 
of a particular NPS changes quite frequently. As a result, new psychoactive substances 
are routinely being identified in drug seizure cases and toxicological investigations. Due 
to this, an untargeted, comprehensive screening method is needed for the identification of 
these compounds for toxicological investigations.  
 Utilizing a liquid chromatography quadrupole time of flight mass spectrometry (LC-
QTOF-MS), a SPE method and two acquisition methods were developed in order to 
detect NPS from multiple NPS classes in human blood specimens. Thirty-three NPS 
representing the arylcyclohexylamine, cathinone, phenethylamine, and synthetic 
cannabinoid classes were selected to demonstrate the applicability of these newly 
developed methods. The limits of detection for these compounds were also determined to 
range from sub ng/mL to the low ng/mL concentration levels in a human blood matrix for 
both acquisition methods. Matrix effects and recovery yields were evaluated in this study. 
It was determined that 26 of the 33 substances displayed ion enhancement or ion 
suppression of less than 25%. Recovery yields ranged from 18% to 91%, with 20 
compounds having recovery yields greater than 50%.  
 The developed methods can be used in toxicological laboratories as untargeted 
acquisition methods to detect the presence of NPS in human blood specimens. While the 
full scan acquisition method was shown to be overall more sensitive, the “All Ions” 
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acquisition method was more selective, as MS/MS product ions are also generated and 
used to confirm the presence of a particular NPS.  As both methods are non-targeted 
acquisition methods, the capability of reanalyzing the data without re-extracting blood 
specimens is possible. This is advantageous as this saves laboratories time and also 
conserves the blood sample which can be limited in some toxicological investigations.        
5.2 Introduction 
  NPS are psychotropic compounds that are created and/or used to evade current 
drug laws. NPS are also known as designer drugs, research chemicals, and legal highs. 
NPS have been categorized by classes which are based on the structure of the compound 
and/or the intended pharmacological effect of the substance. The classes of NPS include 
but are not limited to: arylcyclohexylamines, benzodiazepines, cathinones, 
phenethylamines, piperazines, synthetic cannabinoids, synthetic opioids, and tryptamines.     
The capability of identifying NPS in human specimens is necessary in order to 
perform a comprehensive drug analysis in forensic toxicological investigations where 
questions of impairment or cause of death questions typically arise. This is due to the fact 
that there have been reports of acute intoxications involving different NPS classes that 
are associated with impairment, hospitalization, and death [6, 85, 176-177].  While the 
reported prevalence of NPS has been low in comparison to traditional drugs of abuse, 
there may be an underreporting of these compounds as some laboratories do not have 
analytical methods that capable or not sensitive enough to detect them [178]. 
 The toxicology field is aware of the need to be able to detect NPS and laboratories 
have created analytical methods to confirm and/or quantitate their presence in human 
specimens [179]. Various sample pretreatment techniques such as liquid/liquid extraction 
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(LLE), solid phase extraction (SPE), and “dilute and shoot” have been used in these 
methods prior to instrumental analysis [136, 138, 180-181]. Analytical methods typical 
utilize mass spectrometry that is coupled with a separation technique, such as gas 
chromatography or liquid chromatography, as this provides the necessary selectivity and 
sensitivity required for detecting analytes of interest in forensic toxicological specimens. 
Various ionization techniques as well as different mass analyzers, including tandem mass 
spectrometers, have been employed to confirm the presence of NPS as well [140, 159, 
166]. 
Most of the published methods target a small number of NPS and/or only target a 
specific structural class [179, 182]. However, there have been some methods that are 
more comprehensive and some untargeted methods have been published [143]. In 
addition, both data dependent acquisition and data independent acquisition methods have 
been used in an attempt to screen for compounds of interest in forensic toxicological 
investigations.  
 Due to its capabilities, high resolution time of flight mass spectrometry has gained 
favor in the forensic toxicology field as a way to detect NPS. High resolution ensures 
high mass accuracy which enables toxicologists to resolve previously isobaric 
compounds, which can include endogenous and exogenous compounds, based on 
accurate mass of the ion alone. This creates more confidence in the identification of a 
compound. The time of flight mass spectrometer also enables the toxicologist to collect 
data from a large mass range and while maintaining high sensitivity. The full scan data 
that is collected can be used to identify new NPS that were previously unknown or 
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untargeted. The full scan data also enables toxicologists to retrospectively analyze case 
data for the presence of NPS that were unknown at the time of the analysis.    
 The aim of this work was to create a comprehensive extraction and acquisition 
method utilizing HRMS that can be used to identify the presence of NPS in human blood 
specimens. A set of NPS were selected from various classes to demonstrate the 
applicability of this method for identifying NPS from different NPS. Various method 
performance parameters such as limit of detection, matrix effects and recovery 
percentage were determined for the created method.    
5.3 Materials and Methods 
5.3.1 Chemicals and reagents 
 Drug standards were obtained from Cayman Chemical Company (Ann Arbor, MI) 
and Cerilliant Corporation (Round Rock, TX) as neat weighed solids or as standards in 
solution.  Optima grade methanol (ThermoFisher Scientific) was used to prepare 1 
mg/mL stock solutions from the neat standards.  For some compounds, dimethyl 
sulfoxide (ThermoFisher Scientific) was used due to solubility issues encountered with 
the use of methanol.  Standards provided in solution were used as received.  All standards 
were then diluted to a concentration of 10 μg/mL using methanol.  Finally, working 
solutions were created by diluting the 10 μg/mL standards to a concentration of 1 μg/mL 
with methanol. Solvents used for liquid chromatography included acetonitrile (Optima 
LC/MS grade) and water (Optima LC/MS grade) from ThermoFisher Scientific.  Liquid 
chromatography additives used included formic acid (Optima LC/MS) from Fisher 
Scientific and ammonium formate (99%) from Acros Organics.  
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5.3.2 Instrumentation 
 Analytical instrumentation included an Agilent 1290 Infinity UHPLC system coupled 
to an Agilent 6530 Accurate-Mass QTOF MS (Agilent Technologies, Santa Clara, USA).  
The QTOF-MS was operated in positive-ion electrospray mode with a Jet Stream ESI 
ionization source.  
 Agilent MassHunter LC/MS Acquisition software for the 6200 series TOF/6500 
series QTOF, MassHunter Qualitative Analysis software, and Mass Hunter Quantitative 
Analysis software were used to acquire and process the data.  MassHunter Personal 
Computer Database Library (PCDL) Manager software was used as this contained a high 
resolution MS/MS spectral library and compound database for the novel psychoactive 
substances of interest.   
5.3.3 Sample Pretreatment 
  A 1 mL aliquot of sample was treated with 1 mL of cold acetonitrile. The sample was 
then centrifuged at 3500 rpm at -10 C for 10 minutes. The supernatant was transfer to a 
new clean salinized tube before 2 mL of a 0.1 M ammonium acetate buffer (pH =4.8) was 
added. The sample was then vortexed and then subjected to a solid phase extraction 
method utilizing a positive pressure solid phase extraction manifold. 
 The solid phase extraction method consisted of cartridge conditioning steps of 1 mL 
of methanol followed by 1 mL of 0.1 M ammonium acetate buffer (pH = 4.8). The 
sample was then loaded onto the extraction cartridge. Wash steps included 3 mL of the 
ammonium acetate buffer followed by 3 mL of a solution consisting of 50:50 (v:v) 
deionized water: methanol. The extraction cartridge was then dried under nitrogen gas at 
max pressure for 5 minutes. The elution step consisted of two 1 mL aliquots of 
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acetonitrile with 2% ammonium hydroxide. The eluent was collected and dried down 
under nitrogen gas at 35 C. The sample was then reconstituted with 100 µL of the initial 
mobile phase composition.        
5.3.4 Instrumental Analysis  
 Two different acquisition methods were used to confirm the presence of novel 
psychoactive substances. The first method employed a full scan MS acquisition method 
to acquire spectral data. The second method utilized the “All Ions Mode” acquisition 
technique to acquire spectral data. 
 The injection volume was set to 10 µL. An inline filter frit and an Agilent Poroshell 
120 EC-C18 (2.1 x 100 mm 2.7 Micron) analytical column were used. Mobile phase A 
consisted of 5 mM ammonium formate in water with 0.1% formic acid. Mobile phase B 
consisted of 90:10 (acetonitrile: mobile phase A) with 0.1% formic acid. A LC gradient 
method was used with the initial mobile phase composition of 5% B. Mobile phase B was 
then increase to 20% by 1.00 minutes, increased to 70% by 5.00 minutes, and further 
increased to 100% B by 8.75 minutes. This mobile phase composition was held until 
13.00 minutes and at 13.01 minutes the mobile phase composition was returned to 5% B. 
A 3 minute post time was used to re-equilibrate the column in between injections. The 
column compartment temperature was set to 40 C.  
 Both methods utilized a Jet Stream Electrospray ionization source operated in 
positive mode. The source parameters used included: Gas temperature of 325 C, Gas flow 
of 8 L/min, Nebulizer was set to 35 psig, Sheath Gas Temperature of 400 C, Sheath Gas 
Flow of 12 L/min, VCap of 3500 V, Nozzle Voltage of 0V, Fragmentor Voltage of 115 
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V, Skimmer 1 of 65 V. Reference mass were enabled and used both the 121.0509 m/z 
and 922.0098 m/z ions to perform real time x-axis recalibration. 
 The full scan acquisition method used a scan rate of 3 spectra/second and the mass 
range used was from 25 m/z to 1000 m/z. The All Ions acquisition method also used a 
scan rate of 3 spectra/second. The mass range was from 50 m/z to 1000 m/z. In addition, 
the All Ions acquisition method utilized three scan segments that were continuously 
cycled through the entire method. The only difference in these scan segments was the 
collision energy which was set to 0 eV, 20 eV, and 40 eV respectively. 
5.3.5 Data Analysis 
 The MassHunter quantitative analysis software was used to process the data for both 
acquisition methods. The full scan method utilized accurate mass and retention time to 
identify the analytes of interest. The All Ions acquisition also utilized accurate mass and 
retention time. In addition, the All Ions acquisition method also used two qualifier ions 
that were previously determined from the creation of a high resolution MS/MS spectral 
library for identification purposes. Product ion ratios had to agree within 20% of known 
standards.     
5.3.6 Limit of Detection 
 The limit of detection for the selected NPS was determined by fortifying a negative 
blood source at the following concentrations: 0.1 ng/mL, 0.5 ng/mL, 1 ng/mL, 5 ng/mL 
and 10 ng/mL. Concentrations were prepared in triplicate. The positive identification 
criteria used for the full scan data included a Gaussian peak shape, retention time within 
3% of a 100 ng/mL control sample retention time, and a signal to noise ratio greater than 
3. The accurate mass tolerance of the extracted ion chromatogram was set to +/- 20 ppm. 
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The All Ions acquisition method had the same criteria as the full scan acquisition method 
with an additional requirement of two product ions that had to have qualifier ratios 
agreeing within +/- 20 % of the qualifier ratio of the 100 ng/mL control. The reported 
limit of detection was the concentration where all three concentration replicates 
successfully met the positive identification criteria for the individual analyte.          
5.3.7 Matrix Effects and Recovery 
 Matrix effects and recovery percentage were determined by analyzing and comparing 
the peak area of three different experiments performed in triplicate. The first experiment 
involved fortifying a blood sample with the NPS mix to a final concentration of 100 
ng/mL and processing the sample through the solid phase extraction method as described 
earlier. This experiment was considered the pre-extraction addition experiment. The 
second and third experiments involved fortifying a solution consisting of the initial 
mobile phase to a concentration of 1,000 ng/mL. This was the concentration, assuming 
100% recovery, of the analytes after being processed by the solid phase extraction 
method and reconstituted with 100 µL of the initial mobile phase composition solution. 
In experiment 2, a negative blood sample was processed by the solid phase extraction 
method as described before with the exception of the reconstitution step. An aliquot of 
100 µL of the 1,000 ng/mL solution was added to the sample and replaces the 
reconstitution step. This experiment was considered the post-extraction addition 
experiment. The third experiment did not utilize the solid phase extraction method. In this 
experiment the 1,000 ng/mL solution was directly analyzed by the LC-QTOF-MS and 
was known as the neat experiment.  
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 All three experiments were analyzed by the LC-QTOF-MS utilizing the full scan MS 
acquisition method. The peak area of the post-extraction addition experiment was 
compared to the peak area of the neat experiment to determine the matrix effects. The 
recovery percentage was determined by comparing the peak area of the pre-extraction 
addition experiment to the post-extraction addition experiment.    
5.4 Results and Discussion 
 A SPE method and two acquisition methods utilizing a LC-QTOF-MS were 
developed and optimized in order to successfully identify NPS in human blood. Thirty-
three NPS were selected to demonstrate the applicability of this method for identifying 
compounds from different
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Substance   Class (M+H)+ RT (Min.) 
Full Scan LOD 
(ng/mL) 
All Ions LOD 
(ng/mL) 
Matrix 
Effect Recovery 
2C-C Phenethylamine 216.0786 2.9 0.5 0.5 -8% 28% 
2C-D Phenethylamine 196.1332 2.8 0.5 0.5 -5% 42% 
2C-E Phenethylamine 210.1489 3.3 0.5 1 -12% 44% 
2C-H Phenethylamine 182.1176 2.3 0.5 0.5 -4% 46% 
2C-I Phenethylamine 308.0142 3.2 0.5 0.5 -6% 34% 
2C-N Phenethylamine 227.1027 2.5 0.5 5 -4% 42% 
2C-P Phenethylamine 224.1645 3.7 1 5 -13% 37% 
2C-T-2 Phenethylamine 242.1209 3.2 0.5 1 -6% 40% 
2C-T-4 Phenethylamine 256.1366 3.5 0.5 0.5 -9% 40% 
3,4-Dimethylmethcathinone  Cathinone 192.1383 2.8 0.1 0.5 -4% 91% 
4-MMC Cathinone 178.1226 2.4 0.1 1 -2% 79% 
AKB48 Syn. Cannabinoid 366.2540 10.0 5 5 -8% 75% 
AM1220 Syn. Cannabinoid 383.2118 4.4 0.5 5 -40% 56% 
AM2201 Syn. Cannabinoid 360.1758 7.2 0.1 0.5 -17% 65% 
AM2233 Syn. Cannabinoid 459.0928 4.1 0.5 0.5 -62% 50% 
AM694 Syn. Cannabinoid 436.0568 6.8 5 1 -75% 19% 
Cannabipiperidiethanone Syn. Cannabinoid 377.2224 4.0 5 5 -55% 33% 
CB-13 Syn. Cannabinoid 369.1849 10.4 5 5 -32% 44% 
JWH 018 Syn. Cannabinoid 342.1853 8.3 0.5 1 -16% 68% 
JWH 018 adamantyl 
carboxamide Syn. Cannabinoid 365.2588 8.7 0.5 5 -7% 80% 
JWH 019 Syn. Cannabinoid 356.2009 8.8 0.5 1 -6% 84% 
JWH 022 Syn. Cannabinoid 340.1696 7.8 0.5 0.5 -10% 77% 
JWH 073 Syn. Cannabinoid 328.1696 7.8 0.5 0.5 -14% 76% 
JWH 081 Syn. Cannabinoid 372.1958 8.5 0.1 0.5 -9% 73% 
JWH 122 Syn. Cannabinoid 356.2009 8.9 0.5 0.5 -19% 89% 
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Table 5.  The limit of detection (Full scan and All Ion Mode), matrix effect, and recovery percentage of the NPS that were used to evaluate the SPE 
and acquisition methods. 
 
 
JWH 200 Syn. Cannabinoid 385.1911 4.5 0.5 0.5 -44% 57% 
JWH 203 Syn. Cannabinoid 340.1463 8.1 1 5 -36% 49% 
JWH 250 Syn. Cannabinoid 336.1958 7.6 0.1 5 -11% 81% 
JWH 398 Syn. Cannabinoid 376.1463 9.2 0.5 0.5 -13% 73% 
MDPV Cathinone 276.1594 3.0 0.1 0.5 -4% 80% 
Methoxetamine Arylcyclohexylamine 248.1645 2.7 0.1 0.5 -2% 82% 
RCS-4 Syn. Cannabinoid 322.1802 7.4 0.5 5 -17% 70% 
RCS-8 Syn. Cannabinoid 376.2271 8.8 0.5 5 -10% 81% 
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NPS classes. NPS classes present in the selected group of compounds include 
arylcyclohexylamine, cathinone, phenethylamines, and synthetic cannabinoids. At the 
time of development, these compounds were among the most popular NPS and/or 
recently controlled substances by various governments.  
 The optimization of the SPE method included modifying a generic basic drug 
extraction. The SPE sorbent bed consisted of a polymeric mixed mode resin that 
contained as cation exchanger and hydrophobic regions.  Initially, eluents from the 
various solid phase extraction steps were analyzed to determine at which points analytes 
were being retained or being lost. Various conditioning steps, sample pretreatments, wash 
steps, and elution solvents were evaluated and optimized. As the solid phase extraction 
bed utilized two primary retention mechanisms including ionic bonding and hydrophobic 
interactions, solvents with varying pH levels and polarities were investigated. In addition 
to the SPE method, the sample pretreatment step was also optimized by evaluating the 
addition of buffers with different pH levels and an addition of an acetonitrile crash with 
different acetonitrile and sample ratios.  
 The analytical method optimization focused on two major areas. The ionization 
source parameters and the acquisition mode parameters. Electrospray ionization has been 
known to be an inefficient ionization technique when compare to other techniques like 
electron impact ionization, therefore it was necessary to find the optimal source 
conditions that will yield the most amount of protonated adducts for identification as this 
can affect sensitivity. Various source parameters were evaluated including: nozzle 
voltage, drying gas flow rate, nebulizer pressure, sheath gas temperature, fragmentor 
voltage, and capillary voltage.  
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 The acquisition method optimization included evaluating acquisition rates for both 
the full scan acquisition and All Ions acquisition methods. The Auto MS/MS acquisition 
technique was initially evaluated in this stage of the work; however, it was determined 
that it may not be a practical acquisition mode for toxicological investigations. The data 
mining was very consuming and the analytes of interest have varying ionization 
efficiencies make it difficult to set the thresholds needed for the acquisition and data 
analysis methods. The full scan and All Ions acquisition methods were used in further 
experiments to evaluate performance.         
 While many targeted methods have been published and are necessary for quantitation 
purposes, there lies a need to be able to screen compounds that are unknown. Both 
methods presented here can be used to accomplish this challenge as both of these 
methods are non-targeted acquisition methods. The full scan acquisition method was 
typically more sensitive when compared to the All Ions method. However, the All Ions 
method was more selective as it provided MS/MS product ions that could be used to 
further confirm the presence of a NPS.  
 Another advantage of acquiring untargeted data is the capability of retrospective 
analysis for the detection of newer NPS in previously analyzed samples. Once a new NPS 
is identified, data files can be reanalyzed to determine if the NPS is present in cases that 
were analyzed previously. This saves time and also the limited resource of the sample as 
a re-extraction is not required. In addition, the stability of many NPS in the various 
matrices have not been completely evaluated. Therefore, a NPS may be missed if a 
sample is reanalyzed months or years later if the substance in not stable in the collected 
matrix.  
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 The limit of detection for the selected compounds was evaluated and determined for 
each acquisition method. The limit of detections ranged from 0.1 ng/mL to 5 ng/mL for 
the full scan acquisition method and ranged from 0.5 ng/mL to 5 ng/mL for the All Ions 
acquisition method. With the exception of AM-694, the limits of detection determined for 
all of the NPS in the full scan MS acquisition method were either equal to or less than the 
limits of detection determined using the All Ions acquisition method. The sensitivity 
displayed by the limit of detection in both of these methods is necessary as some NPS 
have been demonstrated to be very potent and reported in cases with low ng/mL 
concentration levels. 
 Matrix effects were evaluated to determine the extent of ion enhancement and/or ion 
suppression utilizing this methodology. Slight ion suppression (< 25%) was observed for 
26 of the 33 compounds. The seven compounds that exhibited major ion suppression 
came from the synthetic cannabinoid drug class. The ion suppression for these 
compounds ranged from 32.1% to 75.4%. Future studies are needed to determine if this 
suppression is reproducible (RSD <15%) in different sources of the blood matrix. If it is 
determined to be reproducible than it will satisfy ion enhancement and suppression 
recommendations proposed by SWGTOX.  
 Recovery was also determined for each NPS. The recovery yield ranged from 18.7% 
to 91.2%, with twenty of the thirty-three substances having recoveries greater than a 50% 
recovery yield. Ideally recoveries for each compound would be closer to a 100%. 
However, as this method was designed to be as comprehensive as possible, compound 
recovery percentages may be lower than of other methods that target a specific drug class 
that have similar chemical properties.  AM-694 was the compound that had lowest 
120 
 
recovery percentage of 18.7%. However, AM-694 had limits of detection of 5 and 1 
ng/mL for the full scan acquisition method and the All Ions method acquisition method 
respectively which may be sufficient for identifying AM-694 in toxicological 
investigations.                  
5.5 Conclusions 
 The two acquisition methods that were created are able to successfully identify 33 
selected NPS at low or sub ng/mL concentration levels in blood specimens. The limit of 
detection for these compounds ranged between 0.1 ng/mL to 5 ng/mL and 0.5 ng/mL to 5 
ng/mL for the full scan acquisition method and the All Ions acquisition method 
respectively. While the full scan acquisition method is more sensitive, the All Ions mode 
provided more selectivity by utilizing product ion ratios in order to further confirm the 
presence of a NPS. Matrix effects were evaluated and 26 out of the 33 compounds did not 
exhibit significant ion enhancement or ion suppression. Seven synthetic cannabinoids 
displayed ion suppression greater than 25%. Further studies are needed to determine if 
this suppression is reproducible in different sources of the blood matrix.  
 These two methods can be used in forensic or clinical toxicology laboratories as a 
way to identify NPS in a human blood sample. As these methods are non-targeted, these 
methods have the potential to identify new NPS that may be present in a sample. This is 
advantageous as new NPS appear on the market quite frequently. In addition, 
retrospective data analysis is also possible with these untargeted methods. Retrospective 
identification of NPS can be performed without re-extracting the samples. 
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  Future work is needed to further explore the capabilities of these two methods. Ideally 
a larger set of NPS from the various drug classes will be used to further evaluate the 
capabilities of this method for the identification of NPS in blood specimens.   
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6. SUMMARY  
If recent drug use trends continue, novel psychoactive substances will burden both 
forensic and clinical toxicology laboratories for years to come. Currently, resources that 
are needed in order to successfully screen and confirm these compounds may be too great 
for some laboratories. However, this issue needs to be addressed as many of these 
substances have been documented to be very potent, causing severe impairment or even 
death. The capability of identifying these substances in human performance and post 
mortem cases is necessary in order for a complete comprehensive toxicological 
investigation. This project’s aim was to help aid the toxicology community in achieving 
that goal by generating a large high resolution MS/MS spectral library and compound 
database that contained hundreds of NPS and by creating a method that can used to 
identify NPS from different drug classes. In addition, a collision induced dissociation 
study was perform to determine if MS/MS spectral data alone could be used to 
distinguish even the most difficult NPS, regioisomers.  
Recently, mass spectrometry has gained favor over traditional screening 
techniques such as immunoassays for the identification of NPS. This is mainly due to the 
fact that developing immunoassays to detect NPS is a time- consuming process and 
NPSusage changes relatively quickly. In addition, mass spectrometry provides an easily 
amenable identification technique that achieves the selectivity and sensitivity 
requirements needed to identify NPS in toxicological samples.      
Spectral libraries and compound databases are very useful when screening 
toxicological specimens by mass spectrometry. These resources can help direct 
investigations when drug standards are not readily available or when it is cost prohibited 
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to purchase a large amount of NPS standards. When this data is acquired on a high 
resolution tandem mass spectrometer such as the LC-QTOF, which was used for this 
project, the selectivity is increased which enables a greater confidence in the 
identification of a compound based on accurate mass and MS/MS spectral data. The 
toxicology laboratory can then focus on these identified compounds in an attempt to 
confirm the presence of a novel psychoactive substance in a specimen. The MS/MS 
spectral library and compound database created by this work can help forensic toxicology 
laboratories save time and resources when trying to identify NPS in human specimens.     
In addition to spectral libraries and compound databases, sample preparation 
techniques are necessary in order to analyze toxicological specimens by mass 
spectrometry. Recently, there have been simpler extraction methods such as “dilute and 
shoot” and “protein crash” methods described in literature as liquid chromatography mass 
spectrometers are able to analyze aqueous samples. Unfortunately, there are drawbacks 
associated with these methods. The major drawback is the matrix effect phenomenon 
which is frequently observed in electrospray ionization, a common ionization source used 
in liquid chromatography mass spectrometry. These extraction techniques typically do 
not remove as many endogenous and exogenous compounds from the specimen as more 
intensive extraction methods do. This also leads to more instrument maintenance and 
shorter analytical column life which results in using more of the laboratory’s resources. 
This research generated a solid phase extraction method that was able to successfully 
extract compounds from multiple NPS classes with limit of detections ranging from sub 
to low ng/mL concentrations. This method removed provided a cleaner and more 
concentrated extract when compared to the simpler extraction methods. 
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One of the main advantages of using tandem mass spectrometry is the increased 
selectivity. In targeted acquisition methods, ions of interest are filtered out before being 
subjected to ion dissociation. LC-QTOF-MS instrumentation, which couples a quadruple 
mass analyzer to a time of flight mass analyzer was used for this work. In this 
instrumentation the collision cell is in-line between the two mass analyzers and ions pass 
through this cell before entering the time of flight mass analyzer.  Collision induced 
dissociation occurs at varying collision energies in the collision cell which results in 
product ions which can help elucidate the chemical structure of a precursor ion. This 
increased selectivity is needed as there are many structurally similar compounds in the 
NPS classes.  While some isobars and isomers can be differentiated by retention time or 
by MS/MS data, there are some regioisomers which may be difficult to resolve by these 
means. Another part of this work was to evaluate the differences in relative abundance 
between regioisomers to determine if MS/MS spectral data alone could be used to 
differentiate the various regioisomers. The results of this study show that relative 
abundance of selected product ions could be used to help differentiate some regioisomer 
sets but not all of the regioisomer sets. This suggests that this is very compound specific. 
Future work will be needed as newer NPS appear in the drug market. Libraries 
and databases will need to be expanded to account for these new compounds. In addition 
extraction and acquisition methods may need to be modified in order to identify newer 
NPS in human matrices. The LC-QTOF-MS and other high resolution LC-MS 
instruments should continue to gain favor as a screening technique over immunoassay 
based approaches for novel psychoactive substances in human matrices due to the various 
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advantages of using high resolution mass spectrometry which include but not limited to 
both high sensitivity and high selectivity. 
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APPENDICES 
 
Appendix 1. Compounds included in the compound database. 
Common/Street Name Abbreviation Chemical  Name CAS Number Molecular Formula Structural Class 
AM-2201 2'-naphthyl isomer   (1-(5-fluoropentyl)-1H-indol-3-yl)(naphthalen-2-yl)methanone   C24H22FNO 2-Naphthoylindole 
JWH-018 2'-naphthyl isomer   naphthalen-2-yl-(1-pentylindol-3-yl)methanone 1131605-25-8 C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(1,1-dimethylpropyl) isomer   (1-(2-methylbutan-2-yl)indol-3-yl)-naphthalen-2-ylmethanone 1869951-99-4 C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(1,2-dimethylpropyl) isomer   (1-(3-methylbutan-2-yl)-1H-indol-3-yl)(naphthalen-2-yl)methanone   C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(1-ethylpropyl)   naphthalen-2-yl-(1-pentan-3-ylindol-3-yl)methanone 1869959-37-4 C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(1-methylbutyl) isomer   naphthalen-2-yl(1-(pentan-2-yl)-1H-indol-3-yl)methanone   C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(2,2-dimethylpropyl) isomer   [1-(2,2-dimethylpropyl)indol-3-yl]-naphthalen-2-ylmethanone 1869954-38-0 C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(2-methylbutyl) isomer   1-(2-methylbutyl)-1H-indol-3-yl)(naphthalen-2-yl)methanone   C24H23NO 2-Naphthoylindole 
JWH-018 2'-naphthyl-N-(3-methylbutyl) isomer   (1-isopentyl-1H-indol-3-yl)(naphthalen-2-yl)methanone   C24H23NO 2-Naphthoylindole 
JWH-073 2'-naphthyl isomer   (1-butylindol-3-yl)-naphthalen-2-ylmethanone   C23H21NO 2-Naphthoylindole 
JWH-073 2'-naphthyl-N-(1,1-dimethylethyl) isomer   (1-(tert-butyl)-1H-indol-3-yl)(naphthalen-2-yl)methanone   C23H21NO 2-Naphthoylindole 
JWH-073 2'-naphthyl-N-(1-methylpropyl) isomer   (1-butan-2-ylindol-3-yl)-naphthalen-2-ylmethanone   C23H21NO 2-Naphthoylindole 
JWH-073 2'-naphthyl-N-(2-methylpropyl) isomer   [1-(2-methylpropyl)indol-3-yl]-naphthalen-2-ylmethanone   C23H21NO 2-Naphthoylindole 
JWH-200 2'-naphthyl isomer   [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-2-naphthalenyl-methanone 133438-66-1 C25H24N2O2 2-Naphthoylindole 
5-Fluoro JWH 018 adamantyl analog  5F-AB-001 [1-(5-fluoropentyl)-1H-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone 1364933-62-9 C24H30FNO Adamantoylindole 
AM-1248   [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]tricyclo[3.3.1.13,7]dec-1-yl-methanone 335160-66-2 C26H34N2O Adamantoylindole 
AM-1248 azepane isomer   
(3,5,7)-adamantan-1-yl(1-(1-methylazepan-3-yl)-1H-
indol-3-yl)methanone   C26H34N2O Adamantoylindole 
JWH-018 adamantyl analog   1-adamantyl-(1-pentylindol-3-yl)methanone 1345973-49-0 C24H31NO Adamantoylindole 
AKB48   1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indazole-3-carboxamide 1345973-53-6 C23H31N3O 
Adamantylindazolecarb
oxamide 
AKB48 N-(4-fluorobenzyl) analog  FUB-AKB48 N-((3s,5s,7s)-adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide   C25H26FN3O 
Adamantylindazolecarb
oxamide 
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AKB48 N-(5-fluoropentyl) analog  5F-AKB48 N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 1400742-13-3 C23H30FN3O 
Adamantylindazolecarb
oxamide 
JWH-018 adamantyl carboxamide   1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide 1345973-50-3 C24H32N2O 
Adamantylindolecarbox
amide 
STS-135   1-(5-fluoropentyl)-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide 1354631-26-7 C25H34FNO 
Adamantylindolecarbox
amide 
3-Hydroxy eticyclidine 3-HO-PCE 3-[1-(ethylamino)cyclohexyl]phenol   C14H21NO Arylcyclohexylamine 
3-Hydroxy phencyclidine 3-HO-PCP 3-[1-(1-piperidinyl)cyclohexyl]phenol 79787-43-2 C17H25NO Arylcyclohexylamine 
3-Methoxy phencyclidine 3-MeO-PCP 1-[1-(3-methoxyphenyl)cyclohexyl]piperidine 72242-03-6 C18H27NO Arylcyclohexylamine 
4-Methoxy phencyclidine 4-MeO-PCP 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine 2201-35-6 C18H27NO Arylcyclohexylamine 
Benocyclidine BTPC 1-(1-benzo[b]thien-2-ylcyclohexyl)piperidine 112726-66-6 C19H25NS Arylcyclohexylamine 
Eticyclidine PCE N-ethyl phenylcyclohexylamine 2201-15-2 C14H21N Arylcyclohexylamine 
Methoxetamine MXE 2-(3-methoxyphenyl)-2-(N-ethylamino)cyclohexanone 1239908-48-5 C15H21NO2 Arylcyclohexylamine 
PCEEA   N-(1-phenylcyclohexyl)-2-ethoxyethanamine   C16H25NO Arylcyclohexylamine 
PCEPA   N-(1-phenylcyclohexyl)-3-ethoxypropanamine   C17H27NO Arylcyclohexylamine 
PCMEA   N-(1-phenylcyclohexyl)-2-methoxyethanamine   C15H23NO Arylcyclohexylamine 
PCMPA   N-(1-phenylcyclohexyl)-3-methoxypropanamine   C16H25NO Arylcyclohexylamine 
Phencyclamine PCPr 1-phenyl-N-propyl-cyclohexanamine 18949-81-0 C15H23N Arylcyclohexylamine 
Phencyclidine PCP 1-(1-phenylcyclohexyl)piperidine 77-10-1 C17H25N Arylcyclohexylamine 
Rolicyclidine PCPy 1-(1-phenylcyclohexyl)pyrrolidine 2201-39-0 C16H23N Arylcyclohexylamine 
AM-2201 benzimidazole analog  FUBIMINA (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone 1984789-90-3 C23H21FN2O Benzimidazole 
JWH-018 benzimidazole analog  BIM-018 naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-yl)methanone   C23H22N2O Benzimidazole 
MCHB-1    1-(cyclohexylmethyl)-2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1H-benzimidazole-5-carboxamide 1046140-32-2 C28H37N3O2 Benzimidazole 
PF-03550096    
N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-2,3-
dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1H-
benzimidazole-1-carboxamide 
910376-39-5 C19H28N4O4 Benzimidazole 
AM-2233   (2-iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone 444912-75-8 C22H23IN2O Benzoylindole 
AM-630   (6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl)(4-methoxyphenyl)methanone 164178-33-0 C23H25IN2O3 Benzoylindole 
AM-679   (2-iodophenyl)(1-pentyl-1H-indol-3-yl)methanone 335160-91-3 C20H20INO Benzoylindole 
AM-694   [1-(5-fluoropentyl)-1H-indol-3-yl](2-iodophenyl)methanone 335161-03-0 C20H19FINO Benzoylindole 
AM-694 3-iodo isomer   (1-(5-fluoropentyl)-1H-indol-3-yl)(3-iodophenyl)methanone 1427325-91-4 C20H19FINO Benzoylindole 
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AM-694 4-iodo isomer   (1-(5-fluoropentyl)-1H-indol-3-yl)(4-iodophenyl)methanone 1427325-92-5 C20H19FINO Benzoylindole 
RCS-4   (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone 1345966-78-0 C21H23NO2 Benzoylindole 
RCS-4 2-methoxy isomer   (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone 1345966-76-8 C21H23NO2 Benzoylindole 
RCS-4 3-methoxy isomer   (3-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone 1379922-51-6 C21H23NO2 Benzoylindole 
RCS-4 M10 metabolite   
(1-(5-hydroxypentyl)-1H-indol-3-yl)(4-
hydroxyphenyl)methanone   C20H21NO3 Benzoylindole 
RCS-4 M11 metabolite   5-(3-(4-hydroxybenzoyl)-1H-indol-1-yl)pentan-2-one   C20H19NO3 Benzoylindole 
RCS-4 M9 metabolite   
(1-(4-hydroxypentyl)-1H-indol-3-yl)(4-
hydroxyphenyl)methanone   C20H21NO3 Benzoylindole 
RCS-4 N-(4-hydroxypentyl) metabolite   (1-(4-hydroxypentyl)-1H-indol-3-yl)(4-methoxyphenyl)methanone 1448893-03-5 C21H33NO3 Benzoylindole 
RCS-4 N-(5-carboxypentyl) metabolite   5-(3-(4-methoxybenzoyl)-1H-indol-1-yl)pentanoic acid 1427521-39-8 C21H21NO4 Benzoylindole 
RCS-4 N-(5-hydroxypentyl) metabolite   (1-(5-hydroxypentyl)-1H-indol-3-yl)(4-methoxyphenyl)methanone 1379604-66-6 C21H23NO3 Benzoylindole 
RCS-4-C4 Homolog   (4-methoxyphenyl)(1-butyl-1H-indol-3-yl)methanone 1345966-77-9 C20H21NO2 Benzoylindole 
WIN 48,098 Pravadoline (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-methanone 92623-83-1 C23H26N2O3 Benzoylindole 
WIN 54,461   [6-bromo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone 166599-63-9 C23H25BrN2O3 Benzoylindole 
2,3-Dimethylethcathinone   2,3-DMEC 1-(2,3-dimethylphenyl)-2-(ethylamino)-1-propanone   C13H19NO Cathinone 
2,3-Dimethylmethcathinone   2,3-DMMC 1-(2,3-Dimethylphenyl)-2-(methylamino)-1-propanone   C12H17NO Cathinone 
2,3-Ethylone isomer   2,3-bk-MDEA 1-(benzo[d][1,3]dioxol-4-yl)-2-(ethylamino)-1-propanone   C12H15NO3 Cathinone 
2,3-Methylenedioxy Pyrovalerone  2,3-MDPV 1-(benzo[d][1,3]dioxol-4-yl)-2-(piperidin-1-yl)pentan-1-one   C16H21NO3 Cathinone 
2,3-Methylenedioxymethcathinone  2,3-MDMC 1-(benzo[d][1,3]dioxol-4-yl)-2-(methylamino)propan-1-one   C11H13NO3 Cathinone 
2,3-Pentylone isomer    1-(benzo[d][1,3]dioxol-4-yl)-2-(methylamino)pentan-1-one   C13H17NO3 Cathinone 
2,4-Dimethylethcathinone   2,4-DMEC 1-(2,4-dimethylphenyl)-2-(ethylamino)-1-propanone   C13H19NO Cathinone 
2,4-Dimethylmethcathinone 2,4-DMMC 
1-(2,4-dimethylphenyl)-2-(methylamino)propan-1-
one 1081772-06-6 C12H17NO Cathinone 
2-Ethylethcathinone 2-EEC 2-(ethylamino)-1-(2-ethylphenyl)propan-1-one   C13H19NO Cathinone 
2-Ethylmethcathinone 2-EMC 1-(2-ethylphenyl)-2-(methylamino)propan-1-one   C12H17NO Cathinone 
2-Fluoroethcathinone 2-FEC 2-(ethylamino)-1-(2-fluorophenyl)propan-1-one   C11H14FNO Cathinone 
2-Fluoromethcathinone 2-FMC 1-(2-fluorophenyl)-2-(methylamino)propan-1-one 1186137-35-8 C10H12FNO Cathinone 
2-Methoxymethcathinone 2-MeOMC 1-(2-methoxyphenyl)-2-(methylamino)propan-1-one 882302-55-8 C11H15NO2 Cathinone 
2-Methylethcathinone 2-MEC 2-(ethylamino)-1-(o-tolyl)propan-1-one   C12H17NO Cathinone 
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2-Methylmethcathinone 2-MMC 2-(methylamino)-1-(2-methylphenyl)propan-1-one 1246911-71-6 C11H15NO Cathinone 
2-Methyl-α-Pyrrolidinobutiophenone 2-MePBP 2-(pyrrolidin-1-yl)-1-(o-tolyl)butan-1-one   C15H21NO Cathinone 
2-Methyl-α-Pyrrolidinopropiophenone     2-(pyrrolidin-1-yl)-1-(o-tolyl)propan-1-one   C14H19NO Cathinone 
3,4-Dimethoxymethcathinone     1-(3,4-dimethoxyphenyl)-2-(methylamino)-1-propanone   C12H17NO3 Cathinone 
3,4-Dimethoxy-α-Pyrrolidinohexanophenone   3,4-dimethoxy-α-PHP 1-(3,4-dimethoxyphenyl)-2-(pyrrolidin-1-yl)hexan-1-one   C18H27NO3 Cathinone 
3,4-Dimethoxy-α-Pyrrolidinopentiophenone 3,4-Dimethoxy-α-PVP 
1-(3,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)pentan-1-
one 850442-84-1 C17H25NO3 Cathinone 
3,4-Dimethylethcathinone 3,4-DMEC 1-(3,4-dimethylphenyl)-2-(ethylamino)propan-1-one 1225811-81-3 C13H19NO Cathinone 
3,4-Dimethylmethcathinone 3,4-DMMC 1-(3,4-dimethylphenyl)-2-(methylamino)propan-1-one 1082110-00-6 C12H17NO Cathinone 
3,4-Ethylenedioxymethcathinone bk-EDMA, 3,4-EDMC 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(methylamino)-1-propanone   C12H15NO3 Cathinone 
3,4-Methylenedioxy-5-methylethcathinone     2-(ethylamino)-1-(7-methyl-1,3-benzodioxol-5-yl)-1-propanone   C13H17NO3 Cathinone 
3,4-Methylenedioxy-N-benzylcathinone BMDP 1-(1,3-benzodioxol-5-yl)-2-(phenylamino)propan-1-one 1357477-43-0 C16H15NO3 Cathinone 
3,4-Methylenedioxy-PV8     1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-heptanone   C18H25NO3 Cathinone 
3,4-Methylenedioxypyrovalerone MDPV 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one 687603-66-3 C16H21NO3 Cathinone 
3,4-Methylenedioxy-α-pyrrolidinobutyrophenone MDPBP 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)butan-1-one 784985-33-7 C15H19NO3 Cathinone 
3,4-Methylenedioxy-α-Pyrrolidinohexanophenone   3,4-MDPHP 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1hexanone   C17H23NO3 Cathinone 
3,4-Methylenedioxy-α-pyrrolidinopropiophenone MDPPP 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)propan-1-one 783241-66-7 C14H17NO3 Cathinone 
3,4-Tetramethylene-α-Pyrrolidinovalerophenone   TH-PVP 2-(pyrrolidin-1-yl)-1-(5,6,7,8-tetrahydronaphthalen-2-yl)pentan-1-one   C19H27NO Cathinone 
3,4-Trimethylene-α-Ethylaminovalerophenone  bk-IVP 1-(2,3-dihydro-1H-inden-5-yl)-2-(ethylamino)pentan-1-one   C16H23NO Cathinone 
3,4-Trimethylene-α-Pyrrolidinohexanophenone   5-BPDi 1-(2,3-dihydro-1H-inden-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one   C19H27NO Cathinone 
3-Bromomethcathinone 3-BMC 1-(3-bromophenyl)-2-(methylamino)propan-1-one 486459-02-3 C10H12BrNO Cathinone 
3-Chloromethcathinone   3-CMC 1-(3-chlorophenyl)-2-(methylamino)-1-propanone   C10H12ClNO Cathinone 
3-Desoxy-3,4-Methylenedioxy Pyrovalerone   5-DBFPV 1-(2,3-dihydrobenzofuran-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one   C17H23NO2 Cathinone 
3-Ethylethcathinone 3-EEC 2-(ethylamino)-1-(3-ethylphenyl)propan-1-one   C13H19NO Cathinone 
3-Ethylmethcathinone 3-EMC 1-(3-ethylphenyl)-2-(methylamino)propan-1-one   C12H17NO Cathinone 
3-Fluoroethcathinone 3-FEC 2-(ethylamino)-1-(3-fluorophenyl)propan-1-one   C11H14FNO Cathinone 
3-Fluoromethcathinone 3-FMC 1-(3-fluorophenyl)-2-(methylamino)propan-1-one 1049677-77-1 C10H12FNO Cathinone 
3-Fluoro-α-Pyrrolidinopropiophenone   3-fluoro-α-PPP 1-(3-fluorophenyl)-2-(1-pyrrolidinyl)-1-propanone   C13H16FNO Cathinone 
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3-Methoxymethcathinone 3-MeOMC 1-(3-methoxyphenyl)-2-(methylamino)propan-1-one 882302-56-9 C11H15NO2 Cathinone 
3-Methylbuphedrone   3-methyl BP 2-(methylamino)-1-(m-tolyl)butan-1-one   C12H17NO Cathinone 
3-Methylethcathinone 3-MEC 2-(ethylamino)-1-(m-tolyl)propan-1-one   C12H17NO Cathinone 
3-Methylmethcathinone 3-MMC 2-(methylamino)-1-(3-methylphenyl)propan-1-one 1246911-86-3 C11H15NO Cathinone 
3-Methyl-α-Pyrrolidinobutiophenone 3-MePBP 2-(pyrrolidin-1-yl)-1-(m-tolyl)butan-1-one   C15H21NO Cathinone 
4-Bromomethcathinone 4-BMC 1-(4-bromophenyl)-2-(methylamino)propan-1-one 486459-03-4  C10H12BrNO Cathinone 
4-Chloromethcathinone   4-CMC 1-(4-chlorophenyl)-2-(methylamino)-1-propanone   C10H12ClNO Cathinone 
4-Chloro-α-Pyrrolidinopropiophenone   4-chloro PPP 1-(4-chlorophenyl)-2-(1-pyrrolidinyl)-1-propanone   C13H16ClNO Cathinone 
4-Ethylcathinone 4-EC 2-amino-1-(4-ethylphenyl)propan-1-one 805951-15-9 C11H15NO Cathinone 
4-Ethylethcathinone 4-EEC 2-(ethylamino)-1-(4-ethylphenyl)propan-1-one 1225619-32-8 C13H19NO Cathinone 
4-Ethylmethcathinone 4-EMC 1-(4-ethylphenyl)-2-(methylamino)propan-1-one 1225622-14-9 C12H17NO Cathinone 
4-Ethyl-N,N-dimethylcathinone    2-(dimethylamino)-1-(4-ethylphenyl)propan-1-one 1157738-27-6 C13H19NO Cathinone 
4-Fluoro Pentedrone   4-FPD 1-(4-fluorophenyl)-2-(methylamino)pentan-1-one   C12H16FNO Cathinone 
4-Fluoro PV8   4-fluoro α-PHPP 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)heptan-1-one,   C17H24FNO Cathinone 
4-Fluoro PV8 piperidine analog     1-(4-fluorophenyl)-2-(piperidin-1-yl)heptan-1-one   C18H26FNO Cathinone 
4-Fluoro PV9   para-fluoro-PV9 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)octan-1-one   C18H26FNO Cathinone 
4-Fluoro-(methylamino)butyrophenone 4-F-MABP,  4-FBP 1-(4-fluorophenyl)-2-(methylamino)butan-1-one 1368599-12-5 C11H14FNO Cathinone 
4-Fluoroethcathinone 4-FEC 2-(ethylamino)-1-(4-fluorophenyl)propan-1-one 1225625-74-0 C11H14FNO Cathinone 
4-Fluoromethcathinone 4-FMC 1-(4-fluorophenyl)-2-(methylamino)propan-1-one 7589-35-7 C10H12FNO Cathinone 
4-Fluoro-N-Isopropyl-Pentedrone 4-fluoro NPP 1-(4-fluorophenyl)-2-(isopropylamino)pentan-1-one   C14H20FNO Cathinone 
4-Fluoro-α-Pyrrolidinobutiophenone   4-fluoro PBP 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)butan-1-one   C14H18FNO Cathinone 
4-Fluoro-α-Pyrrolidinopentiophenone   4-fluoro-α-PVP 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)-1-pentanone   C15H20FNO Cathinone 
4-Fluoro-α-Pyrrolidinopropiophenone   4-fluoro-α-PPP 1-(4-fluorophenyl)-2-(1-pyrrolidinyl)-1-propanone   C13H16FNO Cathinone 
4-Methoxy PV8     1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)heptan-1-one   C18H27NO2 Cathinone 
4-Methoxy PV9     1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one   C19H29NO2 Cathinone 
4-Methoxy-N,N-Dimethylcathinone     2-(dimethylamino)-1-(4-methoxyphenyl)-1-propanone   C12H17NO2 Cathinone 
4-Methoxy-α-Pyrrolidinobutiophenone   4-MeOPBP 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)butan-1-one   C15H21NO2 Cathinone 
4-Methoxy-α-Pyrrolidinopentiophenone   4-MeO-α-PVP 1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-1-pentanone   C16H23NO2 Cathinone 
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4-Methoxy-α-pyrrolidinopropiophenone 4-MeO-α-PPP 1-(4-methoxyphenyl)-2-(1-pyrrolidinyl)-1-propanone 478243-09-3 C14H19NO2 Cathinone 
4-Methyl Pentedrone   4-MPD 2-(methylamino)-1-(p-tolyl)pentan-1-one   C13H19NO Cathinone 
4-Methylbuphedrone 4-MeBP 2-(methylamino)-1-(4-methylphenyl)butan-1-one 1337016-51-9 C12H17NO Cathinone 
4-Methylethcathinone 4-MEC 2-(ethylamino)-1-(4-methylphenyl)propan-1-one 1225617-18-4 C12H17NO Cathinone 
4-Methylmethcathinone 4-MMC 2-(methylamino)-1-(4-methylphenyl)propan-1-one 1189726-22-4 C11H15NO Cathinone 
4-Methyl-N,N-Dimethylcathinone   4-methyl-N,N-DMC 2-(dimethylamino)-1-(4-methylphenyl)-1-propanone   C12H17NO Cathinone 
4-Methyl-N-Methylbuphedrone     2-(dimethylamino)-1-(p-tolyl)butan-1-one   C13H19NO Cathinone 
4-Methyl-N-methylhexanophenone     2-(methylamino)-1-(p-tolyl)hexan-1-one   C14H21NO Cathinone 
4-Methyl-α-ethylaminobutiophenone     2-(ethylamino)-1-(4-methylphenyl)-1-butanone   C13H19NO Cathinone 
4-Methyl-α-ethylaminopentiophenone     2-(ethylamino)-1-(4-methylphenyl)-1-pentanone   C14H21NO Cathinone 
4-Methyl-α-pyrrolidinobutiophenone MPBP   1-(4-methylphenyl)-2-(1-pyrrolidinyl)butan-1-one 732180-91-5 C15H21NO Cathinone 
4-Methyl-α-Pyrrolidinobutiophenone     1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-butanone   C15H21NO Cathinone 
4-Methyl-α-pyrrolidinohexanophenone 4-MePHP 2-(pyrrolidin-1-yl)-1-(p-tolyl)hexan-1-one 34138-58-4 C17H25NO Cathinone 
4-Methyl-α-Pyrrolidinohexanophenone   4-methyl-α-PHP 2-(pyrrolidin-1-yl)-1-(p-tolyl)hexan-1-one   C17H25NO Cathinone 
4-Methyl-α-pyrrolidinopropiophenone 4-MePPP 1-(4-methylphenyl)-2-(1-pyrrolidinyl)propan-1-one 28117-80-8 C14H19NO Cathinone 
4-Methyl-α-Pyrrolidinopropiophenone   4-methyl PPP 2-(pyrrolidin-1-yl)-1-(p-tolyl)propan-1-one   C14H19NO Cathinone 
5-Methoxy Methylone     1-(7-methoxybenzo[d][1,3]dioxol-5-yl)-2-(methylamino)propan-1-one   C12H15NO4 Cathinone 
6-Methoxy Methylone     1-(6-methoxybenzo[d][1,3]dioxol-5-yl)-2-(methylamino)propan-1-one   C12H15NO4 Cathinone 
7-MAPB     1-(benzofuran-7-yl)-N-methylpropan-2-amine   C12H15NO Cathinone 
Benzedrone 4-MBC 2-(benzylamino)-1-(p-tolyl)propan-1-one 1225617-75-3 C17H19NO Cathinone 
Benzedrone     1-(4-methylphenyl)-2-[(phenylmethyl)amino]-1-propanone   C17H19NO Cathinone 
bk-2C-B     2-amino-1-(4-bromo-2,5-dimethoxyphenyl)-ethanone   C10H12BrNO3 Cathinone 
bk-EABDI   bk-IBP 1-(2,3-dihydro-1H-inden-5-yl)-2-(ethylamino)butan-1-one   C15H21NO Cathinone 
Buphedrone MABP 2-(methylamino)-1-phenylbutan-1-one 408332-79-6 C11H15NO Cathinone 
Butylone bk-MBDB 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one 802575-11-7 C12H15NO3 Cathinone 
Cathinone   (2S)-2-amino-1-phenylpropan-1-one 71031-15-7 C9H11NO Cathinone 
Dibutylone bk-DMBDB  1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)butan-1-one 802286-83-5 C13H17NO3 Cathinone 
Dimethylone bk-MDDMA   1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)propan-1-one 765231-58-1 C12H15NO3 Cathinone 
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DL-4662     1-(3,4-dimethoxyphenyl)-2-(ethylamino)pentan-1-one   C15H23NO3 Cathinone 
Ethcathinone ETH-CAT 2-ethylamino-1-phenyl-propan-1-one 18259-37-5 C11H15NO Cathinone 
Ethylone MDEC, bk-MDEA 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one 1112937-64-0 C12H15NO3 Cathinone 
Eutylone bk-EBDB 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one 802855-66-9 C13H17NO3 Cathinone 
Methcathinone M-CAT 2-(methylamino)-1-phenylpropan-1-one 5650-44-2 C10H13NO Cathinone 
Methedrone PMMC, bk-PMMA 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one 530-54-1 C11H15NO2 Cathinone 
Methylbuphedrone  3-MeBP 2-(methylamino)-1-(m-tolyl)butan-1-one   C12H17NO Cathinone 
Methylone MDMC, bk-MDMA 1-(1,3-benzodioxol-5-yl)-2-(methylamino)propan-1-one 186028-79-5 C11H13NO3 Cathinone 
N,N-Diethylcathinone    2-(diethylamino)-1-phenyl-1-propanone 90-84-6 C13H19NO Cathinone 
N,N-Dimethylcathinone    2-(dimethylamino)-1-phenyl-1-propanone 15351-09-4 C11H15NO Cathinone 
N,N-Dimethylpentylone   bk-DMBDP 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone   C14H19NO3 Cathinone 
N-Acetyl-3,4-Methylenedioxymethcathinone  N-acetyl-3,4-MDMC N-[2-(1,3-benzodioxol-5-yl)-1-methyl-2-oxoethyl]-N-methyl-acetamide   C13H15NO4 Cathinone 
Naphyrone    1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one 850352-53-3 C19H23NO Cathinone 
Naphyrone 1-naphthyl isomer   1-(naphthalen-1-yl)-2-(pyrrolidin-1-yl)pentan-1-one 1349245-31-3 C19H23NO Cathinone 
N-Ethylbuphedrone   NEB 2-(ethylamino)-1-phenylbutan-1-one   C12H17NO Cathinone 
N-Ethyl-N-Methylcathinone     2-(ethyl(methyl)amino)-1-phenylpropan-1-one   C12H17NO Cathinone 
N-Ethylpentylone     1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone   C14H19NO3 Cathinone 
nor-Mephedrone    2-amino-1-(4-methylphenyl)propan-1-one 31952-47-3 C10H13NO Cathinone 
NRG-3     2-(methylamino)-1-(naphthalen-2-yl)pentan-1-one   C16H19NO Cathinone 
Pentedrone   2-(methylamino)-1-phenyl-pentan-1-one 879722-57-3 C12H17NO Cathinone 
Pentylone  bk-MBDP 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one 698963-77-8 C13H17NO3 Cathinone 
PV8     1-phenyl-2-(1-pyrrolidinyl)-1-heptanone   C17H25NO Cathinone 
PV9     1-phenyl-2-(pyrrolidin-1-yl)octan-1-one   C18H27NO Cathinone 
Pyrovalerone   1-(4-methylphenyl)-2-(1-pyrrolidinyl)pentan-1-one 3563-49-3 C16H23NO Cathinone 
α-Dimethylaminopentiophenone     2-(dimethylamino)-1-phenyl-1-pentanone   C13H19NO Cathinone 
α-Ethylaminopentiophenone     2-(ethylamino)-1-phenyl-1-pentanone   C13H19NO Cathinone 
α-Methylaminohexanophenone     2-(methylamino)-1-phenylhexan-1-one   C13H19NO Cathinone 
α-Phthalimidopropiophenone  α-PAPP 2-(1-methyl-2-oxo-2-phenylethyl)-1H-isoindole-1,3(2H)-dione   C17H13NO3 Cathinone 
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α-Piperidinobutiophenone   α-PipBP 1-phenyl-2-(1-piperidinyl)-1-butanone   C15H21NO Cathinone 
α-Propylaminopentiophenone   N-Propylpentedrone 1-phenyl-2-(propylamino)-1-pentanone   C14H21NO Cathinone 
α-Pyrrolidinobutiophenone α-PBP 1-phenyl-2-(1-pyrrolidinyl)butan-1-one 13415-82-2 C14H19NO Cathinone 
α-Pyrrolidinopentiophenone α-PVP 1-phenyl-2-(1-pyrrolidinyl)pentan-1-one 14530-33-7 C15H21NO Cathinone 
α-Pyrrolidinopentiothiophenone  a-PVT 2-(pyrrolidin-1-yl)-1-(thiophen-2-yl)pentan-1-one   C13H19NOS Cathinone 
α-Pyrrolidinopropiophenone α-PPP 1-phenyl-2-(1-pyrrolidinyl)propan-1-one 19134-50-0 C13H17NO Cathinone 
CP 47,497   2-(3-hydroxycyclohexyl)-5-(2-methyl-2-octanyl)phenol 70434-82-1 C21H34O2 Cyclohexylphenol 
CP 47,497 epimer   
rel-2[(1S,3S)-3-hydroxycyclohexyl)]-5-(2-
methyloctan-2-yl)phenol   C21H34O2 Cyclohexylphenol 
CP 47,497-C7-hydroxy metabolite   5-(8-hydroxy-2-methyloctan-2-yl)-2-((1S,3R)-3-hydroxycyclohexyl)phenol 1554485-44-7 C21H34O3 Cyclohexylphenol 
CP 47,497-C8-homolog   2-(3-hydroxycyclohexyl)-5-(2-methylnonan-2-yl)phenol 70434-92-3 C22H36O2 Cyclohexylphenol 
CP 47,497-C8-homolog 3-epimer   
rel-2-[(1S,3S)-3-hydroxycyclohexyl)]-5-(2-
methylnonan-2-yl)phenol   C22H36O2 Cyclohexylphenol 
CP 47,497-C8-homolog C8-hydroxy metabolite   5-(9-hydroxy-2-methylnonan-2-yl)-2-((1S,3R)-3-hydroxycyclohexyl)phenol 1554485-48-1 C22H36O3 Cyclohexylphenol 
CP 47,497-para-quinone analog   3R-hydroxy-4-(2-methyloctan-2-yl)-[1,1S-bi(cyclohexane)]-3,6-diene-2,5-dione   C21H32O3 Cyclohexylphenol 
CP 50,556-1   
[(6S,6aR,9R,10aR)- 9-hydroxy- 6-methyl- 3-[(2R)-5-
phenylpentan- 2-yl]oxy- 5,6,6a,7,8,9,10,10a-
octahydrophenanthridin- 1-yl] acetate 
71048-87-8 C27H35NO4 Cyclohexylphenol 
CP 55,244   
(2S,4S,4aS,6R,8aR)-6-(hydroxymethyl)-4-[2-
hydroxy-4-(2-methyloctan-2-yl)phenyl]-
1,2,3,4,4a,5,6,7,8,8a-decahydronaphthalen-2-ol 
79678-32-3 C26H42O3 Cyclohexylphenol 
CP 55,940   
2-[(1S,2R,5S)-5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl]-5-(2-methyl-2-
octanyl)phenol 
83002-04-4 C24H40O3 Cyclohexylphenol 
CP 55,940 5-epimer   
rel-2-((1R,2R,5S)-5-hydroxy-2-(3-
hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-
yl)phenol   C24H40O3 
Cyclohexylphenol 
FAB-144    (1-(5-fluoropentyl)-1H-indazol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone   C20H27FN2O 
Cyclopropanoylindazol
e 
A-796,260   
[1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](2,2,3,3-
tetramethylcyclopropyl)methanone 895155-26-7 C22H30N2O2 Cyclopropanoylindole 
A-834,735   
[1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indol-3-
yl](2,2,3,3-tetramethylcyclopropyl)methanone 895155-57-4 C22H29NO2 Cyclopropanoylindole 
AB-005    [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone 895155-25-6 C23H32N2O Cyclopropanoylindole 
FUB-144  FUB-UR-144 (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone   C23H24FNO Cyclopropanoylindole 
MDMB-CHMICA  MMB-CHMINACA methyl (S)-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate   C23H32N2O3 Cyclopropanoylindole 
UR-144   (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 1199943-44-6 C21H29NO Cyclopropanoylindole 
151 
 
UR-144 N-(2-chloropentyl) analog    (1-(2-chloropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone   C21H28ClNO Cyclopropanoylindole 
UR-144 N-(3-chloropentyl) analog    (1-(3-chloropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone   C21H28ClNO Cyclopropanoylindole 
UR-144 N-(5-bromopentyl) analog   
(1-(5-bromopentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone   C21H28BrNO Cyclopropanoylindole 
UR-144 N-(5-chloropentyl) analog   
(1-(5-chloropentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 1445577-42-3 C21H28ClNO Cyclopropanoylindole 
UR-144 N-(5-methylhexyl) analog    (1-(5-methylhexyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone   C23H33NO Cyclopropanoylindole 
UR-144 N-heptyl analog   
(1-heptyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone   C23H33NO Cyclopropanoylindole 
XLR-11   (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 1364933-54-9 C21H28FNO Cyclopropanoylindole 
XLR-11 N-(2-fluoropentyl) isomer   
(1-(2-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone   C21H28FNO Cyclopropanoylindole 
XLR-11 N-(3-fluoropentyl) isomer   
(1-(3-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone   C21H28FNO Cyclopropanoylindole 
XLR-11 N-(4-hydroxypentyl) metabolite   
(1-(5-fluoro-4-hydroxypentyl)-1H-indol-3-yl)(2,2,3,
3-tetramethylcyclopropyl)methanone   C21H28FNO2 Cyclopropanoylindole 
XLR11 N-(4-pentenyl) analog    (1-(pent-4-en-1-yl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 1445578-20-0 C21H27NO Cyclopropanoylindole 
XLR12    (2,2,3,3-tetramethylcyclopropyl)[1-(4,4,4-trifluorobutyl)-1H-indol-3-yl]-methanone 895155-78-9 C20H24F3NO Cyclopropanoylindole 
1-Aminoindane   2,3-dihydro-1H-inden-1-amine 34698-41-4 C9H11N Indane 
2-Aminoindane 2-AI 2,3-dihydro-1H-inden-2-amine 2975-41-9 C9H11N Indane 
5-(2-Aminopropyl)-2,3-dihydro-1H-indene 5-APDI 1-(2,3-dihydro-1H-inden-5-yl)propan-2-amine 152624-02-7 C12H17N Indane 
5,6-Methylenedioxy-2-aminoindane MDAI 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine 132741-81-2 C10H11NO2 Indane 
5-Iodo-2-aminoindane 5-IAI  5-iodo-2,3-dihydro-1H-inden-2-amine 132367-76-1 C9H10IN Indane 
5-Methoxy-6-methyl-2-aminoindane MMAI 2,3-dihydro-5-methoxy-6-methyl-1H-inden-2-amine 132980-16-6 C11H15NO Indane 
5-Chloro AB-PINACA    N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-chloropentyl)-1H-indazole-3-carboxamide 1801552-02-2 C18H25ClN4O2 Indazole 
5-Fluoro ABICA    N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-fluoropentyl)-1H-indole-3-carboxamide 1801338-26-0 C19H26FN3O2 Indazole 
5-Fluoro AB-PINACA    N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 1800101-60-3 C18H25FN4O2 Indazole 
5-Fluoro ADB  5-fluoro MDMB-PINACA 
methyl (R)-2-(1-(5-fluoropentyl)-1H-indazole-3-
carboxamido)-3,3-dimethylbutanoate   C20H28FN3O3 Indazole 
5-Fluoro ADB-PINACA    N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide   C19H27FN4O2 Indazole 
5-Fluoro AEB  5F-EMB-PINACA ethyl (1-(5-fluoropentyl)-1H-indazole-3-carbonyl)-L-valinate   C20H28FN3O3 Indazole 
5-Fluoro AMB  5-fluoro AMP N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine, methyl ester 1801552-03-3 C19H26FN3O3 Indazole 
5-Fluoro CUMYL-PINACA    1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide 1400742-16-6 C22H26FN3O Indazole 
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5-Fluoro MN-18    1-(5-fluoropentyl)-N-1-naphthalenyl-1H-indazole-3-carboxamide 1445581-91-8 C23H22FN3O Indazole 
5-Fluoro NPB-22    1-(5-fluoropentyl)-8-quinolinyl ester-1H-indazole-3-carboxylic acid 1445579-79-2 C22H20FN3O2 Indazole 
5-Fluoro SDB-005    naphthalen-1-yl 1-(5-fluoropentyl)-1H-indazole-3-carboxylate   C23H21FN2O2 Indazole 
5-Fluoro THJ    1-(5-fluoropentyl)-N-(quinolin-8-yl)-1H-indazole-3-carboxamide   C22H21FN4O Indazole 
AB-CHMINACA    N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 1185887-21-1 C20H28N4O2 Indazole 
AB-FUBINACA   
N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 1185282-01-2 C20H21FN4O2 Indazole 
AB-PINACA   
(S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-
1H-indazole-3-carboxamide 1445752-09-9  C18H26N4O2 Indazole 
ADB-FUBINACA    N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 1445583-51-6 C21H23FN4O2 Indazole 
ADB-PINACA    N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-pentyl-1H-indazole-3-carboxamide 1633766-73-0 C19H28N4O2 Indazole 
AMB  AMP methyl (1-pentyl-1H-indazole-3-carbonyl)-L-valinate   C19H27N3O3 Indazole 
APP-CHMINACA  PX 3 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-(cyclohexylmethyl)-1H-Indazole-3-carboxamide 1185887-14-2 C24H28N4O2 Indazole 
APP-FUBINACA    
N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-
[(4-fluorophenyl)methyl]-1H-indazole-3-
carboxamide 
1185282-03-4 C24H21FN4O2 Indazole 
CUMYL-THPINACA    N-(1-methyl-1-phenylethyl)-1-[(tetrahydro-2H-pyran-4-yl)methyl]-1H-indazole-3-carboxamide 1400742-50-8 C23H27N3O2 Indazole 
FUB-AMB  AMB-FUBINACA methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate   C21H22FN3O3 Indazole 
FUB-NPB-22  5-fluoro NIN quinolin-8-yl 1-(4-fluorobenzyl)-1H-indazole-3-carboxylate   C24H16FN3O2 Indazole 
M-144  XLR11 2-methylindole analog 
(1-(5-fluoropentyl)-2-methyl-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone   C22H30FNO Indazole 
MAB-CHMINACA  ADB-CHMINACA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide   C21H30N4O2 Indazole 
MA-CHMINACA  AMB-CHMINACA methyl (1-(cyclohexylmethyl)-1H-indazole-3-carbonyl)-L-valinate   C21H29N3O3 Indazole 
MDMB-CHMINACA    N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-valine, methyl ester 1185888-32-7 C22H31N3O3 Indazole 
MDMB-FUBINACA  FUB-MDMB methyl (S)-2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate   C22H24FN3O3 Indazole 
MN-18    N-1-naphthalenyl-1-pentyl-1H-indazole-3-carboxamide 1391484-80-2 C23H23N3O Indazole 
MO-CHMINACA  MO-AMB 1-methoxy-3,3-dimethyl-1-oxobutan-2-yl 1-(cyclohexylmethyl)-1H-indazole-3-carboxylate   C22H30N2O4 Indazole 
NPB-22    1-pentyl-1H-indazole-3-carboxylic acid, 8-quinolinyl ester 1445579-61-2 C22H21N3O2 Indazole 
SDB-005    naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate   C23H22N2O2 Indazole 
THJ    1-pentyl-N-(quinolin-8-yl)-1H-indazole-3-carboxamide   C22H22N4O Indazole 
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5-Chloro NNEI  5-chloro MN-24 1-(5-chloropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide   C24H23ClN2O Indole 
5-Fluoro ADBICA    N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(5-fluoropentyl)-1H-indole-3-carboxamide 1863065-82-0 C20H28FN3O2 Indole 
5-Fluoro CUMYL-PICA    1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide 1400742-18-8 C23H27FN2O Indole 
5-Fluoro NNEI  5-fluoro MN-24 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide 1445580-60-8 C24H23FN2O Indole 
5-Fluoro PB-22  5-fluoro QUPIC 1-(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid 1400742-41-7 C23H21FN2O2 Indole 
5-Fluoro SDB-006    N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide   C21H23FN2O Indole 
5-Fluoropentyl-3-pyridinoylindole   (1-(5-fluoropentyl)-1H-indol-3-yl)(pyridin-3-yl)methanone   C19H19FN2O Indole 
AB-CHMICA    (S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide   C21H29N3O2 Indole 
ADB-CHMICA  MAB-CHMICA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indole-3-carboxamide   C22H31N3O2 Indole 
ADBICA    N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamide 1445583-48-1 C20H29N3O2 Indole 
AM-1241   (2-iodo-5-nitrophenyl)(1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl)methanone 444912-48-5 C22H22IN3O3 Indole 
AM2201 8-quinolinyl carboxamide    1-(5-fluoropentyl)-N-(quinolin-8-yl)-1H-indole-3-carboxamide   C23H22FN3O Indole 
APP-PICA    (S)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-pentyl-1H-indole-3-carboxamide   C23H27N3O2 Indole 
BB-22  QUCHIC 1-(cyclohexylmethyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid 1400742-42-8 C25H24N2O2 Indole 
CBL-018    naphthalen-1-yl 1-pentyl-1H-indole-3-carboxylate   C24H23NO2 Indole 
CUMYL-PICA    N-(1-methyl-1-phenylethyl)-1-pentyl-1H-indole-3-carboxamide 1400742-32-6 C23H28N2O Indole 
FDU-NNEI   1-(4-fluorobenzyl)-N-(naphthalen-1-yl)-1H-indole-3-carboxamide   C26H19FN2O Indole 
FDU-PB-22    1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 1-naphthalenyl ester 1883284-94-3 C26H18FNO2 Indole 
FUB-PB-22    1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylic acid, 8-quinolinyl ester 1800098-36-5 C25H17FN2O2 Indole 
IMMA   
1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-
3-acetic acid 53-86-1 C23H23ClN2O4 Indole 
MDA 19   (2Z)-2-(1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene)hydrazide, benzoic acid 1048973-47-2 C21H23N3O2 Indole 
MDA 77   2Z-(1,2-dihydro-6-methoxy-2-oxo-1-pentyl-3H-indol-3-ylidene)hydrazide, benzoic acid 1103774-21-5 C21H23N3O3 Indole 
MMB018    methyl (1-pentyl-1H-indole-3-carbonyl)-L-valinate   C20H28N2O3 Indole 
MMB2201  AMB-PICA methyl (1-(5-fluoropentyl)-1H-indole-3-carbonyl)-L-valinate   C20H27FN2O3 Indole 
MMB-CHMICA    methyl (1-(cyclohexylmethyl)-1H-indole-3-carbonyl)-L-valinate   C22H30N2O3 Indole 
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MN-25  UR-12 
7-methoxy-1-[2-(4-morpholinyl)ethyl]-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-
1H-indole-3-carboxamide 
501926-82-5 C26H37N3O3 Indole 
MN-25-2-methyl derivative    
7-methoxy-2-methyl-1-[2-(4-morpholinyl)ethyl]-N-
[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-
1H-indole-3-carboxamide 
501927-29-3 C27H39N3O3 Indole 
NM2201  CBL-2201 naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate   C24H22FNO2 Indole 
NNEI   N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide 1338925-11-3 C24H24N2O Indole 
PB-22 (QUPIC)   
1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl 
ester 1400742-17-7 C23H22N2O2 Indole 
PTI-1    N,N-diethyl-2-(1-pentyl-1H-indol-3-yl-4-thiazolemethanamine   C21H29N3S Indole 
PTI-2    N-(2-methoxyethyl)-N-(1-methylethyl)-2-(1-pentyl-1H-indol-3-yl)-4-thiazolemethanamine   C23H33N3OS Indole 
PX 1  5-fluoro APP-PICA (S)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide   C23H26FN3O2 Indole 
PX 2  5-fluoro APP-PINACA (R)-N-(1-amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide   C22H25FN4O2 Indole 
SDB-006 N-phenyl analog    1-pentyl-N-phenyl-1H-indole-3-carboxamide 1430634-87-9 C20H22N2O Indole 
THJ 018  JWH 018 indazole analog 1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone 1364933-55-0 C23H22N2O Naphthoylindazole 
THJ2201    [1-(5-fluoropentyl)-1H-indazol-3-yl]-1-naphthalenyl-methanone 1801552-01-1 C23H21FN2O Naphthoylindazole 
1-Naphthoyl indole   1H-indol-3-yl-1-naphthalenyl-methanone 109555-87-5 C19H13NO Naphthoylindole 
3-CAF    naphthalen-2-yl 1-(2-fluorophenyl)-1H-indazole-3-carboxylate   C24H15FN2O2 Naphthoylindole 
AM-1220   [1-[[(2R)-1-methyl-2-piperidyl]methyl]indol-3-yl]-(1-naphthyl)methanone 137642-54-7 C26H26N2O Naphthoylindole 
AM-1235   [1-(5-fluoropentyl)-6-nitro-1H-indol-3-yl]-1-naphthalenyl-methanone 335161-27-8 C24H21FN2O3 Naphthoylindole 
AM-2201   [1-(5-fluoropentyl)indol-3-yl]-naphthalen-1-yl-methanone 335161-24-5 C24H22FNO Naphthoylindole 
AM-2201  6-hydroxyindole metabolite   (1-(5-fluoropentyl)-6-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427521-35-4 C24H22FNO2 Naphthoylindole 
AM-2201  7-hydroxyindole metabolite   (1-(5-fluoropentyl)-7-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1537889-11-4 C24H22FNO2 Naphthoylindole 
AM-2201  N-(4-hydroxypentyl) metabolite   (1-(5-fluoro-4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427521-34-3 C24H22FNO2 Naphthoylindole 
AM-2201 N-(2-fluoropentyl) isomer   (1-(2-fluoropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C24H22FNO Naphthoylindole 
AM-2201 N-(3-fluoropentyl) isomer   (1-(3-fluoropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C24H22FNO Naphthoylindole 
AM-2201 N-(4-fluoropentyl) isomer   (1-(4-fluoropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427325-95-8 C24H22FNO Naphthoylindole 
AM-2232   3-(1-naphthalenylcarbonyl)-1H-indole-1-pentanenitrile 335161-19-8 C24H20N2O Naphthoylindole 
Cl2201    (4-chloro-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-methanone 1391486-12-6 C24H21ClFNO Naphthoylindole 
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EAM-2201   (4-ethyl-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]methanone 1364933-60-7 C26H26FNO Naphthoylindole 
F2201  5-fluoro JWH 412 (4-fluoro-1-naphthalenyl)[1-(5-fluoropentyl)-1H-indol-3-yl]-methanone 1391485-39-4 C24H21F2NO Naphthoylindole 
FUB-JWH 018    (1-(4-fluorobenzyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C26H18FNO Naphthoylindole 
JWH 081-N-(cyclohexylmethyl) analog    [1-(cyclohexylmethyl)-1H-indol-3-yl](4-methoxy-1-naphthalenyl)-methanone 1373876-34-6 C27H27NO2 Naphthoylindole 
JWH-007   (2-methyl-1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone 155471-10-6 C25H25NO Naphthoylindole 
JWH-011   [2-methyl-1-(1-methylhexyl)-1H-indol-3-yl]-1-naphthalenyl-methanone 155471-13-9 C27H29NO Naphthoylindole 
JWH-015   (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone 155471-08-2 C23H21NO Naphthoylindole 
JWH-016   (1-butyl-2-methyl-1H-indol-3-yl)-1-naphthalenyl-methanone 155471-09-3 C24H23NO Naphthoylindole 
JWH-018   (1-pentyl-1H-indol-3-yl)-1-naphthalenyl-methanone 209414-07-3 C24H23NO Naphthoylindole 
JWH-018 4-hydroxyindole metabolite   (4-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-42-4 C24H23NO2 Naphthoylindole 
JWH-018 5-hydroxyindole metabolite   (5-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-43-5 C24H23NO2 Naphthoylindole 
JWH-018 6-hydroxyindole metabolite   (6-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-44-6 C24H23NO2 Naphthoylindole 
JWH-018 6-methoxyindole analog   (6-methoxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427325-49-2 C25H25NO2 Naphthoylindole 
JWH-018 7-hydroxyindole metabolite   (7-hydroxy-1-pentyl-1H-indol-3-yl)naphthalen-1-yl)methanone 1307803-45-7 C24H23NO2 Naphthoylindole 
JWH-018 N-(1,1-dimethylpropyl) isomer   naphthalen-1-yl(1-(tert-pentyl)-1H-indol-3-yl)methanone 1358118-35-0 C24H23NO Naphthoylindole 
JWH-018 N-(1,2-dimethylpropyl) isomer   (1-(3-methylbutan-2-yl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427325-40-3 C24H23NO Naphthoylindole 
JWH-018 N-(1-ethylpropyl) isomer   naphthalen-1-yl(1-(pentan-3-yl)-1H-indol-3-yl)methanone   C24H23NO Naphthoylindole 
JWH-018 N-(1-methylbutyl) isomer   naphthalen-1-yl(1-(pentan-2-yl)-1H-indol-3-yl)methanone 1427325-45-8 C24H23NO Naphthoylindole 
JWH-018 N-(2,2-dimethylpropyl) isomer   naphthalen-1-yl(1-neopentyl-1H-indol-3-yl)methanone 1427325-47-0 C24H23NO Naphthoylindole 
JWH-018 N-(2-hydroxypentyl) metabolite   (1-(2-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C24H23NO2 Naphthoylindole 
JWH-018 N-(2-methylbutyl) isomer   N-(2-methylbutyl)-3-(1-naphthoyl)indole 1427325-50-5 C24H23NO Naphthoylindole 
JWH-018 N-(3-hydroxypentyl) metabolite   (1-(3-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C24H23NO2 Naphthoylindole 
JWH-018 N-(3-methylbutyl) isomer   N-(3-methylbutyl)-3-(1-naphthoyl)indole 1346604-93-0 C24H23NO Naphthoylindole 
JWH-018 N-(4,5-epoxypentyl) analog   naphthalen-1-yl(1-(3-(oxiran-2-yl)propyl)-1H-indol-3-yl)methanone   C24H21NO2 Naphthoylindole 
JWH-018 N-(4-hydroxypentyl) metabolite   (1-(4-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1320363-47-0 C24H23NO2 Naphthoylindole 
JWH-018 N-(4-oxo-pentyl) metabolite   5-(3-(1-naphthoyl)-1H-indol-1-yl)pentan-2-one   C24H21NO2 Naphthoylindole 
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JWH-018 N-(5-bromopentyl) analog   (1-(5-bromopentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1445578-62-0 C24H22BrNO Naphthoylindole 
JWH-018 N-(5-chloropentyl) analog   (1-(5-chloropentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1445578-56-2 C24H22ClNO Naphthoylindole 
JWH-018 N-(5-hydroxypentyl) metabolite   (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 335161-21-2 C24H23NO2 Naphthoylindole 
JWH-018 N-(5-hydroxypentyl) β-D-glucuronide   
(2S,3S,4S,5R)-6-((5-(3-(1-naphthoyl)-1H-indol-1-
yl)pentyl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-
2-carboxylic acid 
1307803-55-9 C30H31NO8 Naphthoylindole 
JWH-018 N-pentanoic acid metabolite   5-(3-(1-naphthoyl)-1H-indol-1-yl)pentanoic acid 1254475-87-0 C24H21NO3 Naphthoylindole 
JWH-018 2-hydroxyindole metabolite   (2-hydroxy-1-pentyl-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427325-32-3 C24H23NO2 Naphthoylindole 
JWH-019   (1-hexyl-1H-indol-3-yl)-1-naphthalenyl-methanone 209414-08-4 C25H25NO Naphthoylindole 
JWH-019 5-hydroxyindole metabolite   (1-hexyl-5-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1379604-70-2 C25H25NO2 Naphthoylindole 
JWH-019 N-(6-hydroxyhexyl) metabolite   (1-(6-hydroxyhexyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1435934-29-4 C25H25NO2 Naphthoylindole 
JWH-020   (1-heptyl-1H-indol-3-yl)-1-naphthalenyl-methanone 209414-09-5 C26H27NO Naphthoylindole 
JWH-022   1-naphthalenyl[1-(4-penten-1-yl)-1H-indol-3-yl]methanone 209414-16-4 C24H21NO Naphthoylindole 
JWH-071   (1-ethyl-1H-indol-3-yl)-1-naphthalenyl-methanone 209414-05-1 C21H17NO Naphthoylindole 
JWH-072   1-naphthalenyl(1-propyl-1H-indol-3-yl)methanone 209414-06-2 C22H19NO Naphthoylindole 
JWH-073   (1-butyl-1H-indol-3-yl)-1-naphthalenyl-methanone 208987-48-8 C23H21NO Naphthoylindole 
JWH-073 2-hydroxyindole metabolite   (1-butyl-2-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427325-54-9 C23H21NO2 Naphthoylindole 
JWH-073 2-methylnaphthyl analog   (1-butyl-1H-indol-3-yl)(2-methylnaphthalen-1-yl)methanone 1427325-61-8 C24H23NO Naphthoylindole 
JWH-073 4-hydroxyindole metabolite   (1-butyl-4-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-46-8 C23H21NO2 Naphthoylindole 
JWH-073 4-methylnaphthyl analog   (1-butyl-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone 1354631-21-2 C24H23NO Naphthoylindole 
JWH-073 5-hydroxyindole metabolite   (1-butyl-5-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-47-9 C23H21NO2 Naphthoylindole 
JWH-073 6-hydroxyindole metabolite   (1-butyl-6-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-48-0 C23H21NO2 Naphthoylindole 
JWH-073 6-methoxyindole analog   
(1-butyl-6-methoxy-1H-indol-3-yl)(naphthalen-1-
yl)methanone   C24H23NO2 Naphthoylindole 
JWH-073 7-hydroxyindole metabolite   (1-butyl-7-hydroxy-1H-indol-3-yl)(naphthalen-1-yl)methanone 1307803-49-1 C23H21NO2 Naphthoylindole 
JWH-073 N-(1,1-dimethylethyl) isomer   (1-(tert-butyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C23H21NO Naphthoylindole 
JWH-073 N-(1-methylpropyl) isomer   (1-(sec-butyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C23H21NO Naphthoylindole 
JWH-073 N-(2-methylpropyl) isomer   (1-isobutyl-1H-indol-3-yl)(naphthalen-1-yl)methanone   C23H21NO Naphthoylindole 
JWH-073 N-(3-hydroxybutyl) metabolite   (1-(3-hydroxybutyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1320363-48-1 C23H21NO2 Naphthoylindole 
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JWH-073 N-(4-hydroxybutyl) metabolite   (1-(4-hydroxybutyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 335161-14-3 C23H21NO2 Naphthoylindole 
JWH-073 N-butanoic acid metabolite   4-(3-(1-naphthoyl)-1H-indol-1-yl)butanoic acid 1307803-52-6 C23H19NO3 Naphthoylindole 
JWH-080   
(1-butyl-1H-indol-3-yl)(4-methoxy-1-naphthalenyl)
methanone 210179-44-5 C24H23NO2 Naphthoylindole 
JWH-081   (4-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 210179-46-7 C25H25NO2 Naphthoylindole 
JWH-081  2-methoxynaphthyl isomer   (2-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 824960-76-1 C25H25NO2 Naphthoylindole 
JWH-081  3-methoxynaphthyl isomer   (3-methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C25H25NO2 Naphthoylindole 
JWH-081  5-methoxynaphthyl isomer   (5-methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1427325-65-2 C25H25NO2 Naphthoylindole 
JWH-081  6-methoxynaphthyl isomer   (6-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 824961-41-3 C25H25NO2 Naphthoylindole 
JWH-081  7-methoxynaphthyl isomer   (7-methoxy-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 824961-61-7 C25H25NO2 Naphthoylindole 
JWH-081  8-methoxynaphthyl isomer   (8-methoxynaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1349837-48-4 C25H25NO2 Naphthoylindole 
JWH-081 N-(5-hydroxypentyl) metabolite   (1-(5-hydroxypentyl)-1H-indol-3-yl)(4-methoxynaphthalen-1-yl)methanone   C25H25NO3 Naphthoylindole 
JWH-098   (4-methoxy-1-naphthalenyl)(2-methyl-1-pentyl-1H-indol-3-yl)methanone 316189-74-9 C26H27NO2 Naphthoylindole 
JWH-116   
(2-ethyl-1-pentyl-1H-indol-3-yl)-1-naphthalenyl-
methanone 619294-64-3 C26H27NO Naphthoylindole 
JWH-122   (4-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 619294-47-2 C25H25NO Naphthoylindole 
JWH-122 2-methylnaphthyl isomer   (2-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1427325-69-6 C25H25NO Naphthoylindole 
JWH-122 3-methylnaphthyl isomer   (3-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1391052-25-7 C25H25NO Naphthoylindole 
JWH-122 5-methylnaphthyl isomer   (5-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1391052-02-0 C25H25NO Naphthoylindole 
JWH-122 6-methylnaphthyl isomer   (6-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1427325-68-5 C25H25NO Naphthoylindole 
JWH-122 7-methylnaphthyl isomer   (7-methyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 824960-56-7 C25H25NO Naphthoylindole 
JWH-122 8-methylnaphthyl isomer   (8-methylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C25H25NO Naphthoylindole 
JWH-122 N-(4-pentenyl) analog   (4-methylnaphthalen-1-yl)(1-(pent-4-en-1-yl)-1H-indol-3-yl)methanone 1445577-68-3 C25H23NO Naphthoylindole 
JWH-122 N-(5-hydroxypentyl) metabolite   (1-(5-hydroxypentyl)-1H-indol-3-yl)(4-methylnaphthalen-1-yl)methanone 1379604-68-8 C24H23NO2 Naphthoylindole 
JWH-149   
(4-methyl-1-naphthalenyl)(2-methyl-1-pentyl-1H-
indol-3-yl)methanone  548461-82-1 C26H27NO Naphthoylindole 
JWH-180   (1-propyl-1H-indol-3-yl)(4-propyl-1-naphthalenyl)methanone 824959-87-7 C25H25NO Naphthoylindole 
JWH-182   (1-pentyl-1H-indol-3-yl)(4-propyl-1-naphthalenyl)methanone 824960-02-3 C27H29NO Naphthoylindole 
JWH-193   
(4-methyl-1-naphthalenyl)[1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl]methanone 133438-58-1 C26H26N2O2 Naphthoylindole 
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JWH-198   (1-(2-morpholin-4-ylethyl)indol-3-yl)-4-methoxynaphthalen-1-yl-methanone 166599-76-4 C26H26N2O3 Naphthoylindole 
JWH-200   [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone 103610-04-4 C25H24N2O2 Naphthoylindole 
JWH-200 4-hydroxyindole metabolite   4-hydroxy[1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone 1427325-73-2 C25H24N2O3 Naphthoylindole 
JWH-200 5-hydroxyindole metabolite   (5-hydroxy-1-(2-morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 133438-72-9 C25H24N2O3 Naphthoylindole 
JWH-200 6-hydroxyindole metabolite   (6-hydroxy-1-(2-morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 1427325-76-5 C25H24N2O3 Naphthoylindole 
JWH-200 7-hydroxyindole metabolite   (7-hydroxy-1-(2-morpholinoethyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone   C25H24N2O3 Naphthoylindole 
JWH-210   (4-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 824959-81-1 C26H27NO Naphthoylindole 
JWH-210 2-ethylnaphthyl isomer   (2-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1427325-79-8 C26H27NO Naphthoylindole 
JWH-210 3-ethylnaphthyl isomer   (3-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C26H27NO Naphthoylindole 
JWH-210 5-ethylnaphthyl isomer   (5-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C26H27NO Naphthoylindole 
JWH-210 5-hydroxyindole metabolite   (4-ethylnaphthalen-1-yl)(5-hydroxy-1-pentyl-1H-indol-3-yl)methanone 1427325-81-2 C26H27NO2 Naphthoylindole 
JWH-210 6-ethylnaphthyl isomer   (6-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C26H27NO Naphthoylindole 
JWH-210 7-ethylnaphthyl isomer   (7-ethyl-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)methanone 824960-64-7 C26H27NO Naphthoylindole 
JWH-210 8-ethylnaphthyl isomer   (8-ethylnaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C26H27NO Naphthoylindole 
JWH-210 N-(4-hydroxypentyl) metabolite   (4-ethylnaphthalen-1-yl)(1-(4-hydroxypentyl)-1H-indol-3-yl)methanone 1427521-37-6 C26H27NO2 Naphthoylindole 
JWH-210 N-(5-carboxypentyl) metabolite   5-(3-(4-ethyl-1-naphthoyl)-1H-indol-1-yl)pentanoic acid 1427521-36-5 C26H25NO3 Naphthoylindole 
JWH-210 N-(5-hydroxypentyl) metabolite   (4-ethylnaphthalen-1-yl)(1-(5-hydroxypentyl)-1H-indol-3-yl)methanone 1427521-40-1 C26H27NO2 Naphthoylindole 
JWH-387   
(4-bromo-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)
methanone 1366067-59-5 C24H22BrNO Naphthoylindole 
JWH-398   (4-chloronaphthalen-1-yl)(1-pentylindolin-3-yl)methanone 1292765-18-4 C24H22ClNO Naphthoylindole 
JWH-398 2-chloronaphthyl isomer   (2-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1391054-25-3 C24H22ClNO Naphthoylindole 
JWH-398 3-chloronaphthyl isomer   (3-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C24H22ClNO Naphthoylindole 
JWH-398 5-chloronaphthyl isomer   (5-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1427325-89-0 C24H22ClNO Naphthoylindole 
JWH-398 6-chloronaphthyl isomer   (6-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone   C24H22ClNO Naphthoylindole 
JWH-398 7-chloronaphthyl isomer   (7-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1391051-95-8 C24H22ClNO Naphthoylindole 
JWH-398 8-chloronaphthyl isomer   (8-chloronaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1366067-88-0 C24H22ClNO Naphthoylindole 
JWH-398 N-(5-hydroxypentyl) metabolite   (4-chloronaphthalen-1-yl)(1-(5-hydroxypentyl)-1H-indol-3-yl)methanone 1379604-69-9 C24H22ClNO2 Naphthoylindole 
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JWH-412   
(4-fluoro-1-naphthalenyl)(1-pentyl-1H-indol-3-
yl)methanone 1364933-59-4 C24H22FNO Naphthoylindole 
JWH-424   (8-bromonaphthalen-1-yl)(1-pentyl-1H-indol-3-yl)methanone 1366068-04-3 C24H22BrNO Naphthoylindole 
MAM-2201   [1-(5-fluoropentyl)-1H-indol-3-yl](4-methyl-1-naphthalenyl)methanone 1354631-24-5 C25H24FNO Naphthoylindole 
MAM-2201 N-(3-fluoropentyl) isomer   
(1-(3-fluoropentyl)-1H-indol-3-yl)(4-
methylnaphthalen-1-yl)methanone   C25H24FNO Naphthoylindole 
MAM-2201 N-(5-chloropentyl) analog   
(1-(5-chloropentyl)-1H-indol-3-yl)(4-
methylnaphthalen-1-yl)methanone 1445578-25-5 C25H24ClNO Naphthoylindole 
JWH-030   1-naphthalenyl(1-pentyl-1H-pyrrol-3-yl)methanone 162934-73-8 C20H21NO Naphthoylpyrrole  
JWH-031   (1-hexyl-1H-pyrrol-3-yl)-1-naphthalenyl-methanone 162934-74-9 C21H23NO Naphthoylpyrrole  
JWH-145    1-naphthalenyl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)methanone 914458-19-8 C26H25NO Naphthoylpyrrole  
JWH-147   (1-hexyl-5-phenyl-1H-pyrrol-3-yl)-1-naphthalenyl-methanone 914458-20-1 C27H27NO Naphthoylpyrrole  
JWH-307   5-(2-fluorophenic)-1-1pentylpyrro(-3-yl)-naphthalene-1-yl-methanone 914458-26-7 C26H24FNO Naphthoylpyrrole  
JWH-309   1-naphthalenyl[5-(1-naphthalenyl)-1-pentyl-1H-pyrrol-3-yl]methanone 914458-42-7 C30H27NO Naphthoylpyrrole  
JWH-368   [5-(3-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone 914458-31-4 C26H24FNO Naphthoylpyrrole  
JWH-369   [5-(2-chlorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone 914458-27-8 C26H24ClNO Naphthoylpyrrole  
JWH-370   [5-(2-methylphenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-methanone 914458-22-3 C27H27NO Naphthoylpyrrole  
JWH-175   3-(1-naphthalenylmethyl)-1-pentyl-1H-indole 619294-35-8 C24H25N Naphthylmethylindole 
2-Fluoroisocathinone   2-FIC 1-amino-1-(2-fluorophenyl)propan-2-one   C9H10FNO Other 
2-Thiothinone     2-(methylamino)-1-(2-thienyl)-1-propanone   C8H11NOS Other 
3-Fluorophenmetrazine   3-FPM 2-(3-fluorophenyl)-3-methylmorpholine   C11H14FNO Other 
Isopentedrone     1-(methylamino)-1-phenylpentan-2-one   C12H17NO Other 
MTTA     3,4-dihydro-2-[(methylamino)methyl]-1(2H)-naphthalenone   C12H15NO Other 
4-Quinolone-3-carboxamide   
1,4-dihydro-8-methoxy-4-oxo-1-pentyl-N-
tricyclo[3.3.1.13,7]dec-1-yl-3-quinolinecarboxamide 1314230-69-7 C26H34N2O3 Other Cannabinoid 
5-Fluoro PCN 5-fluoro MN-21 1-(5-fluoropentyl)-N-(naphthalen-1-yl)-1H-pyrrolo[3,2-c]pyridine-3-carboxamide   C23H22FN3O Other Cannabinoid 
AM-1172   4-hydroxy-N-[(5Z,8Z,11Z,14Z)-5,8,11,14-icosatetraen-1-yl]benzamide 251908-92-6 C27H39NO2 Other Cannabinoid 
AM-251   1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4-methyl-N-piperidin-1-yl-pyrazole-3-carboxamide 183232-66-8 C22H21Cl2IN4O Other Cannabinoid 
AM-3102   N-[(1R)-2-hydroxy-1-methylethyl-9Z-octadecenamide 213182-22-0 C21H41NO2 Other Cannabinoid 
AM-356   N-(2-hydroxy-1R-methylethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide 157182-49-5 C23H39NO2 Other Cannabinoid 
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Cannabipiperidiethanone   2-(2-methoxyphenyl)-1-[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]ethanone 1345970-43-5 C24H28N2O2 Other Cannabinoid 
CB-13   1-naphthyl[4-(pentyloxy)-1-naphthyl]methanone 432047-72-8 C26H24O2 Other Cannabinoid 
CB-25   N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)undecanamide 869376-63-6 C25H41NO3 Other Cannabinoid 
CB-52   N-cyclopropyl-11-(5-hydroxy-2-pentylphenoxy)undecanamide 869376-90-9 C25H41NO3 Other Cannabinoid 
CB-86   N-cyclopropyl-8-[3-(1,1-dimethylheptyl)-5-hydroxyphenoxy]octanamide 1150586-64-3 C26H43NO3 Other Cannabinoid 
Dimethylheptylpyran   6,6,9-trimethyl-3-(3-methyl-2-octanyl)-7,8,9,10-tetrahydro-6H-benzo[c]chromen-1-ol 32904-22-6 C25H38O2 Other Cannabinoid 
EG 018    naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone   C28H25NO Other Cannabinoid 
EG 2201    (9-(5-fluoropentyl)-9H-carbazol-3-yl)(naphthalen-1-yl)methanone   C28H24FNO Other Cannabinoid 
HU-210   
3-(1,1-dimethylheptyl)-6aR,7,10,10aR-tetrahydro-1-
hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-
methanol 
112830-95-2 C25H38O3 
Other Cannabinoid 
HU-211   
3-(1,1-dimethylheptyl)-6aS,7,10,10aS-tetrahydro-1-
hydroxy-6,6-dimethyl-6H-dibenzo[b,d]pyran-9-
methanol 
112924-45-5 C25H38O3 
Other Cannabinoid 
HU-308   4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo[3.1.1]hept-2-ene-2-methanol 256934-39-1 C27H42O3 Other Cannabinoid 
HU-331   
3-hydroxy-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-
2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-1,4-
dione 
137252-25-6 C21H28O3 
Other Cannabinoid 
JP 104   3-carbamoyl-biphenyl-3-yl-undecynecarbamate 887264-45-1 C25H30N2O3 Other Cannabinoid 
JW 618   
1,1,1,3,3,3-hexafluoropropan-2-yl-methyl(3-(pyridin-
4-yl)benzyl)carbamate   C17H14F6N2O2 Other Cannabinoid 
JW 642   
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(3-
phenoxybenzyl)piperazine-1-carboxylate 1416133-89-5 C21H20F6N2O3 Other Cannabinoid 
JWH-133   (6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro -6,6,9-trimethyl-6H-dibenzo[b,d]pyran   C22H32O Other Cannabinoid 
JWH-176   1-([(1e)-3-pentylinden-1-ylidine]methyl)naphthalene 619294-62-1 C25H24 Other Cannabinoid 
JZL 184   4-nitrophenyl-4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate 1101854-58-3 C27H24N2O9 Other Cannabinoid 
JZL 195   4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate 1210004-12-8 C24H23N3O5 Other Cannabinoid 
KML29   
1,1,1,3,3,3-hexafluoropropan-2-yl 4-(bis(benzo[d][1,
3]dioxol-5-yl)(hydroxy)methyl)piperidine-1-
carboxylate 
1380424-42-9 C24H21F6NO7 Other Cannabinoid 
Nabilone   
(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyl-2-
octanyl)-6,6a,7,8,10,10a-hexahydro-9H-
benzo[c]chromen-9-one 
56496-90-3 C24H36O3 Other Cannabinoid 
O-1125   
6-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]-N,N,6-
trimethylheptanamide 
  C26H39NO3 Other Cannabinoid 
O-1238   (6aS)-3-[(2Z)-6-azido-2-hexen-1-yl]-6,6,9-trimethyl-6a,7,10,10a-tetrahydro-6H-benzo[c]chromen-1-ol   C22H29N3O2 Other Cannabinoid 
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O-1302   N-(piperidinyl)-1-(2,4-dichlorophenyl)-4-methyl-5-(4-pentylphenyl)-1H-pyrazole-3-carboxamide   C27H32Cl2N4O Other Cannabinoid 
O-1602   5-methyl-4-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol 317321-41-8 C17H22O2 Other Cannabinoid 
O-1821   5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol 35482-50-9 C17H22O2 Other Cannabinoid 
O-1918   1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]benzene 536697-79-7 C19H26O2 Other Cannabinoid 
O-806   3-(6-bromohex-2-ynyl)-6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol   C22H27BrO2 Other Cannabinoid 
O-823   
7-[(6aR,10aR)-1-hydroxy-6,6,9-trimethyl-
6a,7,10,10a-tetrahydrobenzo[c]chromen-3-yl]hept-5-
yne-nitrile 
  C23H27NO2 Other Cannabinoid 
SER-601   
1,4-dihydro-6-(1-methylethyl)-4-oxo-1-pentyl-N-
tricyclo[3.3.1.13,7]dec-1-yl-3-quinolinecarboxamide 1048038-90-9 C28H38N2O2 Other Cannabinoid 
URB447   [4-amino-1-[(4-chlorophenyl)methyl]-2-methyl-5-phenyl-1H-pyrrol-3-yl]phenyl-methanone 1132922-57-6 C25H21ClN2O Other Cannabinoid 
URB597   (3-(aminocarbonyl)[1,1-biphenyl]-3-yl)-cyclohexylcarbamate 546141-08-6 C20H22N2O3 Other Cannabinoid 
URB602   cyclohexyl biphenyl-3-ylcarbamate 565460-15-3 C19H21NO2 Other Cannabinoid 
URB754   6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one 86672-58-4 C16H14N2O2 Other Cannabinoid 
URB937   3-carbamoyl-6-hydroxy-[1,1-biphenyl]-3-yl cyclohexylcarbamate 1357160-72-5 C20H22N2O4 Other Cannabinoid 
WIN 55,212-2   
(R)-(+)-[2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-
benzoxazin-6-yl]-1-napthalenylmethanone 
131543-22-1 C27H26N2O3 Other Cannabinoid 
4-Fluoroisocathinone    1-amino-1-(4-fluorophenyl)propan-2-one 1270532-42-7 C9H10FNO Other Stimulant 
Desoxypipradrol 2-DPMP 2-benzhydrylpiperidine 519-74-4 C18H21N Other Stimulant 
Ethylphenidate     Ethyl phenyl(2-piperidinyl)acetate 19716-79-1 C15H21NO2 Other Stimulant 
MDMA methylene homolog    3-(1,3-benzenodioxol-5-yl)-N,2-dimethylpropan-1-amine   C12H17NO2 Other Stimulant 
Tenocyclidine TCP 1-[1-(2-thienyl)cyclohexyl]piperidine 21500-98-1 C15H23NS Other Stimulant 
 3-Methoxy-4-Methylamphetamine MMA 1-(3-methoxy-4-methylphenyl)propan-2-amine 87179-33-7 C11H17NO Phenethylamine 
1-(4-Fluorophenyl) butan-2-amine   α-ethyl-4-fluoro-benzeneethanamine 23292-09-3 C10H14FN Phenethylamine 
1,4-Dimethoxynaphthyl-2-ethylamine 2C-G-N 2-(1,4-dimethoxynaphthalen-2-yl)ethanamine 207740-21-4 C14H17NO2 Phenethylamine 
1,4-Dimethoxynaphthyl-2-isopropylamine G-N 1-(1,4-dimethoxynaphthalen-2-yl)propan-2-amine   C15H19NO2 Phenethylamine 
2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine DMCPA 2-(2,5-dimethoxy-4-methylphenyl)cyclopropanamine 69854-49-5 C12H17NO2 Phenethylamine 
2-(3,4-Dimethoxyphenyl)-N-methylethylamine N-Me-DMPEA 3,4-dimethoxy-N-methyl-benzeneethanamine 3490-06-0 C11H17NO2 Phenethylamine 
2,3,4,5-Tetramethoxyamphetamine   2,3,4,5-tetramethoxy-α-methyl-benzeneethanamine 23693-26-7 C13H21NO4 Phenethylamine 
2,3,4-Trimethoxyamphetamine TMA-3 1-(2,3,4-trimethoxyphenyl)-2-propanamine 1082-23-1 C12H19NO3 Phenethylamine 
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2,3,5-Trimethoxyamphetamine TMA-4 1-(2,3,5-trimethoxyphenyl)-2-propanamine 23693-14-3 C12H19NO3 Phenethylamine 
2,3,6-Trimethoxyamphetamine TMA-5 1-(2,3,6-trimethoxyphenyl)-2-propanamine 20513-16-0 C12H19NO3 Phenethylamine 
2,3-Dimethoxy-4,5-methylenedioxyamphetamine DMMDA-2 1-(6,7-dimethoxy-1,3-benzodioxol-5-yl)propan-2-amine   C12H17NO4 Phenethylamine 
2,3-Methylenedioxyamphetamine 2,3-MDA 1-(1,3-benzodioxol-4-yl)propan-2-amine 23693-17-6 C10H13NO2 Phenethylamine 
2,3-Methylenedioxymethylamphetamine 2,3-MDMA N,α-dimethyl-1,3-benzodioxole-4-ethanamine 168967-99-5 C11H15NO2 Phenethylamine 
2,4,5-Triethoxyamphetamine EEE 2,4,5-triethoxy-α-methyl-benzeneethanamine 23693-42-7 C15H25NO3 Phenethylamine 
2,4,5-Trimethoxyamphetamine TMA-2 1-(2,4,5-trimethoxyphenyl)-2-propanamine 1083-09-6 C12H19NO3 Phenethylamine 
2,4,5-Trimethoxyphenethylamine 2C-O 2-(2,4,5-trimethoxyphenyl)ethanamine 15394-83-9 C11H17NO3 Phenethylamine 
2,4,6-Trimethoxyamphetamine TMA-6 1-(2,4,6-trimethoxyphenyl)-2-propanamine 15402-79-6 C12H19NO3 Phenethylamine 
2,4-Diethoxy-5-methoxyamphetamine EEM 1-(2,4-diethoxy-5-methoxyphenyl)propan-2-amine 23693-33-6 C14H23NO3 Phenethylamine 
2,4-Dimethoxy-5-ethoxyamphetamine MME 1-(5-ethoxy-2,4-dimethoxyphenyl)propan-2-amine 23693-32-5 C13H21NO3 Phenethylamine 
2,4-Dimethoxyamphetamine 2,4-DMA 1-(2,4-dimethoxyphenyl)propan-2-amine 23690-13-3 C11H17NO2 Phenethylamine 
2,5,β-Trimethoxy-4-methylphenethylamine BOD 2-(2,5-dimethoxy-4-methylphenyl)-2-methoxyethanamine 98537-41-8 C12H19NO3 Phenethylamine 
2,5-Bismethylthio-4-methylamphetamine bis-TOM 1-[4-methyl-2,5-bis(methylsulfanyl)phenyl]propan-2-amine   C12H19NS2 Phenethylamine 
2,5-Diethoxy-4-methoxyamphetamine EME 1-(2,5-diethoxy-4-methoxyphenyl)propan-2-amine 23693-34-7 C14H23NO3 Phenethylamine 
2,5-Dimethoxy-3,4-(tetramethylene)amphetamine G-4 1-(1,4-dimethoxy-5,6,7,8-tetrahydronaphthalen-2-yl)propan-2-amine   C15H23NO2 Phenethylamine 
2,5-Dimethoxy-3,4-(tetramethylene)phenethylamine 2C-G-4 2-(1,4-dimethoxy-5,6,7,8-tetrahydronaphthalen-2-yl)ethanamine 952006-59-6 C14H21NO2 Phenethylamine 
2,5-Dimethoxy-3,4-(trimethylene)amphetamine G-3 1-(4,7-dimethoxy-2,3-dihydro-1H-inden-5-yl)propan-2-amine   C14H21NO2 Phenethylamine 
2,5-Dimethoxy-3,4-(trimethylene)phenethylamine 2C-G-3 2-(4,7-dimethoxy-2,3-dihydro-1H-inden-5-yl)ethanamine 207740-19-0 C13H19NO2 Phenethylamine 
2,5-Dimethoxy-3,4-dimethylphenethylamine 2C-G 2-(2,5-dimethoxy-3,4-dimethylphenyl)ethanamine 207740-18-9 C12H19NO2 Phenethylamine 
2,5-Dimethoxy-3,4-methylenedioxyamphetamine DMMDA 1-(4,7-dimethoxy-1,3-benzodioxol-5-yl)propan-2-amine 15183-13-8 C12H17NO4 Phenethylamine 
2,5-Dimethoxy-4-(2-fluoroethyl)amphetamine DOEF 1-[4-(2-fluoroethyl)-2,5-dimethoxyphenyl]propan-2-amine 121649-01-2 C13H20FNO2 Phenethylamine 
2,5-Dimethoxy-4-(2-fluoroethylthio)phenethylamine 2C-T-21 
2-(4-[(2-fluoroethyl)sulfanyl]-2,5-
dimethoxyphenyl)ethanamine 207740-33-8 C12H18FNO2S Phenethylamine 
2,5-Dimethoxy-4-(2-methoxyethylthio)phenethylamine 2C-T-13 2-(2,5-dimethoxy-4-[(2-methoxyethyl)sulfanyl]phenyl)ethanamine 207740-30-5 C13H21NO3S Phenethylamine 
2,5-Dimethoxy-4-Bromo-N-(2-
methoxybenzyl)phenethylamine 25B-NBOMe 
4-bromo-2,5-dimethoxy-N-[(2-
methoxyphenyl)methyl]benzeneethanamine 1026511-90-9 C18H22BrNO3 Phenethylamine 
2,5-Dimethoxy-4-bromophenethylamine 2C-B 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine 66142-81-2 C10H14BrNO2 Phenethylamine 
2,5-Dimethoxy-4-chloroamphetamine DOC 1-(4-chloro-2,5-dimethoxyphenyl)-2-propanamine 123431-31-2 C11H16ClNO2 Phenethylamine 
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2,5-Dimethoxy-4-Chloro-N-(2-
methoxybenzyl)phenethylamine 25C-NBOMe 
4-chloro-2,5-dimethoxy-N-[(2-
methoxyphenyl)methyl]benzeneethanamine 1227608-02-7 C18H22ClNO3 Phenethylamine 
2,5-Dimethoxy-4-chlorophenethylamine 2C-C 4-chloro-2,5-dimethoxy-benzeneethanamine 88441-14-9 C10H14ClNO2 Phenethylamine 
2,5-Dimethoxy-4-cyclopropylmethylthiophenethylamine 2C-T-8 2-(4-[(cyclopropylmethyl)sulfanyl]-2,5-dimethoxyphenyl)ethanamine 207740-27-0 C14H21NO2S Phenethylamine 
2,5-Dimethoxy-4-cyclopropylthiophenethylamine 2C-T-15 2-[4-(cyclopropylsulfanyl)-2,5-dimethoxyphenyl]ethanamine 952006-95-0 C13H19NO2S Phenethylamine 
2,5-Dimethoxy-4-ethoxyamphetamine MEM 1-(4-ethoxy-2,5-dimethoxyphenyl)propan-2-amine 16128-88-4 C13H21NO3 Phenethylamine 
2,5-Dimethoxy-4-ethylamphetamine DOET 2,5-dimethoxy-4-ethylamphetamine 22004-32-6 C13H21NO2 Phenethylamine 
2,5-Dimethoxy-4-ethylphenethylamine 2C-E 2-(4-ethyl-2,5-dimethoxyphenyl)ethanamine 71539-34-9 C12H19NO2 Phenethylamine 
2,5-Dimethoxy-4-ethylthioamphetamine ALEPH-2 1-[4-(ethylsulfanyl)-2,5-dimethoxyphenyl]propan-2-amine 185562-00-9 C13H21NO2S Phenethylamine 
2,5-Dimethoxy-4-ethylthio-N-hydroxyphenethylamine HOT-2 2-[4-(ethylsulfanyl)-2,5-dimethoxyphenyl]-N-hydroxyethanamine 207740-38-3 C12H19NO3S Phenethylamine 
2,5-Dimethoxy-4-ethylthiophenethylamine 2C-T-2 2-(4-ethylsulfanyl-2,5-dimethoxyphenyl)ethanamine 207740-24-7 C12H19NO2S Phenethylamine 
2,5-Dimethoxy-4-fluorophenethylamine 2C-F 2-(4-fluoro-2,5-dimethoxyphenyl)ethanamine 207740-15-6 C10H14FNO2 Phenethylamine 
2,5-Dimethoxy-4-iodo-N-(2,3-
methylenedioxybenzyl)phenethylamine 25I-NBMD  
N-(benzo[d][1,3]dioxol-4-ylmethyl)-2-(4-iodo-2,5-
dimethoxyphenyl)ethanamine 919797-25-4 C18H20INO4 Phenethylamine 
2,5-Dimethoxy-4-iodo-N-(2-
methoxybenzyl)phenethylamine 25I-NBOMe 
2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine 919797-19-6 C18H22INO3 Phenethylamine 
2,5-Dimethoxy-4-iodophenethylamine 2C-I 2-(4-iodo-3-methoxyphenyl)-2-methoxyethanamine 64584-32-3 C10H14INO2 Phenethylamine 
2,5-Dimethoxy-4-isopropoxyphenethylamine 2C-O-4 2-[2,5-dimethoxy-4-(propan-2-yloxy)phenyl]ethanamine   C13H21NO3 Phenethylamine 
2,5-Dimethoxy-4-isopropylthioamphetamine ALEPH-4 1-[4-(isopropylsulfanyl)-2,5-dimethoxyphenyl]-2-propanamine 123643-26-5 C14H23NO2S Phenethylamine 
2,5-Dimethoxy-4-isopropylthiophenethylamine 2C-T-4 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine 207740-25-8 C13H21NO2S Phenethylamine 
2,5-Dimethoxy-4-methylamphetamine DOM 1-(2,5-dimethoxy-4-methylphenyl)propan-2-amine 18539-33-8 C12H19NO2 Phenethylamine 
2,5-Dimethoxy-4-methylphenethylamine 2C-D 2-(2,5-dimethoxy-4-methylphenyl)ethanamine 24333-19-5 C11H17NO2 Phenethylamine 
2,5-Dimethoxy-4-methylselenophenethylamine 2C-SE 2-[2,5-dimethoxy-4-(methylselanyl)phenyl]ethanamine   C11H17NO2Se Phenethylamine 
2,5-Dimethoxy-4-methylthioamphetamine ALEPH, DOT 1-(2,5-dimethoxy-4-methylsulfanylphenyl)propan-2-amine 61638-07-1 C12H19NO2S Phenethylamine 
2,5-Dimethoxy-4-methylthiophenethylamine 2C-T 2,5-dimethoxy-4-(methylthio)-benzeneethanamine 61638-09-3 C11H17NO2S Phenethylamine 
2,5-Dimethoxy-4-n-amylamphetamine DOAM 1-(2,5-dimethoxy-4-pentylphenyl)propan-2-amine 63779-90-8 C16H27NO2 Phenethylamine 
2,5-Dimethoxy-4-n-butylamphetamine DOBU 1-(4-butyl-2,5-dimethoxyphenyl)propan-2-amine 63779-89-5 C15H25NO2 Phenethylamine 
2,5-Dimethoxy-4-nitrophenethylamine 2C-N 2,5-dimethoxy-4-nitro-benzeneethanamine 261789-00-8 C10H14N2O4 Phenethylamine 
2,5-Dimethoxy-4-n-propylphenethylamine 2C-P 2-(2,5-dimethoxy-4-propylphenyl)ethanamine 207740-22-5 C13H21NO2 Phenethylamine 
2,5-Dimethoxy-4-n-propylthioamphetamine ALEPH-7 1-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]-2-propanamine 207740-16-7 C14H23NO2S Phenethylamine 
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2,5-Dimethoxy-4-n-propylthiophenethylamine 2C-T-7 2-(2,5-dimethoxy-4-propylsulfanylphenyl)ethanamine 207740-26-9 C13H21NO2S Phenethylamine 
2,5-Dimethoxy-4-phenylthioamphetamine ALEPH-6 1-[2,5-dimethoxy-4-(phenylsulfanyl)phenyl]-2-propanamine 952006-44-9 C17H21NO2S Phenethylamine 
2,5-Dimethoxy-4-propoxyamphetamine MPM 1-(2,5-dimethoxy-4-propoxyphenyl)propan-2-amine   C14H23NO3 Phenethylamine 
2,5-Dimethoxy-4-sec-butylthio-N-
hydroxyphenethylamine HOT-17 
2-[4-(butan-2-ylsulfanyl)-2,5-dimethoxyphenyl]-N-
hydroxyethanamine 207740-40-7 C14H23NO3S Phenethylamine 
2,5-Dimethoxy-4-sec-butylthiophenethylamine 2C-T-17 2-[4-(butan-2-ylsulfanyl)-2,5-dimethoxyphenyl]ethanamine 207740-32-7 C14H23NO2S Phenethylamine 
2,5-Dimethoxy-4-tert-butylthiophenethylamine 2C-T-9 2-[4-(tert-butylsulfanyl)-2,5-dimethoxyphenyl]ethanamine   C14H23NO2S Phenethylamine 
2,5-Dimethoxyamphetamine 2,5-DMA 1-(2,5-dimethoxyphenyl)propan-2-amine 2801-68-5 C11H17NO2 Phenethylamine 
2,5-Dimethoxy-N-(2-methoxybenzyl)-4-
methylphenethylamine 25D-NBOMe  
2-(2,5-dimethoxy-4-methylphenyl)-N-(2-
methoxybenzyl)ethanamine 1354632-02-2 C19H25NO3 Phenethylamine 
2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine 25H-NBOMe  
2,5-dimethoxy-N-[(2-methoxyphenyl)
methyl]benzeneethanamine 919797-16-3 C18H23NO3 Phenethylamine 
2,5-Dimethoxy-N,N-dimethyl-4-iodoamphetamine IDNNA 1-(4-iodo-2,5-dimethoxyphenyl)-N,N-dimethylpropan-2-amine 67707-78-2 C13H20INO2 Phenethylamine 
2,5-Dimethoxy-N-hydroxy-4-n-propylthiophenethylamine HOT-7 2-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]-N-hydroxyethanamine 207740-39-4 C13H21NO3S Phenethylamine 
2,5-Dimethoxy-N-methylamphetamine Methyl-DMA 1-(2,5-dimethoxyphenyl)-N-methylpropan-2-amine 54687-43-3 C12H19NO2 Phenethylamine 
2,5-Dimethoxyphenethylamine 2C-H 2-(2,5-dimethoxyphenyl)ethanamine 3600-86-0 C10H15NO2 Phenethylamine 
2,5-Dimethoxy-β-hydroxy-4-methylphenethylamine BOHD 2-amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol 29348-16-1 C11H17NO3 Phenethylamine 
2,6-Dimethoxy-4-isopropylthiophenethylamine 2C-T-4 (Ψ homologue) 2-[4-(isopropylthio)-2,6-dimethoxyphenyl]ethanamine   C13H21NO2S Phenethylamine 
2,6-Dimethoxy-4-methylamphetamine DOM (Ψ homologue) 1-(2,6-dimethoxy-4-methylphenyl)propan-2-amine   C12H19NO2 Phenethylamine 
2,N-Dimethyl-4,5-methylenedioxyamphetamine MADAM-6 N-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)propan-2-amine 207740-46-3 C12H17NO2 Phenethylamine 
25B-NBF   2C-B-NBF 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-fluorobenzyl)ethan-1-amine   C17H19BrFNO2 Phenethylamine 
25B-NBOH    2-({[2-(4-Bromo-2,5-dimethoxyphenyl)ethyl]amino}methyl)phenol   C17H20BrNO3 Phenethylamine 
25C-NB3OMe   - 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(3-methoxybenzyl)ethan-1-amine   C18H22ClNO3 Phenethylamine 
25C-NBF     2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-fluorobenzyl)ethan-1-amine   C17H19ClFNO2 Phenethylamine 
25C-NBOH     2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol   C17H20ClNO3 Phenethylamine 
25E-NBOMe     2-(4-ethyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine   C20H27NO3 Phenethylamine 
25G-NBOMe     2-(2,5-Dimethoxy-3,4-dimethylphenyl)-N-(2-methoxybenzyl)ethan-1-amine   C20H27NO3 Phenethylamine 
25H-NBOMe imine analog   
(e)-2-(2,5-dimethoxyphenyl)-N-(2-
methoxybenzylidene)ethanamine   C18H21NO3 Phenethylamine 
25I-NBOH     2-({[2-(4-Iodo-2,5-dimethoxyphenyl)ethyl]amino}methyl)phenol   C17H20INO3 Phenethylamine 
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25I-NBOMe 3-methoxy isomer     2-(4-iodo-2,5-dimethoxyphenyl)-N-(3-methoxybenzyl)ethan-1-amine   C18H22INO3 Phenethylamine 
25I-NBOMe 4-methoxy isomer     2-(4-iodo-2,5-dimethoxyphenyl)-N-(4-methoxybenzyl)ethan-1-amine   C18H22INO3 Phenethylamine 
25I-NBOMe imine analog   
(e)-2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzylidene)ethanamine   C18H20INO3 Phenethylamine 
25iP-NBOMe     2-(4-isopropyl-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine   C21H29NO3 Phenethylamine 
25N-NBOMe     2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine   C18H22N2O5 Phenethylamine 
25T2-NBOMe     2-[4-(Ethylsulfanyl)-2,5-dimethoxyphenyl]-N-(2-methoxybenzyl)ethan-1-amine   C20H27NO3S Phenethylamine 
25T4-NBOMe     2-[2,5-Dimethoxy-4-(propan-2-ylsulfanyl)phenyl]-N-(2-methoxybenzyl)ethan-1-amine   C21H29NO3S Phenethylamine 
25T7-NBOMe     2-[2,5-Dimethoxy-4-(propylsulfanyl)phenyl]-N-(2-methoxybenzyl)ethan-1-amine   C21H29NO3S Phenethylamine 
2-Bromo-4,5-methylenedioxyamphetamine 6-Br-MDA 1-(6-bromo-1,3-benzodioxol-5-yl)propan-2-amine   C10H12BrNO2 Phenethylamine 
2C-B-Fly   2-(4-bromo-2,3,6,7-tetrahydrofuro[2,3-f][1]benzofuran-8-yl)ethanamine 178557-21-6 C12H14BrNO2 Phenethylamine 
2C-iP     2-[2,5-Dimethoxy-4-(propan-2-yl)phenyl]ethan-1-amine   C13H21NO2 Phenethylamine 
2C-TFM     2-[2,5-Dimethoxy-4-(trifluoromethyl)phenyl]ethan-1-amine   C11H14F3NO2 Phenethylamine 
2-Ethoxy-4,5-dimethoxyamphetamine EMM 1-(2-ethoxy-4,5-dimethoxyphenyl)propan-2-amine 23693-30-3 C13H21NO3 Phenethylamine 
2-Ethylamino-1-(3,4-methylenedioxyphenyl)butane EBDB, Ethyl-J 1-(1,3-benzodioxol-5-yl)-N-ethylbutan-2-amine 167394-39-0 C13H19NO2 Phenethylamine 
2-Fluoroamphetamine 2-FA 1-(2-fluorophenyl)propan-2-amine 1716-60-5 C9H12FN Phenethylamine 
2-Fluoromethamphetamine 2-FMA 2-fluoro-N,α-dimethyl-benzeneethanamine 1017176-48-5 C10H14FN Phenethylamine 
2-Methoxy-3,4-methylenedioxyamphetamine MMDA-3a 1-(4-methoxy-1,3-benzodioxol-5-yl)propan-2-amine   C11H15NO3 Phenethylamine 
2-Methoxy-4,5-diethoxyamphetamine MEE 1-(4,5-diethoxy-2-methoxyphenyl)propan-2-amine 23693-35-8 C14H23NO3 Phenethylamine 
2-Methoxy-4,5-methylenedioxyamphetamine MMDA-2 1-(6-methoxy-2H-benzo[d]1,3-dioxolan-5-yl)prop-2-ylamine 23693-18-7 C11H15NO3 Phenethylamine 
2-Methoxy-4-methyl-5-methylsulfinylamphetamine TOMSO 1-[2-methoxy-4-methyl-5-(methylsulfinyl)phenyl]propan-2-amine   C12H19NO2S Phenethylamine 
2-Methoxy-4-methyl-5-methylthioamphetamine 5-TOM 1-[2-methoxy-4-methyl-5-(methylsulfanyl)phenyl]propan-2-amine   C12H19NOS Phenethylamine 
2-Methoxyamphetamine 2-MeO-Amp 1-(2-methoxyphenyl)propan-2-amine 15402-84-3 C10H15NO Phenethylamine 
2-Methoxymethamphetamine 2-MeO-MA 2-methoxy-N,α-dimethyl-benzeneethanamine 93-30-1 C11H17NO Phenethylamine 
2-Methoxy-N-methyl-4,5-methylenedioxyamphetamine Methyl-MMDA-2 1-(6-methoxy-1,3-benzodioxol-5-yl)-N-methylpropan-2-amine   C12H17NO3 Phenethylamine 
2-Methylamino-1-(3,4-methylenedioxyphenyl)butane MBDB 1-(1,3-benzodioxol-5-yl)-N-methylbutan-2-amine 103818-46-8 C12H17NO2 Phenethylamine 
2-Methylamino-1-phenylbutane     α-ethyl-N-methyl-benzeneethanamine   C11H17N Phenethylamine 
2-Methylamphetamine 2-MA 1-(2-methylphenyl)propan-2-amine 5580-32-5 C10H15N Phenethylamine 
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2-Methylmethamphetamine 2-MMA N,α,2-trimethyl-benzeneethanamine 861007-65-0 C11H17N Phenethylamine 
2-Thioisomescaline 2-TIM 2-[3,4-dimethoxy-2-(methylsulfanyl)phenyl]ethanamine   C11H17NO2S Phenethylamine 
2-TOM 2-TOM 1-[5-methoxy-4-methyl-2-(methylsulfanyl)phenyl]propan-2-amine   C12H19NOS Phenethylamine 
3,4,5,β-Tetramethoxyphenethylamine BOM 2-methoxy-2-(3,4,5-trimethoxyphenyl)ethanamine 98537-40-7 C12H19NO4 Phenethylamine 
3,4-Dihydroxymethamphetamine HHMA 4-[2-(methylamino)propyl]-1,2-benzenediol   C10H15NO2 Phenethylamine 
3,4-Dimethoxyamphetamine 3,4-DMA 1-(3,4-dimethoxyphenyl)propan-2-amine 120-26-3 C11H17NO2 Phenethylamine 
3,4-Dimethoxymethamphetamine  3,4-DMMA 3,4-dimethoxy-N,α-dimethyl-benzeneethanamine 33236-61-2 C12H19NO2 Phenethylamine 
3,4-Dimethoxy-N,N,α-trimethyl-amphetamine   3,4-dimethoxy-N,N,α-trimethyl-benzeneethanamine 58993-77-4 C13H21NO2 Phenethylamine 
3,4-Dimethoxyphenethylamine DMPEA 2-(3,4-dimethoxyphenyl)ethanamine 120-20-7 C10H15NO2 Phenethylamine 
3,4-Dimethoxy-β-hydroxyphenethylamine DME 2-amino-1-(3,4-dimethoxyphenyl)ethanol 6924-15-8 C10H15NO3 Phenethylamine 
3,4-Dimethyl-2,5-dimethoxyamphetamine  Ganesha 2-(2,5-dimethoxy-3,4-dimethyl-phenyl)-1-methyl-ethylamine 207740-37-2 C13H21NO2 Phenethylamine 
3,4-Ethylenedioxy-N-methylamphetamine EDMA 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-methylpropan-2-amine   C12H17NO2 Phenethylamine 
3,4-Methylenedioxy-2-methylthioamphetamine 2T-MMDA-3a 1-[4-(methylsulfanyl)-1,3-benzodioxol-5-yl]propan-2-amine   C11H15NO2S Phenethylamine 
3,4-Methylenedioxyamphetamine MDA 1-(1,3-benzodioxol-5-yl)propan-2-amine 4764-17-4 C10H13NO2 Phenethylamine 
3,4-Methylenedioxy-N-(2-methoxyethyl)amphetamine MDMEOET 1-(1,3-benzodioxol-5-yl)-N-(2-methoxyethyl)propan-2-amine 74698-44-5 C13H19NO3 Phenethylamine 
3,4-Methylenedioxy-N,N-dimethylamphetamine MDDM 1-(1,3-benzodioxol-5-yl)-N,N-dimethylpropan-2-amine 74698-50-3 C12H17NO2 Phenethylamine 
3,4-Methylenedioxy-N-allylamphetamine MDAL N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]prop-2-en-1-amine 74698-45-6 C13H17NO2 Phenethylamine 
3,4-Methylenedioxy-N-benzylamphetamine MDBZ 1-(1,3-benzodioxol-5-yl)-N-benzylpropan-2-amine 65033-29-6 C17H19NO2 Phenethylamine 
3,4-Methylenedioxy-N-butylamphetamine MDBU N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]butan-1-amine 74698-38-7 C14H21NO2 Phenethylamine 
3,4-Methylenedioxy-N-cyclopropylmethylamphetamine MDCPM 1-(1,3-benzodioxol-5-yl)-N-(cyclopropylmethyl)propan-2-amine 22698-08-4 C14H19NO2 Phenethylamine 
3,4-Methylenedioxy-N-ethylamphetamine MDEA 1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine 82801-81-8 C12H17NO2 Phenethylamine 
3,4-Methylenedioxy-N-ethyl-α-propylphenethylamine EBDP, Ethyl-K 1-(1,3-benzodioxol-5-yl)-N-ethylpentan-2-amine 952016-47-6 C14H21NO2 Phenethylamine 
3,4-Methylenedioxy-N-hydroxyethylamphetamine MDHOET 2-([1-(1,3-benzodioxol-5-yl)propan-2-yl]amino)ethanol 74698-43-4 C12H17NO3 Phenethylamine 
3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine MDHMA 
1-(1,3-benzodioxol-5-yl)-N-hydroxy-N-
methylpropan-2-amine 214414-88-7 C11H15NO3 Phenethylamine 
3,4-Methylenedioxy-N-isopropylamphetamine N-Isopropyl-MDA 1-(1,3-benzodioxol-5-yl)-N-(propan-2-yl)propan-2-amine 74698-37-6 C13H19NO2 Phenethylamine 
3,4-Methylenedioxy-N-methylamphetamine MDMA 1-(1,3-benzodioxol-5-yl)-N-methylpropan-2-amine 42542-10-9 C11H15NO2 Phenethylamine 
3,4-Methylenedioxy-N-methylphentermine MDMP 1-(1,3-benzodioxol-5-yl)-N,2-dimethylpropan-2-amine 81262-69-3 C12H17NO2 Phenethylamine 
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3,4-Methylenedioxy-N-methyoxyamphetamine MDMEO 1-(1,3-benzodioxol-5-yl)-N-methoxypropan-2-amine 74698-48-9 C11H15NO3 Phenethylamine 
3,4-Methylenedioxy-N-propargylamphetamine MDPL N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]prop-2-yn-1-amine 74698-46-7 C13H15NO2 Phenethylamine 
3,4-Methylenedioxy-N-propylamphetamine MDPR N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]propan-1-amine 74698-36-5 C13H19NO2 Phenethylamine 
3,4-Methylenedioxyphenethylamine MDPEA 2-(1,3-benzodioxol-5-yl)ethanamine 1484-85-1 C9H11NO2 Phenethylamine 
3,4-Methylenedioxyphentermine MDPH 1-(1,3-benzodioxol-5-yl)-2-methylpropan-2-amine 39235-63-7 C11H15NO2 Phenethylamine 
3,4-Methylenedioxy-α-propyl-N-methylphenethylamine MBDP 1-(1,3-benzodioxol-5-yl)-N-methylpentan-2-amine 952016-78-3 C13H19NO2 Phenethylamine 
3,4-Methylenedioxy-β-methoxyphenethylamine BOH 2-(1,3-benzodioxol-5-yl)-2-methoxyethanamine 73304-06-0 C10H13NO3 Phenethylamine 
3,4-Norbornyl-2,5-dimethoxyamphetamine G-5 1-(5,8-dimethoxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl)propan-2-amine   C16H23NO2 Phenethylamine 
3,4-Norbornyl-2,5-dimethoxyphenethylamine 2C-G-5 2-(5,8-dimethoxy-1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl)ethanamine 207740-20-3 C15H21NO2 Phenethylamine 
3,5-Dimethoxy-4-ethoxyamphetamine 3C-E 1-(4-ethoxy-3,5-dimethoxyphenyl)propan-2-amine 146849-92-5 C13H21NO3 Phenethylamine 
3,5-Dimethoxy-4-n-propoxyamphetamine 3C-P 3,5-dimethoxy-α-methyl-4-propoxy-benzeneethanamine 501700-11-4 C14H23NO3 Phenethylamine 
3,5-Methoxy-4-trideutero methoxy phenethylamine 4-D 3,5-Methoxy-4-trideuteromethoxyphenethylamine   C11H14D3NO3 Phenethylamine 
30C-NBOMe     2-(4-chloro-2,5-dimethoxyphenyl)-N-(3,4,5-trimethoxybenzyl)ethanamine   C20H26ClNO5 Phenethylamine 
3C-B-FLY   
8-bromo-2,3,6,7-tetrahydro-a-methyl-benzo[1,2-b:4,
5-b]difuran-4-ethanamine 219986-75-1 C13H16BrNO2 Phenethylamine 
3-Fluoro-4-methoxyamphetamine   1-(3-fluoro-4-methoxyphenyl)propan-2-amine 863667-46-3 C10H14FNO Phenethylamine 
3-Fluoroamphetamine 3-FA 1-(3-fluorophenyl)-2-propanamine 1626-71-7 C9H12FN Phenethylamine 
3-Fluoromethamphetamine 3-FMA 3-fluoro-N,α-dimethyl-benzeneethanamine 1182818-14-9 C10H14FN Phenethylamine 
3-Methoxy-4,5-ethylenedioxyamphetamine MEDA 1-(8-methoxy-2,3-dihydro-1,4-benzodioxin-6-yl)propan-2-amine 23693-25-6 C12H17NO3 Phenethylamine 
3-Methoxy-4,5-methylenedioxyamphetamine MMDA 1-(7-methoxy-1,3-benzodioxol-5-yl)propan-2-amine 13674-05-0 C11H15NO3 Phenethylamine 
3-Methoxy-4,5-methylenedioxyphenethylamine MMDPEA 2-(7-methoxy-1,3-benzodioxol-5-yl)ethanamine 23693-38-1 C10H13NO3 Phenethylamine 
3-Methoxy-4-allyloxy-phenethylamine MAPEA 2-[3-Methoxy-4-(prop-2-en-1-yloxy)phenyl]ethanamine   C11H15NO2 Phenethylamine 
3-Methoxy-4-ethoxyphenethylamine MEPEA 2-(4-ethoxy-3-methoxyphenyl)ethanamine 36377-59-0 C11H17NO2 Phenethylamine 
3-Methoxyamphetamine   1-(3-methoxyphenyl)propan-2-amine 17862-85-0 C10H15NO Phenethylamine 
3-Methoxymethamphetamine 3-MeO-MA 1-(3-methoxyphenyl)-N-methylpropan-2-amine 124206-66-2 C11H17NO Phenethylamine 
3-Methoxytyramine 3-MT 4-(2-aminoethyl)-2-methoxyphenol   C9H13NO2 Phenethylamine 
3-Methyl-4,5-methylenedioxyamphetamine 5-Me-MDA 1-(7-methyl-1,3-benzodioxol-5-yl)-2-propanamine 749191-14-8 C11H15NO2 Phenethylamine 
3-Methylamphetamine 3-MA 1-(3-methylphenyl)propan-2-amine 588-06-7 C10H15N Phenethylamine 
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3-Methylmethamphetamine 3-MMA N-methyl-1-(3-methylphenyl)-2-propanamine 861007-68-3 C11H17N Phenethylamine 
3-Thioasymbescaline 3-TASB 2-[4-ethoxy-3-(ethylsulfanyl)-5-methoxyphenyl]ethanamine   C13H21NO2S Phenethylamine 
3-Thioescaline 3-TE 2-[4-ethoxy-3-methoxy-5-(methylsulfanyl)phenyl]ethanamine   C12H19NO2S Phenethylamine 
3-Thioisomescaline 3-TIM 2-[2,4-dimethoxy-3-(methylsulfanyl)phenyl]ethanamine   C11H17NO2S Phenethylamine 
3-Thiomescaline 3-TM 2-[3,4-dimethoxy-5-(methylsulfanyl)phenyl]ethanamine   C11H17NO2S Phenethylamine 
3-Thiometaescaline 3-TME 2-[3-(ethylsulfanyl)-4,5-dimethoxyphenyl]ethanamine   C12H19NO2S Phenethylamine 
3-Thiosymbescaline 3-TSB 2-[3-ethoxy-5-(ethylsulfanyl)-4-methoxyphenyl]ethanamine   C13H21NO2S Phenethylamine 
3-Thiotrescaline 3-T-TRIS 2-[3,4-diethoxy-5-(ethylsulfanyl)phenyl]ethanamine   C14H23NO2S Phenethylamine 
4,5-Dimethoxy-2-methylthioamphetamine o-DOT 1-[4,5-dimethoxy-2-(methylsulfanyl)phenyl]propan-2-amine   C12H19NO2S Phenethylamine 
4,5-Thiomethyleneoxy-2-methoxyamphetamine 4T-MMDA-2 1-(5-methoxy-1,3-benzoxathiol-6-yl)propan-2-amine   C11H15NO2S Phenethylamine 
4-APB     α-methyl-4-benzofuranethanamine   C11H13NO Phenethylamine 
4-Benzyloxy-3,5-dimethoxyamphetamine 3C-BZ 
1-[4-(benzyloxy)-3,5-dimethoxyphenyl]propan-2-
amine 147947-26-0 C18H23NO3 Phenethylamine 
4-Bromo-2,5-dimethoxy-N-methylamphetamine Methyl-DOB 1-(4-bromo-2,5-dimethoxyphenyl)-N-methylpropan-2-amine 155638-80-5 C12H18BrNO2 Phenethylamine 
4-Bromo-2,5-β-trimethoxyphenethylamine BOB 2-(4-bromo-2,5-dimethoxyphenyl)-2-methoxyethanamine 98537-42-9 C11H16BrNO3 Phenethylamine 
4-Bromo-3,5-dimethoxyamphetamine   1-(4-bromo-3,5-dimethoxyphenyl)propan-2-amine   C11H16BrNO2 Phenethylamine 
4-Chlorophenylisobutylamine 4-CAB  1-(4-chlorophenyl)butan-2-amine   C10H14ClN Phenethylamine 
4-Cyclopropylmethoxy-3,5-dimethoxyphenethylamine CPM 2-[4-(cyclopropylmethoxy)-3,5-dimethoxyphenyl]ethanamine 207740-23-6 C14H21NO3 Phenethylamine 
4-Ethyl-2-methoxy-5-methylthioamphetamine 5-TOET 1-[4-ethyl-2-methoxy-5-(methylsulfanyl)phenyl]propan-2-amine   C13H21NOS Phenethylamine 
4-Fluoroamphetamine 4-FA  1-(4-fluorophenyl)-2-propanamine 459-02-9 C9H12FN Phenethylamine 
4-Fluoromethamphetamine 4-FMA 1-(4-fluorophenyl)-N-methyl-2-propanamine 351-03-1 C10H14FN Phenethylamine 
4-Hydroxy-3-methoxyamphetamine HMA 5-(2-aminopropyl)-2-methoxyphenol   C10H15NO2 Phenethylamine 
4-Hydroxy-3-methoxyethylamphetamine HMEA 4-[2-(ethylamino)propyl]-2-methoxyphenol 69389-97-5 C12H19NO2 Phenethylamine 
4-Hydroxy-3-methoxymethamphetamine HMMA 2-methoxy-5-[2-(methylamino)propyl]phenol   C11H17NO2 Phenethylamine 
4-Hydroxyamphetamine  4-HA 4-(2-aminopropyl)phenol 103-86-6 C9H13NO Phenethylamine 
4-Hydroxymethamphetamine  4-HO-MA 4-[2-(methylamino)propyl]phenol 370-14-9 C10H15NO Phenethylamine 
4-Iodo-2,5-dimethoxyamphetamine DOI 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine 64584-34-5 C11H16INO2 Phenethylamine 
4-MAPB     1-(benzofuran-4-yl)-N-methylpropan-2-amine   C12H15NO Phenethylamine 
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4-Methoxy-2,3-methylenedioxyamphetamine MMDA-3b 1-(7-methoxy-1,3-benzodioxol-4-yl)propan-2-amine   C11H15NO3 Phenethylamine 
4-Methoxyamphetamine PMA 1-(4-methoxyphenyl)propan-2-amine 64-13-1 C10H15NO Phenethylamine 
4-Methoxyethylamphetamine PMEA N-ethyl-1-(4-methoxyphenyl)propan-2-amine 14367-46-5 C12H19NO Phenethylamine 
4-Methoxymethamphetamine PMMA 1-(4-methoxyphenyl)-N-methylpropan-2-amine 22331-70-0 C11H17NO Phenethylamine 
4-Methoxyphenylethylamine   2-(4-methoxyphenyl)ethylamine 55-81-2 C9H13NO Phenethylamine 
4-Methyl-2,5-dimethoxymethamphetamine MDOM 1-(2,5-dimethoxy-4-methylphenyl)-N-methylpropan-2-amine 92206-37-6 C13H21NO2 Phenethylamine 
4-Methyl-3,5-dimethoxyphenethylamine DESOXY 2-(3,5-dimethoxy-4-methylphenyl)ethanamine 63037-49-0 C11H17NO2 Phenethylamine 
4-Methylamphetamine 4-MA 1-(4-methylphenyl)propan-2-amine 22683-78-9 C10H15N Phenethylamine 
4-Methylmethamphetamine 4-MMA N-methyl-1-(4-methylphenyl)-2-propanamine 714965-56-7 C11H17N Phenethylamine 
4-Methylthioamphetamine 4-MTA 1-(4-methylsulfanylphenyl)propan-2-amine 14116-06-4 C10H15NS Phenethylamine 
4-Methylthiobutylamphetamine 4-MTBA 4-(2-methyliminohydrazinyl)benzoic acid 40843-84-3 C8H9N3O2 Phenethylamine 
4-Methylthiodimethamphetamine 4-MTDMA N,N-dimethyl-1-(4-methylsulfanylphenyl)propan-2-amine 634607-25-3 C12H19NS Phenethylamine 
4-Methylthioethylamphetamine 4-MTEA N-ethyl-1-[4-(methylsulfanyl)phenyl]propan-2-amine 634607-27-5 C12H19NS Phenethylamine 
4-Methylthiomethamphetamine 4-MTMA N-methyl-1-(4-methylsulfanylphenyl)propan-2-amine 547736-90-3 C11H17NS Phenethylamine 
4-Methylthiopropylamphetamine 4-MTPA α-methyl-4-(methylthio)-N-propyl-benzeneethanamine 634607-29-7 C13H21NS Phenethylamine 
4-Nitro-2,5-dimethoxyamphetamine DON 1-(2,5-dimethoxy-4-nitrophenyl)propan-2-amine 67460-68-8 C11H16N2O4 Phenethylamine 
4-Propyl-2,5-dimethoxyamphetamine DOPR 1-(2,5-dimethoxy-4-propylphenyl)propan-2-amine 63779-88-4 C14H23NO2 Phenethylamine 
4-propynyloxy-3,5-dimethoxyphenethylamine Propynyl 2-[3,5-dimethoxy-4-(prop-2-yn-1-yloxy)phenyl]ethanamine 952017-05-9 C13H17NO3 Phenethylamine 
4-Thioasymbescaline 4-TASB 
2-[3-ethoxy-4-(ethylsulfanyl)-5-
methoxyphenyl]ethanamine   C13H21NO2S Phenethylamine 
4-Thiobuscaline TB 2-[4-(butylsulfanyl)-3,5-dimethoxyphenyl]ethanamine   C14H23NO2S Phenethylamine 
4-Thioescaline 4-TE 2-[4-(ethylsulfanyl)-3,5-dimethoxyphenyl]ethanamine   C12H19NO2S Phenethylamine 
4-Thioisomescaline 4-TIM 2-[2,3-dimethoxy-4-(methylsulfanyl)phenyl]ethanamine   C11H17NO2S Phenethylamine 
4-Thiomescaline 4-TM 2-[3,5-dimethoxy-4-(methylsulfanyl)phenyl]ethanamine   C11H17NO2S Phenethylamine 
4-Thiometaescaline 4-TME 2-[3-ethoxy-5-methoxy-4-(methylsulfanyl)phenyl]ethanamine   C12H19NO2S Phenethylamine 
4-Thiosymbescaline 4-TSB 2-[3,5-diethoxy-4-(methylsulfanyl)phenyl]ethanamine   C13H21NO2S Phenethylamine 
4-Thiotrescaline 4-T-TRIS 2-[3,5-diethoxy-4-(ethylsulfanyl)phenyl]ethanamine   C14H23NO2S Phenethylamine 
5-(2-Aminopropyl)-2,3-dihydrobenzofuran 5-APDB 2,3-dihydro-α-methyl-5-benzofuranethanamine 152624-03-8 C11H15NO Phenethylamine 
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5-(2-Aminopropyl)benzofuran 5-APB  1-(1-benzofuran-5-yl)-2-propanamine 286834-81-9 C11H13NO Phenethylamine 
5-Bromo-2,4-dimethoxyamphetamine meta-DOB 1-(5-bromo-2,4-dimethoxyphenyl)propan-2-amine 60917-67-1 C11H16BrNO2 Phenethylamine 
5-Ethoxy-2-methoxy-4-methylamphetamine 5-Et-DOM 1-(5-ethoxy-2-methoxy-4-methylphenyl)propan-2-amine   C13H21NO2 Phenethylamine 
5-Fluoro-2-methoxyamphetamine   1-(5-fluoro-2-methoxyphenyl)propan-2-amine 863667-45-2 C10H14FNO Phenethylamine 
5-Methylthio-2,4-dimethoxyamphetamine meta-DOT 1-[2,4-dimethoxy-5-(methylsulfanyl)phenyl]propan-2-amine 79440-52-1 C12H19NO2S Phenethylamine 
5-Thioasymbescaline 5-TASB 
2-[3,4-diethoxy-5-
(methylsulfanyl)phenyl]ethanamine   C13H21NO2S Phenethylamine 
5-Thiometaescaline 5-TME 
2-[3-ethoxy-4-methoxy-5-
(methylsulfanyl)phenyl]ethanamine   C12H19NO2S Phenethylamine 
6-(2-Aminopropyl)-2,2-dimethyl-5-methoxy-2,3-
dihydrobenzofuran F-22 
1-(5-methoxy-2,2-dimethyl-2,3-dihydro-1-
benzofuran-6-yl)propan-2-amine 952016-51-2 C14H21NO2 Phenethylamine 
6-(2-Aminopropyl)-2,3-dihydrobenzofuran 6-APDB 1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine 152623-93-3 C11H15NO Phenethylamine 
6-(2-Aminopropyl)-5-methoxy-2-methyl-2,3-
dihydrobenzofuran F-2 
1-(5-methoxy-2-methyl-2,3-dihydro-1-benzofuran-6-
yl)propan-2-amine   C13H19NO2 Phenethylamine 
6-(2-Aminopropyl)benzofuran 6-APB 1-(1-benzofuran-6-yl)-2-propanamine 286834-85-3 C11H13NO Phenethylamine 
Allylescaline   2-[4-(allyloxy)-3,5-dimethoxyphenyl]ethanamine   C12H17NO3 Phenethylamine 
Amphetamine   1-phenylpropan-2-amine 300-62-9 C9H13N Phenethylamine 
Ariadne α-Et-DOM 1-(2,5-dimethoxy-4-methylphenyl)butan-2-amine 52842-59-8 C13H21NO2 Phenethylamine 
Asymbescaline   2-(3,4-diethoxy-5-methoxyphenyl)ethanamine 63918-08-1 C13H21NO3 Phenethylamine 
Benzodioxolylbutanamine BDB 1-(1,3-benzodioxol-5-yl)butan-2-amine 107447-03-0 C11H15NO2 Phenethylamine 
Bromo-DragonFLY   (2R)-1-(8-bromofuro[2,3-f][1]benzofuran-4-yl)-2-propanamine 502759-67-3 C13H12BrNO2 Phenethylamine 
Bromo-DragonFLY     8-bromo-α-methyl-benzo[1,2-b:4,5-b]difuran-4-ethanamine   C13H12BrNO2 Phenethylamine 
Buscaline   2-(4-butoxy-3,5-dimethoxyphenyl)ethanamine 64778-75-2 C14H23NO3 Phenethylamine 
Dimethoxybromoamphetamine DOB 2,5-dimethoxy-4-bromoamphetamine 64638-07-9 C11H16BrNO2 Phenethylamine 
Dimethylamphetamine N,N-DMA N,N-dimethyl-1-phenylpropan-2-amine 4075-96-1 C11H17N Phenethylamine 
Dimethylphenethylamine   N,N-dimethyl-2-phenylethanamine 1126-71-2 C10H15N Phenethylamine 
Escaline   3,5-dimethoxy-4-ethoxy-phenethylamine 39201-82-6 C12H19NO3 Phenethylamine 
Ethylamphetamine   N-ethyl-1-phenylpropan-2-amine 457-87-4 C11H17N Phenethylamine 
Hordenine   4-(2-dimethylaminoethyl)phenol 539-15-1 C10H15NO Phenethylamine 
Isomescaline   2-(2,3,4-trimethoxyphenyl)ethanamine   C11H17NO3 Phenethylamine 
Isoproscaline   2-[3,5-dimethoxy-4-(propan-2-yloxy)phenyl]ethanamine   C13H21NO3 Phenethylamine 
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Mescaline   2-(3,4,5-trimethoxyphenyl)ethanamine 54-04-6 C11H17NO3 Phenethylamine 
Mescaline NBOMe   
N-(2-methoxybenzyl)-3,4,5-
trimethoxyphenethylamine   C19H25NO4 Phenethylamine 
Metaescaline   2-(3-ethoxy-4,5-dimethoxyphenyl)ethanamine   C12H19NO3 Phenethylamine 
Metaproscaline   2-(3,4-dimethoxy-5-propoxyphenyl)ethanamine   C13H21NO3 Phenethylamine 
Methallylescaline   2-(3,5-dimethoxy-4-[(2-methylprop-2-en-1-yl)oxy]phenyl)ethanamine   C14H21NO3 Phenethylamine 
Methamphetamine   (2S)-N-methyl-1-phenylpropan-2-amine 537-46-2 C10H15N Phenethylamine 
Methylthio-ethyl-methoxyamphetamine 2-TOET 1-[4-ethyl-5-methoxy-2-(methylsulfanyl)phenyl]propan-2-amine   C13H21NOS Phenethylamine 
N-(2-Fluorobenzyl)-4-iodo-2,5-dimethoxyphenethylamine 25I-NBF 
N-(2-fluorobenzyl)-2-(4-iodo-2,5-
dimethoxyphenyl)ethanamine 919797-21-0 C17H19FINO2 Phenethylamine 
N-Acetyl 4,4-methylene dianiline N-Acetyl-MDA N-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]acetamide 36209-71-9 C12H15NO3 Phenethylamine 
N-Ethyl-4-fluoroamphetamine N-Ethyl-4-FA N-ethyl-1-(4-fluorophenyl)-2-propanamine   C11H16FN Phenethylamine 
N-Hydroxy-3,4-methylenedioxyamphetamine N-HO-MDA 1-(1,3-benzodioxol-5-yl)-N-hydroxypropan-2-amine 74698-47-8 C10H13NO3 Phenethylamine 
N-Hydroxy-4-fluoroamphetamine N-HO-4-FA 4-fluoro-N-hydroxy-α-methyl-benzeneethanamine 1112937-74-2 C9H12FNO Phenethylamine 
Phenescaline   2-[3,5-dimethoxy-4-(2-phenylethoxy)phenyl]ethanamine 207740-42-9 C18H23NO3 Phenethylamine 
Phenethylamine   2-phenylethanamine 64-04-0 C8H11N Phenethylamine 
Propylamphetamine   N-(1-methyl-2-phenylethyl)propan-1-amine 51799-32-7 C12H19N Phenethylamine 
Proscaline   3,5-dimethoxy-4-n-propoxy-phenethylamine 39201-78-0 C13H21NO3 Phenethylamine 
Symbescaline   2-(3,5-diethoxy-4-methoxyphenyl)ethanamine 90109-61-8 C13H21NO3 Phenethylamine 
Thioproscaline   2-[3,5-dimethoxy-4-(propylsulfanyl)phenyl]ethanamine 90109-55-0 C13H21NO2S Phenethylamine 
Trescaline   2-(3,4,5-triethoxyphenyl)ethanamine   C14H23NO3 Phenethylamine 
Trimethoxyamphetamine TMA 1-(3,4,5-trimethoxyphenyl)propan-2-amine 1082-88-8 C12H19NO3 Phenethylamine 
α-Ethylmescaline   1-(3,4,5-trimethoxyphenyl)butan-2-amine 17097-73-3 C13H21NO3 Phenethylamine 
α-Ethyl-N-methylpiperonylamine M-ALPHA α-ethyl-N-methyl-1,3-benzodioxole-5-methanamine 127292-43-7 C11H15NO2 Phenethylamine 
α-Ethylphenethylamine AEPEA 1-phenylbutan-2-amine 53309-89-0 C10H15N Phenethylamine 
β-Methylphenethylamine BMPEA   β-methyl-benzeneethanamine   C9H13N Phenethylamine 
JWH-167   1-(1-pentyl-1H-indol-3-yl)-2-phenyl-ethanone 864445-37-4 C21H23NO Phenylacetylindole 
JWH-201   2-(4-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-47-6 C22H25NO2 Phenylacetylindole 
JWH-203   2-(2-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-54-5 C21H22ClNO Phenylacetylindole 
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JWH-203 3-chlorophenyl isomer   2-(3-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-56-7 C21H22ClNO Phenylacetylindole 
JWH-203 4-chlorophenyl isomer   2-(4-chlorophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-58-9 C21H22ClNO Phenylacetylindole 
JWH-249   2-(2-bromophenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-60-3 C21H22BrNO Phenylacetylindole 
JWH-250   1-(1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)ethanone 864445-43-2 C22H25NO2 Phenylacetylindole 
JWH-250 5-hydroxyindole metabolite   1-(5-hydroxy-1-pentyl-1H-indol-3-yl)-2-(2-methoxyphenyl)ethanone 1379604-67-7 C22H25NO3 Phenylacetylindole 
JWH-250 N-(4-hydroxypentyl) metabolite   1-(1-(4-hydroxypentyl)-1H-indol-3-yl)-2-(2-methoxyphenyl)ethanone 1427521-38-7 C22H25NO3 Phenylacetylindole 
JWH-250 N-(5-carboxypentyl) metabolite   5-(3-(2-(2-methoxyphenyl)acetyl)-1H-indol-1-yl)pentanoic acid 1379604-65-5 C22H23NO4 Phenylacetylindole 
JWH-250 N-(5-hydroxypentyl) metabolite   1-(1-(5-hydroxypentyl)-1H-indol-3-yl)-2-(2-methoxyphenyl)ethanone 1427325-83-4 C22H25NO3 Phenylacetylindole 
JWH-251   2-(2-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)methanone 864445-39-6 C22H25NO Phenylacetylindole 
JWH-251  3-methylphenyl isomer   1-(1-pentyl-1H-indol-3-yl)-2-(m-tolyl)ethanone 1427325-88-9 C22H25NO Phenylacetylindole 
JWH-251  4-methylphenyl isomer   2-(4-methylphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-41-0 C22H25NO Phenylacetylindole 
JWH-302   2-(3-methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 864445-45-4 C22H25NO2 Phenylacetylindole 
RCS-8   1-(1-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(2-methoxyphenyl)ethanone 1345970-42-4 C25H29NO2 Phenylacetylindole 
RCS-8 3-methoxy isomer   1-(1-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(3-methoxyphenyl)ethanone 1427326-08-6 C25H29NO2 Phenylacetylindole 
RCS-8 4-methoxy isomer   1-(1-(2-cyclohexylethyl)-1H-indol-3-yl)-2-(4-methoxyphenyl)ethanone 1427326-10-0 C25H29NO2 Phenylacetylindole 
1-(2,3-Dimethylphenyl)piperazine 2,3-XP 1-(2,3-dimethylphenyl)piperazine 1013-22-5 C12H18N2 Piperazine 
1-(2,4-Dimethylphenyl)piperazine 2,4-XP 1-(2,4-dimethylphenyl)piperazine 1013-76-9 C12H18N2 Piperazine 
1-(2,5-Dimethylphenyl)piperazine 2,5-XP 1-(2,5-dimethylphenyl)piperazine 1013-25-8 C12H18N2 Piperazine 
1-(2-Chlorophenyl) piperazine oCPP 1-(2-chlorophenyl) piperazine 39512-50-0 C10H13ClN2 Piperazine 
1-(2-Fluorophenyl)piperazine 2-FPP 1-(2-fluorophenyl)piperazine 1011-15-0 C10H13FN2 Piperazine 
1-(2-Methoxyphenyl)piperazine 2-MeOPP 1-(2-methoxyphenyl)piperazine 5464-78-8 C11H16N2O Piperazine 
1-(2-Phenylethyl)piperazine 2-PEP 1-(2-phenylethyl)piperazine 5321-49-3 C12H18N2 Piperazine 
1-(3,4-Dimethylphenyl)piperazine 3,4-XP 1-(3,4-dimethylphenyl)piperazine 1014-05-7 C12H18N2 Piperazine 
1-(3,4-Methylenedioxybenzyl)piperazine MDBZP 1-(benzo[1,3]dioxol-5-ylmethyl)piperazine 32231-06-4 C12H16N2O2 Piperazine 
1-(3-Fluorophenyl)piperazine 3-FPP 1-(3-fluorophenyl)piperazine 3801-89-6 C10H13FN2 Piperazine 
1-(3-Methoxyphenyl)piperazine 3-MeOPP 1-(3-methoxyphenyl)piperazine 16015-71-7 C11H16N2O Piperazine 
1-(3-Thienylmethyl)piperazine 3-TMP 1-(thiophen-3-ylmethyl)piperazine 130288-91-4 C9H14N2S Piperazine 
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1-(4-Chlorophenyl)piperazine pCPP 1-(4-chlorophenyl)piperazine 38212-33-8 C10H13ClN2 Piperazine 
1-(4-Methoxyphenyl)piperazine 4-MeOPP 1-(4-methoxyphenyl)piperazine 38212-30-5 C11H16N2O Piperazine 
1-[(4-Bromo-2,5-dimethoxybenzyl)-piperazine 2C-B-BZP 1-[(4-bromo-2,5-dimethoxyphenyl)methyl]-piperazine 1094424-37-9 C13H19BrN2O2 Piperazine 
1-[4-(Trifluoromethyl)phenyl]piperazine 4-TFMPP 1-[4-(trifluoromethyl)phenyl]piperazine 30459-17-7 C11H13F3N2 Piperazine 
1-Benzyl-4-methylpiperazine MBZP 1-benzyl-4-methylpiperazine 374898-00-7 C12H18N2 Piperazine 
3-Methylbenzylpiperazine   1-[(3-methylphenyl)methyl]piperazine 5321-48-2 C12H18N2 Piperazine 
3-Trifluoromethylphenylpiperazine TFMPP 1-[3-(trifluoromethyl)phenyl]piperazine 15532-75-9 C11H13F3N2 Piperazine 
4-Fluorobenzylpiperazine 4-FBZP 1-[(4-fluorophenyl)methyl]piperazine 70931-28-1 C11H15FN2 Piperazine 
Benzylpiperazine BZP 1-benzylpiperazine 110475-31-5 C11H16N2 Piperazine 
Dibenzylpiperazine DBZP 1,4-dibenzylpiperazine 1034-11-3 C18H22N2 Piperazine 
meta-Chlorophenylpiperazine mCPP 1-(3-chlorophenyl)piperazine 6640-24-0 C10H13ClN2 Piperazine 
para-Fluorophenylpiperazine 4-FPP 1-(4-fluorophenyl)piperazine 2252-63-3 C10H13FN2 Piperazine 
Phenylpiperazine    1-phenylpiperazine 92-54-6 C10H14N2 Piperazine 
5-Fluoro-3,5-AB-PFUPPYCA  5-fluoro AB-FUPPYCA 
(S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-
fluoropentyl)-3-(4-fluorophenyl)-1H-pyrazole-5-
carboxamide 
  C20H26F2N4O2 Pyrazole 
2-Diphenylmethylpyrrolidine Desoxy-D2PM 2-(diphenylmethyl)-pyrrolidine 383127-45-5 C17H19N Pyrrolidine 
Diphenylprolinol D2PM  diphenyl-2-pyrrolidinemethanol 112068-01-6 C17H19NO Pyrrolidine 
2,N,N-Trimethyltryptamine 2-Me-DMT N,N-dimethyl-2-(2-methyl-1H-indol-3-yl)ethanamine 1080-95-1 C13H18N2 Tryptamine 
2,α-Dimethyltryptamine 2,α-DMT 1-(2-methyl-1H-indol-3-yl)propan-2-amine 4966-28-3 C12H16N2 Tryptamine 
4-Acetoxy-N,N-diethyltryptamine 4-Acetoxy-DET 3-[2-(diethylamino)ethyl]-, 4-acetate1H-indol-4-ol 1135424-15-5 C16H22N2O2 Tryptamine 
4-Acetoxy-N,N-diisopropyltryptamine 4-Acetoxy-DiPT 3-[2-(dipropan-2-ylamino)ethyl]-1H-indol-4-yl acetate 936015-60-0 C18H26N2O2 Tryptamine 
4-Acetoxy-N,N-dimethyltryptamine 4-Acetoxy-DMT [3-[2-(dimethylamino)ethyl]-1H-indol-4-yl] acetate 92292-84-7 C14H18N2O2 Tryptamine 
4-Acetoxy-N-isopropyl-N-methyltryptamine 4-Acetoxy-MiPT 3-[2-[methyl(1-methylethyl)amino]ethyl]-, 4-1H-indol-4-ol 1024612-25-6 C16H22N2O2 Tryptamine 
4-Acetoxy-N-methyl-N-ethyltryptamine 4-Acetoxy-MET 3-(2-[ethyl(methyl)amino]ethyl)-1H-indol-4-yl acetate 1445751-40-5 C15H20N2O2 Tryptamine 
4-Hydroxy-N,N-diisopropyltryptamine 4-HO-DiPT 3-(2-[di(propan-2-yl)amino]ethyl)-1H-indol-4-ol 132328-45-1 C16H24N2O Tryptamine 
4-Hydroxy-N-isopropyl-N-methyltryptamine 4-HO-MiPT 3-[2-[methyl(propan-2-yl)amino]ethyl]-1H-indol-4-ol 77872-43-6 C14H20N2O Tryptamine 
4-Hydroxy-N-methyl-N-propyltryptamine 4-HO-MPT 3-(2-[methyl(propyl)amino]ethyl)-1H-indol-4-ol 763035-03-6 C14H20N2O Tryptamine 
4-Hydroxypyrrolidyltryptamine 4-HO-pyr-T 3-[2-(pyrrolidin-1-yl)ethyl]-1H-indol-4-ol 63097-26-7 C14H18N2O Tryptamine 
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4-Methoxy-N,N-dimethyltryptamine 4-MeO-DMT 2-(4-methoxy-1H-indol-3-yl)-N,N-dimethyl-ethanamine 3965-97-7 C13H18N2O Tryptamine 
5-(2-Aminopropyl)indole 5-API 1-(1H-indol-5-yl)propan-2-amine 3784-30-3 C11H14N2 Tryptamine 
5,6-Dimethoxy-N-isopropyl-N-methyltryptamine 5,6-MeO-MiPT N-[2-(5,6-dimethoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine   C16H24N2O2 Tryptamine 
5-Hydroxytryptamine 5-HO-T 3-(2-aminoethyl)-1H-indol-5-ol 50-67-9 C10H12N2O Tryptamine 
5-Methoxy-2,N,N-trimethyltryptamine 5-MeO-TMT 2-(5-methoxy-2-methyl-1H-indol-3-yl)-N,N-dimethylethanamine   C14H20N2O Tryptamine 
5-Methoxy-N,N-dimethyltryptamine 5-MeO-DMT 2-(5-methoxy-1H-indol-3-yl)-N,N-dimethylethanamine 1019-45-0 C13H18N2O Tryptamine 
5-Methoxy-N,N-dipropyltryptamine 5-MeO-DPT N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propyl-propan-1-amine 2427-80-7 C17H26N2O Tryptamine 
5-Methoxy-N,N-tetramethylenetryptamine 5-MeO-pyr-T 5-methoxy-3-[2-(pyrrolidin-1-yl)ethyl]-1H-indole 3949-14-2 C15H20N2O Tryptamine 
5-Methoxy-N-ethyl-N-isopropyltryptamine 5-MeO-EiPT N-ethyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl]propan-2-amine 850032-66-5 C16H26N2O Tryptamine 
5-Methoxy-N-methyltryptamine 5-MeO-NMT 2-(5-methoxy-1H-indol-3-yl)-N-methylethanamine 2009-03-2 C12H16N2O Tryptamine 
5-Methoxytryptamine 5-MeO-T 2-(5-methoxy-1H-indol-3-yl)ethanamine 608-07-1 C11H14N2O Tryptamine 
5-Methoxy-α-methyltryptamine 5-MeO-AMT 1-(5-methoxy-1H-indol-3-yl)-2-propanamine 1137-04-8 C12H16N2O Tryptamine 
6-(2-Aminopropyl)indole 6-API α-methyl-1H-indole-6-ethanamine 21005-63-0 C11H14N2 Tryptamine 
6,N,N-Triethyl-6-norlysergamide ETH-LAD (8β)-N,N,6-triethyl-9,10-didehydroergoline-8-carboxamide 65527-62-0 C21H27N3O Tryptamine 
6-Allyl-N,N-diethyl-6-norlysergamide AL-LAD (8β)-N,N-diethyl-6-(prop-2-en-1-yl)-9,10-didehydroergoline-8-carboxamide 65527-61-9 C22H27N3O Tryptamine 
6-Methoxy-1,2,3,4-tetrahydroharman 6-MeO-THH 2,3,4,9-tetrahydro-6-methoxy-1-methyl-1H-pyrido[3,4-b]indole 1210-56-6 C13H16N2O Tryptamine 
6-Propyl-6-nor-lysergic acid diethylamide PRO-LAD (8β)-N,N-diethyl-6-propyl-9,10-didehydroergoline-8-carboxamide 65527-63-1 C22H29N3O Tryptamine 
7-Methoxy-1,2,3,4-tetrahydroharman 7-MeO-THH 2,3,4,9-tetrahydro-7-methoxy-1-methyl-1H-pyrido[3,4-b]indole 17019-01-1 C13H16N2O Tryptamine 
Dimethyltryptamine N-oxide DMT-N-oxide [2-(1H-indol-3-yl)ethyl]dimethylamine oxide   C12H16N2O Tryptamine 
Harmine   7-methoxy-1-methyl-9H-β-carboline 442-51-3 C13H12N2O Tryptamine 
H-Hydroxy-a-methyltryptamine N-OH-AMT N-hydroxy-α-methyl-1H-indole-3-ethanamine 63-33-2 C11H14N2O Tryptamine 
Ibogaine   12-methoxyibogamine 83-74-9 C20H26N2O Tryptamine 
Methylbutyltryptamine MBT N-[2-(1H-indol-3-yl)ethyl]-N-methylbutan-1-amine   C15H22N2 Tryptamine 
Methylethyltryptamine MET N-ethyl-2-(1H-indol-3-yl)-N-methylethanamine 5599-69-9 C13H18N2 Tryptamine 
Methylisopropyltryptamine MiPT N-methyl-N-(1-methylethyl)-1H-indole-3-ethanamine 96096-52-5 C14H20N2 Tryptamine 
N,N-Diallyl-5-methoxytryptamine 5-MeO-DALT N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-prop-2-enylprop-2-en-1-amine 928822-98-4 C17H22N2O Tryptamine 
N,N-Diallyltryptamine DALT N-allyl-N-[2-(1H-indol-3-yl)ethyl]-2-propen-1-amine 60676-77-9 C16H20N2 Tryptamine 
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N,N-Dibutyl-4-hydroxytryptamine 4-HO-DBT 3-[2-(dibutylamino)ethyl]-1H-indol-4-ol 63065-89-4 C18H28N2O Tryptamine 
N,N-Dibutyltryptamine DBT N-butyl-N-[2-(1H-indol-3-yl)ethyl]butan-1-amine 15741-77-2 C18H28N2 Tryptamine 
N,N-Diethyl-2-methyltryptamine 2-Me-DET N,N-diethyl-2-(2-methyl-1H-indol-3-yl)ethanamine 26628-88-6 C15H22N2 Tryptamine 
N,N-Diethyl-4-hydroxytryptamine 4-HO-DET 3-[2-(diethylamino)ethyl]-1H-indol-4-ol 22204-89-3 C14H20N2O Tryptamine 
N,N-Diethyl-4-phosphoryloxytryptamine 4-HO-DET phosphate ester 
3-[2-(diethylamino)ethyl]-1H-indol-4-yl dihydrogen 
phosphate   C14H21N2O4P Tryptamine 
N,N-Diethyl-5-methoxytryptamine 5-MeO-DET N,N-diethyl-5-methoxy-1H-indole-3-ethanamine 1218-40-2 C15H22N2O Tryptamine 
N,N-Diethyl-d-lysergamide LSD (8β)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide 50-37-3 C20H25N3O Tryptamine 
N,N-Diethyltryptamine DET N,N-diethyl-2-(1H-indol-3-yl)ethanamine 61-51-8 C14H20N2 Tryptamine 
N,N-Diisobutyltryptamine DiBT N-[2-(1H-indol-3-yl)ethyl]-N-isobutyl-2-methyl-1-propanamine 15741-78-3 C18H28N2 Tryptamine 
N,N-Diisopropyl-4,5-methylenedioxytryptamine 4,5-MDO-DiPT N-[2-(6H-[1,3]dioxolo[4,5-e]indol-8-yl)ethyl]-N-(propan-2-yl)propan-2-amine   C17H24N2O2 Tryptamine 
N,N-Diisopropyl-5,6-methylenedioxytryptamine 5,6-MDO-DiPT N-[2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)ethyl]-N-(propan-2-yl)propan-2-amine   C17H24N2O2 Tryptamine 
N,N-Diisopropyl-5-methoxytryptamine 5-MeO-DiPT N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-propan-2-ylpropan-2-amine 4021-34-5 C17H26N2O Tryptamine 
N,N-Diisopropyltryptamine DiPT N-[2-(1H-indol-3-yl)ethyl]-N-isopropyl-2-propanamine 14780-24-6 C16H24N2 Tryptamine 
N,N-Dimethyl-4,5-methylenedioxytryptamine 4,5-MDO-DMT 2-(6H-[1,3]dioxolo[4,5-e]indol-8-yl)-N,N-dimethylethanamine   C13H16N2O2 Tryptamine 
N,N-Dimethyl-4-hydroxytryptamine 4-HO-DMT 3-[2-(dimethylamino)ethyl]-1H-indol-4-ol 520-53-6 C12H16N2O Tryptamine 
N,N-Dimethyl-5,6-methylenedioxytryptamine 5,6-MDO-DMT 2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)-N,N-dimethylethanamine   C13H16N2O2 Tryptamine 
N,N-Dimethyl-5-hydroxytryptamine 5-HO-DMT 3-[2-(dimethylamino)ethyl]-1H-indol-5-ol 487-93-4 C12H16N2O Tryptamine 
N,N-Dimethyl-5-methylthiotryptamine 5-MeS-DMT N,N-dimethyl-2-[5-(methylsulfanyl)-1H-indol-3-yl]ethanamine 5102-11-4 C13H18N2S Tryptamine 
N,N-Dimethyltryptamine DMT 2-(1H-indol-3-yl)-N,N-dimethylethanamine 61-50-7 C12H16N2 Tryptamine 
N,N-Dipropyl-4-hydroxytryptamine 4-HO-DPT 3-[2-(dipropylamino)ethyl]-1H-indol-4-ol 63065-88-3 C16H24N2O Tryptamine 
N,N-Dipropyltryptamine DPT N-[2-(1H-indol-3-yl)ethyl]-N-propylpropan-1-amine 61-52-9 C16H24N2 Tryptamine 
N,N-Tetramethylenetryptamine Pyr-T 3-[2-(pyrrolidin-1-yl)ethyl]-1H-indole 14008-96-9 C14H18N2 Tryptamine 
N-Ethyl-4-hydroxy-N-methyltryptamine 4-HO-MET 3-[2-[ethyl(methyl)amino]ethyl]-1H-indol-4-ol 77872-41-4 C13H18N2O Tryptamine 
N-Ethyl-N-isopropyltryptamine EiPT N-ethyl-N-[2-(1H-indol-3-yl)ethyl]propan-2-amine 848130-11-0 C15H22N2 Tryptamine 
N-Ethyltryptamine NET N-ethyl-2-(1H-indol-3-yl)ethanamine 61-53-0 C12H16N2 Tryptamine 
N-Isopropyl-4-methoxy-N-methyltryptamine 4-MeO-MiPT N-[2-(4-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine   C15H22N2O Tryptamine 
N-Isopropyl-5-methoxy-N-methyltryptamine 5-MeO-MiPT N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-N-methylpropan-2-amine 96096-55-8 C15H22N2O Tryptamine 
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N-Isopropyl-N-methyl-5,6-methylenedioxytryptamine 5,6-MDO-MiPT N-[2-(5H-[1,3]dioxolo[4,5-f]indol-7-yl)ethyl]-N-methylpropan-2-amine   C15H20N2O2 Tryptamine 
N-Isopropyltryptamine NiPT N-[2-(1H-indol-3-yl)ethyl]propan-2-amine 14121-10-9 C13H18N2 Tryptamine 
N-Methyltryptamine NMT 2-(1H-indol-3-yl)-N-methylethanamine 61-49-4 C11H14N2 Tryptamine 
Psilocybin   3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate 520-52-5 C12H17N2O4P Tryptamine 
Tryptamine   2-(1H-indol-3-yl)ethanamine 61-54-1 C10H12N2 Tryptamine 
α,N-Dimethyl-5-methoxytryptamine α,N,O-TMS 1-(5-methoxy-1H-indol-3-yl)-N-methylpropan-2-amine 4822-13-3 C13H18N2O Tryptamine 
α,N-Dimethyltryptamine α,N-DMT 1-(1H-indol-3-yl)-N-methylpropan-2-amine   C12H16N2 Tryptamine 
α-Ethyl-5-methoxytryptamine 5-MeO-α-ET α-ethyl-5-methoxy-1H-indole-3-ethanamine 4765-10-0 C13H18N2O Tryptamine 
α-Ethyltryptamine AET 1-(1H-indol-3-yl)butan-2-amine 2235-90-7 C12H16N2 Tryptamine 
α-Methyltryptamine AMT 1-(1H-indol-3-yl)propan-2-amine 299-26-3 C11H14N2 Tryptamine 
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Appendix 2. The chemical structures of the synthetic cannabinoids that were added to the MS/MS spectral library. 
Structural Class Compound Substitution 
R1 R2 R3 R4 R5 R6 R7 R8 X 
Adamantoylindoles           
 
 
 
JWH-018 
adamantyl 
analog 
(CH2)3CH3 - - - - - - - - 
AM 1248 
N-
Methylpiperi
dine 
                
Adamantyl indazolecarboxamides and indolecarboxamides 
 
 
AKB48  CH2CH3 - - - - - - - N 
JWH-018 
adamantyl 
carboxamide 
 CH2CH3 - - - - - - - 
C
H 
STS-135 (CH2)2F - - - - - - - 
C
H 
Benzoylindoles 
 
 
AM-2233 H H I H H 
N-
Methylpiperidine       
AM-630 OCH3 H H CH3 I 
CH2-
(morpholine)       
AM-679 H H I H H (CH2)3CH3 - - - 
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AM-694 H H I H H (CH2)4F - - - 
AM-694 3-iodo 
isomer 
H 
 I H H H (CH2)4F - - - 
AM-694 4-iodo 
isomer I H H H H (CH2)4F - - - 
RCS-4 OCH3 H H H H (CH2)3CH3 - - - 
RCS-4 2-
methoxy isomer H H OCH3 H H (CH2)3CH3 - - - 
RCS-4 3-
methoxy isomer H OCH3 H H H (CH2)3CH3 - - - 
RCS-4 C4 
homolog OCH3 H H H H  (CH2)2CH3 - - - 
WIN-48,098 OCH3 H H CH3 H 
CH2-
(morpholine) - - - 
WIN-54,461 OCH3 H H CH3 Br 
CH2-
(morpholine) - - - 
Cyclopropanoylindoles   
 
 UR-144 CH3 - - - - - - - - 
XLR-11 CH2F - - - - - - - - 
Naphthoylindoles (2')                   
  
AM-2201 2’-
naphthyl isomer H H H (CH2)3F H H     - 
  
JWH-018 2’-
naphthyl-N-(1-
ethylpropyl) 
H CH2CH3 H CH3 H H     - 
 
 
JWH-018 2'-
naphthyl isomer 
H H H (CH2)2CH3 H H     - 
  
JWH-018 2'-
naphthyl-N-(1,1- H CH3 CH3 CH3 H H     - 
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dimethylpropyl) 
isomer 
  
JWH-018 2'-
naphthyl-N-(1,2-
dimethylpropyl) 
isomer 
H CH3 H CH3 CH3 H     - 
  
JWH-018 2'-
naphthyl-N-(1-
methylbutyl) 
isomer 
H CH3 H CH2CH3 H H     - 
  
JWH-018 2'-
naphthyl-N-(2,2-
dimethylpropyl) 
isomer 
H H H CH3 CH3 CH3     - 
  
JWH-018 2'-
naphthyl-N-(2-
methylbutyl) 
isomer 
H H H CH2CH3 CH3 H     - 
  JWH-018 2'-
naphthyl-N-(3-
methylbutyl) 
isomer 
H H H CH(CH3)2 H H     - 
  
JWH-073 2'-
naphthyl isomer H H H CH2CH3 H H     - 
  
JWH-073 2'-
naphthyl-N-(1,1-
dimethylethyl) 
isomer 
H CH3 CH3 H H H     - 
  
JWH-073 2'-
naphthyl-N-(1-
methylpropyl) 
isomer 
H CH3 H CH3 H H     - 
  
JWH-073 2'-
naphthyl-N-(2-
methylpropyl) 
isomer 
H H H CH3 CH3 H     - 
  
JWH-200 2'-
naphthyl isomer H H H morpholine H H     - 
Naphthoylindoles                   
  AM-1235 H H H H H (CH2)3F NO2 H - 
  AM-2201 H H H H H (CH2)3F H H - 
  
AM-2201 N-(2-
fluoropentyl) 
isomer 
H H H H F (CH2)2CH3 H H - 
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AM-2201 N-(3-
fluoropentyl) 
isomer 
H H H H H CHFCH2CH3 H H - 
  
AM-2201 N-(4-
fluoropentyl) 
isomer 
H H H H H CH2CHFCH3 H H - 
  AM-2232 H H H H H (CH2)2C≡N H H - 
  JWH-007 CH3 H H H H  (CH2)2CH3 H H - 
  JWH-011 CH3 CH3 H H H (CH2)3CH3 H H - 
  JWH-015 CH3 H H H H CH3 H H - 
  JWH-016 CH3 H H H H  CH2CH3 H H - 
  JWH-018 H H H H H  (CH2)2CH3 H H - 
 
 
JWH-018 6-
methoxyindole 
analog 
H H H H H  (CH2)2CH3 OCH3 H - 
  
JWH-018 N-
(1,1-
dimethylpropyl) 
isomer 
H CH3 CH3 H H CH3 H H - 
  
JWH-018 N-
(1,2-
dimethylpropyl) 
isomer 
H CH3 H H CH3 CH3 H H - 
  
JWH-018 N-(1-
ethylpropyl) 
isomer 
H  CH2CH3 H H H CH3 H H - 
  
JWH-018 N-(1-
methylbutyl) 
isomer 
H CH3 H H H  CH2CH3 H H - 
  
JWH-018 N-
(2,2-
dimethylpropyl) 
isomer 
H H H CH3 CH3 CH3 H H - 
  
JWH-018 N-(2-
methylbutyl) 
isomer 
H H H H CH3  CH2CH3 H H - 
  
JWH-018 N-(3-
methylbutyl) 
isomer 
H H H H H CH(CH3)2 H H - 
  
JWH-018 N-
(4,5-
epoxypentyl) 
analog 
H H H H H CH2CHCH2O H H - 
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JWH-018 N-(5-
bromopentyl) 
analog 
H H H H H (CH2)3Br H H - 
  
JWH-018 N-(5-
chloropentyl) 
analog 
H H H H H (CH2)3Cl H H - 
  JWH-019 H H H H H (CH2)3CH3 H H - 
  JWH-020 H H H H H (CH2)4CH3 H H - 
  JWH-022 H H H H H CH2CH=CH2 H H - 
  JWH-072 H H H H H CH3 H H - 
  JWH-073 H H H H H CH2CH3 H H - 
  
JWH-073 2-
methylnaphthyl 
analog 
H H H H H CH2CH3 H 
CH3 
(C2") 
- 
  
JWH-073 4-
methylnaphthyl 
analog 
H H H H H CH2CH3 H 
CH3 
(C4") 
- 
  
JWH-073 N-
(1,1-
dimethylethyl) 
isomer 
H CH3 CH3 H H H H H - 
  
JWH-073 N-(1-
methylpropyl) 
isomer 
H CH3 H H H CH3 H H - 
  
JWH-073 N-(2-
methylpropyl) 
isomer 
H H H H CH3 CH3 H H - 
  JWH-081 H H H H H (CH2)2CH3 H 
 OCH3 
(C4") 
- 
  
JWH-081  2-
methoxynaphthy
l isomer 
H H H H H (CH2)2CH3 H 
 OCH3 
(C2") 
- 
  
JWH-081  3-
methoxynaphthy
l isomer 
H H H H H (CH2)2CH3 H 
 OCH3 
(C3") 
- 
  
JWH-081  5-
methoxynaphthy
l isomer 
H H H H H (CH2)2CH3 H 
 OCH3 
(C5") 
- 
  
JWH-081  6-
methoxynaphthy
l isomer 
H H H H H (CH2)2CH3 H 
 OCH3 
(C6") 
- 
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JWH-081  7-
methoxynaphthy
l isomer 
H H H H H (CH2)2CH3 H 
 OCH3 
(C7") 
- 
  
JWH-081  8-
methoxynaphthy
l isomer 
H H H H H (CH2)2CH3 H 
 OCH3 
(C8") 
- 
  JWH-098 CH3 H H H H (CH2)2CH3 H 
 OCH3 
(C4") 
- 
  JWH-122 H H H H H (CH2)2CH3 H 
CH3 
(C4") 
- 
  JWH-122 2-
methylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH3 
(C2") 
- 
  
JWH-122 3-
methylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH3 
(C3") 
- 
  
JWH-122 5-
methylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH3 
(C5") 
- 
  
JWH-122 6-
methylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH3 
(C6") 
- 
  
JWH-122 7-
methylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH3 
(C7") 
- 
  
JWH-122 8-
methylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH3 
(C8") 
- 
  
JWH-122 N-(4-
pentenyl) analog H H H H H CH2CH=CH2 H 
CH3 
(C4") 
- 
  JWH-180 
H H H H H CH3 H 
(CH2)2
CH3 
(C4") 
- 
  JWH-182 
H H H H H (CH2)2CH3 H 
(CH2)2
CH3 
(C4") 
- 
  JWH-200 H H H H H morpholine H H - 
  JWH-210 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C4") 
- 
  
JWH-210 2-
ethylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C2") 
- 
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JWH-210 3-
ethylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C3") 
- 
  
JWH-210 5-
ethylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C5") 
- 
  
JWH-210 6-
ethylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C6") 
- 
  
JWH-210 7-
ethylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C7") 
- 
  
JWH-210 8-
ethylnaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
CH2C
H3 
(C8") 
- 
  JWH-398 H H H H H (CH2)2CH3 H 
Cl 
(C4") 
- 
  
JWH-398 2-
chloronaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
Cl 
(C2") 
- 
  
JWH-398 3-
chloronaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
Cl 
(C3") 
- 
  JWH-398 5-
chloronaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
Cl 
(C5") 
- 
  
JWH-398 6-
chloronaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
Cl 
(C6") 
- 
  
JWH-398 7-
chloronaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
Cl 
(C7") 
- 
  
JWH-398 8-
chloronaphthyl 
isomer 
H H H H H (CH2)2CH3 H 
Cl 
(C8") 
- 
  JWH-424 H H H H H (CH2)2CH3 H 
Br 
(C8") 
- 
  MAM-2201 H H H H H (CH2)3F H 
CH3 
(C4") 
- 
Naphthoylpyrroles 
 JWH-145 CH3 H H - - - - - - 
  JWH-147 CH2CH3 H H - - - - - - 
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  JWH-307 CH3 F H - - - - - - 
  JWH-309 CH3 
CH=CHCH=CHR3 
Benzyl 
CH=CHCH=CHR2 
Benzyl - - - - - - 
  JWH-368 CH3 H F - - - - - - 
  JWH-369 CH3 Cl H - - - - - - 
  JWH-370 CH3 CH3 H             
Naphthylmethylindole                   
 
 
JWH 175 - - - - - - - - - 
Phenylacetylindoles                   
 
 
JWH-201 (CH2)2CH3 H H OCH3 - - - - - 
JWH-203 (CH2)2CH3 Cl H H - - - - - 
JWH-203 3-
chlorophenyl 
isomer 
(CH2)2CH3 H Cl H - - - - - 
JWH-203 4-
chlorophenyl 
isomer 
(CH2)2CH3 H H Cl - - - - - 
JWH-249 (CH2)2CH3 Br H H - - - - - 
JWH-250 (CH2)2CH3 OCH3 H H - - - - - 
JWH-251 (CH2)2CH3 CH3 H H - - - - - 
JWH-251 3-
methylphenyl 
isomer 
(CH2)2CH3 H CH3 H - - - - - 
JWH-251 4-
methylphenyl 
isomer 
(CH2)2CH3 H H CH3 - - - - - 
185 
 
JWH-302 (CH2)2CH3 H OCH3 H - - - - - 
RCS-8 cyclohexyl OCH3 H H - - - - - 
RCS-8 3-
methoxy isomer cyclohexyl H OCH3 H - - - - - 
RCS-8 4-
methoxy isomer cyclohexyl H H OCH3 - - - - - 
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Appendix 3. The chemical structures of the non-synthetic cannabinoids that were added to the MS/MS library.    
Structural Class Compound Substitution 
R1 R2 R3 R4 R5 R6 R7 
Arylcyclohexylamines 
 
 
Methoxetamine H CH2CH3 phenyl (3-MeO)  =O H - - 
Cathinones 
 
 
2,3-MDMC CH3 H CH3 OCH2OR5 OCH2OR4 H - 
2,3-MDPV (CH2)4R2 (CH2)4R1 (CH2)2CH3 OCH2OR5 OCH2OR4 H - 
2,3-Pentylone CH3 H (CH2)2CH3 OCH2OR5 OCH2OR4 H - 
2-Ethylethcathinone CH2CH3 H CH3 CH2CH3 H H - 
2-Ethylmethcathinone CH3 H CH3 CH2CH3 H H - 
2-Fluoroethcathinone CH2CH3 H CH3 F H H - 
2-Fluoromethcathinone CH3 H CH3 F H H - 
2-Methylethcathinone CH2CH3 H CH3 CH3 H H - 
2-Methoxymethcathinone CH3 H CH3 OCH3 H H - 
3,4-Methylenedioxy-α-
pyrrolidinobutyrophenone (CH2)4R2 (CH2)4R1 CH2CH3 H OCH2OR6 OCH2OR5 - 
2-Methylmethcathinone CH3 H CH3 CH3 H H - 
3-Methyl-α-Pyrrolidinobutiophenone (CH2)4R2 (CH2)4R1 CH2CH3 H CH3 H - 
3,4-Dimethylmethcathinone CH3 H CH3 H CH3 CH3 - 
3-Ethylethcathinone CH2CH3 H CH3 H CH2CH3 H - 
3-Ethylmethcathinone CH3 H CH3 H CH2CH3 H - 
3-Fluoroethcathinone CH2CH3 H CH3 H F H - 
3-Fluoromethcathinone CH3 H CH3 H F H - 
3-Methylethcathinone CH2CH3 H CH3 H CH3 H - 
3-Methoxymethcathinone CH3 H CH3 H OCH3 H - 
3-Methylmethcathinone CH3 H CH3 H CH3 H - 
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4-Ethylethcathinone CH2CH3 H CH3 H H CH2CH3 - 
4-Ethylmethcathinone CH3 H CH3 H H CH2CH3 - 
4-Ethyl-N,N-dimethylcathinone CH3 CH3 CH3 H H CH2CH3 - 
4-Fluoroethcathinone CH2CH3 H CH3 H H F - 
4-Fluoromethcathinone CH3 H CH3 H H F - 
4-Methylethcathinone CH2CH3 H CH3 H H CH3 - 
4'-Methyl-α-
pyrrolidinohexanophenone (CH2)4R2 (CH2)4R1 (CH2)3CH3 H H CH3 - 
4'-Methyl-α-
pyrrolidinopropiophenone (CH2)4R2 (CH2)4R1 CH3 H H CH3 - 
4-Methylmethcathinone CH3 H CH3 H H CH3 - 
Dibutylone CH3 CH3 CH2CH3 H OCH2OR6 OCH2OR5 - 
Eutylone CH2CH3 H CH2CH3 H OCH2OR6 OCH2OR5 - 
Butylone CH3 H CH2CH3 H OCH2OR6 OCH2OR5 - 
Dimethylone CH3 CH3 CH3 H OCH2OR6 OCH2OR5 - 
Cathinone H H CH3 H H H - 
Ethcathinone CH2CH3 H CH3 H H H - 
Buphedrone CH3 H CH2CH3 H H H - 
Ethylone CH2CH3 H CH3 H OCH2OR6 OCH2OR5 - 
3,4-Methylenedioxy-α-
pyrrolidinobutiophenone (CH2)4R2 (CH2)4R1 CH2CH3 H OCH2OR6 OCH2OR5 - 
3,4-Methylenedioxy-α-
pyrrolidinopropiophenone (CH2)4R2 (CH2)4R1 CH3 H OCH2OR6 OCH2OR5 - 
3,4-Methylenedioxypyrovalerone (CH2)4R2 (CH2)4R1 (CH2)2CH3 H OCH2OR6 OCH2OR5 - 
Methcathinone CH3 H CH3 H H H - 
Methedrone CH3 H CH3 H H OCH3 - 
Methylone CH3 H CH3 H OCH2OR6 OCH2OR5 - 
4-Methoxy-α-
pyrrolidinopropiophenone (CH2)4R2 (CH2)4R1 CH3 H H OCH3 - 
4-Methyl-α-pyrrolidinobutiophenone (CH2)4R2 (CH2)4R1 CH2CH3 H H CH3 - 
N,N-Diethylcathinone CH2CH3 CH2CH3 CH3 H H H - 
N,N-Dimethylcathinone CH3 CH3 CH3 H H H - 
Naphyrone (CH2)4R2 (CH2)4R1 (CH2)2CH3 H C4H4R6 C4H4R5 - 
Naphyrone 1-naphthyl isomer (CH2)4R2 (CH2)4R1 (CH2)2CH3 C4H4R5 C4H4R4 H - 
nor-Mephedrone H H CH3 H H CH3 - 
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Pentedrone CH3 H (CH2)2CH3 H H H - 
Pentylone CH3 H (CH2)2CH3 H OCH2OR6 OCH2OR5 - 
Pyrovalerone (CH2)4R2 (CH2)4R1 (CH2)2CH3 H H CH3 - 
α-Pyrrolidinobutiophenone (CH2)4R2 (CH2)4R1 CH2CH3 H H H - 
α-Pyrrolidinopropiophenone (CH2)4R2 (CH2)4R1 CH3 H H H - 
α-Pyrrolidinopentiophenone (CH2)4R2 (CH2)4R1 (CH2)2CH3 H H H - 
Indanes 
 
 
2-Aminoindane H H - - - - - 
5-IAI I H - - - - - 
MDAI OCH2OR2 OCH2OR1 - - - - - 
Phenethylamines 
 
 
2C-B H H OCH3 H Br OCH3 H 
2C-C H H OCH3 H Cl OCH3 H 
2C-D H H OCH3 H CH3 OCH3 H 
2C-E H H OCH3 H  CH2CH3 OCH3 H 
2C-H H H OCH3 H H OCH3 H 
2C-I H H OCH3 H I OCH3 H 
2C-N H H OCH3 H NO2 OCH3 H 
2C-P H H OCH3 H  (CH2)2CH3 OCH3 H 
2C-T-2 H H OCH3 H SCH2CH3 OCH3 H 
2C-T-4 H H OCH3 H SCH(CH3)2 OCH3 H 
2C-T-7 H H OCH3 H  S(CH2)2CH3 OCH3 H 
2-Fluoroamphetamine H CH3 F H H H H 
2-Fluoromethamphetamine CH3 CH3 F H H H H 
3,4-Dimethoxymethamphetamine  CH3 CH3 H OCH3 OCH3 H H 
3-Fluoroamphetamine H CH3 H F H H H 
3-Fluoromethamphetamine CH3 CH3 H F H H H 
4-Fluoroamphetamine H CH3 H H F H H 
4-Fluoromethamphetamine CH3 CH3 H H F H H 
5-APB H CH3 H CH=CHOR5 OCH=CHR4 H H 
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DOB H CH3 OCH3 H Br OCH3 H 
DOM H CH3 OCH3 H CH3 OCH3 H 
Ethylamphetamine CH2CH3 CH3 H H H H H 
TMA H CH3 H OCH3 OCH3 OCH3 H 
TMA-2 H CH3 OCH3 H OCH3 OCH3 H 
Piperazines (Benzylpiperazines) 
 
 
4-Fluorobenzylpiperazine H F - - - - - 
Benzylpiperazine H H - - - - - 
Dibenzylpiperazine CH2C6H5 H - - - - - 
Piperazines (Phenylpiperazines) 
 
 
para-Fluorophenylpiperazine H F H - - - - 
meta-Chlorophenylpiperazine H H Cl - - - - 
Phenylpiperazine H H H - - - - 
3-Trifluoromethylphenylpiperazine H H CF3 - - - - 
Pyrrolidines 
 
 
Diphenylprolinol OH - - - - - - 
2-Diphenylmethylpyrrolidine H - - - - - - 
Tryptamines 
 
 
4-Methoxy-N,N-dimethyltryptamine CH3 CH3 H OCH3 H - - 
N,N-Diallyl-5-methoxytryptamine CH2CH=CH2 CH2CH=CH2 H H OCH3 - - 
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N,N-Diisopropyl-5-
methoxytryptamine CH(CH3)2 CH(CH3)2 H H OCH3 - - 
5-Methoxy-N,N-dimethyltryptamine CH3 CH3 H H OCH3 - - 
N-Isopropyl-5-methoxy-N-
methyltryptamine CH(CH3)2 CH3 H H OCH3 - - 
α-Methyltryptamine H H CH3 H H - - 
N,N-Dimethyltryptamine CH3 CH3 H H H - - 
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Appendix 4. The chemical structures of novel psychoactive substances that were added to the MS/MS 
spectral library that were not included in Appendix 2 and 3.  
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Appendix 5. The novel psychoactive substances that were added to the library along with the ions 
that had a relative abundance greater than 10% in the MS/MS spectra at the various collision 
energies. 
Substance CE  Ion (Relative Abundance %) 
1-Naphthoyl Indole 
10 eV 272.1062 (100), 155.0489 (19), 144.0441 (11) 
20 eV 155.0488 (100), 144.0443 (55), 272.1067 (14), 127.0542 (12) 
40 eV 127.0539 (100), 144.0441 (30), 116.0494 (18), 155.0488 (12) 
2,3-Methylenedioxy Pyrovalerone  
10 eV 276.1588 (100) 
20 eV 135.0437 (100), 276.1592 (97), 175.0751 (77), 126.1277 (34) 
40 eV 135.0441 (100), 126.1278 (88), 149.0233 (37), 84.0809 (23), 65.0386 (17), 175.0753 (15), 79.0544 (12), 77.0387 (12), 146.0361 (11) 
2,3-
Methylenedioxymethcathinone  
10 eV 160.0749 (100), 208.0965 (46), 190.0859 (20) 
20 eV 160.0747 (100), 132.0804 (44), 147.0435 (10) 
40 eV 
117.057 (100), 132.0804 (95), 91.054 (62), 131.0724 (34), 65.0383 
(25), 77.0383 (14), 130.0647 (12), 103.0539 (12), 58.0649 (12), 
160.0753 (11) 
2,3-Pentylone isomer  
10 eV 236.1277 (100), 188.1067 (76), 218.1175 (49), 175.075 (30), 135.0441 (24), 205.0858 (20) 
20 eV 188.1066 (100), 135.0441 (42), 175.0748 (38), 160.1116 (22), 218.1174 (19) 
40 eV 131.0729 (100), 135.0439 (29), 159.0676 (27), 77.0387 (21), 130.0652 (19), 65.0387 (13), 79.0543 (12), 91.0543 (11) 
2,4,5-Trimethoxyamphetamine 
10 eV 209.116 (100) 
20 eV 
194.0932 (100), 209.1168 (91), 181.0854 (78), 179.0698 (45), 
178.0982 (35), 151.0747 (31), 121.0643 (11), 177.0903 (10), 
162.0671 (10),  
40 eV 
91.0539 (100), 151.0745 (77), 123.0436 (65), 103.0538 (52), 
121.0641 (52), 179.0695 (48), 107.0489 (46), 77.0382 (43), 136.0513 
(39), 105.0694 (37), 79.0539 (36), 135.0794 (28), 131.0485 (27), 
78.046 (26), 119.0485 (26), 108.0566 (26), 121.0283 (25), 65.0383 
(21), 133.064 (21), 147.0792 (20), 115.0539 (20), 123.0771 (20), 
163.0745 (14), 67.054 (13), 147.0434 (13), 149.0589 (13), 95.0488 
(12), 110.0359 (12), 117.0691 (11), 93.0695 (11), 137.0591 (11), 
135.0436 (11), 93.0332 (10), 80.0616 (10) 
2,5-Dimethoxy-4-
bromophenethylamine 
10 eV 243.0012 (100), 227.9772 (16) 
20 eV 227.9779 (100), 243.001 (69), 164.0819 (30), 134.0721 (18), 212.955 (16), 149.0598 (12),  
40 eV 
212.954 (100), 106.0417 (67), 91.0537 (65), 119.0493 (33), 227.9775 
(22), 134.0718 (21), 121.0642 (21), 149.0591 (17), 78.0458 (15), 
104.061 (13), 184.9602 (12) 
2,5-Dimethoxy-4-
chlorophenethylamine 
10 eV 199.0525 (100), 184.0288 (17) 
20 eV 184.029 (100), 199.0525 (44), 169.0055 (20), 164.0834 (20) 
40 eV 169.0054 (100), 77.039 (78), 91.0548 (60), 141.0103 (31), 113.0157 (26), 119.0496 (22), 121.0651 (21), 103.0548 (13), 102.0471 (10) 
2,5-Dimethoxy-4-
ethylphenethylamine 
10 eV 193.1208 (100), 178.0974 (21) 
20 eV 178.0971 (100), 193.1204 (57), 163.0736 (29), 105.0687 (26), 135.0786 (24), 163.1071 (13) 
40 eV 
91.0531 (100), 105.0685 (87), 79.0533 (68), 77.0376 (64), 163.0736 
(60), 103.053 (54), 135.0787 (31), 115.0526 (30), 120.0559 (24), 
133.0634 (19), 117.0684 (17), 119.0476 (16), 121.0637 (15), 
107.0478 (14), 107.0837 (14) 
10 eV 225.0942 (100) 
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Substance CE  Ion (Relative Abundance %) 
2,5-Dimethoxy-4-
ethylthiophenethylamine 
20 eV 225.0942 (100), 210.0706 (42), 164.0828 (21), 134.0724 (14), 167.052 (11), 195.0816 (10), 195.0479 (10) 
40 eV 
91.0541 (100), 121.0644 (40), 134.0724 (40), 119.049 (40), 58.9949 
(32), 151.0208 (25), 105.0696 (20), 77.0385 (18), 167.0162 (18), 
149.059 (18), 133.0642 (16), 103.0538 (14), 104.0621 (14), 135.0337 
(13), 152.0288 (13), 79.054 (12), 165.0364 (12), 120.0568 (12), 
123.0263 (12), 136.0511 (11) 
2,5-Dimethoxy-4-iodo-N-(2-
methoxybenzyl)phenethylamine 
10 eV 428.07 (100), 121.0645 (43) 
20 eV 121.0644 (100), 91.0545 (12) 
40 eV 91.0543 (100), 121.0646 (67), 93.07 (21) 
2,5-Dimethoxy-4-
iodophenethylamine  
10 eV 290.9868 (100), 275.9643 (12), 308.0131 (12) 
20 eV 275.9638 (100), 290.9872 (90), 164.0821 (23), 134.072 (16), 149.059 (14), 260.9408 (13) 
40 eV 
260.9405 (100), 91.0542 (77), 106.0408 (69), 275.9634 (40), 
119.0493 (36), 78.0467 (33), 104.062 (33), 121.0638 (31), 134.0715 
(28), 149.0592 (25), 134.0365 (18), 77.0385 (13), 103.0543 (11) 
2,5-Dimethoxy-4-
isopropylthiophenethylamine 
10 eV 239.1094 (100), 197.0621 (21) 
20 eV 197.0622 (100), 182.0392 (23), 239.1092 (22), 164.0822 (13) 
40 eV 
167.0155 (100), 91.0537 (55), 134.0717 (36), 121.0641 (36), 182.039 
(32), 149.0592 (26), 119.0481 (25), 125.0049 (16), 139.0206 (13), 
152.0278 (13), 164.0819 (10) 
2,5-Dimethoxy-4-
methylamphetamine 
10 eV 193.1209 (100), 165.0895 (20), 178.0972 (15) 
20 eV 178.097 (100), 165.0893 (87), 135.0789 (50), 163.0736 (39), 193.1205 (36), 105.0685 (15) 
40 eV 
91.0531 (100), 163.0736 (67), 135.0788 (60), 79.0531 (57), 105.0686 
(55), 103.0529 (52), 77.0373 (50), 115.0527 (22), 121.0632 (22), 
117.0684 (18), 107.0841 (16), 131.0478 (14), 120.0553 (14), 65.0377 
(12), 92.0606 (11), 107.0475 (11), 67.0531 (10), 147.0782 (10) 
2,5-Dimethoxy-4-
methylphenethylamine 
10 eV 179.1058 (100), 164.0822 (25) 
20 eV 164.0823 (100), 179.1056 (45), 149.0588 (26), 119.0848 (20), 91.0539 (18), 117.0691 (14), 149.092 (13) 
40 eV 91.0537 (100), 77.0381 (46), 149.0587 (42), 115.0537 (27), 121.0641 (15), 103.0536 (14), 93.0694 (11), 65.0382 (10) 
2,5-Dimethoxy-4-
nitrophenethylamine 
10 eV 210.0757 (100), 227.1012 (15) 
20 eV 
151.0748 (100), 195.0508 (65), 165.0548 (50), 210.0764 (37), 
121.0649 (37), 109.0648 (32), 137.058 (32), 179.0706 (30), 135.0452 
(26), 119.049 (25), 133.0636 (24), 150.059 (22), 91.0545 (20), 
163.0753 (19), 79.0539 (18), 209.1522 (16), 107.0488 (16), 95.0497 
(16), 149.0597 (15), 93.0691 (15), 95.0856 (15), 134.0716 (13), 
116.0603 (13), 148.0424 (13), 77.0388 (12), 123.082 (10), 135.0722 
(10) 
40 eV 
91.0544 (100), 77.0392 (87), 79.0548 (39), 103.0539 (35), 65.0391 
(32), 78.0467 (19), 105.0715 (19), 119.048 (18), 121.0649 (17), 
107.0492 (15) 
2,5-Dimethoxy-4-n-
propylphenethylamine 
10 eV 207.137 (100), 192.1141 (16) 
20 eV 192.1141 (100), 207.1375 (78), 163.0749 (23), 135.0799 (17), 177.1261 (10), 165.0903 (10) 
40 eV 
105.0697 (100), 91.054 (86), 163.0747 (59), 79.0541 (55), 103.054 
(49), 133.0644 (48), 77.0384 (48), 117.0695 (38), 149.0597 (35), 
120.0564 (32), 121.0645 (31), 115.0537 (27), 135.0796 (25), 41.0384 
(17), 43.0541 (13), 119.0849 (13), 107.0487 (10), 147.0795 (10), 
135.0438 (10) 
2,5-Dimethoxy-4-n-
propylthiophenethylamine 
10 eV 239.1096 (100) 
20 eV 239.1095 (100), 197.0624 (42), 224.0859 (30), 164.0819 (20), 167.0513 (19), 182.0391 (17) 
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Substance CE  Ion (Relative Abundance %) 
40 eV 
167.0154 (100), 91.0538 (64), 134.0723 (57), 121.0645 (38), 
119.0492 (35), 149.0593 (29), 182.038 (26), 125.0053 (20), 152.0287 
(17), 135.0292 (12), 139.02 (12), 151.0211 (11), 120.0574 (11) 
2,5-Dimethoxyphenethylamine 
10 eV 165.0912 (100), 150.0678 (45) 
20 eV 150.0678 (100), 135.0444 (23), 105.0702 (21), 165.0911 (19) 
40 eV 77.0389 (100), 135.0443 (68), 79.0545 (45), 107.0495 (34), 91.0545 (26), 103.0547 (17) 
2-Aminoindane 
10 eV 117.0703 (100), 134.0967 (16) 
20 eV 117.0703 (100), 115.0548 (56), 91.0547 (27) 
40 eV 91.0548 (100), 115.0547 (79), 65.0391 (42), 89.0393 (12) 
2-Diphenylmethylpyrrolidine 
10 eV 238.1582 (100), 117.0699 (22), 91.0543 (18), 143.0853 (13) 
20 eV 91.0539 (100), 117.0697 (56), 143.0851 (18) 
40 eV 91.0538 (100), 115.0539 (19), 117.0695 (13), 128.0616 (11) 
2-Ethylethcathinone   
10 eV 188.143 (100), 206.1539 (61), 160.112 (18), 159.1042 (15) 
20 eV 159.1042 (100), 144.0809 (55), 160.1121 (49), 188.1434 (39), 132.0809 (25), 131.0732 (12), 158.0963 (11) 
40 eV 144.0806 (100), 130.0653 (24), 158.0964 (14), 128.0605 (12), 143.0732 (12) 
2-Ethylmethcathinone 
10 eV 174.1273 (100), 192.1383 (28), 146.0966 (22), 145.0888 (20) 
20 eV 145.0881 (100), 146.0963 (40), 144.0806 (34), 174.1274 (22), 131.073 (11), 159.1038 (11) 
40 eV 144.0802 (100), 130.065 (11) 
2-Fluoroamphetamine  
10 eV 109.0451 (100), 137.0766 (23) 
20 eV 109.0452 (100) 
40 eV 83.0297 (100), 109.0454 (98), 57.0141 (13), 59.0297 (11) 
2-Fluoroethcathinone  
10 eV 178.1028 (100), 196.1135 (94), 150.0718 (22), 149.064 (10) 
20 eV 150.0718 (100), 149.0639 (77), 178.103 (59), 123.061 (38), 135.0518 (27), 148.056 (22), 103.055 (15), 163.0793 (14) 
40 eV 
148.0561 (100), 135.0485 (68), 77.0392 (55), 103.0549 (52), 
115.0548 (22), 95.0296 (18), 109.0454 (17), 133.0452 (12), 108.0377 
(11) 
2-Fluoromethamphetamine  
10 eV 109.0443 (100), 168.1179 (44), 137.0757 (29) 
20 eV 109.0441 (100) 
40 eV 109.0443 (100), 83.0289 (51) 
2-Fluoromethcathinone  
10 eV 164.0871 (100), 182.0979 (39), 149.0639 (20) 
20 eV 149.0636 (100), 164.0873 (41), 123.0609 (18), 148.056 (15), 103.0547 (11) 
40 eV 148.056 (100), 77.039 (41), 103.0546 (20), 149.0638 (16) 
2-Methoxymethcathinone  
10 eV 176.1066 (100), 161.0836 (20), 194.1178 (17), 163.0755 (11) 
20 eV 161.0833 (100), 176.1072 (34), 145.0887 (25), 146.0603 (22), 135.0805 (12) 
40 eV 118.0655 (100), 146.0603 (54), 132.081 (53), 144.081 (44), 77.0389 (34), 91.0546 (28), 117.0579 (27), 160.0757 (22) 
2-Methylethcathinone  
10 eV 174.1274 (100), 192.1384 (47), 146.0964 (20), 145.0885 (15) 
20 eV 145.0884 (100), 146.0963 (68), 174.1275 (46), 144.0806 (42), 159.104 (35), 131.0739 (26), 119.0853 (23) 
40 eV 144.0808 (100), 130.0651 (46), 91.0543 (38), 131.0729 (17), 115.0543 (12), 77.0387 (11), 117.0692 (10) 
2-Methylmethcathinone  10 eV 160.1109 (100), 145.0876 (26), 178.1216 (19) 
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Substance CE  Ion (Relative Abundance %) 
20 eV 145.0874 (100), 160.1108 (27), 144.0796 (24), 119.0844 (10) 
40 eV 144.0797 (100), 91.0533 (22), 130.0641 (11), 77.0377 (11) 
2-Methyl-α-
pyrrolidinobutiophenone  
10 eV 232.169 (100) 
20 eV 105.0701 (100), 232.1698 (92), 112.1124 (72), 161.0961 (51), 119.0494 (48), 133.1013 (27), 70.0654 (12) 
40 eV 91.0547 (100), 105.0703 (71), 112.1123 (53), 119.0494 (32), 84.0811 (18), 70.0654 (12) 
3,4-Dimethoxymethamphetamine  
10 eV 179.1057 (100), 151.075 (11), 210.1487 (10) 
20 eV 151.0751 (100), 179.1065 (53), 164.0829 (20), 136.0517 (16), 138.0676 (15), 147.0804 (10) 
40 eV 
91.0544 (100), 107.0492 (98), 77.0387 (73), 151.0752 (51), 121.0648 
(48), 135.044 (37), 103.0542 (33), 79.0542 (25), 105.0696 (24), 
147.0802 (23), 108.0568 (21), 131.0489 (20), 93.07 (20), 149.0594 
(19), 95.0493 (19), 78.0465 (18), 117.0699 (18), 136.0518 (18), 
115.0541 (17), 90.0464 (16), 133.0645 (14), 104.0619 (14), 58.0653 
(13), 65.0387 (13), 106.0414 (12), 123.0441 (11), 105.0334 (11), 
80.062 (10) 
3,4-Dimethylmethcathinone  
10 eV 174.1269 (100), 192.1381 (23), 159.104 (20) 
20 eV 159.1036 (100), 174.1275 (36), 158.0961 (15) 
40 eV 158.0959 (100), 144.0804 (46), 91.0541 (13), 115.0541 (12), 143.0728 (11), 105.0698 (10), 159.1038 (10) 
3,4-Methylenedioxypyrovalerone 
10 eV 276.1589 (100) 
20 eV 276.1587 (100), 126.1272 (87), 175.0743 (84), 205.0848 (74), 135.0436 (71), 149.0225 (35), 147.0794 (15), 174.0903 (10) 
40 eV 126.1273 (100), 135.0436 (76), 149.0227 (65), 121.0284 (36), 84.0801 (31), 65.0383 (15), 72.0803 (11), 175.0741 (11) 
3,4-Methylenedioxy-α-
pyrrolidinobutyrophenone 
10 eV 262.1431 (100) 
20 eV 262.1438 (100), 161.0597 (94), 191.0703 (75), 112.1123 (75), 163.0753 (45), 149.0234 (27), 133.065 (10) 
40 eV 
112.1123 (100), 149.0234 (57), 105.0701 (42), 121.0285 (31), 
133.0648 (23), 161.0596 (22), 84.0811 (22), 135.0442 (22), 65.0388 
(14), 70.0654 (12) 
3,4-Methylenedioxy-α-
pyrrolidinopropiophenone 
10 eV 248.1274 (100) 
20 eV 98.0968 (100), 248.1284 (99), 147.0443 (81), 177.0548 (37), 149.0599 (28) 
40 eV 98.0967 (100), 91.0547 (59), 119.0494 (37), 147.0442 (28), 56.0499 (14), 149.0597 (14) 
3-Ethylethcathinone  
10 eV 188.1431 (100), 206.1539 (79), 160.1122 (16), 159.1044 (14) 
20 eV 
159.1044 (100), 160.1125 (51), 144.0812 (48), 188.1438 (47), 
132.0812 (24), 131.0738 (11), 105.0704 (11), 133.1012 (10), 
158.0967 (10) 
40 eV 144.0809 (100), 130.0657 (23), 105.0703 (17), 158.0968 (14), 143.0735 (10), 117.0639 (10) 
3-Ethylmethcathinone  
10 eV 174.1278 (100), 192.1389 (37), 146.0969 (19), 145.0892 (18) 
20 eV 145.0891 (100), 146.0973 (41), 144.0817 (31), 174.1285 (26), 159.105 (11) 
40 eV 144.0813 (100) 
3-Fluoroamphetamine  
10 eV 109.0448 (100), 137.0761 (23) 
20 eV 109.0448 (100) 
40 eV 83.0295 (100), 109.0452 (84), 57.0138 (13) 
3-Fluoroethcathinone  
10 eV 178.1031 (100), 196.1139 (95), 150.0718 (37), 149.064 (10) 
20 eV 150.072 (100), 149.0641 (53), 178.1031 (34), 123.0611 (24), 135.0497 (24), 148.0562 (17), 103.0549 (11) 
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40 eV 148.0563 (100), 135.0486 (87), 103.0549 (51), 77.0393 (51), 95.0298 (21), 115.0547 (15), 109.0456 (15), 108.0374 (15), 133.0454 (10) 
3-Fluoromethamphetamine  
10 eV 109.0448 (100), 168.1182 (49), 137.0762 (30) 
20 eV 109.0447 (100) 
40 eV 109.0448 (100), 83.0294 (59) 
3-Fluoromethcathinone  
10 eV 164.0863 (100), 182.0973 (38.75933), 149.0635 (20.98906) 
20 eV 149.0629 (100), 164.0868 (40.39218), 148.0557 (20.80779), 123.0604 (14.65683), 103.0543 (10.34477) 
40 eV 148.0553 (100), 77.0388 (32.5626), 103.0544 (16.10737), 149.0634 (11.10015), 95.0293 (10.02891) 
3-Methoxymethcathinone  
10 eV 176.1056 (100), 194.1167 (32), 161.0826 (23) 
20 eV 161.0822 (100), 176.106 (32), 146.0591 (26), 145.0876 (21), 135.0795 (11) 
40 eV 
118.0644 (100), 132.0798 (59), 146.059 (43), 77.0379 (29), 91.0537 
(28), 117.0566 (25), 144.0796 (22), 79.0536 (15), 103.0535 (13), 
160.0745 (11) 
3-Methylethcathinone  
10 eV 174.1268 (100), 192.1375 (57), 146.0959 (20), 145.088 (14) 
20 eV 145.0881 (100), 146.0958 (69), 174.1271 (49), 144.0802 (38), 159.1036 (32), 119.0851 (29), 131.074 (24) 
40 eV 144.0803 (100), 91.0539 (48), 130.0647 (44), 131.0724 (19), 115.0538 (13), 77.0383 (12), 117.0691 (11),  
3-Methylmethcathinone 
10 eV 160.1117 (100), 145.0886 (25), 178.1226 (23) 
20 eV 145.0881 (100), 160.112 (31), 144.0809 (22), 119.0856 (13) 
40 eV 144.0806 (100), 91.0545 (26), 77.0388 (12), 130.0652 (10) 
3-Methyl-α-
pyrrolidinobutiophenone  
10 eV 232.1691 (100) 
20 eV 105.0697 (100), 232.1694 (68), 161.0958 (47), 112.112 (28), 133.1008 (26), 119.0489 (19), 70.065 (15) 
40 eV 105.0698 (100), 91.0542 (72), 112.1119 (47), 84.0807 (25), 119.0491 (25), 70.065 (13) 
3-Trifluoromethylphenylpiperazine 
10 eV 231.11 (100) 
20 eV 188.0677 (100), 231.11 (77), 44.0498 (24) 
40 eV 
188.0679 (100), 118.0651 (91), 44.0498 (75), 145.0255 (62), 
119.0725 (55), 127.0347 (43), 148.0559 (39), 168.0603 (27), 
166.0461 (27), 141.0521 (24), 128.0488 (16), 174.0512 (15), 186.051 
(15), 91.0542 (14), 117.0575 (13), 56.0504 (13), 104.0499 (12), 
172.0361 (11), 140.0321 (10), 121.0445 (10), 161.0446 (10) 
4-Ethylethcathinone  
10 eV 188.1422 (100), 206.1532 (58), 160.1115 (13), 159.1037 (12) 
20 eV 159.1033 (100), 188.1426 (54), 160.1113 (52), 144.08 (45), 132.0801 (22), 133.1001 (11), 105.0694 (11), 131.0728 (10) 
40 eV 144.0797 (100), 130.0645 (21), 105.0693 (21), 158.0955 (14), 115.0537 (12), 91.0537 (11), 117.0645 (11), 143.0723 (10) 
4-Ethylmethcathinone  
10 eV 174.1282 (100), 192.1393 (27), 146.0973 (15), 145.0895 (15) 
20 eV 145.0893 (100), 146.0974 (41), 174.1286 (31), 144.0817 (28), 159.1051 (12), 105.0707 (10) 
40 eV 144.0814 (100) 
4-Ethyl-N,N-Dimethylcathinone  
10 eV 206.1533 (100), 161.0961 (24) 
20 eV 133.1009 (100), 72.081 (77), 161.096 (63), 105.0702 (57), 133.065 (47), 206.1537 (24), 143.0854 (17) 
40 eV 72.081 (100), 105.0701 (86), 79.0544 (32), 77.0388 (20), 103.0545 (19), 91.0545 (15) 
4-Fluoroamphetamine 10 eV 109.0447 (100), 137.0758 (39) 
197 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 109.0443 (100) 
40 eV 109.0444 (100), 83.0288 (96), 57.0133 (11), 59.029 (10) 
4-Fluorobenzylpiperazine 
10 eV 195.1294 (100), 109.0454 (44) 
20 eV 109.0452 (100) 
40 eV 109.0453 (100), 83.0298 (31) 
4-Fluoroethcathinone  
10 eV 178.1021 (100), 196.1129 (64), 150.0711 (24), 149.0633 (11) 
20 eV 150.0711 (100), 149.0634 (81), 178.1024 (47), 123.0603 (31), 135.0513 (23), 148.0555 (22), 163.0789 (12), 103.0543 (11) 
40 eV 
148.0555 (100), 135.0479 (55), 103.0542 (47), 77.0385 (41), 
115.0541 (17), 109.0448 (15), 95.0291 (12), 108.0369 (10), 133.0448 
(10) 
4-Fluoroisocathinone  
10 eV 151.0557 (100), 123.0609 (81), 103.0548 (11) 
20 eV 123.0609 (100), 103.0548 (91), 77.0392 (12) 
40 eV 77.0391 (100), 103.0547 (34) 
4-Fluoromethamphetamine  
10 eV 109.0454 (100), 137.0766 (60), 168.1185 (25) 
20 eV 109.0452 (100) 
40 eV 109.0456 (100), 83.0305 (47) 
4-Fluoromethcathinone 
10 eV 164.0866 (100), 149.0632 (22), 182.097 (19) 
20 eV 149.0632 (100), 164.0865 (38), 123.0601 (20), 148.0555 (18), 103.0541 (13) 
40 eV 148.0554 (100), 77.0387 (46), 103.0542 (28), 149.063 (17), 95.0291 (11) 
4-Methoxy-N,N-
dimethyltryptamine 
10 eV 58.0659 (100), 219.1489 (42), 174.0909 (33) 
20 eV 58.0659 (100), 174.0909 (34) 
40 eV 58.0661 (100), 159.0674 (16), 115.0541 (13), 130.0648 (12) 
4-Methoxy-α-
pyrrolidinopropiophenone  
10 eV 234.1479 (100), 98.0969 (11) 
20 eV 98.0967 (100), 163.0748 (65), 135.0802 (64), 234.1483 (41) 
40 eV 98.0967 (100), 105.0699 (50), 135.0799 (37), 79.0549 (27), 103.0544 (22), 56.0505 (22), 77.0392 (18), 120.0567 (10) 
4-Methylethcathinone 
10 eV 174.1267 (100), 192.1373 (31), 146.0955 (22), 145.0876 (17) 
20 eV 145.0876 (100), 146.0954 (66), 144.0799 (45), 174.1267 (43), 119.0844 (36), 159.1031 (33), 131.0737 (27), 91.0538 (13) 
40 eV 144.0797 (100), 91.0536 (57), 130.0641 (43), 115.0535 (18), 131.0724 (17), 77.0379 (15), 117.0688 (14), 103.0535 (10) 
4-Methylmethcathinone 
10 eV 160.1112 (100),145.0879 (28),178.1212 (14) 
20 eV 145.0877 (100),160.1108 (30),144.0797 (25),119.0847 (14) 
40 eV 144.0798 (100),91.0537 (31),77.0379 (15),130.0645 (11),103.0533 (10) 
4-Methyl-α-
pyrrolidinobutiophenone  
10 eV 232.1688 (100), 161.0958 (10) 
20 eV 105.0705 (100), 161.0962 (65), 232.1695 (53), 112.1127 (35), 133.1014 (32), 119.0496 (22), 70.0665 (10) 
40 eV 105.0705 (100), 91.0552 (59), 112.1125 (49), 119.0494 (30), 84.0818 (22), 70.0663 (11) 
4'-Methyl-α-
pyrrolidinohexanophenone  
10 eV 260.2001 (100) 
20 eV 105.0699 (100), 260.2005 (67), 189.1269 (48), 140.1429 (24), 119.049 (19), 133.0644 (12) 
40 eV 105.07 (100), 91.0546 (43), 140.1429 (38), 119.049 (33), 84.0814 (24) 
198 
 
Substance CE  Ion (Relative Abundance %) 
4'-Methyl-α-
pyrrolidinopropiophenone  
10 eV 218.1534 (100), 147.0804 (10) 
20 eV 119.0858 (100), 147.0807 (81), 218.1542 (66), 98.0969 (63), 70.0657 (12) 
40 eV 
98.0969 (100), 91.0547 (86), 119.0858 (57), 117.0703 (36), 56.05 
(25), 84.0813 (12), 70.0656 (12), 103.0546 (12), 77.039 (12), 55.0548 
(10) 
4-Quinolone-3-Carboxamide CB2 
Ligand 
10 eV 423.2635 (100) 
20 eV 135.1166 (100), 423.2639 (98), 272.1281 (28) 
40 eV 135.1164 (100), 93.0704 (10) 
5-(2-Aminopropyl)benzofuran 
10 eV 159.0803 (100), 131.0495 (63), 131.0826 (20) 
20 eV 131.0494 (100), 131.0829 (34), 91.055 (15) 
40 eV 91.055 (100), 131.0493 (90), 77.0397 (89), 115.0545 (43), 103.0548 (23), 116.0625 (23), 65.0398 (16) 
5,6-Methylenedioxy-2-
aminoindane 
10 eV 161.0594 (100), 131.0492 (31), 178.0861 (18) 
20 eV 131.0492 (100), 103.0545 (64), 161.0597 (37) 
40 eV 103.0544 (100), 77.0387 (65) 
5-Iodo-2-aminoindane 
10 eV 242.9662 (100), 259.9928 (67), 116.0619 (32) 
20 eV 116.0619 (100), 242.966 (34) 
40 eV 116.0619 (100), 115.0541 (68) 
5-Methoxy-N,N-
dimethyltryptamine 
10 eV 58.065 (100), 174.0905 (66), 219.1484 (18) 
20 eV 58.0649 (100), 174.0902 (73), 159.0668 (16) 
40 eV 58.0649 (100), 130.0644 (52), 131.072 (44), 159.067 (22), 143.0716 (18) 
AKB48 
10 eV 366.2537 (100), 135.1167 (72) 
20 eV 135.1165 (100) 
40 eV 135.1165 (100), 93.0705 (13), 107.0858 (11), 79.0551 (10) 
AM1220 
10 eV 383.2113 (100) 
20 eV 112.1122 (100), 98.0969 (81), 383.2119 (49), 286.1226 (43), 155.049 (38) 
40 eV 98.0968 (100), 112.1122 (36), 155.0488 (26), 127.054 (14) 
AM1235 
10 eV 405.1591 (100) 
20 eV 405.1587 (100)277.097 (47), 155.0487 (34) 
40 eV 155.0483 (100)127.0547 (71), 189.0288 (37), 143.0356 (28), 277.0974 (26), 231.1034 (15) 
AM1241 
10 eV 98.0963 (100), 112.1119 (12) 
20 eV 98.0966 (100), 504.0741 (53), 112.1119 (16) 
40 eV 504.0763 (100), 98.0966 (18) 
AM1248 
10 eV 391.2736 (100) 
20 eV 391.2733 (100), 135.1169 (30), 112.1125 (10) 
40 eV 135.1167 (100), 112.1124 (38), 98.0971 (32) 
AM2201 
10 eV 360.1745 (100) 
20 eV 360.1745 (100), 155.048 (90), 232.1126 (22) 
40 eV 127.0534 (100), 155.0483 (81), 144.0437 (17), 232.1124 (10) 
AM2201 2'-naphthyl isomer 10 eV 360.1755 (100) 
199 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 155.0491 (100), 360.1758 (92), 232.113 (23) 
40 eV 127.0543 (100), 155.049 (83), 144.0444 (22), 232.1131 (13) 
AM2201 N-(2-fluoropentyl) isomer 
10 eV 360.1753 (100) 
20 eV 360.175 (100), 155.0486 (88), 232.112 (29) 
40 eV 127.0539 (100), 155.0487 (76), 232.113 (18), 144.0445 (12) 
AM2201 N-(3-fluoropentyl) isomer 
10 eV 360.1752 (100) 
20 eV 360.1757 (100), 155.0491 (95), 232.1136 (23) 
40 eV 127.0543 (100), 155.0492 (81), 232.1136 (12) 
AM2201 N-(4-fluoropentyl) isomer 
10 eV 360.1751 (100) 
20 eV 360.1748 (100), 155.0482 (93), 232.1126 (20) 
40 eV 127.0535 (100), 155.0484 (84), 144.0437 (14) 
AM2232 
10 eV 353.1638 (100), 155.0484 (13) 
20 eV 155.048 (100), 353.1644 (28), 225.1016 (15) 
40 eV 127.0535 (100), 155.0485 (64), 144.0437 (13), 225.1015 (11) 
AM2233 
10 eV 459.0913 (100), 112.1118 (10) 
20 eV 98.0965 (100), 112.1121 (78), 459.0915 (73), 362.003 (38), 230.9286 (22) 
40 eV 98.0966 (100), 112.112 (27), 230.9299 (25) 
AM251 
10 eV 555.0199 (100) 
20 eV 555.0203 (100), 454.9208 (59) 
40 eV 454.9205 (100) 
AM630 
10 eV 505.0983 (100), 135.0446 (51) 
20 eV 135.0441 (100), 505.0992 (17) 
40 eV 135.0442 (100), 114.092 (19) 
AM679 
10 eV 418.0658 (100) 
20 eV 230.9305 (100), 418.0668 (83), 291.1625 (16) 
40 eV 230.9307 (100), 202.9361 (53) 
AM694 
10 eV 436.0563 (100) 
20 eV 436.0564 (100), 230.9298 (84), 309.1527 (15) 
40 eV 230.9297 (100), 202.9353 (40) 
AM694 3-iodo isomer 
10 eV 436.0561 (100) 
20 eV 436.0562 (100), 230.93 (95) 
40 eV 230.93 (100), 202.9357 (56) 
AM694 4-iodo isomer 
10 eV 436.0563 (100) 
20 eV 230.9303 (100), 436.0568 (96) 
40 eV 230.9303 (100), 202.935 (34) 
Benzylpiperazine 
10 eV 177.1386 (100),91.0546 (47),85.0763 (11) 
20 eV 91.0546 (100) 
40 eV 91.0546 (100),65.0389 (35) 
Buphedrone  10 eV 160.111 (100), 178.1221 (36), 132.0803 (21), 147.0799 (15), 131.0727 (13), 91.0545 (12) 
200 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 131.0724 (100), 132.0804 (51), 91.0546 (50), 160.1113 (32), 130.0646 (18), 145.0879 (14) 
40 eV 130.0648 (100), 91.0546 (50), 77.0391 (41), 131.0725 (25), 144.0802 (12), 117.0575 (12) 
Butylone 
10 eV 204.1017 (100), 174.091 (90), 222.1122 (72), 191.07 (27), 72.0808 (17), 161.0594 (12) 
20 eV 174.0908 (100), 175.0624 (29), 146.0961 (22), 204.1017 (16), 72.0807 (16), 161.059 (14) 
40 eV 
131.0726 (100), 174.0548 (27), 146.0954 (26), 130.0648 (25), 
72.0807 (22), 175.0623 (21), 65.0385 (19), 159.0671 (18), 105.0695 
(15), 117.0573 (15), 121.0281 (14), 118.0652 (13), 174.0877 (12), 
119.0725 (10), 77.0385 (10), 79.0538 (10) 
Cannabipiperidiethanone 
10 eV 377.2207 (100) 
20 eV 112.111 (100), 377.2213 (56), 121.0636 (45), 98.0954 (27), 229.1686 (26), 280.1322 (13) 
40 eV 98.0955 (100), 112.111 (88), 121.0637 (54), 91.0533 (30), 58.0642 (22), 70.0642 (10) 
Cathinone 
10 eV 132.0802 (100), 105.0695 (19), 133.0642 (19), 117.057 (16) 
20 eV 117.0568 (100), 105.0695 (48), 132.0802 (44) 
40 eV 77.0383 (100), 90.046 (80), 117.0568 (79), 89.0383 (56), 51.023 (23), 79.0539 (21), 103.0538 (14), 130.0645 (10) 
CB-13 
10 eV 369.1843 (100) 
20 eV 155.0492 (100), 171.0442 (71), 299.1069 (70), 369.1851 (54), 241.1222 (13) 
40 eV 171.0442 (100), 155.0493 (86), 127.0545 (75), 143.0492 (29), 115.0545 (10) 
CB-25 
10 eV 404.3142 (100), 58.0659 (10) 
20 eV 58.0658 (100), 181.1212 (32), 347.2572 (31), 404.315 (13) 
40 eV 58.0658 (100), 111.0436 (15), 43.0549 (14), 181.1212 (10) 
CB-52 
10 eV 105.0708 (100), 387.1801 (93), 404.3145 (70), 121.0646 (29), 267.1225 (23), 147.0627 (10) 
20 eV 105.0698 (100), 121.0642 (48), 58.0653 (28), 69.0343 (15) 
40 eV 105.07 (100), 93.0702 (44), 121.0632 (34), 58.0648 (28), 69.034 (18), 43.0555 (11) 
CB-86 
10 eV 418.3293 (100) 
20 eV 58.0644 (100), 418.3299 (37), 361.2721 (21), 275.163 (12), 182.1523 (12), 71.0845 (11), 237.1835 (10) 
40 eV 58.0644 (100), 71.0846 (15), 57.069 (12), 55.0535 (12), 43.0536 (10) 
Desoxypipradrol  
10 eV 252.1745 (100) 
20 eV 91.0557 (100), 252.1753 (66), 131.0863 (34), 167.086 (29), 129.0706 (19), 157.1017 (12), 143.0862 (12), 117.0709 (12), 193.1016 (11) 
40 eV 91.0556 (100), 115.0551 (19), 129.0706 (13), 165.0702 (10) 
Dibenzylpiperazine 
10 eV 267.1851 (100) 
20 eV 91.0545 (100), 267.1857 (59), 175.123 (51), 134.0966 (26) 
40 eV 91.0542 (100) 
Dibutylone 
10 eV 236.1284 (100), 191.071 (21), 86.098 (11) 
20 eV 86.0979 (100), 161.0606 (90), 149.0241 (52), 191.0711 (42), 163.076 (40), 236.1289 (22), 133.0656 (19), 135.045 (12), 105.0712 (10) 
40 eV 
86.098 (100), 121.0294 (46), 149.024 (44), 105.071 (36), 65.0403 
(35), 71.0746 (29), 135.0448 (15), 79.0558 (15), 133.0656 (12), 
77.0401 (10) 
Dimethoxybromoamphetamine 10 eV 257.0165 (100), 228.985 (21), 178.0986 (12) 
201 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 228.985 (100), 178.0981 (70), 241.9932 (38), 257.0164 (33), 163.0754 (18), 198.9727 (16) 
40 eV 
135.0793 (100), 105.0685 (62), 226.9697 (57), 91.0532 (47), 
198.9745 (43), 163.0742 (41), 105.033 (41), 77.0377 (38), 103.0542 
(33), 120.057 (32), 90.0456 (24), 79.0545 (24), 148.0503 (23), 
168.9648 (20), 92.0619 (18), 43.0178 (10) 
Dimethylone 
10 eV 222.113 (100), 72.0814 (18), 177.0552 (11), 147.0445 (10) 
20 eV 72.0814 (100), 147.0445 (76), 149.0601 (41), 222.1131 (18), 177.0549 (17), 119.0497 (14) 
40 eV 72.0814 (100), 91.0549 (91), 119.0496 (27), 65.0391 (18), 147.0446 (13) 
Diphenylprolinol 
10 eV 236.1428 (100), 254.154 (11) 
20 eV 236.1427 (100), 158.0964 (14), 130.0653 (12) 
40 eV 
130.0654 (100), 178.0777 (31), 117.0579 (30), 91.055 (27), 165.0699 
(23), 167.0855 (22), 152.062 (20), 179.0855 (15), 206.0962 (14), 
158.0964 (12), 115.0545 (12) 
Ethcathinone  
10 eV 160.1113 (100), 178.1221 (53), 132.0806 (35), 131.0728 (16) 
20 eV 132.0806 (100), 131.0729 (94), 105.07 (42), 160.1117 (37), 130.0651 (34), 117.0595 (25), 145.0883 (11) 
40 eV 130.0651 (100), 77.0394 (51), 117.0575 (46), 79.0549 (20), 105.0701 (19), 103.0545 (17), 115.0543 (15), 91.0548 (14) 
Ethylamphetamine 
10 eV 91.0536 (100),119.0846 (33),164.1422 (27) 
20 eV 91.0535 (100) 
40 eV 91.0534 (100),65.0378 (38) 
Ethylone 
10 eV 222.1122 (100), 204.1017 (88), 174.0913 (72), 72.082 (13) 
20 eV 174.0908 (100), 204.1019 (20), 175.0626 (17), 146.0962 (16) 
40 eV 
91.0551 (100), 118.0654 (68), 146.096 (58), 174.0553 (46), 117.0575 
(31), 131.0731 (31), 103.0546 (28), 174.0881 (25), 146.0602 (24), 
119.0501 (19), 65.0397 (18), 130.0653 (15), 72.0819 (13), 77.0398 
(11), 175.0628 (10), 128.0616 (10) 
Eutylone  
10 eV 236.1278 (100), 218.1175 (77), 188.1069 (42), 191.0702 (17) 
20 eV 188.1066 (100), 189.0782 (49), 218.1173 (34), 161.0592 (17), 86.0973 (15), 160.1105 (11) 
40 eV 
174.0547 (100), 145.0882 (28), 117.0597 (28), 105.0701 (23), 
132.0805 (18), 121.0287 (18), 160.1107 (17), 65.0398 (17), 189.0779 
(16), 149.0231 (14), 115.0544 (14), 86.0973 (14), 116.0499 (13), 
160.0749 (13), 135.0441 (12), 130.0652 (11), 173.0833 (11), 79.0552 
(11), 77.0394 (10) 
HU-210 
10 eV 387.2898 (100) 
20 eV 
243.1379 (100), 71.0866 (86), 387.2893 (62), 85.1019 (52), 57.0713 
(48), 261.1484 (32), 201.0906 (28), 43.0556 (17), 133.1013 (14), 
187.0753 (13), 369.2788 (13), 95.0861 (11), 147.0438 (10) 
40 eV 43.0556 (100), 57.0711 (71), 71.0867 (59), 85.1019 (20), 201.0907 (18), 41.0399 (11), 105.0702 (11), 123.0444 (10) 
HU-211 
10 eV 387.2897 (100) 
20 eV 
243.138 (100), 71.0865 (97), 387.2894 (65), 85.102 (51), 57.071 (49), 
261.1488 (33), 201.0909 (30), 43.0556 (18), 133.1009 (15), 187.0747 
(14), 369.2788 (13), 95.0862 (12), 147.0442 (10) 
40 eV 43.0554 (100), 57.0711 (78), 71.0866 (61), 85.1017 (20), 105.0698 (19), 201.091 (18), 123.0447 (11), 41.0399 (10) 
HU-308 
10 eV 415.3199 (100), 215.106 (24), 229.1219 (23), 271.1689 (19), 151.0751 (19) 
20 eV 151.075 (100), 215.1063 (95), 229.1223 (83), 71.0858 (53), 85.1009 (36), 57.0701 (35), 91.0533 (29), 271.1697 (24), 133.1008 (23), 
202 
 
Substance CE  Ion (Relative Abundance %) 
43.0544 (16), 277.2166 (13), 415.3203 (11), 105.0689 (10), 79.0537 
(10) 
40 eV 
43.0544 (100), 91.0544 (100), 57.0703 (82), 71.086 (72), 151.0751 
(42), 105.0693 (34), 214.0974 (26), 85.1016 (26), 200.0823 (22), 
79.0539 (21), 93.0701 (20), 215.1063 (16), 41.0388 (12), 121.0636 
(11), 133.1003 (11), 123.0799 (10) 
HU-331 
10 eV 329.2107 (100), 287.1645 (11) 
20 eV 
286.1561 (100), 287.164 (86), 329.2104 (76), 259.169 (36), 209.1177 
(31), 273.1487 (25), 95.0854 (20), 229.085 (19), 213.0908 (15), 
233.1165 (14), 311.1998 (13), 217.0853 (12), 207.1001 (12), 
247.1324 (12), 223.1315 (11), 81.07 (10), 199.0748 (10) 
40 eV 
229.0856 (100), 43.0548 (19), 105.07 (16), 69.0696 (14), 41.039 (13), 
153.056 (12), 91.0545 (12), 81.0704 (11), 95.0853 (10), 67.0544 (10), 
79.0542 (10), 213.0898 (10) 
IMMA 
10 eV 427.1416 (100), 138.9947 (14), 312.0791 (11) 
20 eV 138.9946 (100), 312.079 (31), 427.1421 (20), 88.0759 (10) 
40 eV 138.9944 (100), 110.9999 (20) 
JP104 
10 eV 214.0867 (100), 407.2329 (59), 197.0602 (21), 390.2067 (13), 212.1648 (13) 
20 eV 214.0867 (100), 197.06 (93), 171.0804 (17) 
40 eV 197.0601 (100), 153.0704 (64), 171.0807 (55), 169.065 (13), 141.0705 (11) 
JWH 007 
10 eV 356.2009 (100) 
20 eV 155.0496 (100), 356.2017 (95), 228.1388 (15) 
40 eV 127.0548 (100), 155.0497 (92), 158.0605 (13) 
JWH 011 
10 eV 384.2319 (100) 
20 eV 384.2326 (100), 155.0494 (77) 
40 eV 155.0494 (100), 127.0548 (57), 158.0604 (27) 
JWH 015 
10 eV 328.1693 (100) 
20 eV 155.0481 (100), 328.1694 (48), 200.1067 (16) 
40 eV 127.0536 (100), 155.0487 (49), 158.0596 (11) 
JWH 016 
10 eV 342.1847 (100) 
20 eV 155.0487 (100), 342.185 (64), 214.1226 (15) 
40 eV 127.0542 (100), 155.0491 (63), 158.0601 (11) 
JWH 018 
10 eV 342.1838 (100) 
20 eV 155.0483 (100), 342.1846 (81), 214.122 (21) 
40 eV 127.0538 (100), 155.0485 (61), 144.0438 (14) 
JWH-018 2'-naphthyl-N-(1-
ethylpropyl) 
10 eV 342.1848 (100) 
20 eV 155.0492 (100), 342.1856 (77), 214.1234 (11) 
40 eV 127.0547 (100), 155.0496 (80), 144.0451 (51) 
JWH 018 2'-naphthyl isomer 
10 eV 342.185 (100), 155.0489 (8) 
20 eV 155.0491 (100), 342.1853 (61), 214.1225 (20) 
40 eV 127.0543 (100), 155.049 (63), 144.0441 (18) 
JWH 018 2'naphthyl-N-(1,1-
dimethylpropyl) isomer 
10 eV 342.1847 (100), 272.107 (22) 
20 eV 272.1064 (100), 155.0486 (33), 144.0438 (22), 342.1847 (13) 
203 
 
Substance CE  Ion (Relative Abundance %) 
40 eV 144.0439 (100), 155.0485 (82), 127.0539 (60) 
JWH 018 2'-naphthyl-N-(1,2-
dimethylpropyl) isomer 
10 eV 342.1841 (100) 
20 eV 155.0485 (100), 342.1844 (96), 272.1069 (12)144.0441 (10) 
40 eV 127.0541 (100), 155.0487 (96), 144.0443 (61) 
JWH 018 2'-naphthyl-N-(1-
methylbutyl) isomer 
10 eV 342.1847 (100) 
20 eV 155.0487 (100), 342.1853 (76), 214.1229 (11) 
40 eV 127.0542 (100), 155.0491 (76), 144.0445 (43) 
JWH 018 2'-naphthyl-N-(2,2-
dimethylpropyl) isomer 
10 eV 342.1846 (100) 
20 eV 342.1847 (100), 155.0489 (81), 214.1227 (13) 
40 eV 127.0543 (100), 155.049 (88), 144.0444 (29) 
JWH 018 2'-naphthyl-N-(2-
methylbutyl) isomer 
10 eV 342.1849 (100) 
20 eV 155.0486 (100), 342.1852 (79), 214.1226 (17) 
40 eV 127.054 (100), 155.0489 (68), 144.0444 (21) 
JWH 018 2'-naphthyl-N-(3-
methylbutyl) isomer 
10 eV 342.1848 (100) 
20 eV 155.0493 (100), 342.1856 (79), 214.1227 (19) 
40 eV 127.0545 (100), 155.0493 (66), 144.0443 (15) 
JWH 018 6-methoxyindole analog 
10 eV 372.1951 (100) 
20 eV 155.0485 (100), 372.1957 (52) 
40 eV 127.0539 (100), 155.0488 (94) 
JWH 018 adamantyl analog 
10 eV 350.2472 (100) 
20 eV 350.2473 (100), 135.1174 (29) 
40 eV 135.117 (100), 93.071 (15), 107.0863 (14), 79.0555 (10) 
JWH 018 adamantyl carboxamide 
10 eV 365.2581 (100) 
20 eV 365.2583 (100), 135.1169 (37), 214.1225 (12) 
40 eV 135.1165 (100), 93.0705 (17), 107.0858 (15), 79.0551 (11) 
JWH 018 N-(1,1-dimethylpropyl) 
isomer 
10 eV 342.185 (100)272.1077 (25) 
20 eV 272.1066 (100), 155.0493 (32), 144.0446 (17), 342.1857 (10) 
40 eV 155.0491 (100), 144.0444 (80), 127.0543 (72) 
JWH 018 N-(1,2-dimethylpropyl) 
isomer 
10 eV 342.1848 (100) 
20 eV 342.1852 (100), 155.0491 (87), 272.1075 (17), 144.0447 (11) 
40 eV 155.0492 (100), 127.0545 (97), 144.0448 (52) 
JWH 018 N-(1-ethylpropyl) isomer 
10 eV 342.1841 (100) 
20 eV 155.0486 (100), 342.1849 (94), 214.1227 (12), 144.0445 (10) 
40 eV 127.0542 (100), 155.049 (87), 144.0446 (46) 
JWH 018 N-(1-methylbutyl) isomer 
10 eV 342.1839 (100) 
20 eV 155.0479 (100), 342.1839 (92), 214.1218 (13) 
40 eV 127.0533 (100), 155.0483 (83), 144.0438 (39) 
JWH 018 N-(2,2-dimethylpropyl) 
isomer 
10 eV 342.1849 (100) 
20 eV 342.1848 (100), 155.0488 (68), 214.1225 (12) 
204 
 
Substance CE  Ion (Relative Abundance %) 
40 eV 127.0541 (100), 155.049 (90), 144.0444 (26) 
JWH 018 N-(2-methylbutyl) isomer 
10 eV 342.1845 (100) 
20 eV 155.0486 (100), 342.1847 (94), 214.1225 (19) 
40 eV 127.0538 (100), 155.0487 (69), 144.0441 (18) 
JWH 018 N-(3-methylbutyl) isomer 
10 eV 342.1853 (100) 
20 eV 155.0489 (100), 342.1844 (96), 214.1229 (21) 
40 eV 127.0543 (100), 155.0491 (66), 144.0448 (12) 
JWH 018 N-(4,5-epoxypentyl) 
analog 
10 eV 356.1639 (100), 155.0489 (20) 
20 eV 155.0483 (100), 356.1643 (17) 
40 eV 127.0538 (100), 155.0486 (71) 
JWH 018 N-(5-bromopentyl) 
analog 
10 eV 420.0947 (100) 
20 eV 420.0953 (100), 155.0486 (66) 
40 eV 155.0487 (100), 127.0538 (78), 292.0327 (12), 144.0438 (10) 
JWH 018 N-(5-chloropentyl) analog 
10 eV 376.1449 (100) 
20 eV 376.1453 (100), 155.0488 (79), 248.0831 (20) 
40 eV 127.0542 (100), 155.0488 (96), 144.0441 (15), 248.0832 (11) 
JWH 019 
10 eV 356.201 (100) 
20 eV 356.2003 (100), 155.0487 (91), 228.1381 (19) 
40 eV 127.0543 (100), 155.0489 (83), 144.0443 (15) 
JWH 020 
10 eV 370.216 (100) 
20 eV 370.2161 (100), 155.0491 (72), 242.154 (15) 
40 eV 155.0491 (100), 127.0545 (97), 144.0445 (16) 
JWH 022 
10 eV 340.1685 (100) 
20 eV 155.0485 (100), 340.1693 (59), 212.1067 (20) 
40 eV 127.0541 (100), 155.0489 (52) 
JWH 030 
10 eV 292.1693 (100), 155.0492 (72) 
20 eV 155.0487 (100) 
40 eV 127.0542 (100), 155.0493 (21) 
JWH 031 
10 eV 306.1851 (100), 155.0495 (53) 
20 eV 155.0491 (100) 
40 eV 127.0546 (100), 155.0497 (30) 
JWH 072 
10 eV 314.1538 (100) 
20 eV 155.049 (100), 314.1544 (39), 186.0915 (22) 
40 eV 127.0543 (100), 155.0495 (34), 144.0447 (14) 
JWH 073 
10 eV 328.1687 (100) 
20 eV 155.0484 (100), 328.169 (55), 200.1067 (21) 
40 eV 127.0537 (100), 155.0488 (56), 144.0441 (15) 
JWH 073 2-methylnaphthyl analog 
10 eV 342.1846 (100) 
20 eV 342.1842 (100), 169.0636 (99), 200.106 (58) 
205 
 
Substance CE  Ion (Relative Abundance %) 
40 eV 141.0689 (100), 144.0435 (47), 169.0638 (38), 200.1057 (19) 
JWH 073 2'-naphthyl isomer 
10 eV 328.1691 (100) 
20 eV 155.0487 (100), 328.1699 (50), 200.1071 (20) 
40 eV 127.0541 (100), 155.0493 (47), 144.0446 (17) 
JWH 073 2'-naphthyl-N-(1,1-
dimethylethyl) isomer 
10 eV 328.1695 (100), 272.1072 (18) 
20 eV 272.1075 (100), 155.0494 (48), 144.0446 (29), 328.1696 (21) 
40 eV 144.0447 (100), 155.0493 (75), 127.0546 (67) 
JWH 073 2'-naphthyl-N-(1-
methylpropyl) isomer 
10 eV 328.1691 (100) 
20 eV 155.0484 (100), 328.1694 (59), 200.1067 (13) 
40 eV 127.0539 (100), 155.0489 (57), 144.0443 (37) 
JWH 073 2'-naphthyl-N-(2-
methylpropyl) isomer 
10 eV 328.1691 (100) 
20 eV 155.0491 (100), 328.1697 (60), 200.1075 (19) 
40 eV 127.0544 (100), 155.0495 (52), 144.0448 (22) 
JWH 073 4-methylnaphthyl analog 
10 eV 342.1846 (100) 
20 eV 169.0644 (100), 342.1851 (74), 200.107 (31) 
40 eV 141.0697 (100), 169.0648 (66), 144.0444 (24), 200.107 (12) 
JWH 073 N-(1,1-dimethylethyl) 
isomer 
10 eV 328.1684 (100), 272.1067 (17) 
20 eV 272.1062 (100), 155.0487 (40), 144.0441 (21), 328.1695 (19) 
40 eV 155.0486 (100), 127.0538 (91), 144.0439 (85) 
JWH 073 N-(1-methylpropyl) 
isomer 
10 eV 328.1687 (100) 
20 eV 155.049 (100), 328.1696 (70), 200.1074 (14) 
40 eV 127.0544 (100), 155.0495 (60), 144.0449 (31) 
JWH 073 N-(2-methylpropyl) 
isomer 
10 eV 328.1694 (100) 
20 eV 155.049 (100), 328.1696 (71), 200.1074 (20) 
40 eV 127.0544 (100), 155.0494 (53), 144.0449 (17) 
JWH 081 
10 eV 372.1955 (100) 
20 eV 185.0592 (100), 372.1957 (84), 214.1227 (32) 
40 eV 185.0595 (100), 157.0648 (47), 144.0444 (25), 214.1225 (14), 127.0543 (10) 
JWH 081 2-methoxynaphthyl 
isomer 
10 eV 372.195 (100), 185.0597 (38) 
20 eV 185.0587 (100) 
40 eV 185.0586 (100), 142.0408 (25), 170.0356 (13), 127.0537 (11) 
JWH 081 3-methoxynaphthyl 
isomer 
10 eV 372.1954 (100) 
20 eV 372.1952 (100), 185.0589 (86), 214.1222 (45) 
40 eV 129.0695 (100), 185.0592 (82), 144.0438 (62), 214.122 (37), 128.0616 (36), 127.0536 (36) 
JWH 081 5-methoxynaphthyl 
isomer 
10 eV 372.1952 (100), 185.06 (10) 
20 eV 185.059 (100), 372.1955 (46) 
40 eV 185.0594 (100), 157.0647 (49), 127.0543 (44), 129.07 (35), 128.0622 (19), 144.0444 (16) 
10 eV 372.1946 (100) 
206 
 
Substance CE  Ion (Relative Abundance %) 
JWH 081 6-methoxynaphthyl 
isomer 
20 eV 372.1947 (100), 185.0588 (74), 214.1222 (66) 
40 eV 157.0641 (100), 185.059 (50), 144.0439 (44), 214.1219 (30), 142.0411 (16) 
JWH 081 7-methoxynaphthyl 
isomer 
10 eV 372.1952 (100), 185.0593 (92) 
20 eV 185.0588 (100) 
40 eV 170.0357 (100), 185.0594 (63) 
JWH 081 8-methoxynaphthyl 
isomer 
10 eV 372.1958 (100), 185.0597 (90) 
20 eV 185.059 (100) 
40 eV 170.0359 (100), 185.0597 (62) 
JWH 098 
10 eV 386.2114 (100) 
20 eV 185.0592 (100), 386.2114 (68), 228.1381 (24) 
40 eV 185.0592 (100), 157.0646 (37), 158.0598 (16), 228.138 (13) 
JWH 122 
10 eV 356.2009 (100) 
20 eV 356.2011 (100), 169.0649 (97), 214.1233 (30) 
40 eV 141.0703 (100), 169.0653 (86), 144.045 (24), 214.1232 (13) 
JWH 122 2-methylnaphthyl isomer 
10 eV 356.2003 (100) 
20 eV 356.2004 (100), 169.0647 (76), 214.1229 (42) 
40 eV 141.07 (100), 169.0649 (50), 144.0446 (46), 214.1226 (20) 
JWH 122 3-methylnaphthyl isomer 
10 eV 356.2 (100) 
20 eV 356.1992 (100), 169.0634 (93), 214.1214 (44) 
40 eV 141.0686 (100), 169.0638 (56), 144.0435 (30), 214.1219 (15) 
JWH 122 5-methylnaphthyl isomer 
10 eV 356.2003 (100) 
20 eV 169.0641 (100), 356.2004 (91), 214.1226 (22) 
40 eV 141.0696 (100), 169.0646 (66), 144.0443 (18) 
JWH 122 6-methylnaphthyl isomer 
10 eV 356.2006 (100) 
20 eV 356.2008 (100), 169.0648 (97), 214.123 (39) 
40 eV 141.0699 (100), 169.065 (53), 144.0447 (23), 214.1227 (11) 
JWH 122 7-methylnaphthyl isomer 
10 eV 356.1996 (100) 
20 eV 169.0638 (100), 356.2 (83), 214.1222 (25) 
40 eV 141.0691 (100), 169.0643 (64), 144.0441 (18) 
JWH 122 8-methylnaphthyl isomer 
10 eV 356.1996 (100) 
20 eV 356.2003 (100), 169.0647 (72), 214.1228 (27) 
40 eV 141.0699 (100), 169.0648 (61), 144.0446 (27), 214.1228 (13) 
JWH 122 N-(4-pentenyl) analog 
10 eV 354.185 (100) 
20 eV 169.0647 (100), 354.1853 (77), 212.1075 (29) 
40 eV 141.0702 (100), 169.0651 (75), 144.0449 (14), 212.1074 (11) 
JWH 145  
10 eV 368.2003 (100), 155.0491 (52) 
20 eV 155.0486 (100) 
40 eV 127.0541 (100), 155.049 (83) 
JWH 147 10 eV 382.2159 (100), 155.0492 (46) 
207 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 155.0488 (100) 
40 eV 155.049 (100), 127.0542 (99) 
JWH 175 
10 eV 328.2059 (100), 141.0699 (88) 
20 eV 141.0698 (100) 
40 eV 141.0698 (100), 115.0542 (10) 
JWH 180 
10 eV 356.1995 (100) 
20 eV 356.2004 (100), 197.0954 (96), 186.0912 (37) 
40 eV 141.0695 (100), 197.096 (91), 144.0442 (47), 186.0911 (44), 169.1007 (17), 154.0774 (14) 
JWH 182 
10 eV 384.2311 (100) 
20 eV 384.2313 (100), 197.0955 (65), 214.1223 (23) 
40 eV 197.0957 (100), 141.0696 (63), 144.0441 (31), 214.1223 (28), 169.1006 (15) 
JWH 200 
10 eV 385.1912 (100), 155.0499 (18) 
20 eV 155.0492 (100), 114.0921 (37), 385.1922 (24) 
40 eV 155.0496 (100), 114.092 (96), 127.0548 (71), 70.0656 (18) 
JWH 200 2'-naphthyl isomer 
10 eV 385.1905 (100), 155.049 (18) 
20 eV 155.049 (100), 114.0914 (23), 385.1908 (18) 
40 eV 155.049 (100), 127.0542 (78), 114.0913 (66), 70.0652 (13) 
JWH 201 
10 eV 336.1945 (100) 
20 eV 121.0627 (100), 336.1939 (79), 149.0576 (40), 135.042 (31) 
40 eV 121.0626 (100), 135.042 (33), 144.0426 (13), 77.0368 (10) 
JWH 203 
10 eV 340.1457 (100) 
20 eV 340.1465 (100), 125.0156 (93), 188.1436 (22), 214.1227 (11) 
40 eV 125.0153 (100), 144.0445 (10) 
JWH 203 3-chlorophenyl isomer 
10 eV 340.1443 (100) 
20 eV 340.1448 (100), 125.0139 (79), 214.121 (52), 188.1417 (43) 
40 eV 125.0139 (100), 144.0428 (43), 214.1209 (26) 
JWH 203 4-chlorophenyl isomer 
10 eV 340.1456 (100) 
20 eV 340.1452 (100), 125.0147 (85), 188.1431 (28), 214.1223 (19) 
40 eV 125.0145 (100), 144.0441 (16) 
JWH 210 
10 eV 370.2156 (100) 
20 eV 370.2155 (100), 183.0799 (77), 214.1225 (27) 
40 eV 183.0799 (100), 155.0854 (59), 144.0442 (31), 153.0696 (27), 214.1224 (22), 154.0775 (12) 
JWH 210 2-ethylnaphthyl isomer 
10 eV 370.2153 (100) 
20 eV 370.2154 (100), 183.0797 (59), 214.122 (44) 
40 eV 
144.0439 (100), 155.0849 (81), 183.0799 (71), 214.122 (60), 
141.0694 (52), 153.0692 (26), 165.069 (15), 43.0542 (13), 154.0771 
(11),  
JWH 210 3-ethylnaphthyl isomer 
10 eV 370.2161 (100) 
20 eV 370.2161 (100), 183.08 (72), 214.1225 (40) 
208 
 
Substance CE  Ion (Relative Abundance %) 
40 eV 155.0853 (100), 183.0802 (83), 144.0442 (55), 214.1224 (36), 153.0696 (32), 154.0774 (13) 
JWH 210 5-ethylnaphthyl isomer 
10 eV 370.2163 (100) 
20 eV 370.2162 (100), 183.0803 (91), 214.1229 (21) 
40 eV 183.0805 (100), 155.0856 (88), 153.0701 (31), 144.0446 (27), 214.1226 (19), 154.0776 (14) 
JWH 210 6-ethylnaphthyl isomer 
10 eV 370.2155 (100) 
20 eV 370.2158 (100), 183.0799 (75), 214.1223 (33) 
40 eV 155.085 (100), 183.0802 (63), 144.0442 (28), 214.1222 (19) 
JWH 210 7-ethylnaphthyl isomer 
10 eV 370.2163 (100) 
20 eV 183.0802 (100), 370.2164 (94), 214.1229 (25) 
40 eV 155.0856 (100), 183.0806 (75), 144.0447 (21), 214.1229 (13) 
JWH 210 8-ethylnaphthyl isomer 
10 eV 370.2164 (100) 
20 eV 370.2162 (100), 183.0801 (93), 214.1225 (26), 165.0697 (11) 
40 eV 155.0854 (100), 183.0803 (75), 165.0696 (31), 144.0444 (29), 153.0696 (19), 214.1222 (17) 
JWH 249 
10 eV 384.095 (100) 
20 eV 384.0956 (100), 168.9645 (81), 188.1428 (17), 214.1222 (14) 
40 eV 168.9645 (100), 214.1222 (14), 144.0441 (13) 
JWH 250 
10 eV 336.1952 (100), 121.0647 (24) 
20 eV 121.0648 (100), 336.1954 (12) 
40 eV 91.0545 (100), 121.0646 (61), 93.0701 (20), 130.0648 (18), 144.0795 (13) 
JWH 251 
10 eV 320.2007 (100) 
20 eV 320.2004 (100), 105.0697 (94), 214.1222 (76), 188.1428 (12) 
40 eV 105.0696 (100), 144.0441 (65), 214.1221 (35), 43.0544 (10) 
JWH 251 3-methylphenyl isomer 
10 eV 320.1981 (100) 
20 eV 105.0693 (100), 214.1206 (99), 320.1982 (77), 188.1418 (25) 
40 eV 144.0429 (100), 105.0694 (97), 214.1207 (49), 43.0551 (17) 
JWH 251 4-methylphenyl isomer 
10 eV 320.2004 (100) 
20 eV 105.0695 (100), 320.2003 (95), 214.1221 (48), 119.0488 (21), 188.1428 (14) 
40 eV 105.0695 (100), 144.0439 (43), 214.122 (21), 119.0487 (15), 91.0539 (11) 
JWH 302 
10 eV 336.1952 (100), 121.0644 (10) 
20 eV 121.0648 (100), 214.1222 (59), 336.1948 (28), 188.1429 (27) 
40 eV 121.0647 (100), 144.044 (25), 214.1216 (61), 91.0545 (20), 43.0551 (13) 
JWH 307 
10 eV 386.1914 (100), 155.0494 (42) 
20 eV 155.0487 (100) 
40 eV 127.0539 (100), 155.0491 (94) 
JWH 309 
10 eV 418.2159 (100), 155.0493 (43) 
20 eV 155.0486 (100) 
40 eV 155.049 (100), 127.0543 (67) 
209 
 
Substance CE  Ion (Relative Abundance %) 
JWH 368 
10 eV 386.1906 (100), 155.0487 (40) 
20 eV 155.0481 (100) 
40 eV 127.0537 (100), 155.0485 (95) 
JWH 369 
10 eV 402.1617 (100), 155.0493 (43) 
20 eV 155.0487 (100) 
40 eV 155.0489 (100), 127.0543 (91) 
JWH 370 
10 eV 382.2155 (100), 155.049 (47) 
20 eV 155.0486 (100) 
40 eV 127.0542 (100), 155.0489 (99) 
JWH 398 
10 eV 376.1453 (100) 
20 eV 189.0097 (100), 376.1458 (93), 214.1221 (11) 
40 eV 189.0097 (100), 161.0149 (80), 144.044 (10) 
JWH 398 2-chloronaphthyl isomer 
10 eV 376.146 (100) 
20 eV 376.1465 (100), 189.0102 (89) 
40 eV 189.0103 (100), 161.0154 (49) 
JWH 398 3-chloronaphthyl isomer 
10 eV 376.1465 (100) 
20 eV 189.0107 (100), 376.147 (98), 214.123 (10) 
40 eV 161.0156 (100), 189.0106 (91), 144.045 (11) 
JWH 398 5-chloronaphthyl isomer 
10 eV 376.1454 (100) 
20 eV 189.0102 (100), 376.1462 (95), 214.1226 (10) 
40 eV 161.0152 (100), 189.0103 (90) 
JWH 398 6-chloronaphthyl isomer 
10 eV 376.1454 (100) 
20 eV 189.0102 (100), 376.1462 (99), 214.1225 (17) 
40 eV 161.0152 (100), 189.0103 (73), 144.0445 (11) 
JWH 398 7-chloronaphthyl isomer 
10 eV 376.1453 (100) 
20 eV 189.0096 (100), 376.1456 (84) 
40 eV 161.0146 (100), 189.0096 (92) 
JWH 398 8-chloronaphthyl isomer 
10 eV 376.146 (100) 
20 eV 376.1464 (100), 189.0105 (78) 
40 eV 189.0104 (100), 161.0155 (66) 
JWH 424 
10 eV 420.0955 (100) 
20 eV 420.0962 (100), 232.9601 (61) 
40 eV 232.9601 (100), 204.965 (62), 214.1227 (15), 167.0491 (12), 284.1074 (11), 270.0918 (10) 
JZL 195 
10 eV 434.1697 (100), 183.0799 (28) 
20 eV 183.0795 (100), 434.1707 (17) 
40 eV 183.0798 (100), 155.0853 (18), 165.0695 (16), 168.0566 (15), 153.0695 (11) 
MAM2201 
10 eV 374.1903 (100) 
20 eV 374.1908 (100), 169.0643 (73), 232.1122 (25) 
40 eV 169.0641 (100), 141.0697 (84), 144.0443 (28), 232.1133 (20) 
210 
 
Substance CE  Ion (Relative Abundance %) 
MDA 19 
10 eV 350.1862 (100), 105.0337 (61) 
20 eV 105.0333 (100) 
40 eV 105.0335 (100), 77.0387 (53) 
MDA 77 
10 eV 366.1805 (100), 105.0336 (25) 
20 eV 105.0331 (100) 
40 eV 105.0334 (100), 77.0385 (44) 
MDMA methylene homolog  
10 eV 208.1325 (100), 135.0441 (26) 
20 eV 135.0436 (100), 147.0803 (12) 
40 eV 77.0388 (100), 135.0441 (92), 91.0545 (29), 79.0543 (28), 105.0337 (22), 51.0232 (17) 
meta-Chlorophenylpiperazine  
10 eV 197.0832 (100), 154.041 (12) 
20 eV 154.0409 (100), 197.0833 (49), 119.0724 (41), 44.0493 (22), 118.0645 (12) 
40 eV 118.0646 (100), 119.0722 (25), 44.0492 (17), 110.9988 (15), 91.0539 (15), 104.0488 (12) 
Methcathinone 
10 eV 146.0961 (100), 131.0724 (34), 164.1067 (20) 
20 eV 131.0726 (100), 146.096 (34), 130.0646 (26), 105.0695 (26) 
40 eV 130.0647 (100), 77.0383 (58), 103.0538 (18), 79.054 (14), 131.0723 (11) 
Methedrone 
10 eV 176.1064 (100), 161.083 (17), 194.1168 (15), 58.0651 (14) 
20 eV 161.0827 (100), 176.1062 (45), 146.0593 (33), 145.0879 (30), 135.0799 (21), 58.0651 (20) 
40 eV 
118.0648 (100), 146.0593 (88), 77.0381 (46), 144.0801 (37), 91.0539 
(36), 132.0802 (33), 79.0539 (26), 58.0652 (25), 103.0536 (25), 
117.057 (20), 105.0695 (19) 
Methoxetamine 
10 eV 203.1061 (100), 248.1638 (52), 175.1108 (17), 46.0659 (16) 
20 eV 175.1108 (100), 121.0646 (91), 203.1057 (70), 67.0547 (28), 46.0659 (18), 159.0791 (13) 
40 eV 121.0646 (100), 91.0545 (35), 67.0547 (16), 77.0392 (10) 
Methylone 
10 eV 160.0752 (100), 190.0857 (70), 208.0965 (42), 58.0651 (12) 
20 eV 160.0751 (100), 132.0804 (35) 
40 eV 132.0802 (100), 117.0571 (82), 91.054 (54), 131.0724 (28), 65.0383 (24), 58.065 (19), 160.0751 (14), 130.065 (11), 115.0539 (11) 
N,N-Diallyl-5-methoxytryptamine 
10 eV 110.0966 (100), 174.0913 (49), 271.1808 (30) 
20 eV 110.0966 (100), 174.0909 (81) 
40 eV 
159.0679 (100), 131.0731 (72), 41.04 (47), 143.073 (46), 130.0654 
(37), 174.0912 (36), 110.0968 (34), 79.0552 (19), 81.0708 (10), 
115.0547 (10) 
N,N-Diethylcathinone  
10 eV 206.1533 (100) 
20 eV 105.0698 (100), 100.1123 (57), 206.153 (35), 133.0644 (314), 72.0815 (17) 
40 eV 
77.0391 (100), 105.0698 (86), 100.1122 (58), 79.0548 (51), 72.0815 
(37), 103.0542 (34), 58.066 (32), 44.0505 (32), 130.0647 (21), 
105.0333 (19), 117.0575 (12) 
N,N-Diisopropyl-5-
methoxytryptamine 
10 eV 114.1272 (100), 275.2113 (76), 174.0904 (46) 
20 eV 174.0903 (100), 114.127 (90), 72.0801 (10) 
40 eV 159.0668 (100), 131.072 (63), 174.0903 (50), 143.0719 (43), 72.0803 (33), 130.0644 (31), 114.1267 (17), 115.0539 (10) 
N,N-Dimethylcathinone  10 eV 178.1218 (100)133.0646 (30), 105.0697 (18) 
211 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 105.0697 (100), 72.0808 (51), 133.0647 (24), 178.1223 (10) 
40 eV 77.0386 (100), 72.0807 (78), 79.0542 (37), 105.0696 (32), 103.0542 (23), 44.0496 (12) 
N,N-Dimethyltryptamine 
10 eV 58.0652 (100), 144.0804 (51), 189.1382 (15) 
20 eV 58.0651 (100), 144.0805 (84) 
40 eV 58.0651 (100), 143.0725 (37), 115.0538 (36), 117.0647 (27), 91.0543 (22), 144.0802 (19), 127.054 (18) 
Naphyrone  
10 eV 282.185 (100) 
20 eV 141.0693 (100), 282.185 (88), 211.1115 (78), 126.1276 (23), 155.0487 (16) 
40 eV 141.0694 (100), 127.054 (41), 126.1274 (41), 155.0488 (21), 84.0808 (18) 
Naphyrone 1-naphthyl isomer  
10 eV 282.1846 (100) 
20 eV 282.1849 (100), 211.1115 (81), 126.1275 (73), 141.0698 (61), 155.0489 (31), 169.0647 (12) 
40 eV 141.0697 (100), 127.0542 (92), 126.1276 (79), 155.049 (49), 84.0807 (23) 
N-Isopropyl-5-methoxy-N-
methyltryptamine 
10 eV 
91.0544 (100), 77.0392 (87), 79.0548 (39), 103.0539 (35), 65.0391 
(32), 78.0467 (19), 105.0715 (19), 119.048 (18), 121.0649 (17), 
107.0492 (15) 
20 eV 86.097 (100), 174.0908 (74), 44.0508 (10) 
40 eV 44.0508 (100), 131.0728 (89), 159.0675 (88), 130.065 (56), 143.0728 (48), 86.0972 (44), 174.0909 (22), 115.0542 (13), 43.0557 (11) 
Nor-Mephedrone  
10 eV 146.0957 (100)131.0725 (20), 147.0799 (12) 
20 eV 131.0726 (100), 146.0957 (33), 130.0647 (24), 119.085 (21) 
40 eV 130.0647 (100), 91.0539 (16), 77.0382 (13), 103.0539 (10) 
para-Fluorophenylpiperazine 
10 eV 181.1131 (100), 138.0713 (16) 
20 eV 138.0713 (100), 181.1134 (35), 136.0556 (15), 44.0498 (14) 
40 eV 
95.0292 (100), 109.0448 (84), 96.0371 (75), 136.0556 (69), 83.0291 
(59), 91.0545 (59), 44.0498 (54), 75.023 (41), 138.0713 (40), 
110.0407 (37), 111.0489 (31), 101.0385 (30), 124.0556 (23), 
117.0573 (23), 77.0384 (22), 97.0449 (17), 122.04 (16), 118.0648 
(15), 42.0342 (14), 137.0632 (11), 56.0498 (11) 
Pentedrone  
10 eV 174.1274 (100), 192.1385 (61), 132.0808 (34), 161.096 (25), 91.0545 (21) 
20 eV 132.0811 (100), 91.0547 (88), 131.0732 (46), 174.1277 (28), 144.0808 (18), 117.0578 (15), 105.0339 (14), 145.0887 (12) 
40 eV 91.0546 (100), 130.0653 (64), 77.0388 (52), 144.0807 (46), 117.0578 (31), 131.073 (25), 65.0388 (14) 
Pentylone 
10 eV 236.1278 (100), 218.1174 (93), 188.1069 (59), 205.0857 (30), 86.0966 (16), 175.0727 (13) 
20 eV 188.1067 (100), 175.0685 (36), 218.1175 (24), 86.0967 (22), 135.0442 (19), 160.1115 (11) 
40 eV 
131.0731 (100), 135.0441 (35), 175.0631 (32), 174.0548 (30), 
188.0717 (227), 159.0676 (25), 121.0286 (23), 65.0389 (23), 44.0501 
(22), 86.0967 (19), 118.0652 (18), 130.0652 (18), 149.0232 (17), 
146.0596 (17), 119.0743 (13), 77.0387 (13), 117.0583 (13), 188.1034 
(10),  
Phenylpiperazine  
10 eV 163.1217 (100), 120.08 (23) 
20 eV 120.0797 (100), 163.1218 (27), 118.064 (15) 
40 eV 77.0377 (100), 118.0639 (24), 91.0534 (23), 44.049 (17), 51.0224 (16), 120.0797 (15), 103.0534 (13) 
Pravadoline 10 eV 379.2012 (100), 135.0441 (64) 
212 
 
Substance CE  Ion (Relative Abundance %) 
20 eV 135.0438 (100) 
40 eV 135.044 (100), 114.0918 (26), 107.0495 (11), 77.039 (11) 
Pyrovalerone 
10 eV 246.1847 (100) 
20 eV 105.0701 (100), 175.1117 (51), 246.1855 (50), 126.1279 (26), 119.0494 (22) 
40 eV 105.0703 (100), 91.0545 (57), 126.1278 (44), 119.0495 (34), 84.081 (27) 
RCS-4 
10 eV 322.1794 (100), 135.044 (10) 
20 eV 135.0436 (100), 322.1802 (35) 
40 eV 135.0438 (100), 77.0388 (30), 107.0495 (22) 
RCS-4 2-methoxy isomer 
10 eV 322.1793 (100), 135.0439 (23) 
20 eV 135.0436 (100), 322.1802 (11) 
40 eV 135.0437 (100), 77.0388 (35) 
RCS-4 3-methoxy isomer 
10 eV 322.1801 (100) 
20 eV 135.0442 (100), 322.1804 (50) 
40 eV 107.0497 (100), 135.0446 (78), 77.0392 (64), 144.0448 (16), 92.0263 (15) 
RCS-4-C4 Homolog 
10 eV 308.1638 (100), 135.0439 (14) 
20 eV 135.0436 (100), 308.1644 (23) 
40 eV 135.0438 (100), 77.0388 (40), 107.0494 (27) 
RCS-8 
10 eV 376.2264 (100), 121.0645 (10) 
20 eV 121.0647 (100), 376.2258 (52) 
40 eV 121.0647 (100), 91.0546 (65), 144.0799 (26), 93.07 (20) 
RCS-8 3-methoxy isomer 
10 eV 376.2255 (100) 
20 eV 376.2261 (100), 121.0637 (86), 254.1532 (41), 228.1737 (30), 132.0797 (10) 
40 eV 121.0637 (100), 254.1532 (62), 144.0433 (32), 69.0689 (18), 158.0588 (13), 91.0533 (10), 132.0797 (10) 
RCS-8 4-methoxy isomer 
10 eV 376.2265 (100) 
20 eV 376.2258 (100), 121.0642 (37), 149.0589 (13) 
40 eV 121.0638 (100), 135.0433 (32) 
STS-135 
10 eV 383.2487 (100) 
20 eV 383.2488 (100), 135.1168 (25) 
40 eV 135.1167 (100), 93.0702 (14), 107.0856 (13) 
Trimethoxyamphetamine 
10 eV 209.1163 (100) 
20 eV 
181.0849 (100), 194.0927 (98), 178.0976 (87), 209.1162 (72), 
168.0771 (45), 179.0691 (37), 166.0605 (31), 163.0741 (26), 
151.0743 (22), 162.0661 (22), 147.0427 (17), 165.0533 (17), 
177.0893 (16), 153.054 (16), 121.0639 (15), 147.0778 (14), 135.0786 
(10) 
40 eV 
91.0533 (100), 107.0481 (57), 77.0379 (39), 119.0484 (39), 103.0535 
(37), 121.0643 (28), 79.053 (25), 65.0377 (22), 105.0695 (22), 
151.0735 (21), 147.0422 (17), 148.0502 (16), 78.0448 (16), 115.0534 
(16), 136.0509 (16), 135.079 (15), 137.0595 (14), 125.0593 (11), 
131.0484 (11), 93.0333 (11), 163.0737 (11), 147.0789 (10) 
UR-144 
10 eV 312.2317 (100) 
20 eV 312.2322 (100), 125.0964 (78), 214.123 (28), 294.222 (13) 
213 
 
Substance CE  Ion (Relative Abundance %) 
40 eV 
55.0547 (100), 144.0447 (58), 57.0703 (45), 125.0965 (42), 97.1016 
(33), 214.1228 (25), 69.0701 (25), 264.1748 (16), 43.0547 (15), 
83.0857 (15), 130.0655 (13), 208.1122 (11), 222.128 (10) 
URB447 
10 eV 401.1411 (100) 
20 eV 105.0338 (100), 401.1416 (69), 296.1076 (42), 276.1254 (14) 
40 eV 105.0337 (100), 171.0915 (41), 77.0388 (30), 125.0154 (20), 198.0786 (10) 
URB597 
10 eV 214.0862 (100), 197.0594 (16) 
20 eV 197.0593 (100), 214.0858 (50), 171.0798 (24) 
40 eV 153.0692 (100), 197.0592 (45), 171.0797 (31), 141.0694 (25), 152.0616 (22), 169.0641 (20) 
URB602 
10 eV 214.0857 (100), 170.0956 (23), 196.0755 (13) 
20 eV 170.0959 (100), 196.0749 (63), 168.08 (30), 214.0862 (25), 153.0689 (18) 
40 eV 153.0693 (100), 152.0617 (59), 168.0801 (48), 141.0695 (28), 170.0962 (26), 151.053 (10) 
URB754 
10 eV 267.1136 (100), 160.0397 (27) 
20 eV 160.0392 (100), 267.1127 (12) 
40 eV 104.0497 (100), 160.0392 (46), 77.0388 (41), 106.0654 (30), 79.0544 (19) 
URB937 
10 eV 230.0815 (100), 213.0551 (22), 355.1672 (22) 
20 eV 213.0546 (100), 230.0816 (46), 187.0751 (12) 
40 eV 
213.0547 (100), 141.0699 (57), 185.0598 (49), 157.0646 (46), 
169.0655 (36), 187.0758 (26), 129.0694 (19), 167.0497 (10), 
115.0535 (10) 
WIN 54461 
10 eV 457.1107 (100), 135.0437 (47) 
20 eV 135.0435 (100), 457.1111 (13) 
40 eV 135.0436 (100), 114.0912 (24) 
WIN 55212-2 
10 eV 427.2018 (100), 155.0492 (19) 
20 eV 155.0492 (100), 427.2014 (44) 
40 eV 155.0492 (100), 127.0543 (32), 100.0759 (21) 
XLR11 
10 eV 330.2221 (100) 
20 eV 330.2215 (100), 125.0953 (53), 232.1124 (21) 
40 eV 
55.0538 (100), 144.0434 (63), 125.0952 (55), 57.0693 (43), 97.1004 
(39), 232.1126 (38), 69.0691 (30), 282.1644 (21), 83.0847 (17), 
130.0643 (15), 222.1269 (12), 41.0382 (11), 297.1875 (10) 
α-Methyltryptamine 
10 eV 158.0959 (100) 
20 eV 158.0958 (100),143.0725 (85),130.0649 (77),117.0572 (48) 
40 eV 
117.0571 (100),143.0725 (84),115.054 (72),130.0649 (51),90.0464 
(40),142.0648 (37),77.0385 (32),116.0612 (22),91.0537 (22),89.0382 
(21),103.0541 (21),128.0507 (12) 
α-Pyrrolidinobutiophenone  
10 eV 218.1531 (100) 
20 eV 91.0541 (100), 218.1536 (69), 147.0801 (35), 112.1119 (32), 105.0334 (20), 70.065 (19), 119.0853 (15) 
40 eV 91.054 (100), 77.0385 (61), 112.1118 (41), 105.0333 (32), 84.0806 (24), 70.0649 (16) 
α-Pyrrolidinopentiophenone  
10 eV 232.1687 (100) 
20 eV 91.0546 (100), 232.1697 (75), 126.1279 (30), 161.0961 (29), 105.0339 (24), 70.0655 (18), 119.0495 (12) 
214 
 
Substance CE  Ion (Relative Abundance %) 
40 eV 91.0547 (100), 77.039 (60), 126.128 (37), 105.0339 (37), 84.0811 (29), 70.0653 (10) 
α-Pyrrolidinopropiophenone  
10 eV 204.1374 (100) 
20 eV 105.07 (100), 204.1382 (89), 98.0966 (63), 133.0649 (50), 70.0652 (23) 
40 eV 
98.0966 (100), 105.0699 (94), 77.0387 (70), 79.0544 (44), 56.0496 
(31), 103.0543 (27), 70.0653 (22), 84.081 (17), 105.0336 (16), 
55.0545 (13) 
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AM-694 4-iodo isomer 
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Appendix 6. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the AM 694 set of regioisomers. 
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Appendix 7. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the ethylethcathinone set of 
regioisomers. 
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Appendix 8. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the fluoroamphetamine set of 
regioisomers.  
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Appendix 9. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the fluoroethcathinone set of 
regioisomers. 
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Appendix 10. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the fluoromethamphetamine set of 
regioisomers. 
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Appendix 11. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the fluoromethcathinone set of 
regioisomers. 
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Appendix 12. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the JWH 203 set of regioisomers. 
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Appendix 13. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the JWH 251 set of regioisomers. 
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Appendix 14. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the methylenedioxy 
pyrovalerone set of regioisomers. 
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Appendix 15. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the methoxymethcathinone set of 
regioisomers. 
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Appendix 16. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the methoxy-N,N-
dimethyltryptamine set of regioisomers. 
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Appendix 17. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the methylethcathinone set of 
regioisomers. 
227 
 
 
 
 
 
 
  
40 eV 
20 eV 
10 eV 
2,3-MDMC Methylone 
100
80
60
40
20
0
R
el
at
iv
e 
Ab
un
da
nc
e 
(%
)
250200150100500
m/z
208.0968
190.0863
58.0651
160.0757
100
80
60
40
20
0
R
el
at
iv
e 
Ab
un
da
nc
e 
(%
)
250200150100500
m/z
132.0808
160.0747
100
80
60
40
20
0
R
el
at
iv
e 
Ab
un
da
nc
e 
(%
)
250200150100500
m/z
160.0747
132.0808
91.0542
65.0386
117.0573
58.0651
100
80
60
40
20
0
R
el
at
iv
e 
Ab
un
da
nc
e 
(%
)
250200150100500
m/z
208.0968
190.0863
160.0757
58.0651
100
80
60
40
20
0
R
el
at
iv
e 
Ab
un
da
nc
e 
(%
)
250200150100500
m/z
160.0747
132.0808
100
80
60
40
20
0
R
el
at
iv
e 
Ab
un
da
nc
e 
(%
)
250200150100500
m/z
160.0747
132.0808
117.0573
91.0542
65.0386
58.0651
Appendix 18. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the 
methylenedioxymethcathinone set of regioisomers. 
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Appendix 19. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the RCS 4 set of regioisomers. 
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Appendix 20. The MS/MS spectral data collected at 10 eV, 20 eV and 40 eV collision energy levels for the RCS 8 set of regioisomers. 
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Appendix 21. Results of the collision induced dissociation study. The mean and relative standard deviation % is shown for the reproducibility, 
concentration and mobile phase experiments for all of the ions of interest. Concentration and mobile phase experiment data is not shown for ions 
that were not determined to be significantly different in the reproducibility experiment. 
AM 694 Regioisomers  Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
AM 694 3-iodo isomer 436.0568 10 100 0.0%                         
AM 694 4-iodo isomer     100 0.0%                    
AM 694     100 0.0%                         
AM694 3-iodo isomer 230.9301 20 100 0.0% 93 4.8% 89 2.0% 93 7.2% 95 3.7% 99 0.9% 100 0.0% 
AM694 4-iodo isomer     100 0.0% 98 3.2% 97 2.3% 98 2.7% 99 1.7% 100 0.0% 100 0.0% 
AM 694     90 4.4% 91 5.4% 89 5.7% 85 3.4% 84 6.1% 84 2.8% 83 4.0% 
AM 694 3-iodo isomer 309.1523 20 0 308.2% 0 128.5% 0 - 13 27.3% 5 22.0% 0 - 0 - 
AM 694 4-iodo isomer     0 352.5% 0 265.0% 0 - 10 12.9% 4 31.5% 0 - 0 - 
AM 694     16 6.2% 17 10.6% 16 4.9% 17 14.3% 17 12.9% 16 4.8% 16 4.9% 
AM694 3-iodo isomer 436.0568 20 80 6.2% 100 1.6% 100 0.0% 99 1.5% 100 0.0% 94 6.4% 96 1.6% 
AM694 4-iodo isomer     74 7.5% 97 3.4% 100 0.2% 95 5.3% 99 1.6% 83 3.7% 87 0.6% 
AM 694     100 1.2% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
AM694 3-iodo isomer 202.9352 40 61 4.5% 56 6.4% 54 1.6% 48 8.2% 51 10.3% 54 11.5% 57 3.5% 
AM694 4-iodo isomer     41 6.4% 37 8.2% 35 1.6% 45 8.0% 44 2.9% 38 8.8% 37 4.2% 
AM 694     45 4.0% 43 3.9% 44 5.6% 42 10.8% 39 10.6% 38 1.8% 38 5.4% 
AM 694 3-iodo isomer 230.9301 40 100 0.0%                         
AM 694 4-iodo isomer     100 0.0%                    
AM 694     100 0.0%                         
                 
Ethylethcathinone  Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
2-Ethylethcathinone  159.1043 10 21 7.3% 20 3.4% 19 2.2% 18 1.0% 19 3.0% 19 0.9% 19 2.2% 
3-Ethylethcathinone      19 6.0% 16 5.5% 16 2.8% 17 1.8% 17 3.3% 17 1.5% 17 1.5% 
4-Ethylethcathinone      16 6.0% 14 6.9% 13 2.0% 14 0.7% 14 1.2% 15 2.6% 15 3.2% 
2-Ethylethcathinone  160.1121 10 23 6.7% 21 4.3% 20 2.1% 21 2.2% 21 2.8% 21 2.2% 21 1.2% 
3-Ethylethcathinone      20 7.2% 18 6.0% 17 2.1% 18 0.8% 19 2.2% 18 2.3% 19 1.1% 
4-Ethylethcathinone      17 5.4% 15 6.8% 14 2.0% 15 1.0% 16 2.9% 15 1.9% 16 2.5% 
2-Ethylethcathinone  188.1434 10 100 0.0%                         
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3-Ethylethcathinone      100 0.0%                    
4-Ethylethcathinone      100 0.0%                    
2-Ethylethcathinone  206.1539 10 52 5.6% 54 5.2% 53 2.6% 61 1.4% 62 2.9% 60 1.2% 60 0.9% 
3-Ethylethcathinone      61 4.9% 74 3.6% 73 1.8% 77 1.3% 79 1.2% 76 0.8% 75 0.6% 
4-Ethylethcathinone      44 5.3% 54 3.4% 53 1.4% 57 0.9% 60 1.5% 58 0.7% 57 2.0% 
2-Ethylethcathinone  132.0808 20 27 8.1%                         
3-Ethylethcathinone      26 7.5%                    
4-Ethylethcathinone      23 5.3%                    
2-Ethylethcathinone  144.0808 20 64 6.0% 60 2.2% 60 3.8% 57 1.5% 56 1.0% 57 0.8% 58 1.2% 
3-Ethylethcathinone      56 5.8% 52 4.6% 49 1.3% 48 0.8% 49 1.7% 49 1.6% 51 2.0% 
4-Ethylethcathinone      52 5.0% 47 8.5% 45 1.6% 45 2.0% 45 2.6% 46 1.0% 46 0.9% 
2-Ethylethcathinone  159.1043 20 100 0.0%                         
3-Ethylethcathinone      100 0.0%                    
4-Ethylethcathinone      100 0.0%                    
2-Ethylethcathinone  160.1121 20 46 5.5%                         
3-Ethylethcathinone      47 6.3%                    
4-Ethylethcathinone      47 4.8%                    
2-Ethylethcathinone  188.1434 20 33 3.6% 34 6.2% 33 3.5% 39 0.9% 38 2.2% 39 1.7% 38 0.7% 
3-Ethylethcathinone      38 5.9% 45 3.9% 43 1.4% 46 1.4% 47 1.4% 47 0.8% 46 1.5% 
4-Ethylethcathinone      43 5.7% 52 5.6% 50 2.0% 53 1.4% 54 0.9% 53 0.7% 53 0.8% 
2-Ethylethcathinone  105.0699 40 10 6.9% 10 3.4% 10 2.7% 9 3.6% 9 3.1% 9 3.8% 9 1.5% 
3-Ethylethcathinone      19 8.5% 18 7.1% 17 1.5% 17 2.6% 17 1.0% 16 0.7% 17 1.6% 
4-Ethylethcathinone      22 6.9% 22 8.1% 21 1.4% 21 1.7% 20 1.0% 20 0.8% 20 0.6% 
2-Ethylethcathinone  130.0651 40 27 5.7%                         
3-Ethylethcathinone      25 5.5%                    
4-Ethylethcathinone      22 9.1%                    
2-Ethylethcathinone  144.0808 40 100 0.0%                         
3-Ethylethcathinone      100 0.0%                    
4-Ethylethcathinone      100 0.0%                         
 
                
Fluoroamphetamine Regioisomers 
 
Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
2-Fluoroamphetamine  
109.0448 10 
100 0.0%                         
3-Fluoroamphetamine  100 0.0%                       
4-Fluoroamphetamine  100 0.0%                       
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2-Fluoroamphetamine  
137.0761 10 
20 6.4% 24 10.1% 23 2.4% 28 1.9% 29 2.6% 29 4.9% 31 1.9% 
3-Fluoroamphetamine  18 9.1% 24 7.7% 24 2.9% 30 6.2% 30 7.5% 31 4.0% 33 4.8% 
4-Fluoroamphetamine  28 9.6% 38 8.1% 38 2.5% 47 4.5% 47 4.7% 49 3.9% 52 3.5% 
2-Fluoroamphetamine  
109.0448 20 
100 0.0%                         
3-Fluoroamphetamine  100 0.0%                       
4-Fluoroamphetamine  100 0.0%                       
2-Fluoroamphetamine  
83.0292 40 
100 0.6% 97 3.7% 99 1.2% 86 0.8% 85 1.5% 84 3.7% 83 2.3% 
3-Fluoroamphetamine  100 0.0% 100 0.0% 100 0.0% 98 1.9% 97 2.4% 97 2.1% 93 3.0% 
4-Fluoroamphetamine  99 2.6% 94 7.3% 93 2.1% 81 3.2% 79 4.2% 76 6.0% 79 2.4% 
2-Fluoroamphetamine  
109.0448 40 
96 4.7% 96 5.9% 99 1.2% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
3-Fluoroamphetamine  78 8.9% 87 7.5% 87 2.1% 100 0.4% 100 0.0% 99 1.4% 100 0.0% 
4-Fluoroamphetamine  94 7.5% 99 4.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
                 
Fluoroethcathinone Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
2-Fluoroethcathinone  150.0714 10 26 6.1% 25 6.7% 24 2.6% 25 2.0% 26 0.7% 26 3.8% 26 0.6% 
3-Fluoroethcathinone     43 6.7% 38 8.1% 37 1.8% 38 2.8% 38 1.7% 38 1.3% 39 1.9% 
4-Fluoroethcathinone     31 6.8% 27 6.1% 26 1.8% 28 1.3% 28 1.4% 29 1.6% 29 0.9% 
2-Fluoroethcathinone  178.1027 10 100 0.0%                         
3-Fluoroethcathinone     100 0.0%                   
4-Fluoroethcathinone     100 0.0%                   
2-Fluoroethcathinone  196.1132 10 84 4.0% 91 6.1% 91 1.1% 97 1.7% 99 1.1% 96 1.7% 97 0.8% 
3-Fluoroethcathinone     79 4.1% 95 2.8% 95 1.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
4-Fluoroethcathinone      50 6.0% 61 3.9% 61 1.6% 66 0.9% 68 0.7% 67 1.8% 65 0.9% 
2-Fluoroethcathinone  103.0554 20 19 10.9% 17 22.7% 16 3.3% 15 2.9% 15 5.2% 16 1.5% 15 1.5% 
3-Fluoroethcathinone     14 11.2% 12 6.6% 11 3.1% 10 2.7% 10 2.9% 10 1.9% 10 3.9% 
4-Fluoroethcathinone      15 8.3% 13 10.4% 12 3.0% 11 1.1% 11 2.8% 12 2.7% 11 1.7% 
2-Fluoroethcathinone  123.0605 20 43 5.2% 42 11.7% 41 1.6% 39 1.6% 38 0.8% 39 0.9% 39 2.2% 
3-Fluoroethcathinone     27 9.8% 25 5.4% 24 1.9% 23 1.9% 23 1.1% 23 3.1% 23 2.7% 
4-Fluoroethcathinone     35 9.3% 33 7.1% 32 2.1% 30 1.8% 30 2.3% 30 2.4% 30 0.9% 
2-Fluoroethcathinone  135.0479 20 32 5.0%                         
3-Fluoroethcathinone     28 8.4%                   
4-Fluoroethcathinone      28 6.7%                         
2-Fluoroethcathinone  148.0557 20 26 6.5%                         
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3-Fluoroethcathinone     23 7.2%                   
4-Fluoroethcathinone      28 6.7%                         
2-Fluoroethcathinone  149.0635 20 83 2.4% 79 7.7% 81 1.8% 78 1.8% 77 1.8% 79 1.6% 78 1.5% 
3-Fluoroethcathinone     58 6.1% 56 5.7% 54 1.3% 51 1.4% 51 0.8% 51 1.7% 52 2.0% 
4-Fluoroethcathinone      89 4.6% 85 4.4% 84 1.0% 80 1.3% 81 0.9% 81 2.4% 80 0.5% 
2-Fluoroethcathinone  150.0714 20 100 0.0%                         
3-Fluoroethcathinone     100 0.0%                   
4-Fluoroethcathinone      100 0.0%                         
2-Fluoroethcathinone  163.0792 20 16 7.3% 15 17.8% 14 2.5% 13 4.8% 13 1.8% 14 4.9% 14 1.7% 
3-Fluoroethcathinone     6 10.9% 7 9.6% 6 2.6% 6 5.2% 5 4.9% 6 3.3% 6 2.4% 
4-Fluoroethcathinone     14 13.7% 13 7.7% 12 2.6% 11 2.8% 11 1.4% 12 3.9% 11 2.2% 
2-Fluoroethcathinone  178.1027 20 53 3.1% 58 13.4% 56 1.6% 58 1.7% 58 0.9% 58 1.6% 56 0.7% 
3-Fluoroethcathinone     30 7.4% 35 6.0% 33 2.1% 35 2.4% 34 1.6% 35 0.4% 34 1.5% 
4-Fluoroethcathinone      41 7.0% 46 5.0% 45 2.2% 47 1.4% 47 1.2% 47 2.0% 46 1.6% 
2-Fluoroethcathinone  77.0386 40 60 6.3% 59 13.8% 56 2.8% 54 3.6% 52 2.6% 55 3.3% 53 2.7% 
3-Fluoroethcathinone     54 9.2% 50 8.2% 49 2.2% 45 2.3% 45 1.6% 46 1.2% 46 2.4% 
4-Fluoroethcathinone     45 7.2% 42 8.2% 41 1.7% 38 1.7% 38 0.6% 38 3.3% 38 1.2% 
2-Fluoroethcathinone  95.0292 40 20 5.4% 18 18.7% 19 2.4% 19 5.5% 18 3.2% 19 7.1% 18 4.3% 
3-Fluoroethcathinone     23 11.3% 23 10.5% 22 2.7% 20 2.3% 21 1.7% 22 1.8% 21 0.6% 
4-Fluoroethcathinone      14 10.8% 14 10.8% 13 3.0% 12 3.4% 12 2.8% 13 2.7% 13 2.7% 
2-Fluoroethcathinone  103.0554 40 55 3.1%                         
3-Fluoroethcathinone     49 8.9%                   
4-Fluoroethcathinone      46 20.7%                         
2-Fluoroethcathinone  108.0370 40 13 7.3%                         
3-Fluoroethcathinone     15 18.7%                   
4-Fluoroethcathinone      12 11.5%                         
2-Fluoroethcathinone  109.0448 40 18 5.6%                         
3-Fluoroethcathinone     15 8.9%                   
4-Fluoroethcathinone      16 16.8%                         
2-Fluoroethcathinone  115.0554 40 23 10.1% 22 16.4% 22 4.0% 23 3.9% 21 4.2% 23 4.4% 23 3.9% 
3-Fluoroethcathinone     14 16.6% 15 14.9% 15 3.7% 15 4.5% 14 4.1% 15 2.5% 15 2.3% 
4-Fluoroethcathinone      17 8.2% 18 10.3% 17 2.2% 16 2.6% 16 2.0% 18 4.1% 17 3.6% 
2-Fluoroethcathinone  135.0479 40 71 2.3% 73 8.9% 73 2.5% 73 1.7% 71 2.1% 74 2.1% 71 1.0% 
3-Fluoroethcathinone     86 6.5% 88 7.8% 87 1.7% 85 2.7% 85 1.3% 85 1.0% 86 2.0% 
4-Fluoroethcathinone      55 5.5% 57 5.5% 57 1.2% 55 1.5% 55 2.2% 56 2.2% 56 2.4% 
2-Fluoroethcathinone  148.0570 40 100 0.0%                         
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3-Fluoroethcathinone     100 0.0%                   
4-Fluoroethcathinone      100 0.0%                         
                 
Fluoromethamphetamine Regioisomers 
Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
2-Fluoromethamphetamine  109.0448 10 100 0.0%                         
3-Fluoromethamphetamine      100 0.0%                   
4-Fluoromethamphetamine      100 0.0%                         
2-Fluoromethamphetamine  137.0761 10 26 3.1% 29 4.6% 29 2.2% 32 1.7% 32 1.4% 32 2.6% 31 2.5% 
3-Fluoromethamphetamine      25 5.1% 31 3.2% 30 2.1% 34 1.2% 34 1.5% 35 1.2% 33 1.8% 
4-Fluoromethamphetamine      50 6.7% 62 4.7% 62 1.6% 69 0.9% 70 1.3% 72 1.6% 68 1.9% 
2-Fluoromethamphetamine  168.1183 10 38 8.9% 45 5.8% 45 2.4% 53 1.5% 52 0.9% 52 2.0% 51 1.5% 
3-Fluoromethamphetamine      34 6.8% 51 4.9% 49 2.4% 60 2.7% 60 2.3% 62 1.4% 57 1.2% 
4-Fluoromethamphetamine      18 9.9% 28 6.2% 27 2.2% 32 2.1% 32 1.8% 35 3.4% 31 2.2% 
2-Fluoromethamphetamine  109.0448 20 100 0.0%                         
3-Fluoromethamphetamine      100 0.0%                   
4-Fluoromethamphetamine      100 0.0%                         
2-Fluoromethamphetamine  83.0292 40 56 8.7% 54 4.4% 53 1.0% 45 1.8% 45 2.2% 46 1.5% 47 1.4% 
3-Fluoromethamphetamine      70 3.9% 63 5.6% 61 0.9% 52 1.4% 52 2.1% 53 1.2% 53 2.5% 
4-Fluoromethamphetamine      56 5.6% 50 4.8% 49 1.4% 42 1.2% 42 1.1% 43 2.5% 43 2.5% 
2-Fluoromethamphetamine  109.0448 40 100 0.0%                         
3-Fluoromethamphetamine      100 0.0%                   
4-Fluoromethamphetamine      100 0.0%                         
                 
Fluoromethcathinone Regioisomers Reproducibility Concentration Mobile Phase 
Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
4-Fluoromethcathinone 
149.0635 10 
22 6.3% 19 6.1% 18 2.0% 27 1.5% 18 1.3% 19 2.9% 20 1.3% 
2-Fluoromethcathinone 24 9.2% 22 13.3% 21 3.2% 22 3.1% 22 3.1% 23 2.5% 22 1.0% 
3-Fluoromethcathinone 27 5.2% 23 4.2% 22 1.0% 25 7.2% 25 5.4% 25 3.5% 25 1.9% 
4-Fluoromethcathinone 
164.0870 10 
100 0.0%                         
2-Fluoromethcathinone 100 0.0%                    
3-Fluoromethcathinone 100 0.0%                         
4-Fluoromethcathinone 182.0976 10 20 8.7% 27 6.6% 25 1.2% 27 1.5% 27 2.6% 29 2.4% 27 1.6% 
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2-Fluoromethcathinone 36 7.4% 42 11.9% 40 2.1% 44 0.8% 43 1.7% 45 1.3% 42 1.5% 
3-Fluoromethcathinone 31 7.0% 40 2.0% 39 1.3% 37 3.5% 37 0.5% 36 4.1% 36 3.3% 
4-Fluoromethcathinone 
123.0605 20 
20 7.0% 22 8.3% 20 2.1% 20 1.8% 19 1.6% 21 1.6% 20 1.1% 
2-Fluoromethcathinone 19 4.3% 20 14.0% 19 4.7% 19 3.2% 19 2.6% 19 1.4% 18 4.4% 
3-Fluoromethcathinone 15 6.4% 16 5.1% 15 2.0% 16 1.7% 15 3.3% 15 4.4% 16 2.6% 
4-Fluoromethcathinone 
148.0557 20 
19 7.2% 17 6.6% 16 2.7% 15 1.9% 14 1.0% 15 2.4% 16 3.1% 
2-Fluoromethcathinone 18 10.2% 17 23.1% 16 3.6% 16 1.9% 15 2.5% 16 4.2% 16 2.2% 
3-Fluoromethcathinone 24 2.7% 22 4.6% 21 1.2% 23 4.3% 24 7.3% 23 1.8% 24 2.5% 
4-Fluoromethcathinone 
149.0635 20 
100 0.0%                         
2-Fluoromethcathinone 100 0.0%                    
3-Fluoromethcathinone 100 0.0%                         
4-Fluoromethcathinone 
164.0870 20 
37 4.5%                         
2-Fluoromethcathinone 35 7.9%                    
3-Fluoromethcathinone 31 4.4%                         
4-Fluoromethcathinone 
77.0386 40 
47 4.2% 47 10.7% 43 2.2% 40 1.1% 39 1.6% 41 2.1% 41 3.6% 
2-Fluoromethcathinone 45 8.0% 44 19.7% 42 5.4% 38 2.5% 37 1.2% 39 3.5% 38 2.2% 
3-Fluoromethcathinone 38 3.9% 35 7.2% 34 2.0% 37 4.4% 37 1.5% 37 1.8% 36 1.9% 
4-Fluoromethcathinone 
103.0542 40 
29 9.4% 31 10.4% 29 1.6% 28 2.6% 29 2.2% 30 3.7% 29 2.2% 
2-Fluoromethcathinone 21 4.5% 24 27.4% 22 4.9% 22 4.3% 21 2.4% 22 4.8% 22 1.4% 
3-Fluoromethcathinone 17 9.4% 18 8.7% 18 2.4% 12 5.3% 18 3.8% 18 1.4% 18 4.4% 
4-Fluoromethcathinone 
148.0557 40 
100 0.0%                         
2-Fluoromethcathinone 100 0.0%                    
3-Fluoromethcathinone 100 0.0%                         
4-Fluoromethcathinone 
149.0635 40 
16 9.9% 18 10.3% 17 2.4% 21 3.4% 20 1.7% 22 1.7% 21 1.6% 
2-Fluoromethcathinone 16 8.0% 20 34.9% 17 2.8% 20 4.5% 19 3.6% 20 3.0% 20 1.4% 
3-Fluoromethcathinone 10 8.1% 12 7.3% 12 2.0% 12 4.8% 11 8.4% 12 4.8% 11 4.8% 
                 
JWH 203 Regioisomers Reproducibility 
Concentration Mobile Phase 
Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
JWH 203 3-chlorophenyl isomer 
340.1463 10 
100 0.0%                         
JWH 203 4-chlorophenyl isomer 100 0.0%                    
JWH 203 100 0.0%                         
JWH 203 3-chlorophenyl isomer 125.0153 20 91 6.3%                         
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JWH 203 4-chlorophenyl isomer 94 3.1%                    
JWH 203 85 4.1%                         
JWH 203 3-chlorophenyl isomer 
188.1434 20 
47 6.1% 39 9.5% 39 1.6% 34 20.2% 32 11.1% 48 3.6% 47 2.2% 
JWH 203 4-chlorophenyl isomer 29 3.5% 26 2.0% 24 1.4% 30 5.6% 29 2.2% 30 1.2% 29 1.9% 
JWH 203 22 3.7% 22 5.5% 20 1.1% 26 27.1% 25 3.4% 22 4.8% 22 4.3% 
JWH 203 3-chlorophenyl isomer 
214.1226 20 
61 4.0% 50 8.5% 48 1.9% 35 12.5% 29 9.4% 64 2.4% 63 3.6% 
JWH 203 4-chlorophenyl isomer 22 6.2% 18 2.7% 17 2.0% 23 3.0% 23 0.9% 23 2.6% 23 1.4% 
JWH 203 11 3.8% 11 6.4% 11 1.5% 13 10.2% 16 9.1% 13 4.7% 13 3.5% 
JWH 203 3-chlorophenyl isomer 
340.1463 20 
100 1.2%                         
JWH 203 4-chlorophenyl isomer 100 0.1%                    
JWH 203 100 0.0%                         
JWH 203 3-chlorophenyl isomer 
125.0153 40 
100 0.0%                         
JWH 203 4-chlorophenyl isomer 100 0.0%                    
JWH 203 100 0.0%                         
JWH 203 3-chlorophenyl isomer 
144.0444 40 
45 6.2% 42 7.3% 43 1.3% 21 22.2% 20 6.7% 44 4.3% 43 3.9% 
JWH 203 4-chlorophenyl isomer 17 4.0% 17 4.6% 16 1.1% 18 2.5% 17 4.8% 17 2.7% 17 1.8% 
JWH 203 10 3.5% 10 5.4% 10 1.7% 11 30.4% 13 10.2% 11 4.5% 11 3.8% 
JWH 203 3-chlorophenyl isomer 
214.1226 40 
25 8.7% 26 10.1% 26 2.7% 13 24.1% 12 4.5% 24 2.6% 24 4.6% 
JWH 203 4-chlorophenyl isomer 10 4.5% 11 6.0% 10 1.2% 10 10.4% 9 1.8% 9 4.0% 10 1.5% 
JWH 203 7 5.4% 6 10.0% 6 2.4% 6 54.6% 7 10.6% 6 2.8% 6 4.0% 
                 
JWH 251 Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
JWH 251 3-methylphenyl isomer 320.2009 10 100 0.0%                         
JWH 251 4-methylphenyl isomer     100 0.0%                   
JWH-251     100 0.0%                         
JWH 251 3-methylphenyl isomer 105.0699 20 99 2.7%                   
JWH 251 4-methylphenyl isomer     100 0.0%                   
JWH-251     100 0.0%                   
JWH 251 3-methylphenyl isomer 188.1434 20 21 8.9% 22 8.6% 21 1.6% 15 17.8% 16 4.5% 20 1.5% 19 4.0% 
JWH 251 4-methylphenyl isomer     13 11.2% 14 9.7% 13 1.9% 13 15.1% 14 10.6% 12 3.9% 12 3.5% 
JWH-251     12 10.0% 12 7.2% 11 1.5% 13 12.6% 12 8.0% 11 2.7% 11 8.5% 
JWH 251 3-methylphenyl isomer 214.1266 20 95 4.5% 95 4.3% 98 1.1% 82 10.0% 89 4.8% 98 2.3% 98 1.8% 
JWH 251 4-methylphenyl isomer     50 5.5% 50 5.4% 49 1.4% 67 4.2% 74 6.8% 50 2.4% 50 3.2% 
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JWH-251     81 4.6% 77 4.0% 75 1.2% 85 5.1% 81 6.2% 83 0.4% 85 7.1% 
JWH 251 3-methylphenyl isomer 320.2009 20 66 4.0% 79 6.1% 83 1.3% 70 5.9% 74 4.0% 61 1.8% 60 1.6% 
JWH 251 4-methylphenyl isomer     80 6.0% 95 3.6% 100 0.2% 67 3.5% 73 6.9% 73 1.4% 72 2.7% 
JWH-251     90 4.8% 100 0.0% 100 0.0% 87 6.1% 79 3.3% 80 1.7% 81 8.0% 
JWH 251 3-methylphenyl isomer 43.0542 40 17 16.5% 15 9.6% 14 1.9% 10 20.2% 9 22.7% 12 3.4% 13 6.1% 
JWH 251 4-methylphenyl isomer     7 25.3% 7 23.5% 7 3.0% 7 35.2% 9 17.0% 6 3.2% 6 6.5% 
JWH-251     12 10.8% 11 9.7% 10 2.7% 7 22.9% 8 18.6% 9 3.7% 9 4.2% 
JWH 251 3-methylphenyl isomer 105.0699 40 99 1.8%                   
JWH 251 4-methylphenyl isomer     100 0.0%                   
JWH-251     100 0.0%                   
JWH 251 3-methylphenyl isomer 144.0444 40 95 5.3% 92 5.6% 94 0.9% 84 11.9% 77 1.8% 95 3.2% 97 1.8% 
JWH 251 4-methylphenyl isomer     46 7.7% 46 5.4% 45 1.2% 68 8.6% 69 4.7% 47 2.9% 47 1.1% 
JWH-251     72 5.7% 70 3.5% 68 1.1% 68 3.8% 69 7.0% 69 2.7% 69 4.9% 
JWH 251 3-methylphenyl isomer 214.1226 40 44 5.7% 47 6.2% 47 1.1% 39 3.8% 38 4.0% 42 4.4% 42 2.5% 
JWH 251 4-methylphenyl isomer     22 7.0% 24 10.2% 23 1.9% 29 9.0% 32 5.8% 21 0.6% 21 1.4% 
JWH-251     35 6.3% 38 4.8% 37 1.0% 35 13.2% 34 3.5% 33 2.6% 34 4.1% 
                 
Methoxymethcathinone Regioisomers Reproducibility 
Concentration Mobile Phase 
Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
Methedrone 
161.0835 10 
17 6.3% 17 5.6% 17 2.3% 15 1.9% 16 0.7% 16 3.0% 16 1.5% 
2-Methoxymethcathinone 25 5.8% 23 3.8% 22 2.1% 21 1.8% 21 3.1% 22 1.5% 22 0.9% 
3-Methoxymethcathinone 28 6.6% 26 4.6% 25 1.8% 25 1.4% 26 1.4% 25 0.6% 25 1.5% 
Methedrone 
176.1070 10 
100 0.0%                         
2-Methoxymethcathinone 100 0.0%                    
3-Methoxymethcathinone 100 0.0%                    
Methedrone 
194.1176 10 
17 6.6% 19 6.0% 18 4.6% 20 0.8% 21 1.6% 21 1.0% 20 2.9% 
2-Methoxymethcathinone 15 7.9% 18 6.2% 17 1.4% 18 1.8% 18 2.4% 18 0.8% 17 1.8% 
3-Methoxymethcathinone 28 6.0% 34 4.1% 32 1.2% 34 1.6% 35 0.3% 35 0.6% 34 0.6% 
Methedrone 
135.0804 20 
21 2.3% 20 2.6% 20 1.2% 19 2.8% 19 2.5% 20 3.2% 20 2.6% 
2-Methoxymethcathinone 13 2.0% 13 11.5% 13 1.6% 13 2.0% 12 1.1% 13 2.3% 12 3.0% 
3-Methoxymethcathinone 11 4.8% 12 8.0% 11 2.0% 11 3.1% 10 1.5% 11 3.0% 11 1.7% 
Methedrone 
145.0886 20 
29 4.3% 29 2.4% 28 0.9% 28 2.4% 28 2.1% 29 1.0% 28 2.3% 
2-Methoxymethcathinone 27 3.9% 25 6.3% 25 2.1% 24 2.9% 24 2.2% 24 2.1% 24 0.9% 
3-Methoxymethcathinone 21 2.5% 21 4.1% 20 1.2% 20 1.6% 20 1.3% 21 1.8% 20 1.5% 
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Methedrone 
146.0600 20 
34 8.6%                         
2-Methoxymethcathinone 28 7.2%                    
3-Methoxymethcathinone 30 7.3%                         
Methedrone 
161.0835 20 
100 0.0%                         
2-Methoxymethcathinone 100 0.0%                    
3-Methoxymethcathinone 100 0.0%                         
Methedrone 
176.1070 20 
44 2.2% 45 2.1% 46 2.4% 52 1.6% 52 1.8% 54 1.0% 52 1.2% 
2-Methoxymethcathinone 31 5.1% 33 7.9% 32 2.3% 35 1.7% 35 1.3% 35 2.0% 35 2.3% 
3-Methoxymethcathinone 29 3.6% 31 5.2% 31 1.2% 34 0.8% 33 1.9% 35 1.8% 33 1.0% 
Methedrone 
58.0651 40 
28 5.1% 28 6.9% 27 2.6% 24 3.2% 23 3.2% 25 2.7% 25 5.3% 
2-Methoxymethcathinone 16 10.6% 17 18.7% 16 4.6% 14 3.0% 15 3.4% 15 2.6% 15 3.7% 
3-Methoxymethcathinone 6 7.8% 5 24.6% 5 4.2% 5 2.8% 5 4.4% 5 2.3% 5 6.2% 
Methedrone 
77.0386 40 
46 5.4% 45 2.2% 43 1.8% 38 2.2% 38 1.3% 39 4.8% 40 2.8% 
2-Methoxymethcathinone 35 4.2% 33 9.8% 32 3.2% 32 5.0% 31 0.9% 31 1.0% 32 2.7% 
3-Methoxymethcathinone 31 2.4% 29 9.2% 28 2.8% 26 2.9% 26 2.4% 27 3.6% 27 2.6% 
Methedrone 
79.0542 40 
29 3.9% 29 3.2% 28 2.1% 25 3.0% 25 2.6% 26 3.0% 26 2.2% 
2-Methoxymethcathinone 17 7.2% 17 16.7% 17 4.2% 16 2.0% 16 3.4% 15 6.3% 16 1.8% 
3-Methoxymethcathinone 15 5.3% 15 7.8% 14 2.7% 13 2.9% 13 2.7% 14 4.0% 14 3.0% 
Methedrone 
91.0542 40 
35 2.0% 35 2.8% 34 1.7% 31 2.6% 30 1.6% 32 0.6% 32 2.7% 
2-Methoxymethcathinone 30 7.2% 27 11.9% 28 3.5% 26 3.0% 27 4.1% 27 3.7% 27 1.4% 
3-Methoxymethcathinone 30 3.5% 27 8.7% 27 2.9% 26 1.8% 26 2.7% 26 2.9% 26 2.9% 
Methedrone 
103.0542 40 
27 3.3% 27 2.7% 26 1.8% 25 2.9% 25 1.3% 26 3.1% 26 3.1% 
2-Methoxymethcathinone 15 5.2% 15 14.9% 15 4.4% 14 4.0% 14 3.8% 15 2.8% 15 2.3% 
3-Methoxymethcathinone 14 3.8% 14 13.4% 13 2.7% 13 2.7% 13 2.9% 13 2.9% 13 3.5% 
Methedrone 
105.0699 40 
19 9.0% 19 3.1% 18 2.8% 18 4.5% 18 3.0% 19 2.8% 19 5.1% 
2-Methoxymethcathinone 9 10.3% 10 18.7% 9 5.0% 9 4.5% 9 2.8% 9 6.8% 9 1.9% 
3-Methoxymethcathinone 7 6.4% 8 18.2% 7 1.8% 7 5.4% 7 2.9% 7 1.7% 7 2.6% 
Methedrone 
117.0573 40 
19 9.4% 19   18 1.7% 16 4.5% 16 3.3% 17 2.5% 17 1.8% 
2-Methoxymethcathinone 29 7.8% 27 7.9% 27 2.9% 26 4.5% 26 1.9% 27 0.6% 27 2.1% 
3-Methoxymethcathinone 28 7.7% 27 6.8% 26 2.0% 25 3.7% 24 1.1% 25 3.2% 25 1.2% 
Methedrone 
118.0651 40 
100 0.0%                         
2-Methoxymethcathinone 100 0.0%                    
3-Methoxymethcathinone 100 0.0%                         
Methedrone 132.0808 40 33 3.6% 33 2.0% 32 1.5% 31 2.6% 31 3.6% 33 2.4% 33 2.8% 
2-Methoxymethcathinone 51 3.8% 51 7.2% 51 2.6% 51 2.6% 52 1.2% 52 1.8% 51 1.6% 
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3-Methoxymethcathinone 59 1.5% 59 5.9% 58 0.8% 58 1.1% 58 2.2% 58 0.5% 58 1.6% 
Methedrone 
144.0808 40 
37 4.7% 37 2.5% 35 1.7% 37 1.9% 36 1.2% 37 3.2% 37 1.7% 
2-Methoxymethcathinone 44 6.7% 45 8.9% 44 1.8% 45 3.7% 46 2.8% 45 2.0% 45 2.8% 
3-Methoxymethcathinone 23 4.3% 23 10.0% 22 2.0% 23 2.8% 22 1.4% 23 1.4% 22 1.5% 
Methedrone 
146.0600 40 
95 2.6% 95 2.7% 93 3.0% 100 0.0% 100 0.0% 100 0.0% 99 0.5% 
2-Methoxymethcathinone 50 4.6% 54 10.1% 54 2.0% 55 2.5% 55 2.4% 55 2.8% 54 1.4% 
3-Methoxymethcathinone 42 4.5% 44 6.7% 43 1.5% 45 1.0% 45 1.9% 46 1.1% 45 2.3% 
Methedrone 
160.0757 40 
7 10.5% 8 11.2% 7 2.8% 8 4.2% 7 3.7% 8 8.3% 8 0.8% 
2-Methoxymethcathinone 22 5.1% 23 12.7% 22 3.8% 22 2.6% 22 3.6% 22 1.8% 22 2.0% 
3-Methoxymethcathinone 11 7.6% 12 12.3% 11 3.0% 11 2.5% 11 1.2% 11 2.2% 11 4.5% 
                 
Methoxy-N,N-dimethyltryptamine Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
5-MeO-DMT 58.0651 10 100 0.0%                         
4-MeO-DMT     100 0.0%                         
5-MeO-DMT 174.0913 10 71 3.6% 68 2.3% 69 1.3% 80 1.9% 84 0.9% 79 1.6% 80 1.1% 
4-MeO-DMT     34 3.9% 34 4.8% 34 1.4% 39 1.7% 40 1.0% 40 0.7% 39 0.6% 
5-MeO-DMT 219.1492 10 20 6.8% 24 4.8% 23 2.6% 28 2.2% 29 0.9% 28 1.9% 27 2.2% 
4-MeO-DMT     35 8.5% 41 4.5% 41 2.1% 49 0.9% 49 2.1% 48 1.4% 48 0.4% 
5-MeO-DMT 58.0651 20 100 0.0%                         
4-MeO-DMT     100 0.0%                         
5-MeO-DMT 159.0679 20 14 2.9% 13 7.9% 13 2.1% 14 3.5% 15 1.8% 15 2.4% 15 1.5% 
4-MeO-DMT     7 4.5% 7 5.0% 6 2.2% 7 2.6% 7 1.9% 7 1.5% 7 1.5% 
5-MeO-DMT 174.0913 20 73 5.5% 73 2.5% 74 1.0% 83 2.0% 88 0.7% 81 1.3% 82 0.8% 
4-MeO-DMT     34 3.4% 35 5.1% 35 1.1% 39 1.6% 39 1.8% 39 1.3% 39 1.5% 
5-MeO-DMT 58.0651 40 100 0.0%                         
4-MeO-DMT     100 0.0%                         
5-MeO-DMT 130.0651 40 47 2.5% 43 6.1% 44 2.3% 49 1.6% 50 0.9% 49 2.2% 50 2.7% 
4-MeO-DMT     14 7.0% 11 9.9% 12 2.6% 14 2.3% 13 1.0% 14 2.3% 14 2.1% 
5-MeO-DMT 131.0730 40 41 3.1% 40 5.3% 39 1.2% 44 1.7% 44 1.2% 44 2.5% 44 0.8% 
4-MeO-DMT     8 6.5% 7 7.1% 8 1.8% 9 2.1% 9 2.1% 9 2.5% 9 1.7% 
5-MeO-DMT 143.0730 40 17 4.6% 17 9.5% 17 1.7% 18 2.1% 18 1.9% 19 2.9% 18 2.3% 
4-MeO-DMT     10 5.5% 10 12.8% 9 2.9% 10 2.3% 10 4.2% 10 3.4% 10 3.1% 
5-MeO-DMT 159.0679 40 21 4.9% 23 10.6% 22 1.9% 24 2.5% 24 2.3% 24 1.6% 23 2.2% 
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4-MeO-DMT     17 2.2% 17 9.0% 17 0.9% 18 2.0% 18 1.3% 18 2.3% 18 2.3% 
                 
Methylenedioxymethcathinone  Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
Methylone 58.0651 10 13 6.6% 13 10.0% 13 1.8% 11 4.8% 10 4.7% 11 2.1% 11 2.5% 
2,3-Methylenedioxymethcathinone     3 10.0% 3 11.8% 3 3.4% 2 3.9% 2 1.4% 2 7.3% 2 3.5% 
Methylone 160.0757 10 100 0.0%                         
2,3-Methylenedioxymethcathinone     100 0.0%                   
Methylone 190.0863 10 68 2.8% 73 4.4% 72 1.3% 69 1.3% 68 1.6% 67 1.1% 67 1.1% 
2,3-Methylenedioxymethcathinone      19 2.7% 20 4.3% 19 1.7% 19 0.8% 19 1.2% 18 2.7% 18 1.3% 
Methylone 208.0968 10 37 6.0% 55 5.7% 54 1.2% 54 4.1% 53 1.7% 54 1.9% 52 2.3% 
2,3-Methylenedioxymethcathinone     45 4.5% 44 4.6% 43 1.3% 43 0.9% 45 0.8% 44 1.0% 42 1.1% 
Methylone 132.0808 20 33 4.8% 32 6.8% 30 1.3% 30 4.7% 29 1.5% 30 1.5% 30 0.6% 
2,3-Methylenedioxymethcathinone      50 4.4% 45 3.4% 44 1.9% 42 1.0% 44 0.5% 42 1.2% 43 0.9% 
Methylone 160.0747 20 100 0.0%                         
2,3-Methylenedioxymethcathinone     100 0.0%                   
Methylone 58.0651 40 12 5.5% 19 12.9% 18 2.4% 17 3.1% 16 2.9% 17 5.6% 17 3.4% 
2,3-Methylenedioxymethcathinone     20 5.0% 12 9.4% 11 3.2% 11 2.9% 10 1.5% 10 3.6% 11 1.9% 
Methylone 65.0386 40 29 5.8%                         
2,3-Methylenedioxymethcathinone     23 6.4%                   
Methylone 91.0542 40 58 1.8% 52 6.5% 53 1.4% 54 2.8% 51 2.1% 52 2.8% 53 2.5% 
2,3-Methylenedioxymethcathinone      65 2.4% 64 6.6% 63 1.5% 63 1.5% 62 1.4% 63 1.9% 63 3.2% 
Methylone 117.0573 40 81 2.0% 75 7.0% 77 2.0% 75 3.0% 75 1.1% 74 3.2% 76 1.7% 
2,3-Methylenedioxymethcathinone      100 0.0% 100 0.9% 100 0.0% 100 0.0% 100 0.0% 100 0.5% 100 0.8% 
Methylone 131.0730 40 36 4.2% 24 10.2% 24 2.8% 25 2.4% 25 2.3% 25 4.7% 25 2.5% 
2,3-Methylenedioxymethcathinone     27 6.0% 35 8.1% 34 6.0% 36 1.3% 36 1.6% 36 1.2% 36 0.9% 
Methylone 132.0808 40 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
2,3-Methylenedioxymethcathinone      90 3.5% 95 3.6% 94 1.5% 97 2.0% 99 1.1% 98 1.7% 98 2.1% 
Methylone 160.0747 40 10 5.8% 18 8.3% 17 2.3% 17 6.3% 17 4.5% 17 3.7% 18 3.6% 
2,3-Methylenedioxymethcathinone      17 4.8% 11 12.5% 10 3.4% 11 2.6% 11 2.3% 11 2.9% 11 4.1% 
                 
Methylenedioxy Pyrovalerone   Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
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Methylenedioxy Pyrovalerone   276.1594 10 100 0.0%                         
2,3-Methylenedioxy Pyrovalerone    100 0.0%                    
Methylenedioxy Pyrovalerone   126.1277 20 69 11.6% 61 4.1% 59 1.4% 67 2.6% 67 2.2% 65 2.9% 68 1.0% 
2,3-Methylenedioxy Pyrovalerone    34 3.6% 34 4.5% 33 1.1% 35 2.1% 35 1.6% 33 3.3% 36 3.5% 
Methylenedioxy Pyrovalerone   135.0441 20 54 4.9% 46 3.9% 45 1.1% 54 3.6% 55 5.2% 52 1.7% 55 1.9% 
2,3-Methylenedioxy Pyrovalerone     100 0.0% 97 2.8% 95 1.2% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
Methylenedioxy Pyrovalerone   147.0804 20 5 4.9%                         
2,3-Methylenedioxy Pyrovalerone     8 13.4%                         
Methylenedioxy Pyrovalerone   149.0233 20 28 12.2% 24 6.4% 23 1.5% 28 2.0% 28 4.1% 26 3.0% 27 4.4% 
2,3-Methylenedioxy Pyrovalerone    7 4.7% 7 13.3% 7 2.7% 8 0.9% 8 7.5% 8 3.1% 8 4.2% 
Methylenedioxy Pyrovalerone   175.0754 20 76 4.8%                         
2,3-Methylenedioxy Pyrovalerone     68 3.2%                         
Methylenedioxy Pyrovalerone   205.0858 20 67 4.5% 60 2.6% 59 0.8% 66 2.9% 65 4.1% 64 2.9% 65 0.8% 
2,3-Methylenedioxy Pyrovalerone     10 4.9% 10 8.9% 9 2.0% 10 6.1% 10 4.4% 9 2.8% 10 3.5% 
Methylenedioxy Pyrovalerone   276.1594 20 100 1.9%                         
2,3-Methylenedioxy Pyrovalerone     90 6.0%                         
Methylenedioxy Pyrovalerone   65.0386 40 19 16.0%                         
2,3-Methylenedioxy Pyrovalerone     14 8.1%                         
Methylenedioxy Pyrovalerone   84.0808 40 23 5.6% 30 12.6% 31 1.8% 30 1.5% 30 1.6% 30 1.8% 30 1.5% 
2,3-Methylenedioxy Pyrovalerone     32 2.4% 22 6.1% 22 1.3% 22 2.6% 21 3.2% 22 3.9% 22 0.6% 
Methylenedioxy Pyrovalerone   121.0284 40 4 7.4% 32 6.4% 31 1.8% 33 1.8% 33 2.5% 33 2.4% 33 2.0% 
2,3-Methylenedioxy Pyrovalerone     33 3.4% 4 13.2% 4 4.3% 4 4.9% 4 3.7% 4 1.7% 4 4.2% 
Methylenedioxy Pyrovalerone   126.1277 40 100 0.0% 100 0.0% 100 0.0% 83 3.0% 81 3.5% 83 1.4% 82 3.2% 
2,3-Methylenedioxy Pyrovalerone    90 3.7% 90 5.8% 90 1.1% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
Methylenedioxy Pyrovalerone   135.0441 40 81 5.0% 81 7.5% 80 1.2% 83 3.0% 81 3.5% 83 1.4% 82 3.2% 
2,3-Methylenedioxy Pyrovalerone     100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
Methylenedioxy Pyrovalerone   149.0233 40 69 4.6% 67 7.8% 67 1.1% 70 1.1% 70 2.3% 70 1.5% 69 1.0% 
2,3-Methylenedioxy Pyrovalerone     38 4.3% 37 4.1% 37 1.4% 38 3.3% 38 2.8% 38 2.5% 38 2.8% 
Methylenedioxy Pyrovalerone   175.0754 40 15 5.5%                         
2,3-Methylenedioxy Pyrovalerone     15 6.9%                         
                 
Methylethcathinone Regioisomer Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
4-Methylethcathinone  145.0886 10 16 6.3%                         
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3-Methylethcathinone     18 6.4%                   
4-Methylethcathinone  146.0964 10 22 5.4%                         
3-Methylethcathinone     24 4.2%                   
4-Methylethcathinone  174.1277 10 100 0.0%                         
3-Methylethcathinone     100 0.0%                   
4-Methylethcathinone  192.1383 10 32 5.7% 42 5.0% 40 1.0% 42 3.3% 44 0.7% 41 1.3% 41 0.6% 
3-Methylethcathinone     44 6.2% 56 4.0% 55 0.6% 57 1.1% 60 1.5% 57 1.2% 56 0.4% 
4-Methylethcathinone  119.0855 20 36 6.1% 34 8.7% 33 2.9% 32 2.2% 31 1.5% 32 2.0% 32 2.1% 
3-Methylethcathinone      32 4.5% 32 6.9% 30 2.7% 29 2.8% 29 1.0% 29 2.8% 30 1.3% 
4-Methylethcathinone  131.0730 20 29 5.3%                         
3-Methylethcathinone      30 5.4%                         
4-Methylethcathinone  144.0808 20 45 4.6%                         
3-Methylethcathinone      48 6.5%                         
4-Methylethcathinone  145.0886 20 100 0.0%                         
3-Methylethcathinone      100 0.0%                         
4-Methylethcathinone  146.0964 20 68 4.3%                         
3-Methylethcathinone      65 4.3%                         
4-Methylethcathinone  159.1043 20 34 7.6%                         
3-Methylethcathinone      34 5.1%                         
4-Methylethcathinone  174.1277 20 43 6.3% 53 7.3% 52 1.3% 57 0.7% 57 1.2% 56 1.4% 55 1.3% 
3-Methylethcathinone     38 5.5% 49 5.2% 47 1.9% 51 1.9% 51 1.4% 51 0.8% 50 1.7% 
4-Methylethcathinone  77.0386 40 15 8.0%                         
3-Methylethcathinone      13 9.2%                         
4-Methylethcathinone  91.0542 40 59 5.6% 54 5.9% 55 1.9% 51 1.2% 51 1.8% 53 2.0% 52 2.0% 
3-Methylethcathinone      52 3.7% 51 5.8% 48 1.3% 46 1.8% 45 1.7% 46 1.5% 46 1.2% 
4-Methylethcathinone  115.0542 40 17 11.0%                         
3-Methylethcathinone      15 9.4%                         
4-Methylethcathinone  130.0651 40 43 6.9%                         
3-Methylethcathinone      47 6.4%                         
4-Methylethcathinone  131.0730 40 18 7.5%                         
3-Methylethcathinone      19 7.2%                         
4-Methylethcathinone  144.0808 40 100 0.0%                         
3-Methylethcathinone      100 0.0%                         
                 
RCS-4 Regioisomers Reproducibility Concentration Mobile Phase 
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      Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
RCS-4 2-methoxy isomer 135.0441 10 22 2.5% 22 2.8% 20 1.5% 42 5.0% 41 1.8% 41 1.1% 42 1.0% 
RCS-4 3-methoxy isomer    8 3.3% 8 6.8% 7 1.9% 35 7.5% 31 3.1% 15 1.7% 16 3.0% 
RCS-4     11 3.0% 11 5.0% 11 2.9% 35 4.4% 31 4.4% 24 3.6% 24 2.8% 
RCS-4 2-methoxy isomer 322.1802 10 100 0.0%                         
RCS-4 3-methoxy isomer    100 0.0%                   
RCS-4     100 0.0%                         
RCS-4 2-methoxy isomer 135.0441 20 100 0.0%                         
RCS-4 3-methoxy isomer    100 0.0%                   
RCS-4     100 0.0%                         
RCS-4 2-methoxy isomer 322.1802 20 13 2.9% 13 4.9% 12 1.4% 10 5.3% 10 4.1% 9 1.5% 9 2.1% 
RCS-4 3-methoxy isomer    51 2.2% 52 3.0% 53 1.1% 16 9.5% 18 5.6% 38 1.4% 37 2.4% 
RCS-4     37 2.4% 37 4.5% 36 1.6% 29 11.5% 31 12.8% 28 4.3% 29 7.0% 
RCS-4 2-methoxy isomer 77.0386 40 33 1.6% 38 2.7% 36 2.1% 36 3.0% 37 4.8% 36 2.3% 37 1.6% 
RCS-4 3-methoxy isomer     64 3.4% 67 6.0% 65 2.1% 44 7.1% 45 6.5% 64 2.4% 65 3.4% 
RCS-4     30 3.7% 32 7.5% 29 4.6% 40 15.9% 38 9.0% 39 2.5% 39 2.7% 
RCS-4 2-methoxy isomer 92.0257 40 4 15.0% 5 10.8% 4 2.5% 5 16.1% 5 7.4% 4 7.7% 4 2.8% 
RCS-4 3-methoxy isomer    15 3.6% 16 9.0% 16 2.6% 7 11.5% 7 5.3% 17 1.1% 16 4.0% 
RCS-4     6 6.4% 6 5.6% 6 4.5% 6 28.6% 8 7.8% 9 9.4% 9 7.7% 
RCS-4 2-methoxy isomer 107.0491 40 1 9.0% 1 37.8% 1 4.0% 1 47.0% 2 22.4% 1 2.8% 1 14.7% 
RCS-4 3-methoxy isomer    100 0.0% 100 0.0% 98 9.5% 17 24.7% 24 11.8% 100 0.0% 100 0.0% 
RCS-4     24 3.3% 24 4.0% 22 1.9% 27 6.2% 28 18.7% 26 2.2% 27 6.1% 
RCS-4 2-methoxy isomer 135.0441 40 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
RCS-4 3-methoxy isomer    82 2.2% 79 5.0% 78 1.4% 100 0.0% 100 0.0% 75 2.8% 76 1.7% 
RCS-4     100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
RCS-4 2-methoxy isomer 144.0444 40 1 101.7% 1 56.5% 0 61.8% 1 32.6% 1 54.5% 1 34.5% 1 26.4% 
RCS-4 3-methoxy isomer    17 9.7% 17 9.0% 16 1.7% 4 23.8% 5 4.5% 16 10.1% 16 1.5% 
RCS-4     6 22.5% 6 4.3% 6 2.1% 3 37.1% 5 19.8% 6 5.1% 6 14.4% 
                 
RCS-8 Regioisomers Reproducibility Concentration Mobile Phase 
  Low High  H20 5 mM AF Acetonitrile Methanol 
Compound Ion CE Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD Mean RSD 
RCS-8 3-methoxy isomer 376.2271 10 100 0.0%                         
RCS-8 4-methoxy isomer    100 0.0%                    
RCS-8    100 0.0%                    
244 
 
RCS-8 3-methoxy isomer 121.0648 20 76 2.5% 76 3.6% 72 0.8% 100 0.0% 100 0.0% 89 2.0% 90 0.8% 
RCS-8 4-methoxy isomer    34 3.1% 35 4.5% 32 1.4% 89 5.5% 85 3.9% 40 2.2% 42 1.8% 
RCS-8    100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
RCS-8 3-methoxy isomer 228.1747 20 29 2.3% 29 6.7% 27 1.0% 24 7.2% 23 5.1% 32 1.7% 32 1.7% 
RCS-8 4-methoxy isomer    2 5.7% 2 18.2% 1 26.6% 19 10.0% 18 8.7% 2 7.9% 2 6.7% 
RCS-8     7 3.4% 7 8.0% 7 1.6% 6 15.3% 9 28.9% 7 1.7% 7 4.3% 
RCS-8 3-methoxy isomer 254.1539 20 35 2.1% 35 2.9% 33 1.2% 24 13.5% 25 4.0% 39 1.8% 40 1.4% 
RCS-8 4-methoxy isomer    4 6.3% 4 13.6% 3 3.6% 20 18.7% 21 5.4% 4 2.9% 4 9.0% 
RCS-8    1 13.3% 1 23.4% 1 10.2% 1 79.2% 5 80.1% 1 32.9% 1 9.7% 
RCS-8 3-methoxy isomer 376.2271 20 99 3.6% 100 0.0% 100 0.0% 80 3.1% 84 3.0% 100 0.0% 100 0.0% 
RCS-8 4-methoxy isomer    100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 100 0.0% 
RCS-8    57 2.3% 56 4.3% 57 0.6% 49 8.7% 54 12.8% 46 1.4% 45 1.0% 
RCS-8 3-methoxy isomer 69.0699 40 19 17.9% 18 12.5% 17 4.8% 12 6.4% 12 7.5% 16 3.3% 16 2.3% 
RCS-8 4-methoxy isomer    4 30.3% 4 9.8% 3 2.8% 11 30.4% 10 14.0% 3 12.4% 3 7.3% 
RCS-8    4 38.2% 4 15.0% 4 3.2% 4 56.8% 5 37.7% 4 9.5% 4 4.2% 
RCS-8 3-methoxy isomer 91.0542 40 10 4.5% 10 11.9% 9 1.9% 23 7.4% 22 5.6% 9 1.5% 9 3.9% 
RCS-8 4-methoxy isomer    2 9.3% 2 33.8% 2 3.7% 17 20.3% 15 9.8% 2 6.2% 2 17.4% 
RCS-8     61 3.7% 60 5.7% 59 0.9% 51 23.0% 43 16.1% 55 2.1% 55 2.6% 
RCS-8 3-methoxy isomer 93.0699 40 0 - 0 111.4% 0 - 6 12.9% 6 12.4% 0 - 0 - 
RCS-8 4-methoxy isomer    0 - 0 141.8% 0 - 4 29.6% 4 17.5% 0 - 0 - 
RCS-8     20 16.3% 18 5.4% 18 1.4% 16 13.5% 14 11.0% 17 1.8% 18 3.9% 
RCS-8 3-methoxy isomer 121.0648 40 100 0.0%                         
RCS-8 4-methoxy isomer    100 0.0%                    
RCS-8     100 0.0%                         
RCS-8 3-methoxy isomer 135.0441 40 3 52.9% 3 25.1% 2 4.1% 3 58.8% 4 16.6% 3 4.2% 2 4.7% 
RCS-8 4-methoxy isomer    33 7.0% 32 5.4% 31 0.7% 11 15.5% 12 9.1% 33 4.5% 32 1.4% 
RCS-8     3 28.7% 4 16.8% 4 26.2% 5 13.7% 5 23.8% 4 1.7% 4 4.0% 
RCS-8 3-methoxy isomer 144.0808 40 32 2.3% 30 8.8% 30 1.3% 21 8.3% 22 3.1% 31 3.0% 31 2.4% 
RCS-8 4-methoxy isomer    5 4.8% 5 31.2% 5 2.3% 18 15.6% 17 6.9% 5 5.9% 5 6.7% 
RCS-8    26 3.5% 25 6.2% 25 1.1% 30 17.1% 21 10.1% 25 2.6% 26 3.0% 
RCS-8 3-methoxy isomer 254.1539 40 65 2.7% 62 6.3% 63 0.7% 39 10.5% 41 4.8% 60 1.5% 59 1.1% 
RCS-8 4-methoxy isomer    11 3.4% 10 7.7% 10 1.3% 34 8.0% 33 7.2% 10 5.6% 9 4.7% 
RCS-8     5 5.5% 5 11.9% 5 3.0% 5 11.4% 11 35.5% 5 7.8% 5 6.6% 
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Appendix 22. The relative abundance and the RSD % of all of the ions of interest in the four sets of regioisomers from the reproducibility 
experiment and the solid phase extraction experiment. 
        Reproducibility SPE 
Regioisomer Set Compound Ion CE 
Relative 
Abundance 
Average (%) 
RSD 
Relative 
Abundance 
Average (%) 
RSD 
Fluoroethcathinone  
2-Fluoroethcathinone  
150.0714 10 
26.3 6.1% 35.7 0.1% 
3-Fluoroethcathinone  43.1 6.7% 52.5 1.7% 
4-Fluoroethcathinone  31.1 6.8% 40.9 2.3% 
2-Fluoroethcathinone  
196.1132 10 
84.0 4.0% 98.7 2.2% 
3-Fluoroethcathinone  78.9 4.1% 100.0 0.0% 
4-Fluoroethcathinone  50.0 6.0% 72.8 0.8% 
2-Fluoroethcathinone  
103.0554 20 
19.4 10.9% 22.0 0.6% 
3-Fluoroethcathinone  14.0 11.2% 14.3 2.2% 
4-Fluoroethcathinone  14.7 8.3% 17.0 4.8% 
2-Fluoroethcathinone  
123.0605 20 
42.9 5.2% 42.1 1.8% 
3-Fluoroethcathinone  27.3 9.8% 24.7 1.0% 
4-Fluoroethcathinone  35.5 9.3% 34.2 1.9% 
2-Fluoroethcathinone  
149.0635 20 
82.8 2.4% 78.5 2.9% 
3-Fluoroethcathinone  57.5 6.1% 52.5 2.4% 
4-Fluoroethcathinone  89.2 4.6% 84.9 1.6% 
2-Fluoroethcathinone  
163.0792 20 
15.6 7.3% 14.3 2.2% 
3-Fluoroethcathinone  6.1 10.9% 6.9 4.1% 
4-Fluoroethcathinone  13.8 13.7% 11.4 1.6% 
2-Fluoroethcathinone  
178.1027 20 
52.7 3.1% 61.7 6.8% 
3-Fluoroethcathinone  30.1 7.4% 38.8 1.2% 
4-Fluoroethcathinone  41.3 7.0% 53.2 2.2% 
2-Fluoroethcathinone  
77.0386 40 
60.1 6.3% 58.0 4.7% 
3-Fluoroethcathinone  54.3 9.2% 50.8 4.1% 
4-Fluoroethcathinone  45.0 7.2% 44.0 0.6% 
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2-Fluoroethcathinone  
95.0292 40 
20.2 5.4% 21.0 7.0% 
3-Fluoroethcathinone  22.9 11.3% 22.8 4.8% 
4-Fluoroethcathinone  13.7 10.8% 14.3 3.8% 
2-Fluoroethcathinone  
115.0554 40 
23.2 10.1% 19.8 7.5% 
3-Fluoroethcathinone  14.2 16.6% 13.7 2.1% 
4-Fluoroethcathinone  17.4 8.2% 16.3 0.9% 
2-Fluoroethcathinone  
135.0479 40 
70.8 2.3% 69.5 5.6% 
3-Fluoroethcathinone  85.9 6.5% 82.1 6.6% 
4-Fluoroethcathinone  55.4 5.5% 55.0 0.3% 
JWH 203 
JWH 203 3-chlorophenyl 
isomer 
188.1434 20 
47.0 6.1% 47.2 1.9% 
JWH 203 4-chlorophenyl 
isomer 28.9 3.5% 28.3 2.8% 
JWH 203 21.9 3.7% 21.0 5.1% 
JWH 203 3-chlorophenyl 
isomer 
214.1226 20 
61.3 4.0% 63.8 1.6% 
JWH 203 4-chlorophenyl 
isomer 21.9 6.2% 21.2 4.8% 
JWH 203 11.0 3.8% 12.0 5.3% 
JWH 203 3-chlorophenyl 
isomer 
144.0444 40 
44.8 6.2% 42.5 3.4% 
JWH 203 4-chlorophenyl 
isomer 17.2 4.0% 16.6 0.7% 
JWH 203 10.4 3.5% 10.1 1.1% 
JWH 203 3-chlorophenyl 
isomer 
214.1226 40 
25.0 8.7% 23.5 1.3% 
JWH 203 4-chlorophenyl 
isomer 9.7 4.5% 9.0 2.3% 
JWH 203 7.2 5.4% 5.5 5.5% 
Methoxymethcathinone  
Methedrone 
161.0835 10 
17.3 6.3% 24.5 3.5% 
2-Methoxymethcathinone  24.6 5.8% 32.8 2.2% 
3-Methoxymethcathinone  27.8 6.6% 39.2 0.8% 
Methedrone 194.1176 10 17.3 6.6% 26.8 0.9% 
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2-Methoxymethcathinone  14.7 7.9% 24.5 2.1% 
3-Methoxymethcathinone  28.3 6.0% 41.9 1.8% 
Methedrone 
135.0804 20 
20.6 2.3% 20.4 2.1% 
2-Methoxymethcathinone  13.4 2.0% 12.5 3.9% 
3-Methoxymethcathinone  11.0 4.8% 10.7 4.4% 
Methedrone 
145.0886 20 
29.0 4.3% 29.4 1.8% 
2-Methoxymethcathinone  26.7 3.9% 26.8 1.0% 
3-Methoxymethcathinone  21.1 2.5% 21.9 2.3% 
Methedrone 
176.1070 20 
43.7 2.2% 55.3 1.5% 
2-Methoxymethcathinone  30.7 5.1% 38.6 0.2% 
3-Methoxymethcathinone  28.6 3.6% 37.0 2.3% 
Methedrone 
58.0651 40 
28.0 5.1% 27.6 1.9% 
2-Methoxymethcathinone  15.7 10.6% 15.9 4.8% 
3-Methoxymethcathinone  5.6 7.8% 5.1 8.0% 
Methedrone 
77.0386 40 
45.6 5.4% 45.4 2.5% 
2-Methoxymethcathinone  35.2 4.2% 35.2 1.1% 
3-Methoxymethcathinone  31.3 2.4% 31.0 2.1% 
Methedrone 
79.0542 40 
28.8 3.9% 26.1 2.9% 
2-Methoxymethcathinone  16.6 7.2% 12.9 1.7% 
3-Methoxymethcathinone  15.1 5.3% 14.9 3.0% 
Methedrone 
91.0542 40 
35.4 2.0% 37.4 5.9% 
2-Methoxymethcathinone  29.8 7.2% 30.3 0.5% 
3-Methoxymethcathinone  29.7 3.5% 31.1 1.8% 
Methedrone 
103.0542 40 
27.1 3.2% 25.2 3.4% 
2-Methoxymethcathinone  15.0 5.2% 14.3 1.2% 
3-Methoxymethcathinone  14.1 3.8% 13.2 3.2% 
Methedrone 
105.0699 40 
18.5 9.0% 17.7 2.4% 
2-Methoxymethcathinone  8.8 10.3% 6.7 4.1% 
3-Methoxymethcathinone  7.1 6.4% 8.2 1.7% 
Methedrone 117.0573 40 19.4 9.4% 20.2 1.9% 
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2-Methoxymethcathinone  29.4 7.8% 30.0 2.4% 
3-Methoxymethcathinone  28.4 7.7% 29.2 2.3% 
Methedrone 
132.0808 40 
33.4 3.6% 31.1 2.1% 
2-Methoxymethcathinone  51.2 3.8% 48.5 2.5% 
3-Methoxymethcathinone  59.5 1.5% 55.1 3.4% 
Methedrone 
144.0808 40 
37.2 4.7% 33.5 2.1% 
2-Methoxymethcathinone  43.9 6.7% 40.9 2.5% 
3-Methoxymethcathinone  23.1 4.2% 20.6 1.8% 
Methedrone 
146.0600 40 
94.6 2.6% 92.3 1.4% 
2-Methoxymethcathinone  50.2 4.6% 50.5 2.3% 
3-Methoxymethcathinone  41.5 4.5% 40.1 2.7% 
Methedrone 
160.0757 40 
7.5 10.5% 6.8 7.1% 
2-Methoxymethcathinone  21.6 5.1% 20.3 3.7% 
3-Methoxymethcathinone  10.9 7.6% 10.1 6.6% 
RCS-8  
RCS-8 3-methoxy isomer 
121.0648 20 
75.8 2.5% 95.3 1.1% 
RCS-8 4-methoxy isomer 33.9 3.1% 43.6 2.6% 
RCS-8 100.0 0.0% 100.0 0.0% 
RCS-8 3-methoxy isomer 
228.1747 20 
29.2 2.3% 31.4 0.6% 
RCS-8 4-methoxy isomer 1.8 5.7% 1.7 2.0% 
RCS-8 7.5 3.4% 6.0 4.6% 
RCS-8 3-methoxy isomer 
254.1539 20 
35.3 2.1% 40.7 2.4% 
RCS-8 4-methoxy isomer 3.6 6.3% 3.9 1.1% 
RCS-8 1.2 13.3% 0.7 86.6% 
RCS-8 3-methoxy isomer 
376.2271 20 
98.9 3.6% 100.0 0.0% 
RCS-8 4-methoxy isomer 100.0 0.0% 100.0 0.0% 
RCS-8 56.8 2.3% 44.5 3.4% 
RCS-8 3-methoxy isomer 
69.0699 40 
18.8 17.9% 16.7 3.5% 
RCS-8 4-methoxy isomer 3.9 30.3% 3.2 5.1% 
RCS-8 4.3 38.2% 3.7 10.6% 
RCS-8 3-methoxy isomer 
91.0542 40 
9.9 4.5% 8.5 3.5% 
RCS-8 4-methoxy isomer 2.1 9.3% 1.7 6.5% 
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RCS-8 61.4 3.7% 57.4 3.3% 
RCS-8 3-methoxy isomer 
93.0699 40 
0.0 - 0.0 - 
RCS-8 4-methoxy isomer 0.0 - 0.0 - 
RCS-8 19.6 16.3% 16.9 3.8% 
RCS-8 3-methoxy isomer 
135.0441 40 
2.7 52.9% 2.2 9.4% 
RCS-8 4-methoxy isomer 33.4 7.0% 30.9 1.8% 
RCS-8 3.4 28.7% 3.5 0.9% 
RCS-8 3-methoxy isomer 
144.0808 40 
31.5 2.3% 30.4 1.4% 
RCS-8 4-methoxy isomer 5.3 4.8% 4.8 1.2% 
RCS-8 26.2 3.5% 24.5 3.1% 
RCS-8 3-methoxy isomer 
254.1539 40 
64.9 2.7% 57.0 2.4% 
RCS-8 4-methoxy isomer 10.8 3.4% 8.7 3.6% 
RCS-8 5.4 5.5% 4.3 5.4% 
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